id	sid	tid	token	lemma	pos
eurjchem-2553	1	1	igg	igg	PROPN
eurjchem-2553	1	2	neutralization	neutralization	PROPN
eurjchem-2553	1	3	potential	potential	NOUN
eurjchem-2553	1	4	of	of	ADP
eurjchem-2553	1	5	covishield	covishield	NOUN
eurjchem-2553	1	6	™	™	PROPN
eurjchem-2553	1	7	vaccinated	vaccinate	VERB
eurjchem-2553	1	8	individual	individual	NOUN
eurjchem-2553	1	9	’s	’s	PART
eurjchem-2553	1	10	sera	sera	NOUN
eurjchem-2553	1	11	after	after	ADP
eurjchem-2553	1	12	booster	booster	NOUN
eurjchem-2553	1	13	vaccination	vaccination	NOUN
eurjchem-2553	1	14	:	:	PUNCT
eurjchem-2553	1	15	longitudinal	longitudinal	ADJ
eurjchem-2553	1	16	and	and	CCONJ
eurjchem-2553	1	17	prospective	prospective	ADJ
eurjchem-2553	1	18	cohort	cohort	NOUN
eurjchem-2553	1	19	study	study	NOUN
eurjchem-2553	1	20	european	european	PROPN
eurjchem-2553	1	21	journal	journal	PROPN
eurjchem-2553	1	22	of	of	ADP
eurjchem-2553	1	23	chemistry	chemistry	NOUN
eurjchem-2553	1	24	15	15	NUM
eurjchem-2553	1	25	(	(	PUNCT
eurjchem-2553	1	26	3	3	NUM
eurjchem-2553	1	27	)	)	PUNCT
eurjchem-2553	1	28	(	(	PUNCT
eurjchem-2553	1	29	2024	2024	NUM
eurjchem-2553	1	30	)	)	PUNCT
eurjchem-2553	1	31	274	274	NUM
eurjchem-2553	1	32	-	-	SYM
eurjchem-2553	1	33	281	281	NUM
eurjchem-2553	1	34	european	european	ADJ
eurjchem-2553	1	35	journal	journal	NOUN
eurjchem-2553	1	36	of	of	ADP
eurjchem-2553	1	37	chemistry	chemistry	NOUN
eurjchem-2553	1	38	issn	issn	VERB
eurjchem-2553	1	39	2153	2153	NUM
eurjchem-2553	1	40	-	-	SYM
eurjchem-2553	1	41	2249	2249	NUM
eurjchem-2553	1	42	(	(	PUNCT
eurjchem-2553	1	43	print	print	NOUN
eurjchem-2553	1	44	)	)	PUNCT
eurjchem-2553	1	45	/	/	PUNCT
eurjchem-2553	1	46	issn	issn	PROPN
eurjchem-2553	1	47	2153	2153	NUM
eurjchem-2553	1	48	-	-	SYM
eurjchem-2553	1	49	2257	2257	NUM
eurjchem-2553	1	50	(	(	PUNCT
eurjchem-2553	1	51	online	online	ADJ
eurjchem-2553	1	52	)	)	PUNCT
eurjchem-2553	1	53	–	–	PUNCT
eurjchem-2553	2	1	copyright	copyright	NOUN
eurjchem-2553	2	2	©	©	PROPN
eurjchem-2553	2	3	2024	2024	NUM
eurjchem-2553	2	4	the	the	DET
eurjchem-2553	2	5	authors	author	NOUN
eurjchem-2553	2	6	–	–	PUNCT
eurjchem-2553	2	7	atlanta	atlanta	PROPN
eurjchem-2553	2	8	publishing	publishing	PROPN
eurjchem-2553	2	9	house	house	PROPN
eurjchem-2553	2	10	llc	llc	PROPN
eurjchem-2553	2	11	–	–	PUNCT
eurjchem-2553	2	12	printed	print	VERB
eurjchem-2553	2	13	in	in	ADP
eurjchem-2553	2	14	the	the	DET
eurjchem-2553	2	15	usa	usa	PROPN
eurjchem-2553	2	16	.	.	PUNCT
eurjchem-2553	3	1	this	this	DET
eurjchem-2553	3	2	work	work	NOUN
eurjchem-2553	3	3	is	be	AUX
eurjchem-2553	3	4	published	publish	VERB
eurjchem-2553	3	5	and	and	CCONJ
eurjchem-2553	3	6	licensed	license	VERB
eurjchem-2553	3	7	by	by	ADP
eurjchem-2553	3	8	atlanta	atlanta	PROPN
eurjchem-2553	3	9	publishing	publishing	PROPN
eurjchem-2553	3	10	house	house	PROPN
eurjchem-2553	3	11	llc	llc	PROPN
eurjchem-2553	3	12	–	–	PUNCT
eurjchem-2553	3	13	cc	cc	PROPN
eurjchem-2553	3	14	by	by	ADP
eurjchem-2553	3	15	nc	nc	PROPN
eurjchem-2553	3	16	–	–	PUNCT
eurjchem-2553	3	17	some	some	DET
eurjchem-2553	3	18	rights	right	NOUN
eurjchem-2553	3	19	reserved	reserve	VERB
eurjchem-2553	3	20	.	.	PUNCT
eurjchem-2553	4	1	https://dx.doi.org/10.5155/eurjchem.15.3.274-281.2553	https://dx.doi.org/10.5155/eurjchem.15.3.274-281.2553	PROPN
eurjchem-2553	4	2	european	european	PROPN
eurjchem-2553	4	3	journal	journal	PROPN
eurjchem-2553	4	4	of	of	ADP
eurjchem-2553	4	5	chemistry	chemistry	NOUN
eurjchem-2553	4	6	view	view	NOUN
eurjchem-2553	4	7	journal	journal	PROPN
eurjchem-2553	4	8	online	online	PROPN
eurjchem-2553	4	9	view	view	NOUN
eurjchem-2553	4	10	article	article	NOUN
eurjchem-2553	4	11	online	online	PROPN
eurjchem-2553	4	12	igg	igg	PROPN
eurjchem-2553	4	13	neutralization	neutralization	PROPN
eurjchem-2553	4	14	potential	potential	NOUN
eurjchem-2553	4	15	of	of	ADP
eurjchem-2553	4	16	covishield	covishield	NOUN
eurjchem-2553	4	17	™	™	PROPN
eurjchem-2553	4	18	vaccinated	vaccinate	VERB
eurjchem-2553	4	19	individual	individual	NOUN
eurjchem-2553	4	20	’s	’s	PART
eurjchem-2553	4	21	sera	sera	NOUN
eurjchem-2553	4	22	after	after	ADP
eurjchem-2553	4	23	booster	booster	NOUN
eurjchem-2553	4	24	vaccination	vaccination	NOUN
eurjchem-2553	4	25	:	:	PUNCT
eurjchem-2553	4	26	longitudinal	longitudinal	ADJ
eurjchem-2553	4	27	and	and	CCONJ
eurjchem-2553	4	28	prospective	prospective	ADJ
eurjchem-2553	4	29	cohort	cohort	NOUN
eurjchem-2553	4	30	study	study	NOUN
eurjchem-2553	4	31	naveena	naveena	NOUN
eurjchem-2553	4	32	jagadeesan	jagadeesan	PROPN
eurjchem-2553	4	33	*	*	PROPN
eurjchem-2553	4	34	,	,	PUNCT
eurjchem-2553	4	35	praveen	praveen	PROPN
eurjchem-2553	4	36	kumar	kumar	PROPN
eurjchem-2553	4	37	,	,	PUNCT
eurjchem-2553	4	38	nandini	nandini	PROPN
eurjchem-2553	4	39	puttamasthi	puttamasthi	PROPN
eurjchem-2553	4	40	gowda	gowda	PROPN
eurjchem-2553	4	41	,	,	PUNCT
eurjchem-2553	4	42	kavitha	kavitha	PROPN
eurjchem-2553	4	43	karur	karur	PROPN
eurjchem-2553	4	44	,	,	PUNCT
eurjchem-2553	4	45	manjunath	manjunath	PROPN
eurjchem-2553	4	46	cholenalli	cholenalli	PROPN
eurjchem-2553	4	47	nanjappa	nanjappa	NOUN
eurjchem-2553	4	48	,	,	PUNCT
eurjchem-2553	4	49	prapulla	prapulla	NOUN
eurjchem-2553	4	50	kumari	kumari	PROPN
eurjchem-2553	4	51	,	,	PUNCT
eurjchem-2553	4	52	and	and	CCONJ
eurjchem-2553	4	53	harsha	harsha	PROPN
eurjchem-2553	4	54	tumkur	tumkur	PROPN
eurjchem-2553	4	55	kumar	kumar	PROPN
eurjchem-2553	4	56	department	department	PROPN
eurjchem-2553	4	57	of	of	ADP
eurjchem-2553	4	58	microbiology	microbiology	NOUN
eurjchem-2553	4	59	,	,	PUNCT
eurjchem-2553	4	60	sri	sri	PROPN
eurjchem-2553	4	61	jayadeva	jayadeva	PROPN
eurjchem-2553	4	62	institute	institute	PROPN
eurjchem-2553	4	63	of	of	ADP
eurjchem-2553	4	64	cardiovascular	cardiovascular	ADJ
eurjchem-2553	4	65	sciences	science	NOUN
eurjchem-2553	4	66	and	and	CCONJ
eurjchem-2553	4	67	research	research	NOUN
eurjchem-2553	4	68	,	,	PUNCT
eurjchem-2553	4	69	bengaluru	bengaluru	PROPN
eurjchem-2553	4	70	,	,	PUNCT
eurjchem-2553	4	71	560069	560069	NUM
eurjchem-2553	4	72	,	,	PUNCT
eurjchem-2553	4	73	karnataka	karnataka	PROPN
eurjchem-2553	4	74	,	,	PUNCT
eurjchem-2553	4	75	india	india	PROPN
eurjchem-2553	4	76	*	*	PUNCT
eurjchem-2553	4	77	corresponding	correspond	VERB
eurjchem-2553	4	78	author	author	NOUN
eurjchem-2553	4	79	at	at	ADP
eurjchem-2553	4	80	:	:	PUNCT
eurjchem-2553	4	81	department	department	NOUN
eurjchem-2553	4	82	of	of	ADP
eurjchem-2553	4	83	microbiology	microbiology	NOUN
eurjchem-2553	4	84	,	,	PUNCT
eurjchem-2553	4	85	sri	sri	PROPN
eurjchem-2553	4	86	jayadeva	jayadeva	PROPN
eurjchem-2553	4	87	institute	institute	PROPN
eurjchem-2553	4	88	of	of	ADP
eurjchem-2553	4	89	cardiovascular	cardiovascular	ADJ
eurjchem-2553	4	90	sciences	science	NOUN
eurjchem-2553	4	91	and	and	CCONJ
eurjchem-2553	4	92	research	research	NOUN
eurjchem-2553	4	93	,	,	PUNCT
eurjchem-2553	4	94	bengaluru	bengaluru	PROPN
eurjchem-2553	4	95	,	,	PUNCT
eurjchem-2553	4	96	560069	560069	NUM
eurjchem-2553	4	97	,	,	PUNCT
eurjchem-2553	4	98	karnataka	karnataka	PROPN
eurjchem-2553	4	99	,	,	PUNCT
eurjchem-2553	4	100	india	india	PROPN
eurjchem-2553	4	101	.	.	PUNCT
eurjchem-2553	5	1	e	e	X
eurjchem-2553	5	2	-	-	NOUN
eurjchem-2553	5	3	mail	mail	NOUN
eurjchem-2553	5	4	:	:	PUNCT
eurjchem-2553	5	5	drnaveenaj@gmail.com	drnaveenaj@gmail.com	X
eurjchem-2553	5	6	(	(	PUNCT
eurjchem-2553	5	7	n.	n.	NOUN
eurjchem-2553	5	8	jagadeesan	jagadeesan	PROPN
eurjchem-2553	5	9	)	)	PUNCT
eurjchem-2553	5	10	.	.	PUNCT
eurjchem-2553	6	1	10.5155	10.5155	NUM
eurjchem-2553	6	2	/	/	SYM
eurjchem-2553	6	3	eurjchem.15.3.274	eurjchem.15.3.274	NOUN
eurjchem-2553	6	4	-	-	SYM
eurjchem-2553	6	5	281.2553	281.2553	NUM
eurjchem-2553	6	6	received	receive	VERB
eurjchem-2553	6	7	:	:	PUNCT
eurjchem-2553	6	8	25	25	NUM
eurjchem-2553	6	9	march	march	NOUN
eurjchem-2553	6	10	2024	2024	NUM
eurjchem-2553	6	11	received	receive	VERB
eurjchem-2553	6	12	in	in	ADP
eurjchem-2553	6	13	revised	revise	VERB
eurjchem-2553	6	14	form	form	NOUN
eurjchem-2553	6	15	:	:	PUNCT
eurjchem-2553	6	16	19	19	NUM
eurjchem-2553	6	17	july	july	PROPN
eurjchem-2553	6	18	2024	2024	NUM
eurjchem-2553	6	19	accepted	accept	VERB
eurjchem-2553	6	20	:	:	PUNCT
eurjchem-2553	6	21	20	20	NUM
eurjchem-2553	6	22	august	august	PROPN
eurjchem-2553	6	23	2024	2024	NUM
eurjchem-2553	6	24	published	publish	VERB
eurjchem-2553	6	25	online	online	ADV
eurjchem-2553	6	26	:	:	PUNCT
eurjchem-2553	6	27	30	30	NUM
eurjchem-2553	6	28	september	september	PROPN
eurjchem-2553	6	29	2024	2024	NUM
eurjchem-2553	6	30	printed	print	VERB
eurjchem-2553	6	31	:	:	PUNCT
eurjchem-2553	6	32	30	30	NUM
eurjchem-2553	6	33	september	september	PROPN
eurjchem-2553	6	34	2024	2024	NUM
eurjchem-2553	6	35	the	the	DET
eurjchem-2553	6	36	novel	novel	ADJ
eurjchem-2553	6	37	sars	sar	NOUN
eurjchem-2553	6	38	-	-	PUNCT
eurjchem-2553	6	39	cov-2	cov-2	PART
eurjchem-2553	6	40	(	(	PUNCT
eurjchem-2553	6	41	covid-19	covid-19	PROPN
eurjchem-2553	6	42	)	)	PUNCT
eurjchem-2553	6	43	has	have	AUX
eurjchem-2553	6	44	caused	cause	VERB
eurjchem-2553	6	45	widespread	widespread	ADJ
eurjchem-2553	6	46	human	human	ADJ
eurjchem-2553	6	47	turmoil	turmoil	NOUN
eurjchem-2553	6	48	by	by	ADP
eurjchem-2553	6	49	posing	pose	VERB
eurjchem-2553	6	50	challenges	challenge	NOUN
eurjchem-2553	6	51	concerning	concern	VERB
eurjchem-2553	6	52	infection	infection	NOUN
eurjchem-2553	6	53	prevention	prevention	NOUN
eurjchem-2553	6	54	,	,	PUNCT
eurjchem-2553	6	55	disease	disease	NOUN
eurjchem-2553	6	56	diagnosis	diagnosis	NOUN
eurjchem-2553	6	57	,	,	PUNCT
eurjchem-2553	6	58	and	and	CCONJ
eurjchem-2553	6	59	treatment	treatment	NOUN
eurjchem-2553	6	60	.	.	PUNCT
eurjchem-2553	7	1	several	several	ADJ
eurjchem-2553	7	2	approved	approve	VERB
eurjchem-2553	7	3	vaccines	vaccine	NOUN
eurjchem-2553	7	4	including	include	VERB
eurjchem-2553	7	5	sinovac	sinovac	NOUN
eurjchem-2553	7	6	(	(	PUNCT
eurjchem-2553	7	7	coronavac	coronavac	NOUN
eurjchem-2553	7	8	)	)	PUNCT
eurjchem-2553	7	9	,	,	PUNCT
eurjchem-2553	7	10	covishield	covishield	NOUN
eurjchem-2553	7	11	™	™	PROPN
eurjchem-2553	7	12	(	(	PUNCT
eurjchem-2553	7	13	oxford	oxford	PROPN
eurjchem-2553	7	14	/	/	SYM
eurjchem-2553	7	15	astrazeneca	astrazeneca	PROPN
eurjchem-2553	7	16	formulation	formulation	PROPN
eurjchem-2553	7	17	)	)	PUNCT
eurjchem-2553	7	18	,	,	PUNCT
eurjchem-2553	7	19	janssen	janssen	PROPN
eurjchem-2553	7	20	(	(	PUNCT
eurjchem-2553	7	21	johnson	johnson	PROPN
eurjchem-2553	7	22	&	&	CCONJ
eurjchem-2553	7	23	johnson	johnson	PROPN
eurjchem-2553	7	24	)	)	PUNCT
eurjchem-2553	7	25	,	,	PUNCT
eurjchem-2553	7	26	sputnik	sputnik	PROPN
eurjchem-2553	7	27	v	v	PROPN
eurjchem-2553	7	28	(	(	PUNCT
eurjchem-2553	7	29	gamaleya	gamaleya	PROPN
eurjchem-2553	7	30	)	)	PUNCT
eurjchem-2553	7	31	,	,	PUNCT
eurjchem-2553	7	32	covaxin	covaxin	NOUN
eurjchem-2553	7	33	(	(	PUNCT
eurjchem-2553	7	34	bharat	bharat	NOUN
eurjchem-2553	7	35	biotech	biotech	PROPN
eurjchem-2553	7	36	)	)	PUNCT
eurjchem-2553	7	37	,	,	PUNCT
eurjchem-2553	7	38	pfizer	pfizer	NOUN
eurjchem-2553	7	39	(	(	PUNCT
eurjchem-2553	7	40	bnt162b2	bnt162b2	PROPN
eurjchem-2553	7	41	)	)	PUNCT
eurjchem-2553	7	42	,	,	PUNCT
eurjchem-2553	7	43	and	and	CCONJ
eurjchem-2553	7	44	others	other	NOUN
eurjchem-2553	7	45	are	be	AUX
eurjchem-2553	7	46	being	be	AUX
eurjchem-2553	7	47	used	use	VERB
eurjchem-2553	7	48	to	to	PART
eurjchem-2553	7	49	combat	combat	VERB
eurjchem-2553	7	50	covid-19	covid-19	PROPN
eurjchem-2553	7	51	.	.	PUNCT
eurjchem-2553	8	1	it	it	PRON
eurjchem-2553	8	2	is	be	AUX
eurjchem-2553	8	3	crucial	crucial	ADJ
eurjchem-2553	8	4	to	to	PART
eurjchem-2553	8	5	evaluate	evaluate	VERB
eurjchem-2553	8	6	the	the	DET
eurjchem-2553	8	7	kinetics	kinetic	NOUN
eurjchem-2553	8	8	of	of	ADP
eurjchem-2553	8	9	sars	sar	NOUN
eurjchem-2553	8	10	-	-	PUNCT
eurjchem-2553	8	11	cov-2	cov-2	NOUN
eurjchem-2553	8	12	antibodies	antibodie	VERB
eurjchem-2553	8	13	to	to	PART
eurjchem-2553	8	14	predict	predict	VERB
eurjchem-2553	8	15	the	the	DET
eurjchem-2553	8	16	possibility	possibility	NOUN
eurjchem-2553	8	17	of	of	ADP
eurjchem-2553	8	18	reinfection	reinfection	NOUN
eurjchem-2553	8	19	and	and	CCONJ
eurjchem-2553	8	20	the	the	DET
eurjchem-2553	8	21	longevity	longevity	NOUN
eurjchem-2553	8	22	of	of	ADP
eurjchem-2553	8	23	vaccination	vaccination	NOUN
eurjchem-2553	8	24	protection	protection	NOUN
eurjchem-2553	8	25	.	.	PUNCT
eurjchem-2553	9	1	there	there	PRON
eurjchem-2553	9	2	is	be	VERB
eurjchem-2553	9	3	a	a	DET
eurjchem-2553	9	4	lack	lack	NOUN
eurjchem-2553	9	5	of	of	ADP
eurjchem-2553	9	6	data	datum	NOUN
eurjchem-2553	9	7	on	on	ADP
eurjchem-2553	9	8	longitudinal	longitudinal	ADJ
eurjchem-2553	9	9	humoral	humoral	ADJ
eurjchem-2553	9	10	antibody	antibody	NOUN
eurjchem-2553	9	11	dynamics	dynamic	NOUN
eurjchem-2553	9	12	following	follow	VERB
eurjchem-2553	9	13	two	two	NUM
eurjchem-2553	9	14	and	and	CCONJ
eurjchem-2553	9	15	three	three	NUM
eurjchem-2553	9	16	doses	dose	NOUN
eurjchem-2553	9	17	of	of	ADP
eurjchem-2553	9	18	the	the	DET
eurjchem-2553	9	19	sars	sar	NOUN
eurjchem-2553	9	20	-	-	PUNCT
eurjchem-2553	9	21	cov-2	cov-2	NOUN
eurjchem-2553	9	22	vaccination	vaccination	NOUN
eurjchem-2553	9	23	chadox1	chadox1	NOUN
eurjchem-2553	9	24	-	-	PUNCT
eurjchem-2553	9	25	ncov	ncov	NOUN
eurjchem-2553	9	26	(	(	PUNCT
eurjchem-2553	9	27	covishieldtm	covishieldtm	VERB
eurjchem-2553	9	28	)	)	PUNCT
eurjchem-2553	9	29	in	in	ADP
eurjchem-2553	9	30	indians	indians	PROPN
eurjchem-2553	9	31	.	.	PUNCT
eurjchem-2553	10	1	thus	thus	ADV
eurjchem-2553	10	2	,	,	PUNCT
eurjchem-2553	10	3	concerns	concern	NOUN
eurjchem-2553	10	4	about	about	ADP
eurjchem-2553	10	5	the	the	DET
eurjchem-2553	10	6	efficacy	efficacy	NOUN
eurjchem-2553	10	7	of	of	ADP
eurjchem-2553	10	8	current	current	ADJ
eurjchem-2553	10	9	vaccines	vaccine	NOUN
eurjchem-2553	10	10	have	have	AUX
eurjchem-2553	10	11	been	be	AUX
eurjchem-2553	10	12	raised	raise	VERB
eurjchem-2553	10	13	by	by	ADP
eurjchem-2553	10	14	a	a	DET
eurjchem-2553	10	15	sharp	sharp	ADJ
eurjchem-2553	10	16	rise	rise	NOUN
eurjchem-2553	10	17	in	in	ADP
eurjchem-2553	10	18	coronavirus	coronavirus	NOUN
eurjchem-2553	10	19	disease	disease	NOUN
eurjchem-2553	10	20	2019	2019	NUM
eurjchem-2553	10	21	(	(	PUNCT
eurjchem-2553	10	22	covid-19	covid-19	PROPN
eurjchem-2553	10	23	)	)	PUNCT
eurjchem-2553	10	24	cases	case	NOUN
eurjchem-2553	10	25	caused	cause	VERB
eurjchem-2553	10	26	by	by	ADP
eurjchem-2553	10	27	sub	sub	NOUN
eurjchem-2553	10	28	-	-	NOUN
eurjchem-2553	10	29	variants	variant	NOUN
eurjchem-2553	10	30	of	of	ADP
eurjchem-2553	10	31	sars	sar	NOUN
eurjchem-2553	10	32	-	-	PUNCT
eurjchem-2553	10	33	cov-2	cov-2	PUNCT
eurjchem-2553	10	34	(	(	PUNCT
eurjchem-2553	10	35	severe	severe	ADJ
eurjchem-2553	10	36	acute	acute	ADJ
eurjchem-2553	10	37	respiratory	respiratory	ADJ
eurjchem-2553	10	38	syndrome	syndrome	NOUN
eurjchem-2553	10	39	corona	corona	PROPN
eurjchem-2553	10	40	virus	virus	NOUN
eurjchem-2553	10	41	2	2	NUM
eurjchem-2553	10	42	)	)	PUNCT
eurjchem-2553	10	43	in	in	ADP
eurjchem-2553	10	44	communities	community	NOUN
eurjchem-2553	10	45	that	that	PRON
eurjchem-2553	10	46	have	have	AUX
eurjchem-2553	10	47	received	receive	VERB
eurjchem-2553	10	48	massive	massive	ADJ
eurjchem-2553	10	49	vaccinations	vaccination	NOUN
eurjchem-2553	10	50	.	.	PUNCT
eurjchem-2553	11	1	the	the	DET
eurjchem-2553	11	2	relative	relative	ADJ
eurjchem-2553	11	3	immunogenicity	immunogenicity	NOUN
eurjchem-2553	11	4	and	and	CCONJ
eurjchem-2553	11	5	safety	safety	NOUN
eurjchem-2553	11	6	of	of	ADP
eurjchem-2553	11	7	various	various	ADJ
eurjchem-2553	11	8	covid-19	covid-19	PROPN
eurjchem-2553	11	9	immunizations	immunization	NOUN
eurjchem-2553	11	10	administered	administer	VERB
eurjchem-2553	11	11	as	as	ADP
eurjchem-2553	11	12	a	a	DET
eurjchem-2553	11	13	third	third	ADJ
eurjchem-2553	11	14	(	(	PUNCT
eurjchem-2553	11	15	booster	booster	NOUN
eurjchem-2553	11	16	)	)	PUNCT
eurjchem-2553	11	17	dose	dose	NOUN
eurjchem-2553	11	18	are	be	AUX
eurjchem-2553	11	19	not	not	PART
eurjchem-2553	11	20	well	well	ADV
eurjchem-2553	11	21	known	known	ADJ
eurjchem-2553	11	22	.	.	PUNCT
eurjchem-2553	12	1	we	we	PRON
eurjchem-2553	12	2	examined	examine	VERB
eurjchem-2553	12	3	the	the	DET
eurjchem-2553	12	4	reactogenicity	reactogenicity	NOUN
eurjchem-2553	12	5	and	and	CCONJ
eurjchem-2553	12	6	immunogenicity	immunogenicity	NOUN
eurjchem-2553	12	7	of	of	ADP
eurjchem-2553	12	8	the	the	DET
eurjchem-2553	12	9	covid-19	covid-19	PROPN
eurjchem-2553	12	10	vaccine	vaccine	NOUN
eurjchem-2553	12	11	as	as	ADP
eurjchem-2553	12	12	a	a	DET
eurjchem-2553	12	13	third	third	ADJ
eurjchem-2553	12	14	dose	dose	NOUN
eurjchem-2553	12	15	after	after	ADP
eurjchem-2553	12	16	two	two	NUM
eurjchem-2553	12	17	doses	dose	NOUN
eurjchem-2553	12	18	of	of	ADP
eurjchem-2553	12	19	covishieldtm	covishieldtm	NOUN
eurjchem-2553	12	20	to	to	PART
eurjchem-2553	12	21	produce	produce	VERB
eurjchem-2553	12	22	data	datum	NOUN
eurjchem-2553	12	23	to	to	PART
eurjchem-2553	12	24	optimize	optimize	VERB
eurjchem-2553	12	25	the	the	DET
eurjchem-2553	12	26	selection	selection	NOUN
eurjchem-2553	12	27	of	of	ADP
eurjchem-2553	12	28	booster	booster	NOUN
eurjchem-2553	12	29	vaccinations	vaccination	NOUN
eurjchem-2553	12	30	.	.	PUNCT
eurjchem-2553	13	1	after	after	ADP
eurjchem-2553	13	2	three	three	NUM
eurjchem-2553	13	3	doses	dose	NOUN
eurjchem-2553	13	4	of	of	ADP
eurjchem-2553	13	5	the	the	DET
eurjchem-2553	13	6	covid-19	covid-19	PROPN
eurjchem-2553	13	7	vaccine	vaccine	NOUN
eurjchem-2553	13	8	,	,	PUNCT
eurjchem-2553	13	9	we	we	PRON
eurjchem-2553	13	10	evaluated	evaluate	VERB
eurjchem-2553	13	11	the	the	DET
eurjchem-2553	13	12	sera	sera	NOUN
eurjchem-2553	13	13	of	of	ADP
eurjchem-2553	13	14	covishieldtm	covishieldtm	ADJ
eurjchem-2553	13	15	vaccine	vaccine	NOUN
eurjchem-2553	13	16	recipients	recipient	NOUN
eurjchem-2553	13	17	for	for	ADP
eurjchem-2553	13	18	their	their	PRON
eurjchem-2553	13	19	ability	ability	NOUN
eurjchem-2553	13	20	to	to	PART
eurjchem-2553	13	21	neutralize	neutralize	VERB
eurjchem-2553	13	22	the	the	DET
eurjchem-2553	13	23	virus	virus	NOUN
eurjchem-2553	13	24	.	.	PUNCT
eurjchem-2553	14	1	primary	primary	ADJ
eurjchem-2553	14	2	immunization	immunization	NOUN
eurjchem-2553	14	3	with	with	ADP
eurjchem-2553	14	4	two	two	NUM
eurjchem-2553	14	5	doses	dose	NOUN
eurjchem-2553	14	6	of	of	ADP
eurjchem-2553	14	7	covishieldtm	covishieldtm	ADJ
eurjchem-2553	14	8	vaccine	vaccine	NOUN
eurjchem-2553	14	9	recipients	recipient	NOUN
eurjchem-2553	14	10	provided	provide	VERB
eurjchem-2553	14	11	significant	significant	ADJ
eurjchem-2553	14	12	protection	protection	NOUN
eurjchem-2553	14	13	against	against	ADP
eurjchem-2553	14	14	symptomatic	symptomatic	ADJ
eurjchem-2553	14	15	disease	disease	NOUN
eurjchem-2553	14	16	caused	cause	VERB
eurjchem-2553	14	17	by	by	ADP
eurjchem-2553	14	18	the	the	DET
eurjchem-2553	14	19	sars	sar	NOUN
eurjchem-2553	14	20	-	-	PUNCT
eurjchem-2553	14	21	cov-2	cov-2	NOUN
eurjchem-2553	14	22	variants	variant	NOUN
eurjchem-2553	14	23	.	.	PUNCT
eurjchem-2553	15	1	a	a	DET
eurjchem-2553	15	2	covishieldtm	covishieldtm	ADJ
eurjchem-2553	15	3	vaccine	vaccine	NOUN
eurjchem-2553	15	4	booster	booster	NOUN
eurjchem-2553	15	5	vaccine	vaccine	NOUN
eurjchem-2553	15	6	recipient	recipient	NOUN
eurjchem-2553	15	7	substantially	substantially	ADV
eurjchem-2553	15	8	increased	increase	VERB
eurjchem-2553	15	9	protection	protection	NOUN
eurjchem-2553	15	10	.	.	PUNCT
eurjchem-2553	16	1	the	the	DET
eurjchem-2553	16	2	immunization	immunization	NOUN
eurjchem-2553	16	3	findings	finding	NOUN
eurjchem-2553	16	4	showed	show	VERB
eurjchem-2553	16	5	a	a	DET
eurjchem-2553	16	6	significant	significant	ADJ
eurjchem-2553	16	7	difference	difference	NOUN
eurjchem-2553	16	8	(	(	PUNCT
eurjchem-2553	16	9	p	p	NOUN
eurjchem-2553	16	10	≥	≥	NOUN
eurjchem-2553	16	11	0.001	0.001	NUM
eurjchem-2553	16	12	)	)	PUNCT
eurjchem-2553	16	13	between	between	ADP
eurjchem-2553	16	14	the	the	DET
eurjchem-2553	16	15	covid-19	covid-19	PROPN
eurjchem-2553	16	16	naive	naive	ADJ
eurjchem-2553	16	17	vaccine	vaccine	NOUN
eurjchem-2553	16	18	(	(	PUNCT
eurjchem-2553	16	19	n	n	NOUN
eurjchem-2553	16	20	=	=	SYM
eurjchem-2553	16	21	438	438	NUM
eurjchem-2553	16	22	)	)	PUNCT
eurjchem-2553	16	23	and	and	CCONJ
eurjchem-2553	16	24	the	the	DET
eurjchem-2553	16	25	sera	sera	NOUN
eurjchem-2553	16	26	of	of	ADP
eurjchem-2553	16	27	covid-19	covid-19	PROPN
eurjchem-2553	16	28	-	-	PUNCT
eurjchem-2553	16	29	positive	positive	ADJ
eurjchem-2553	16	30	recovered	recovered	ADJ
eurjchem-2553	16	31	subjects	subject	NOUN
eurjchem-2553	16	32	(	(	PUNCT
eurjchem-2553	16	33	n	n	NOUN
eurjchem-2553	16	34	=	=	NUM
eurjchem-2553	16	35	371	371	NUM
eurjchem-2553	16	36	)	)	PUNCT
eurjchem-2553	16	37	who	who	PRON
eurjchem-2553	16	38	received	receive	VERB
eurjchem-2553	16	39	three	three	NUM
eurjchem-2553	16	40	doses	dose	NOUN
eurjchem-2553	16	41	of	of	ADP
eurjchem-2553	16	42	covishieldtm	covishieldtm	NOUN
eurjchem-2553	16	43	.	.	PUNCT
eurjchem-2553	17	1	our	our	PRON
eurjchem-2553	17	2	findings	finding	NOUN
eurjchem-2553	17	3	reveal	reveal	VERB
eurjchem-2553	17	4	that	that	SCONJ
eurjchem-2553	17	5	anti	anti	ADJ
eurjchem-2553	17	6	-	-	ADJ
eurjchem-2553	17	7	rbd	rbd	ADJ
eurjchem-2553	17	8	antibodies	antibody	NOUN
eurjchem-2553	17	9	persist	persist	VERB
eurjchem-2553	17	10	over	over	ADP
eurjchem-2553	17	11	time	time	NOUN
eurjchem-2553	17	12	,	,	PUNCT
eurjchem-2553	17	13	which	which	PRON
eurjchem-2553	17	14	may	may	AUX
eurjchem-2553	17	15	reduce	reduce	VERB
eurjchem-2553	17	16	the	the	DET
eurjchem-2553	17	17	probability	probability	NOUN
eurjchem-2553	17	18	of	of	ADP
eurjchem-2553	17	19	reinfection	reinfection	NOUN
eurjchem-2553	17	20	.	.	PUNCT
eurjchem-2553	18	1	a	a	DET
eurjchem-2553	18	2	three	three	NUM
eurjchem-2553	18	3	-	-	PUNCT
eurjchem-2553	18	4	dose	dose	NOUN
eurjchem-2553	18	5	vaccination	vaccination	NOUN
eurjchem-2553	18	6	(	(	PUNCT
eurjchem-2553	18	7	n	n	NOUN
eurjchem-2553	18	8	=	=	SYM
eurjchem-2553	18	9	53	53	NUM
eurjchem-2553	18	10	)	)	PUNCT
eurjchem-2553	18	11	increases	increase	VERB
eurjchem-2553	18	12	defense	defense	NOUN
eurjchem-2553	18	13	against	against	ADP
eurjchem-2553	18	14	variations	variation	NOUN
eurjchem-2553	18	15	by	by	ADP
eurjchem-2553	18	16	noticeably	noticeably	ADV
eurjchem-2553	18	17	increasing	increase	VERB
eurjchem-2553	18	18	cross	cross	ADJ
eurjchem-2553	18	19	-	-	ADJ
eurjchem-2553	18	20	neutralizing	neutralizing	ADJ
eurjchem-2553	18	21	antibody	antibody	NOUN
eurjchem-2553	18	22	titers	titer	NOUN
eurjchem-2553	18	23	.	.	PUNCT
eurjchem-2553	19	1	particularly	particularly	ADV
eurjchem-2553	19	2	against	against	ADP
eurjchem-2553	19	3	variants	variant	NOUN
eurjchem-2553	19	4	with	with	ADP
eurjchem-2553	19	5	antibody	antibody	NOUN
eurjchem-2553	19	6	escape	escape	NOUN
eurjchem-2553	19	7	mutations	mutation	NOUN
eurjchem-2553	19	8	.	.	PUNCT
eurjchem-2553	20	1	igg	igg	PROPN
eurjchem-2553	20	2	covid-19	covid-19	PROPN
eurjchem-2553	20	3	immunity	immunity	NOUN
eurjchem-2553	20	4	vaccination	vaccination	NOUN
eurjchem-2553	20	5	covishield	covishield	NOUN
eurjchem-2553	20	6	™	™	VERB
eurjchem-2553	20	7	anti	anti	ADJ
eurjchem-2553	20	8	-	-	ADJ
eurjchem-2553	20	9	sars	sar	NOUN
eurjchem-2553	20	10	-	-	PUNCT
eurjchem-2553	20	11	cov-2	cov-2	NOUN
eurjchem-2553	20	12	cite	cite	VERB
eurjchem-2553	20	13	this	this	PRON
eurjchem-2553	20	14	:	:	PUNCT
eurjchem-2553	20	15	eur	eur	PROPN
eurjchem-2553	20	16	.	.	PUNCT
eurjchem-2553	21	1	j.	j.	PROPN
eurjchem-2553	21	2	chem	chem	PROPN
eurjchem-2553	21	3	.	.	PUNCT
eurjchem-2553	22	1	2024	2024	NUM
eurjchem-2553	22	2	,	,	PUNCT
eurjchem-2553	22	3	15(3	15(3	NUM
eurjchem-2553	22	4	)	)	PUNCT
eurjchem-2553	22	5	,	,	PUNCT
eurjchem-2553	22	6	274	274	NUM
eurjchem-2553	22	7	-	-	SYM
eurjchem-2553	22	8	281	281	NUM
eurjchem-2553	22	9	journal	journal	NOUN
eurjchem-2553	22	10	website	website	NOUN
eurjchem-2553	22	11	:	:	PUNCT
eurjchem-2553	22	12	www.eurjchem.com	www.eurjchem.com	X
eurjchem-2553	22	13	1	1	X
eurjchem-2553	22	14	.	.	PUNCT
eurjchem-2553	23	1	introduction	introduction	NOUN
eurjchem-2553	23	2	the	the	DET
eurjchem-2553	23	3	severe	severe	ADJ
eurjchem-2553	23	4	acute	acute	ADJ
eurjchem-2553	23	5	respiratory	respiratory	ADJ
eurjchem-2553	23	6	syndrome	syndrome	NOUN
eurjchem-2553	23	7	coronavirus	coronavirus	NOUN
eurjchem-2553	23	8	2	2	NUM
eurjchem-2553	23	9	(	(	PUNCT
eurjchem-2553	23	10	sars	sar	NOUN
eurjchem-2553	23	11	-	-	PUNCT
eurjchem-2553	23	12	cov-2)-induced	cov-2)-induce	VERB
eurjchem-2553	23	13	coronavirus	coronavirus	NOUN
eurjchem-2553	23	14	disease	disease	NOUN
eurjchem-2553	23	15	2019	2019	NUM
eurjchem-2553	23	16	(	(	PUNCT
eurjchem-2553	23	17	covid-19	covid-19	PROPN
eurjchem-2553	23	18	)	)	PUNCT
eurjchem-2553	23	19	pandemic	pandemic	NOUN
eurjchem-2553	23	20	has	have	AUX
eurjchem-2553	23	21	wreaked	wreak	VERB
eurjchem-2553	23	22	unimaginable	unimaginable	ADJ
eurjchem-2553	23	23	havoc	havoc	NOUN
eurjchem-2553	23	24	on	on	ADP
eurjchem-2553	23	25	the	the	DET
eurjchem-2553	23	26	global	global	ADJ
eurjchem-2553	23	27	economy	economy	NOUN
eurjchem-2553	23	28	and	and	CCONJ
eurjchem-2553	23	29	health	health	NOUN
eurjchem-2553	24	1	[	[	X
eurjchem-2553	24	2	1	1	NUM
eurjchem-2553	24	3	]	]	PUNCT
eurjchem-2553	24	4	.	.	PUNCT
eurjchem-2553	25	1	vaccination	vaccination	NOUN
eurjchem-2553	25	2	is	be	AUX
eurjchem-2553	25	3	one	one	NUM
eurjchem-2553	25	4	of	of	ADP
eurjchem-2553	25	5	the	the	DET
eurjchem-2553	25	6	most	most	ADV
eurjchem-2553	25	7	effective	effective	ADJ
eurjchem-2553	25	8	treatments	treatment	NOUN
eurjchem-2553	25	9	to	to	PART
eurjchem-2553	25	10	greatly	greatly	ADV
eurjchem-2553	25	11	reduce	reduce	VERB
eurjchem-2553	25	12	the	the	DET
eurjchem-2553	25	13	severity	severity	NOUN
eurjchem-2553	25	14	of	of	ADP
eurjchem-2553	25	15	disease	disease	NOUN
eurjchem-2553	25	16	and	and	CCONJ
eurjchem-2553	25	17	mortality	mortality	NOUN
eurjchem-2553	25	18	caused	cause	VERB
eurjchem-2553	25	19	by	by	ADP
eurjchem-2553	25	20	sars	sar	NOUN
eurjchem-2553	25	21	-	-	PUNCT
eurjchem-2553	25	22	cov-2	cov-2	PART
eurjchem-2553	25	23	infection	infection	NOUN
eurjchem-2553	25	24	.	.	PUNCT
eurjchem-2553	26	1	vaccination	vaccination	NOUN
eurjchem-2553	26	2	campaigns	campaign	NOUN
eurjchem-2553	26	3	are	be	AUX
eurjchem-2553	26	4	being	be	AUX
eurjchem-2553	26	5	carried	carry	VERB
eurjchem-2553	26	6	out	out	ADP
eurjchem-2553	26	7	worldwide	worldwide	ADV
eurjchem-2553	26	8	.	.	PUNCT
eurjchem-2553	27	1	the	the	DET
eurjchem-2553	27	2	global	global	ADJ
eurjchem-2553	27	3	rise	rise	NOUN
eurjchem-2553	27	4	of	of	ADP
eurjchem-2553	27	5	education	education	NOUN
eurjchem-2553	27	6	,	,	PUNCT
eurjchem-2553	27	7	which	which	PRON
eurjchem-2553	27	8	was	be	AUX
eurjchem-2553	27	9	made	make	VERB
eurjchem-2553	27	10	available	available	ADJ
eurjchem-2553	27	11	online	online	ADV
eurjchem-2553	27	12	at	at	ADP
eurjchem-2553	27	13	https://ourworldindata.org/	https://ourworldindata.org/	PROPN
eurjchem-2553	27	14	[	[	X
eurjchem-2553	27	15	2	2	NUM
eurjchem-2553	27	16	]	]	PUNCT
eurjchem-2553	27	17	,	,	PUNCT
eurjchem-2553	27	18	provided	provide	VERB
eurjchem-2553	27	19	information	information	NOUN
eurjchem-2553	27	20	on	on	ADP
eurjchem-2553	27	21	the	the	DET
eurjchem-2553	27	22	covid-19	covid-19	PROPN
eurjchem-2553	27	23	vaccine	vaccine	NOUN
eurjchem-2553	27	24	administration	administration	NOUN
eurjchem-2553	27	25	statistics	statistic	NOUN
eurjchem-2553	27	26	to	to	ADP
eurjchem-2553	27	27	the	the	DET
eurjchem-2553	27	28	present	present	ADJ
eurjchem-2553	27	29	day	day	NOUN
eurjchem-2553	27	30	(	(	PUNCT
eurjchem-2553	27	31	figure	figure	NOUN
eurjchem-2553	27	32	1	1	NUM
eurjchem-2553	27	33	)	)	PUNCT
eurjchem-2553	27	34	.	.	PUNCT
eurjchem-2553	28	1	worldwide	worldwide	ADV
eurjchem-2553	28	2	,	,	PUNCT
eurjchem-2553	28	3	based	base	VERB
eurjchem-2553	28	4	on	on	ADP
eurjchem-2553	28	5	geographic	geographic	ADJ
eurjchem-2553	28	6	variability	variability	NOUN
eurjchem-2553	28	7	across	across	ADP
eurjchem-2553	28	8	the	the	DET
eurjchem-2553	28	9	20	20	NUM
eurjchem-2553	28	10	different	different	ADJ
eurjchem-2553	28	11	regions	region	NOUN
eurjchem-2553	28	12	of	of	ADP
eurjchem-2553	28	13	the	the	DET
eurjchem-2553	28	14	world	world	NOUN
eurjchem-2553	28	15	,	,	PUNCT
eurjchem-2553	28	16	the	the	DET
eurjchem-2553	28	17	global	global	ADJ
eurjchem-2553	28	18	covid-19	covid-19	PROPN
eurjchem-2553	28	19	vaccine	vaccine	NOUN
eurjchem-2553	28	20	administration	administration	NOUN
eurjchem-2553	28	21	doses	dose	NOUN
eurjchem-2553	28	22	were	be	AUX
eurjchem-2553	28	23	found	find	VERB
eurjchem-2553	28	24	to	to	PART
eurjchem-2553	28	25	be	be	AUX
eurjchem-2553	28	26	13.32	13.32	NUM
eurjchem-2553	28	27	billion	billion	NUM
eurjchem-2553	28	28	doses	dose	NOUN
eurjchem-2553	28	29	and	and	CCONJ
eurjchem-2553	28	30	69.7	69.7	NUM
eurjchem-2553	28	31	%	%	NOUN
eurjchem-2553	28	32	of	of	ADP
eurjchem-2553	28	33	the	the	DET
eurjchem-2553	28	34	world	world	NOUN
eurjchem-2553	28	35	’s	’s	PART
eurjchem-2553	28	36	population	population	NOUN
eurjchem-2553	28	37	and	and	CCONJ
eurjchem-2553	28	38	759,319	759,319	NUM
eurjchem-2553	28	39	are	be	AUX
eurjchem-2553	28	40	now	now	ADV
eurjchem-2553	28	41	administered	administer	VERB
eurjchem-2553	28	42	each	each	DET
eurjchem-2553	28	43	day	day	NOUN
eurjchem-2553	28	44	.	.	PUNCT
eurjchem-2553	29	1	the	the	DET
eurjchem-2553	29	2	majority	majority	NOUN
eurjchem-2553	29	3	of	of	ADP
eurjchem-2553	29	4	the	the	DET
eurjchem-2553	29	5	vaccination	vaccination	NOUN
eurjchem-2553	29	6	coverage	coverage	NOUN
eurjchem-2553	29	7	in	in	ADP
eurjchem-2553	29	8	india	india	PROPN
eurjchem-2553	29	9	consists	consist	VERB
eurjchem-2553	29	10	of	of	ADP
eurjchem-2553	29	11	covishieldtm	covishieldtm	NOUN
eurjchem-2553	29	12	.	.	PUNCT
eurjchem-2553	30	1	therefore	therefore	ADV
eurjchem-2553	30	2	,	,	PUNCT
eurjchem-2553	30	3	understanding	understand	VERB
eurjchem-2553	30	4	the	the	DET
eurjchem-2553	30	5	potential	potential	NOUN
eurjchem-2553	30	6	of	of	ADP
eurjchem-2553	30	7	vaccinations	vaccination	NOUN
eurjchem-2553	30	8	to	to	PART
eurjchem-2553	30	9	neutralize	neutralize	VERB
eurjchem-2553	30	10	new	new	ADJ
eurjchem-2553	30	11	strains	strain	NOUN
eurjchem-2553	30	12	,	,	PUNCT
eurjchem-2553	30	13	which	which	PRON
eurjchem-2553	30	14	are	be	AUX
eurjchem-2553	30	15	considered	consider	VERB
eurjchem-2553	30	16	the	the	DET
eurjchem-2553	30	17	cause	cause	NOUN
eurjchem-2553	30	18	of	of	ADP
eurjchem-2553	30	19	the	the	DET
eurjchem-2553	30	20	increase	increase	NOUN
eurjchem-2553	30	21	in	in	ADP
eurjchem-2553	30	22	incidence	incidence	NOUN
eurjchem-2553	30	23	in	in	ADP
eurjchem-2553	30	24	india	india	PROPN
eurjchem-2553	30	25	,	,	PUNCT
eurjchem-2553	30	26	is	be	AUX
eurjchem-2553	30	27	crucial	crucial	ADJ
eurjchem-2553	30	28	.	.	PUNCT
eurjchem-2553	31	1	as	as	ADP
eurjchem-2553	31	2	of	of	ADP
eurjchem-2553	31	3	september	september	PROPN
eurjchem-2553	31	4	1	1	NUM
eurjchem-2553	31	5	,	,	PUNCT
eurjchem-2553	31	6	2022	2022	NUM
eurjchem-2553	31	7	,	,	PUNCT
eurjchem-2553	31	8	1,696.19	1,696.19	NUM
eurjchem-2553	31	9	million	million	NUM
eurjchem-2553	31	10	doses	dose	NOUN
eurjchem-2553	31	11	of	of	ADP
eurjchem-2553	31	12	covishieldtm	covishieldtm	ADJ
eurjchem-2553	31	13	covid-19	covid-19	PROPN
eurjchem-2553	31	14	vaccination	vaccination	NOUN
eurjchem-2553	31	15	had	have	AUX
eurjchem-2553	31	16	been	be	AUX
eurjchem-2553	31	17	delivered	deliver	VERB
eurjchem-2553	31	18	in	in	ADP
eurjchem-2553	31	19	india	india	PROPN
eurjchem-2553	32	1	[	[	X
eurjchem-2553	32	2	3	3	NUM
eurjchem-2553	32	3	]	]	PUNCT
eurjchem-2553	32	4	.	.	PUNCT
eurjchem-2553	33	1	to	to	PART
eurjchem-2553	33	2	assess	assess	VERB
eurjchem-2553	33	3	the	the	DET
eurjchem-2553	33	4	overall	overall	ADJ
eurjchem-2553	33	5	dynamics	dynamic	NOUN
eurjchem-2553	33	6	of	of	ADP
eurjchem-2553	33	7	the	the	DET
eurjchem-2553	33	8	covid-19	covid-19	PROPN
eurjchem-2553	33	9	epidemic	epidemic	NOUN
eurjchem-2553	33	10	and	and	CCONJ
eurjchem-2553	33	11	post	post	ADJ
eurjchem-2553	33	12	-	-	ADJ
eurjchem-2553	33	13	pandemic	pandemic	ADJ
eurjchem-2553	33	14	dynamics	dynamic	NOUN
eurjchem-2553	33	15	,	,	PUNCT
eurjchem-2553	33	16	evidence	evidence	NOUN
eurjchem-2553	33	17	of	of	ADP
eurjchem-2553	33	18	the	the	DET
eurjchem-2553	33	19	immune	immune	ADJ
eurjchem-2553	33	20	responses	response	NOUN
eurjchem-2553	33	21	endurance	endurance	NOUN
eurjchem-2553	33	22	and	and	CCONJ
eurjchem-2553	33	23	long	long	ADJ
eurjchem-2553	33	24	-	-	PUNCT
eurjchem-2553	33	25	term	term	NOUN
eurjchem-2553	33	26	efficacy	efficacy	NOUN
eurjchem-2553	33	27	is	be	AUX
eurjchem-2553	33	28	required	require	VERB
eurjchem-2553	33	29	,	,	PUNCT
eurjchem-2553	33	30	especially	especially	ADV
eurjchem-2553	33	31	in	in	ADP
eurjchem-2553	33	32	light	light	NOUN
eurjchem-2553	33	33	of	of	ADP
eurjchem-2553	33	34	the	the	DET
eurjchem-2553	33	35	recent	recent	ADJ
eurjchem-2553	33	36	emergence	emergence	NOUN
eurjchem-2553	33	37	of	of	ADP
eurjchem-2553	33	38	novel	novel	ADJ
eurjchem-2553	33	39	sars	sar	NOUN
eurjchem-2553	33	40	-	-	PUNCT
eurjchem-2553	33	41	cov-2	cov-2	NOUN
eurjchem-2553	33	42	variants	variant	NOUN
eurjchem-2553	33	43	.	.	PUNCT
eurjchem-2553	34	1	due	due	ADP
eurjchem-2553	34	2	to	to	ADP
eurjchem-2553	34	3	ongoing	ongoing	ADJ
eurjchem-2553	34	4	genetic	genetic	ADJ
eurjchem-2553	34	5	alterations	alteration	NOUN
eurjchem-2553	34	6	in	in	ADP
eurjchem-2553	34	7	the	the	DET
eurjchem-2553	34	8	sars	sar	NOUN
eurjchem-2553	34	9	-	-	PUNCT
eurjchem-2553	34	10	cov-2	cov-2	NOUN
eurjchem-2553	34	11	genome	genome	NOUN
eurjchem-2553	34	12	,	,	PUNCT
eurjchem-2553	34	13	the	the	DET
eurjchem-2553	34	14	covid-19	covid-19	PROPN
eurjchem-2553	34	15	pandemic	pandemic	NOUN
eurjchem-2553	34	16	is	be	AUX
eurjchem-2553	34	17	still	still	ADV
eurjchem-2553	34	18	a	a	DET
eurjchem-2553	34	19	global	global	ADJ
eurjchem-2553	34	20	threat	threat	NOUN
eurjchem-2553	34	21	today	today	NOUN
eurjchem-2553	34	22	[	[	X
eurjchem-2553	34	23	4	4	NUM
eurjchem-2553	34	24	]	]	PUNCT
eurjchem-2553	34	25	.	.	PUNCT
eurjchem-2553	35	1	the	the	DET
eurjchem-2553	35	2	most	most	ADV
eurjchem-2553	35	3	effective	effective	ADJ
eurjchem-2553	35	4	method	method	NOUN
eurjchem-2553	35	5	for	for	ADP
eurjchem-2553	35	6	suppressing	suppress	VERB
eurjchem-2553	35	7	the	the	DET
eurjchem-2553	35	8	covid-19	covid-19	PROPN
eurjchem-2553	35	9	pandemic	pandemic	NOUN
eurjchem-2553	35	10	may	may	AUX
eurjchem-2553	35	11	be	be	AUX
eurjchem-2553	35	12	vaccination	vaccination	NOUN
eurjchem-2553	35	13	.	.	PUNCT
eurjchem-2553	36	1	the	the	DET
eurjchem-2553	36	2	first	first	ADJ
eurjchem-2553	36	3	two	two	NUM
eurjchem-2553	36	4	vaccine	vaccine	NOUN
eurjchem-2553	36	5	administrations	administration	NOUN
eurjchem-2553	36	6	were	be	AUX
eurjchem-2553	36	7	considered	consider	VERB
eurjchem-2553	36	8	the	the	DET
eurjchem-2553	36	9	primary	primary	ADJ
eurjchem-2553	36	10	immunization	immunization	NOUN
eurjchem-2553	36	11	,	,	PUNCT
eurjchem-2553	36	12	and	and	CCONJ
eurjchem-2553	36	13	the	the	DET
eurjchem-2553	36	14	third	third	ADJ
eurjchem-2553	36	15	booster	booster	NOUN
eurjchem-2553	36	16	dose	dose	NOUN
eurjchem-2553	36	17	was	be	AUX
eurjchem-2553	36	18	considered	consider	VERB
eurjchem-2553	36	19	a	a	DET
eurjchem-2553	36	20	secondary	secondary	ADJ
eurjchem-2553	36	21	immunization	immunization	NOUN
eurjchem-2553	37	1	[	[	X
eurjchem-2553	37	2	5	5	NUM
eurjchem-2553	37	3	]	]	PUNCT
eurjchem-2553	37	4	.	.	PUNCT
eurjchem-2553	38	1	abstract	abstract	ADJ
eurjchem-2553	38	2	research	research	NOUN
eurjchem-2553	38	3	article	article	NOUN
eurjchem-2553	38	4	keywords	keyword	VERB
eurjchem-2553	38	5	https://dx.doi.org/10.5155/eurjchem.15.3.274-281.2553	https://dx.doi.org/10.5155/eurjchem.15.3.274-281.2553	PROPN
eurjchem-2553	38	6	https://www.eurjchem.com/	https://www.eurjchem.com/	PROPN
eurjchem-2553	38	7	https://dx.doi.org/10.5155/eurjchem.15.3.274-281.2553	https://dx.doi.org/10.5155/eurjchem.15.3.274-281.2553	PROPN
eurjchem-2553	38	8	mailto:drnaveenaj@gmail.com	mailto:drnaveenaj@gmail.com	PROPN
eurjchem-2553	38	9	http://www.eurjchem.com/	http://www.eurjchem.com/	PROPN
eurjchem-2553	38	10	https://ourworldindata.org/	https://ourworldindata.org/	PROPN
eurjchem-2553	38	11	https://crossmark.crossref.org/dialog/?doi=10.5155/eurjchem.15.3.274-281.2553&domain=pdf&date_stamp=2024-09-30	https://crossmark.crossref.org/dialog/?doi=10.5155/eurjchem.15.3.274-281.2553&domain=pdf&date_stamp=2024-09-30	PROPN
eurjchem-2553	38	12	jagadeesan	jagadeesan	PROPN
eurjchem-2553	38	13	et	et	PROPN
eurjchem-2553	38	14	al	al	PROPN
eurjchem-2553	38	15	.	.	PUNCT
eurjchem-2553	38	16	/	/	SYM
eurjchem-2553	38	17	european	european	PROPN
eurjchem-2553	38	18	journal	journal	PROPN
eurjchem-2553	38	19	of	of	ADP
eurjchem-2553	38	20	chemistry	chemistry	NOUN
eurjchem-2553	38	21	15	15	NUM
eurjchem-2553	38	22	(	(	PUNCT
eurjchem-2553	38	23	3	3	NUM
eurjchem-2553	38	24	)	)	PUNCT
eurjchem-2553	38	25	(	(	PUNCT
eurjchem-2553	38	26	2024	2024	NUM
eurjchem-2553	38	27	)	)	PUNCT
eurjchem-2553	38	28	274	274	NUM
eurjchem-2553	38	29	-	-	SYM
eurjchem-2553	38	30	281	281	NUM
eurjchem-2553	38	31	275	275	NUM
eurjchem-2553	38	32	2024	2024	NUM
eurjchem-2553	38	33	–	–	PUNCT
eurjchem-2553	38	34	european	european	ADJ
eurjchem-2553	38	35	journal	journal	NOUN
eurjchem-2553	38	36	of	of	ADP
eurjchem-2553	38	37	chemistry	chemistry	NOUN
eurjchem-2553	38	38	–	–	PUNCT
eurjchem-2553	38	39	cc	cc	NOUN
eurjchem-2553	38	40	by	by	ADP
eurjchem-2553	38	41	nc	nc	PROPN
eurjchem-2553	38	42	–	–	PUNCT
eurjchem-2553	38	43	doi	doi	PROPN
eurjchem-2553	38	44	:	:	PUNCT
eurjchem-2553	38	45	10.5155	10.5155	NUM
eurjchem-2553	38	46	/	/	SYM
eurjchem-2553	38	47	eurjchem.15.3.274	eurjchem.15.3.274	ADV
eurjchem-2553	38	48	-	-	SYM
eurjchem-2553	38	49	281.2553	281.2553	NUM
eurjchem-2553	38	50	figure	figure	NOUN
eurjchem-2553	38	51	1	1	NUM
eurjchem-2553	38	52	.	.	PUNCT
eurjchem-2553	39	1	covid-19	covid-19	PROPN
eurjchem-2553	39	2	vaccine	vaccine	NOUN
eurjchem-2553	39	3	doses	dose	NOUN
eurjchem-2553	39	4	administrated	administrate	VERB
eurjchem-2553	39	5	in	in	ADP
eurjchem-2553	39	6	men	man	NOUN
eurjchem-2553	39	7	and	and	CCONJ
eurjchem-2553	39	8	women	woman	NOUN
eurjchem-2553	39	9	,	,	PUNCT
eurjchem-2553	39	10	all	all	DET
eurjchem-2553	39	11	ages	age	NOUN
eurjchem-2553	39	12	worldwide	worldwide	ADV
eurjchem-2553	40	1	[	[	X
eurjchem-2553	40	2	2	2	NUM
eurjchem-2553	40	3	]	]	PUNCT
eurjchem-2553	40	4	.	.	PUNCT
eurjchem-2553	41	1	figure	figure	NOUN
eurjchem-2553	41	2	2	2	NUM
eurjchem-2553	41	3	.	.	NOUN
eurjchem-2553	41	4	number	number	NOUN
eurjchem-2553	41	5	of	of	ADP
eurjchem-2553	41	6	anti	anti	ADJ
eurjchem-2553	41	7	-	-	ADJ
eurjchem-2553	41	8	covid-19	covid-19	ADJ
eurjchem-2553	41	9	vaccine	vaccine	NOUN
eurjchem-2553	41	10	(	(	PUNCT
eurjchem-2553	41	11	covishieldtm	covishieldtm	NOUN
eurjchem-2553	41	12	)	)	PUNCT
eurjchem-2553	41	13	doses	dose	NOUN
eurjchem-2553	41	14	administered	administer	VERB
eurjchem-2553	41	15	in	in	ADP
eurjchem-2553	41	16	men	man	NOUN
eurjchem-2553	41	17	and	and	CCONJ
eurjchem-2553	41	18	women	woman	NOUN
eurjchem-2553	41	19	all	all	DET
eurjchem-2553	41	20	ages	age	NOUN
eurjchem-2553	41	21	in	in	ADP
eurjchem-2553	41	22	india	india	PROPN
eurjchem-2553	41	23	.	.	PUNCT
eurjchem-2553	42	1	(	(	PUNCT
eurjchem-2553	42	2	data	datum	NOUN
eurjchem-2553	42	3	retrieved	retrieve	VERB
eurjchem-2553	42	4	from	from	ADP
eurjchem-2553	42	5	https://www.statista.com/statistics/1248301/india-covid-19-vaccines-administered-by-vaccine-type/	https://www.statista.com/statistics/1248301/india-covid-19-vaccines-administered-by-vaccine-type/	NOUN
eurjchem-2553	42	6	)	)	PUNCT
eurjchem-2553	43	1	[	[	X
eurjchem-2553	43	2	12	12	NUM
eurjchem-2553	43	3	]	]	PUNCT
eurjchem-2553	43	4	.	.	PUNCT
eurjchem-2553	44	1	the	the	DET
eurjchem-2553	44	2	us	us	PROPN
eurjchem-2553	44	3	food	food	NOUN
eurjchem-2553	44	4	and	and	CCONJ
eurjchem-2553	44	5	drug	drug	PROPN
eurjchem-2553	44	6	administration	administration	NOUN
eurjchem-2553	44	7	authorized	authorize	VERB
eurjchem-2553	44	8	the	the	DET
eurjchem-2553	44	9	use	use	NOUN
eurjchem-2553	44	10	of	of	ADP
eurjchem-2553	44	11	a	a	DET
eurjchem-2553	44	12	third	third	ADJ
eurjchem-2553	44	13	booster	booster	NOUN
eurjchem-2553	44	14	dose	dose	VERB
eurjchem-2553	44	15	for	for	ADP
eurjchem-2553	44	16	all	all	DET
eurjchem-2553	44	17	individuals	individual	NOUN
eurjchem-2553	44	18	after	after	ADP
eurjchem-2553	44	19	the	the	DET
eurjchem-2553	44	20	completion	completion	NOUN
eurjchem-2553	44	21	of	of	ADP
eurjchem-2553	44	22	primary	primary	ADJ
eurjchem-2553	44	23	vaccination	vaccination	NOUN
eurjchem-2553	44	24	with	with	ADP
eurjchem-2553	44	25	approved	approve	VERB
eurjchem-2553	44	26	covid-19	covid-19	PROPN
eurjchem-2553	44	27	vaccines	vaccine	NOUN
eurjchem-2553	44	28	to	to	PART
eurjchem-2553	44	29	protect	protect	VERB
eurjchem-2553	44	30	against	against	ADP
eurjchem-2553	44	31	the	the	DET
eurjchem-2553	44	32	ongoing	ongoing	ADJ
eurjchem-2553	44	33	resurgence	resurgence	NOUN
eurjchem-2553	44	34	of	of	ADP
eurjchem-2553	44	35	the	the	DET
eurjchem-2553	44	36	covid-19	covid-19	PROPN
eurjchem-2553	44	37	outbreak	outbreak	NOUN
eurjchem-2553	45	1	[	[	X
eurjchem-2553	45	2	6	6	NUM
eurjchem-2553	45	3	]	]	PUNCT
eurjchem-2553	45	4	.	.	PUNCT
eurjchem-2553	46	1	because	because	SCONJ
eurjchem-2553	46	2	early	early	ADJ
eurjchem-2553	46	3	research	research	NOUN
eurjchem-2553	46	4	indicates	indicate	VERB
eurjchem-2553	46	5	that	that	SCONJ
eurjchem-2553	46	6	three	three	NUM
eurjchem-2553	46	7	doses	dose	NOUN
eurjchem-2553	46	8	of	of	ADP
eurjchem-2553	46	9	the	the	DET
eurjchem-2553	46	10	pfizer	pfizer	NOUN
eurjchem-2553	46	11	biotech	biotech	ADJ
eurjchem-2553	46	12	mrna	mrna	PROPN
eurjchem-2553	46	13	vaccine	vaccine	NOUN
eurjchem-2553	46	14	can	can	AUX
eurjchem-2553	46	15	neutralize	neutralize	VERB
eurjchem-2553	46	16	the	the	DET
eurjchem-2553	46	17	omicron	omicron	PROPN
eurjchem-2553	46	18	variant	variant	NOUN
eurjchem-2553	46	19	of	of	ADP
eurjchem-2553	46	20	the	the	DET
eurjchem-2553	46	21	virus	virus	NOUN
eurjchem-2553	46	22	with	with	ADP
eurjchem-2553	46	23	a	a	DET
eurjchem-2553	46	24	roughly	roughly	ADV
eurjchem-2553	46	25	40	40	NUM
eurjchem-2553	46	26	-	-	ADJ
eurjchem-2553	46	27	fold	fold	ADJ
eurjchem-2553	46	28	decrease	decrease	NOUN
eurjchem-2553	46	29	in	in	ADP
eurjchem-2553	46	30	viral	viral	ADJ
eurjchem-2553	46	31	titres	titre	NOUN
eurjchem-2553	46	32	[	[	X
eurjchem-2553	46	33	7	7	NUM
eurjchem-2553	46	34	]	]	PUNCT
eurjchem-2553	46	35	.	.	PUNCT
eurjchem-2553	47	1	for	for	ADP
eurjchem-2553	47	2	several	several	ADJ
eurjchem-2553	47	3	reasons	reason	NOUN
eurjchem-2553	47	4	,	,	PUNCT
eurjchem-2553	47	5	serological	serological	ADJ
eurjchem-2553	47	6	techniques	technique	NOUN
eurjchem-2553	47	7	for	for	ADP
eurjchem-2553	47	8	detecting	detect	VERB
eurjchem-2553	47	9	sars	sar	NOUN
eurjchem-2553	47	10	-	-	PUNCT
eurjchem-2553	47	11	cov2	cov2	PROPN
eurjchem-2553	47	12	antibodies	antibody	NOUN
eurjchem-2553	47	13	are	be	AUX
eurjchem-2553	47	14	important	important	ADJ
eurjchem-2553	47	15	[	[	X
eurjchem-2553	47	16	8	8	NUM
eurjchem-2553	47	17	]	]	PUNCT
eurjchem-2553	47	18	.	.	PUNCT
eurjchem-2553	48	1	serological	serological	ADJ
eurjchem-2553	48	2	assays	assay	NOUN
eurjchem-2553	48	3	help	help	VERB
eurjchem-2553	48	4	to	to	PART
eurjchem-2553	48	5	better	well	ADV
eurjchem-2553	48	6	understand	understand	VERB
eurjchem-2553	48	7	the	the	DET
eurjchem-2553	48	8	host	host	NOUN
eurjchem-2553	48	9	immune	immune	ADJ
eurjchem-2553	48	10	response	response	NOUN
eurjchem-2553	48	11	triggered	trigger	VERB
eurjchem-2553	48	12	by	by	ADP
eurjchem-2553	48	13	viruses	virus	NOUN
eurjchem-2553	48	14	[	[	X
eurjchem-2553	48	15	9	9	NUM
eurjchem-2553	48	16	]	]	PUNCT
eurjchem-2553	48	17	.	.	PUNCT
eurjchem-2553	49	1	additionally	additionally	ADV
eurjchem-2553	49	2	,	,	PUNCT
eurjchem-2553	49	3	it	it	PRON
eurjchem-2553	49	4	is	be	AUX
eurjchem-2553	49	5	crucial	crucial	ADJ
eurjchem-2553	49	6	to	to	PART
eurjchem-2553	49	7	evaluate	evaluate	VERB
eurjchem-2553	49	8	innovative	innovative	ADJ
eurjchem-2553	49	9	vaccines	vaccine	NOUN
eurjchem-2553	49	10	by	by	ADP
eurjchem-2553	49	11	identifying	identify	VERB
eurjchem-2553	49	12	the	the	DET
eurjchem-2553	49	13	quantities	quantity	NOUN
eurjchem-2553	49	14	and	and	CCONJ
eurjchem-2553	49	15	variety	variety	NOUN
eurjchem-2553	49	16	of	of	ADP
eurjchem-2553	49	17	immunoglobulins	immunoglobulin	NOUN
eurjchem-2553	49	18	that	that	PRON
eurjchem-2553	49	19	are	be	AUX
eurjchem-2553	49	20	created	create	VERB
eurjchem-2553	49	21	in	in	ADP
eurjchem-2553	49	22	response	response	NOUN
eurjchem-2553	49	23	to	to	ADP
eurjchem-2553	49	24	various	various	ADJ
eurjchem-2553	49	25	vaccines	vaccine	NOUN
eurjchem-2553	49	26	,	,	PUNCT
eurjchem-2553	49	27	in	in	ADP
eurjchem-2553	49	28	a	a	DET
eurjchem-2553	49	29	dosedependent	dosedependent	NOUN
eurjchem-2553	49	30	and	and	CCONJ
eurjchem-2553	49	31	time	time	NOUN
eurjchem-2553	49	32	-	-	PUNCT
eurjchem-2553	49	33	dependent	dependent	ADJ
eurjchem-2553	49	34	manner	manner	NOUN
eurjchem-2553	49	35	.	.	PUNCT
eurjchem-2553	50	1	due	due	ADP
eurjchem-2553	50	2	to	to	ADP
eurjchem-2553	50	3	decreased	decrease	VERB
eurjchem-2553	50	4	immunity	immunity	NOUN
eurjchem-2553	50	5	and	and	CCONJ
eurjchem-2553	50	6	a	a	DET
eurjchem-2553	50	7	significant	significant	ADJ
eurjchem-2553	50	8	increase	increase	NOUN
eurjchem-2553	50	9	in	in	ADP
eurjchem-2553	50	10	breakthrough	breakthrough	NOUN
eurjchem-2553	50	11	infections	infection	NOUN
eurjchem-2553	50	12	caused	cause	VERB
eurjchem-2553	50	13	by	by	ADP
eurjchem-2553	50	14	viral	viral	ADJ
eurjchem-2553	50	15	diversity	diversity	NOUN
eurjchem-2553	50	16	,	,	PUNCT
eurjchem-2553	50	17	one	one	NUM
eurjchem-2553	50	18	more	more	ADJ
eurjchem-2553	50	19	booster	booster	NOUN
eurjchem-2553	50	20	vaccination	vaccination	NOUN
eurjchem-2553	50	21	dose	dose	NOUN
eurjchem-2553	50	22	is	be	AUX
eurjchem-2553	50	23	recommended	recommend	VERB
eurjchem-2553	50	24	,	,	PUNCT
eurjchem-2553	50	25	according	accord	VERB
eurjchem-2553	50	26	to	to	ADP
eurjchem-2553	50	27	our	our	PRON
eurjchem-2553	50	28	previous	previous	ADJ
eurjchem-2553	50	29	study	study	NOUN
eurjchem-2553	50	30	on	on	ADP
eurjchem-2553	50	31	neutralizing	neutralize	VERB
eurjchem-2553	50	32	antibodies	antibody	NOUN
eurjchem-2553	50	33	[	[	X
eurjchem-2553	50	34	10	10	NUM
eurjchem-2553	50	35	]	]	PUNCT
eurjchem-2553	50	36	.	.	PUNCT
eurjchem-2553	51	1	data	datum	NOUN
eurjchem-2553	51	2	from	from	ADP
eurjchem-2553	51	3	the	the	DET
eurjchem-2553	51	4	centers	center	NOUN
eurjchem-2553	51	5	for	for	ADP
eurjchem-2553	51	6	disease	disease	NOUN
eurjchem-2553	51	7	control	control	NOUN
eurjchem-2553	51	8	and	and	CCONJ
eurjchem-2553	51	9	prevention	prevention	NOUN
eurjchem-2553	51	10	suggest	suggest	VERB
eurjchem-2553	51	11	that	that	SCONJ
eurjchem-2553	51	12	individuals	individual	NOUN
eurjchem-2553	51	13	who	who	PRON
eurjchem-2553	51	14	have	have	AUX
eurjchem-2553	51	15	not	not	PART
eurjchem-2553	51	16	received	receive	VERB
eurjchem-2553	51	17	the	the	DET
eurjchem-2553	51	18	covid-19	covid-19	PROPN
eurjchem-2553	51	19	vaccine	vaccine	NOUN
eurjchem-2553	51	20	have	have	VERB
eurjchem-2553	51	21	a	a	DET
eurjchem-2553	51	22	higher	high	ADJ
eurjchem-2553	51	23	risk	risk	NOUN
eurjchem-2553	51	24	of	of	ADP
eurjchem-2553	51	25	testing	test	VERB
eurjchem-2553	51	26	positive	positive	ADJ
eurjchem-2553	51	27	for	for	ADP
eurjchem-2553	51	28	the	the	DET
eurjchem-2553	51	29	virus	virus	NOUN
eurjchem-2553	51	30	.	.	PUNCT
eurjchem-2553	52	1	therefore	therefore	ADV
eurjchem-2553	52	2	,	,	PUNCT
eurjchem-2553	52	3	it	it	PRON
eurjchem-2553	52	4	is	be	AUX
eurjchem-2553	52	5	essential	essential	ADJ
eurjchem-2553	52	6	to	to	PART
eurjchem-2553	52	7	continuously	continuously	ADV
eurjchem-2553	52	8	assess	assess	VERB
eurjchem-2553	52	9	how	how	SCONJ
eurjchem-2553	52	10	well	well	ADV
eurjchem-2553	52	11	covid-19	covid-19	PROPN
eurjchem-2553	52	12	vaccinations	vaccination	NOUN
eurjchem-2553	52	13	protect	protect	VERB
eurjchem-2553	52	14	against	against	ADP
eurjchem-2553	52	15	increasingly	increasingly	ADV
eurjchem-2553	52	16	virulent	virulent	ADJ
eurjchem-2553	52	17	variants	variant	NOUN
eurjchem-2553	52	18	[	[	X
eurjchem-2553	52	19	11	11	NUM
eurjchem-2553	52	20	]	]	PUNCT
eurjchem-2553	52	21	.	.	PUNCT
eurjchem-2553	53	1	as	as	ADP
eurjchem-2553	53	2	of	of	ADP
eurjchem-2553	53	3	september	september	PROPN
eurjchem-2553	53	4	1	1	NUM
eurjchem-2553	53	5	,	,	PUNCT
eurjchem-2553	53	6	2022	2022	NUM
eurjchem-2553	53	7	,	,	PUNCT
eurjchem-2553	53	8	1,696.19	1,696.19	NUM
eurjchem-2553	53	9	million	million	NUM
eurjchem-2553	53	10	doses	dose	NOUN
eurjchem-2553	53	11	of	of	ADP
eurjchem-2553	53	12	the	the	DET
eurjchem-2553	53	13	covishieldtm	covishieldtm	ADJ
eurjchem-2553	53	14	vaccination	vaccination	NOUN
eurjchem-2553	53	15	had	have	AUX
eurjchem-2553	53	16	been	be	AUX
eurjchem-2553	53	17	administered	administer	VERB
eurjchem-2553	53	18	in	in	ADP
eurjchem-2553	53	19	india	india	PROPN
eurjchem-2553	53	20	.	.	PUNCT
eurjchem-2553	54	1	in	in	ADP
eurjchem-2553	54	2	particular	particular	ADJ
eurjchem-2553	54	3	,	,	PUNCT
eurjchem-2553	54	4	compared	compare	VERB
eurjchem-2553	54	5	to	to	ADP
eurjchem-2553	54	6	covaxin	covaxin	NOUN
eurjchem-2553	54	7	(	(	PUNCT
eurjchem-2553	54	8	351.73	351.73	NUM
eurjchem-2553	54	9	million	million	NUM
eurjchem-2553	54	10	)	)	PUNCT
eurjchem-2553	54	11	and	and	CCONJ
eurjchem-2553	54	12	corbevax	corbevax	VERB
eurjchem-2553	54	13	(	(	PUNCT
eurjchem-2553	54	14	70.69	70.69	NUM
eurjchem-2553	54	15	million	million	NUM
eurjchem-2553	54	16	)	)	PUNCT
eurjchem-2553	54	17	vaccine	vaccine	NOUN
eurjchem-2553	54	18	doses	dose	NOUN
eurjchem-2553	54	19	,	,	PUNCT
eurjchem-2553	54	20	it	it	PRON
eurjchem-2553	54	21	is	be	AUX
eurjchem-2553	54	22	the	the	DET
eurjchem-2553	54	23	type	type	NOUN
eurjchem-2553	54	24	of	of	ADP
eurjchem-2553	54	25	vaccination	vaccination	NOUN
eurjchem-2553	54	26	that	that	PRON
eurjchem-2553	54	27	has	have	AUX
eurjchem-2553	54	28	been	be	AUX
eurjchem-2553	54	29	administered	administer	VERB
eurjchem-2553	54	30	the	the	DET
eurjchem-2553	54	31	most	most	ADV
eurjchem-2553	54	32	frequently	frequently	ADV
eurjchem-2553	54	33	(	(	PUNCT
eurjchem-2553	54	34	figure	figure	NOUN
eurjchem-2553	54	35	2	2	NUM
eurjchem-2553	54	36	)	)	PUNCT
eurjchem-2553	55	1	[	[	X
eurjchem-2553	55	2	12	12	NUM
eurjchem-2553	55	3	]	]	PUNCT
eurjchem-2553	55	4	.	.	PUNCT
eurjchem-2553	56	1	in	in	ADP
eurjchem-2553	56	2	light	light	NOUN
eurjchem-2553	56	3	of	of	ADP
eurjchem-2553	56	4	this	this	PRON
eurjchem-2553	56	5	,	,	PUNCT
eurjchem-2553	56	6	the	the	DET
eurjchem-2553	56	7	focus	focus	NOUN
eurjchem-2553	56	8	of	of	ADP
eurjchem-2553	56	9	research	research	NOUN
eurjchem-2553	56	10	has	have	AUX
eurjchem-2553	56	11	been	be	AUX
eurjchem-2553	56	12	on	on	ADP
eurjchem-2553	56	13	the	the	DET
eurjchem-2553	56	14	mechanism	mechanism	NOUN
eurjchem-2553	56	15	by	by	ADP
eurjchem-2553	56	16	which	which	PRON
eurjchem-2553	56	17	a	a	DET
eurjchem-2553	56	18	vector	vector	NOUN
eurjchem-2553	56	19	-	-	PUNCT
eurjchem-2553	56	20	encoded	encode	VERB
eurjchem-2553	56	21	recombinant	recombinant	ADJ
eurjchem-2553	56	22	antisars	antisar	NOUN
eurjchem-2553	56	23	-	-	PUNCT
eurjchem-2553	56	24	cov-2	cov-2	PART
eurjchem-2553	56	25	vaccine	vaccine	NOUN
eurjchem-2553	56	26	,	,	PUNCT
eurjchem-2553	56	27	covishieldtm	covishieldtm	VERB
eurjchem-2553	56	28	,	,	PUNCT
eurjchem-2553	56	29	induces	induce	VERB
eurjchem-2553	56	30	a	a	DET
eurjchem-2553	56	31	strong	strong	ADJ
eurjchem-2553	56	32	specific	specific	ADJ
eurjchem-2553	56	33	igg	igg	NOUN
eurjchem-2553	56	34	antibody	antibody	NOUN
eurjchem-2553	56	35	response	response	NOUN
eurjchem-2553	56	36	.	.	PUNCT
eurjchem-2553	57	1	we	we	PRON
eurjchem-2553	57	2	conducted	conduct	VERB
eurjchem-2553	57	3	a	a	DET
eurjchem-2553	57	4	prospective	prospective	ADJ
eurjchem-2553	57	5	cohort	cohort	NOUN
eurjchem-2553	57	6	study	study	NOUN
eurjchem-2553	57	7	to	to	PART
eurjchem-2553	57	8	longitudinally	longitudinally	ADV
eurjchem-2553	57	9	assess	assess	VERB
eurjchem-2553	57	10	the	the	DET
eurjchem-2553	57	11	dynamic	dynamic	ADJ
eurjchem-2553	57	12	response	response	NOUN
eurjchem-2553	57	13	of	of	ADP
eurjchem-2553	57	14	antisars	antisar	NOUN
eurjchem-2553	57	15	-	-	PUNCT
eurjchem-2553	57	16	cov-2	cov-2	NOUN
eurjchem-2553	57	17	igg	igg	PROPN
eurjchem-2553	57	18	antibodies	antibodie	VERB
eurjchem-2553	57	19	in	in	ADP
eurjchem-2553	57	20	order	order	NOUN
eurjchem-2553	57	21	to	to	PART
eurjchem-2553	57	22	gain	gain	VERB
eurjchem-2553	57	23	more	more	ADJ
eurjchem-2553	57	24	knowledge	knowledge	NOUN
eurjchem-2553	57	25	about	about	ADP
eurjchem-2553	57	26	igg	igg	PROPN
eurjchem-2553	57	27	in	in	ADP
eurjchem-2553	57	28	vaccine	vaccine	NOUN
eurjchem-2553	57	29	-	-	PUNCT
eurjchem-2553	57	30	elicited	elicit	VERB
eurjchem-2553	57	31	immunity	immunity	NOUN
eurjchem-2553	57	32	,	,	PUNCT
eurjchem-2553	57	33	particularly	particularly	ADV
eurjchem-2553	57	34	over	over	ADP
eurjchem-2553	57	35	longer	long	ADJ
eurjchem-2553	57	36	periods	period	NOUN
eurjchem-2553	57	37	of	of	ADP
eurjchem-2553	57	38	time	time	NOUN
eurjchem-2553	57	39	after	after	ADP
eurjchem-2553	57	40	three	three	NUM
eurjchem-2553	57	41	doses	dose	NOUN
eurjchem-2553	57	42	of	of	ADP
eurjchem-2553	57	43	immunization	immunization	NOUN
eurjchem-2553	57	44	.	.	PUNCT
eurjchem-2553	58	1	2	2	X
eurjchem-2553	58	2	.	.	X
eurjchem-2553	58	3	methods	method	NOUN
eurjchem-2553	58	4	2.1	2.1	NUM
eurjchem-2553	58	5	.	.	PUNCT
eurjchem-2553	59	1	study	study	NOUN
eurjchem-2553	59	2	population	population	NOUN
eurjchem-2553	59	3	and	and	CCONJ
eurjchem-2553	59	4	characteristics	characteristic	NOUN
eurjchem-2553	59	5	a	a	DET
eurjchem-2553	59	6	total	total	NOUN
eurjchem-2553	59	7	of	of	ADP
eurjchem-2553	59	8	371	371	NUM
eurjchem-2553	59	9	healthcare	healthcare	NOUN
eurjchem-2553	59	10	workers(hcw	workers(hcw	PROPN
eurjchem-2553	59	11	)	)	PUNCT
eurjchem-2553	60	1	,	,	PUNCT
eurjchem-2553	60	2	working	work	VERB
eurjchem-2553	60	3	at	at	ADP
eurjchem-2553	60	4	the	the	DET
eurjchem-2553	60	5	sri	sri	PROPN
eurjchem-2553	60	6	jayadeva	jayadeva	PROPN
eurjchem-2553	60	7	institute	institute	PROPN
eurjchem-2553	60	8	of	of	ADP
eurjchem-2553	60	9	cardiovascular	cardiovascular	ADJ
eurjchem-2553	60	10	sciences	science	NOUN
eurjchem-2553	60	11	and	and	CCONJ
eurjchem-2553	60	12	research	research	NOUN
eurjchem-2553	60	13	,	,	PUNCT
eurjchem-2553	60	14	including	include	VERB
eurjchem-2553	60	15	doctors	doctor	NOUN
eurjchem-2553	60	16	,	,	PUNCT
eurjchem-2553	60	17	nurses	nurse	NOUN
eurjchem-2553	60	18	,	,	PUNCT
eurjchem-2553	60	19	paramedics	paramedic	NOUN
eurjchem-2553	60	20	,	,	PUNCT
eurjchem-2553	60	21	technologists	technologist	NOUN
eurjchem-2553	60	22	,	,	PUNCT
eurjchem-2553	60	23	female	female	ADJ
eurjchem-2553	60	24	community	community	NOUN
eurjchem-2553	60	25	health	health	NOUN
eurjchem-2553	60	26	volunteers	volunteer	NOUN
eurjchem-2553	60	27	,	,	PUNCT
eurjchem-2553	60	28	and	and	CCONJ
eurjchem-2553	60	29	sanitation	sanitation	NOUN
eurjchem-2553	60	30	workers	worker	NOUN
eurjchem-2553	60	31	and	and	CCONJ
eurjchem-2553	60	32	office	office	NOUN
eurjchem-2553	60	33	assistants	assistant	NOUN
eurjchem-2553	60	34	,	,	PUNCT
eurjchem-2553	60	35	had	have	AUX
eurjchem-2553	60	36	received	receive	VERB
eurjchem-2553	60	37	the	the	DET
eurjchem-2553	60	38	first	first	ADJ
eurjchem-2553	60	39	,	,	PUNCT
eurjchem-2553	60	40	second	second	ADJ
eurjchem-2553	60	41	,	,	PUNCT
eurjchem-2553	60	42	and	and	CCONJ
eurjchem-2553	60	43	third	third	ADJ
eurjchem-2553	60	44	doses	dose	NOUN
eurjchem-2553	60	45	of	of	ADP
eurjchem-2553	60	46	the	the	DET
eurjchem-2553	60	47	covishieldtm	covishieldtm	ADJ
eurjchem-2553	60	48	vaccine	vaccine	NOUN
eurjchem-2553	60	49	.	.	PUNCT
eurjchem-2553	61	1	blood	blood	NOUN
eurjchem-2553	61	2	samples	sample	NOUN
eurjchem-2553	61	3	were	be	AUX
eurjchem-2553	61	4	taken	take	VERB
eurjchem-2553	61	5	from	from	ADP
eurjchem-2553	61	6	371	371	NUM
eurjchem-2553	61	7	healthy	healthy	ADJ
eurjchem-2553	61	8	adults	adult	NOUN
eurjchem-2553	61	9	twelve	twelve	NUM
eurjchem-2553	61	10	months	month	NOUN
eurjchem-2553	61	11	after	after	ADP
eurjchem-2553	61	12	the	the	DET
eurjchem-2553	61	13	third	third	ADJ
eurjchem-2553	61	14	dose	dose	NOUN
eurjchem-2553	61	15	of	of	ADP
eurjchem-2553	61	16	immunization	immunization	NOUN
eurjchem-2553	61	17	(	(	PUNCT
eurjchem-2553	61	18	table	table	NOUN
eurjchem-2553	61	19	1	1	NUM
eurjchem-2553	61	20	)	)	PUNCT
eurjchem-2553	61	21	.	.	PUNCT
eurjchem-2553	62	1	samples	sample	NOUN
eurjchem-2553	62	2	were	be	AUX
eurjchem-2553	62	3	examined	examine	VERB
eurjchem-2553	62	4	for	for	ADP
eurjchem-2553	62	5	sars	sar	NOUN
eurjchem-2553	62	6	-	-	PUNCT
eurjchem-2553	62	7	cov2	cov2	PROPN
eurjchem-2553	62	8	specific	specific	ADJ
eurjchem-2553	62	9	neutralization	neutralization	NOUN
eurjchem-2553	62	10	antibody	antibody	NOUN
eurjchem-2553	62	11	(	(	PUNCT
eurjchem-2553	62	12	nab	nab	NOUN
eurjchem-2553	62	13	)	)	PUNCT
eurjchem-2553	62	14	responses	response	NOUN
eurjchem-2553	62	15	using	use	VERB
eurjchem-2553	62	16	the	the	DET
eurjchem-2553	62	17	enzyme	enzyme	NOUN
eurjchem-2553	62	18	-	-	PUNCT
eurjchem-2553	62	19	linked	link	VERB
eurjchem-2553	62	20	immunoassay	immunoassay	NOUN
eurjchem-2553	62	21	(	(	PUNCT
eurjchem-2553	62	22	elisa	elisa	NOUN
eurjchem-2553	62	23	)	)	PUNCT
eurjchem-2553	62	24	.	.	PUNCT
eurjchem-2553	63	1	after	after	ADP
eurjchem-2553	63	2	immunization	immunization	NOUN
eurjchem-2553	63	3	,	,	PUNCT
eurjchem-2553	63	4	sequential	sequential	ADJ
eurjchem-2553	63	5	blood	blood	NOUN
eurjchem-2553	63	6	samples	sample	NOUN
eurjchem-2553	63	7	were	be	AUX
eurjchem-2553	63	8	taken	take	VERB
eurjchem-2553	63	9	from	from	ADP
eurjchem-2553	63	10	each	each	DET
eurjchem-2553	63	11	individual	individual	NOUN
eurjchem-2553	63	12	to	to	PART
eurjchem-2553	63	13	track	track	VERB
eurjchem-2553	63	14	and	and	CCONJ
eurjchem-2553	63	15	analyze	analyze	VERB
eurjchem-2553	63	16	variability	variability	NOUN
eurjchem-2553	63	17	in	in	ADP
eurjchem-2553	63	18	virus	virus	NOUN
eurjchem-2553	63	19	-	-	PUNCT
eurjchem-2553	63	20	specific	specific	ADJ
eurjchem-2553	63	21	nab	nab	NOUN
eurjchem-2553	63	22	titers	titer	NOUN
eurjchem-2553	63	23	.	.	PUNCT
eurjchem-2553	64	1	this	this	DET
eurjchem-2553	64	2	study	study	NOUN
eurjchem-2553	64	3	was	be	AUX
eurjchem-2553	64	4	approved	approve	VERB
eurjchem-2553	64	5	by	by	ADP
eurjchem-2553	64	6	the	the	DET
eurjchem-2553	64	7	institutional	institutional	ADJ
eurjchem-2553	64	8	ethics	ethic	NOUN
eurjchem-2553	64	9	committee	committee	PROPN
eurjchem-2553	64	10	and	and	CCONJ
eurjchem-2553	64	11	adhered	adhere	VERB
eurjchem-2553	64	12	to	to	ADP
eurjchem-2553	64	13	the	the	DET
eurjchem-2553	64	14	ethical	ethical	ADJ
eurjchem-2553	64	15	guidelines	guideline	NOUN
eurjchem-2553	64	16	.	.	PUNCT
eurjchem-2553	65	1	the	the	DET
eurjchem-2553	65	2	ethical	ethical	ADJ
eurjchem-2553	65	3	study	study	NOUN
eurjchem-2553	65	4	approval	approval	NOUN
eurjchem-2553	65	5	code	code	NOUN
eurjchem-2553	65	6	was	be	AUX
eurjchem-2553	65	7	sjicr	sjicr	NOUN
eurjchem-2553	65	8	/	/	SYM
eurjchem-2553	65	9	ec/2023	ec/2023	PROPN
eurjchem-2553	65	10	-	-	PUNCT
eurjchem-2553	65	11	24/003	24/003	NUM
eurjchem-2553	65	12	.	.	PUNCT
eurjchem-2553	66	1	demographics	demographic	NOUN
eurjchem-2553	66	2	,	,	PUNCT
eurjchem-2553	66	3	history	history	NOUN
eurjchem-2553	66	4	of	of	ADP
eurjchem-2553	66	5	sars	sar	NOUN
eurjchem-2553	66	6	-	-	PUNCT
eurjchem-2553	66	7	cov-2	cov-2	NOUN
eurjchem-2553	66	8	infection	infection	NOUN
eurjchem-2553	66	9	,	,	PUNCT
eurjchem-2553	66	10	and	and	CCONJ
eurjchem-2553	66	11	vaccination	vaccination	NOUN
eurjchem-2553	66	12	details	detail	NOUN
eurjchem-2553	66	13	were	be	AUX
eurjchem-2553	66	14	noted	note	VERB
eurjchem-2553	66	15	at	at	ADP
eurjchem-2553	66	16	the	the	DET
eurjchem-2553	66	17	time	time	NOUN
eurjchem-2553	66	18	of	of	ADP
eurjchem-2553	66	19	sample	sample	NOUN
eurjchem-2553	66	20	collection	collection	NOUN
eurjchem-2553	66	21	from	from	ADP
eurjchem-2553	66	22	the	the	DET
eurjchem-2553	66	23	patient	patient	NOUN
eurjchem-2553	66	24	’s	’s	PART
eurjchem-2553	66	25	medical	medical	ADJ
eurjchem-2553	66	26	record	record	NOUN
eurjchem-2553	66	27	.	.	PUNCT
eurjchem-2553	67	1	1,696.19	1,696.19	NUM
eurjchem-2553	67	2	351.73	351.73	NUM
eurjchem-2553	67	3	70.69	70.69	NUM
eurjchem-2553	67	4	1.23	1.23	NUM
eurjchem-2553	67	5	0.02	0.02	NUM
eurjchem-2553	67	6	0	0	NUM
eurjchem-2553	67	7	200	200	NUM
eurjchem-2553	67	8	400	400	NUM
eurjchem-2553	67	9	600	600	NUM
eurjchem-2553	67	10	800	800	NUM
eurjchem-2553	67	11	1000	1000	NUM
eurjchem-2553	67	12	1200	1200	NUM
eurjchem-2553	67	13	1400	1400	NUM
eurjchem-2553	67	14	1600	1600	NUM
eurjchem-2553	67	15	1800	1800	NUM
eurjchem-2553	67	16	covishield	covishield	NOUN
eurjchem-2553	67	17	covaxin	covaxin	PROPN
eurjchem-2553	67	18	corbevax	corbevax	VERB
eurjchem-2553	67	19	sputnik	sputnik	X
eurjchem-2553	67	20	covovax	covovax	PROPN
eurjchem-2553	67	21	number	number	NOUN
eurjchem-2553	67	22	of	of	ADP
eurjchem-2553	67	23	vaccines	vaccine	NOUN
eurjchem-2553	67	24	administered	administer	VERB
eurjchem-2553	67	25	in	in	ADP
eurjchem-2553	67	26	millions	millions	NUM
eurjchem-2553	67	27	https://www.statista.com/statistics/1248301/india-covid-19-vaccines-administered-by-vaccine-type/	https://www.statista.com/statistics/1248301/india-covid-19-vaccines-administered-by-vaccine-type/	NOUN
eurjchem-2553	67	28	276	276	NUM
eurjchem-2553	67	29	jagadeesan	jagadeesan	NOUN
eurjchem-2553	67	30	et	et	PROPN
eurjchem-2553	67	31	al	al	PROPN
eurjchem-2553	67	32	.	.	PUNCT
eurjchem-2553	67	33	/	/	SYM
eurjchem-2553	67	34	european	european	PROPN
eurjchem-2553	67	35	journal	journal	PROPN
eurjchem-2553	67	36	of	of	ADP
eurjchem-2553	67	37	chemistry	chemistry	NOUN
eurjchem-2553	67	38	15	15	NUM
eurjchem-2553	67	39	(	(	PUNCT
eurjchem-2553	67	40	3	3	NUM
eurjchem-2553	67	41	)	)	PUNCT
eurjchem-2553	67	42	(	(	PUNCT
eurjchem-2553	67	43	2024	2024	NUM
eurjchem-2553	67	44	)	)	PUNCT
eurjchem-2553	67	45	274	274	NUM
eurjchem-2553	67	46	-	-	SYM
eurjchem-2553	67	47	281	281	NUM
eurjchem-2553	67	48	2024	2024	NUM
eurjchem-2553	67	49	–	–	PUNCT
eurjchem-2553	67	50	european	european	ADJ
eurjchem-2553	67	51	journal	journal	NOUN
eurjchem-2553	67	52	of	of	ADP
eurjchem-2553	67	53	chemistry	chemistry	NOUN
eurjchem-2553	67	54	–	–	PUNCT
eurjchem-2553	67	55	cc	cc	NOUN
eurjchem-2553	67	56	by	by	ADP
eurjchem-2553	67	57	nc	nc	PROPN
eurjchem-2553	67	58	–	–	PUNCT
eurjchem-2553	67	59	doi	doi	PROPN
eurjchem-2553	67	60	:	:	PUNCT
eurjchem-2553	67	61	10.5155	10.5155	NUM
eurjchem-2553	67	62	/	/	SYM
eurjchem-2553	67	63	eurjchem.15.3.274	eurjchem.15.3.274	ADJ
eurjchem-2553	67	64	-	-	SYM
eurjchem-2553	67	65	281.2553	281.2553	NUM
eurjchem-2553	67	66	table	table	NOUN
eurjchem-2553	67	67	1	1	NUM
eurjchem-2553	67	68	.	.	PUNCT
eurjchem-2553	67	69	demographic	demographic	ADJ
eurjchem-2553	67	70	characteristics	characteristic	NOUN
eurjchem-2553	67	71	of	of	ADP
eurjchem-2553	67	72	the	the	DET
eurjchem-2553	67	73	participants	participant	NOUN
eurjchem-2553	67	74	who	who	PRON
eurjchem-2553	67	75	received	receive	VERB
eurjchem-2553	67	76	the	the	DET
eurjchem-2553	67	77	first	first	ADJ
eurjchem-2553	67	78	,	,	PUNCT
eurjchem-2553	67	79	second	second	ADJ
eurjchem-2553	67	80	,	,	PUNCT
eurjchem-2553	67	81	and	and	CCONJ
eurjchem-2553	67	82	third	third	ADJ
eurjchem-2553	67	83	doses	dose	NOUN
eurjchem-2553	67	84	of	of	ADP
eurjchem-2553	67	85	the	the	DET
eurjchem-2553	67	86	covishieldtm	covishieldtm	ADJ
eurjchem-2553	67	87	vaccine	vaccine	NOUN
eurjchem-2553	67	88	(	(	PUNCT
eurjchem-2553	67	89	n	n	NOUN
eurjchem-2553	67	90	=	=	NUM
eurjchem-2553	67	91	371	371	NUM
eurjchem-2553	67	92	)	)	PUNCT
eurjchem-2553	67	93	.	.	PUNCT
eurjchem-2553	68	1	characteristics	characteristic	NOUN
eurjchem-2553	68	2	value	value	NOUN
eurjchem-2553	68	3	gender	gender	NOUN
eurjchem-2553	68	4	female	female	NOUN
eurjchem-2553	68	5	,	,	PUNCT
eurjchem-2553	68	6	n	n	ADV
eurjchem-2553	68	7	214	214	NUM
eurjchem-2553	68	8	(	(	PUNCT
eurjchem-2553	68	9	57.7	57.7	NUM
eurjchem-2553	68	10	%	%	NOUN
eurjchem-2553	68	11	)	)	PUNCT
eurjchem-2553	68	12	male	male	NOUN
eurjchem-2553	68	13	,	,	PUNCT
eurjchem-2553	68	14	n	n	PROPN
eurjchem-2553	68	15	157	157	NUM
eurjchem-2553	68	16	(	(	PUNCT
eurjchem-2553	68	17	42.3	42.3	NUM
eurjchem-2553	68	18	%	%	NOUN
eurjchem-2553	68	19	)	)	PUNCT
eurjchem-2553	68	20	previous	previous	ADJ
eurjchem-2553	68	21	positive	positive	ADJ
eurjchem-2553	68	22	sars	sar	NOUN
eurjchem-2553	68	23	-	-	PUNCT
eurjchem-2553	68	24	cov-2rt	cov-2rt	PROPN
eurjchem-2553	68	25	-	-	PUNCT
eurjchem-2553	68	26	pcr	pcr	PROPN
eurjchem-2553	68	27	,	,	PUNCT
eurjchem-2553	68	28	n	n	PRON
eurjchem-2553	68	29	161	161	NUM
eurjchem-2553	68	30	(	(	PUNCT
eurjchem-2553	68	31	43.4	43.4	NUM
eurjchem-2553	68	32	%	%	NOUN
eurjchem-2553	68	33	)	)	PUNCT
eurjchem-2553	68	34	previous	previous	ADJ
eurjchem-2553	68	35	negative	negative	ADJ
eurjchem-2553	68	36	sars	sar	NOUN
eurjchem-2553	68	37	-	-	PUNCT
eurjchem-2553	68	38	cov-2rt	cov-2rt	PROPN
eurjchem-2553	68	39	-	-	PUNCT
eurjchem-2553	68	40	pcr	pcr	PROPN
eurjchem-2553	68	41	,	,	PUNCT
eurjchem-2553	68	42	n	n	PRON
eurjchem-2553	68	43	210	210	NUM
eurjchem-2553	68	44	(	(	PUNCT
eurjchem-2553	68	45	56.6	56.6	NUM
eurjchem-2553	68	46	%	%	NOUN
eurjchem-2553	68	47	)	)	PUNCT
eurjchem-2553	68	48	age	age	NOUN
eurjchem-2553	68	49	≤	≤	NUM
eurjchem-2553	68	50	20	20	NUM
eurjchem-2553	68	51	years	year	NOUN
eurjchem-2553	68	52	2	2	NUM
eurjchem-2553	68	53	(	(	PUNCT
eurjchem-2553	68	54	0.5	0.5	NUM
eurjchem-2553	68	55	%	%	NOUN
eurjchem-2553	68	56	)	)	PUNCT
eurjchem-2553	68	57	21	21	NUM
eurjchem-2553	68	58	-	-	SYM
eurjchem-2553	68	59	30	30	NUM
eurjchem-2553	68	60	years	year	NOUN
eurjchem-2553	68	61	62	62	NUM
eurjchem-2553	68	62	(	(	PUNCT
eurjchem-2553	68	63	16.7	16.7	NUM
eurjchem-2553	68	64	%	%	NOUN
eurjchem-2553	68	65	)	)	PUNCT
eurjchem-2553	68	66	31	31	NUM
eurjchem-2553	68	67	-	-	SYM
eurjchem-2553	68	68	40	40	NUM
eurjchem-2553	68	69	years	year	NOUN
eurjchem-2553	68	70	125	125	NUM
eurjchem-2553	68	71	(	(	PUNCT
eurjchem-2553	68	72	33.7	33.7	NUM
eurjchem-2553	68	73	%	%	NOUN
eurjchem-2553	68	74	)	)	PUNCT
eurjchem-2553	68	75	41	41	NUM
eurjchem-2553	68	76	-	-	SYM
eurjchem-2553	68	77	50	50	NUM
eurjchem-2553	68	78	years	year	NOUN
eurjchem-2553	68	79	96	96	NUM
eurjchem-2553	68	80	(	(	PUNCT
eurjchem-2553	68	81	25.9	25.9	NUM
eurjchem-2553	68	82	%	%	NOUN
eurjchem-2553	68	83	)	)	PUNCT
eurjchem-2553	68	84	51	51	NUM
eurjchem-2553	68	85	-	-	SYM
eurjchem-2553	68	86	60	60	NUM
eurjchem-2553	68	87	years	year	NOUN
eurjchem-2553	68	88	73	73	NUM
eurjchem-2553	68	89	(	(	PUNCT
eurjchem-2553	68	90	19.7	19.7	NUM
eurjchem-2553	68	91	%	%	NOUN
eurjchem-2553	68	92	)	)	PUNCT
eurjchem-2553	68	93	>	>	PUNCT
eurjchem-2553	69	1	60	60	NUM
eurjchem-2553	69	2	years	year	NOUN
eurjchem-2553	69	3	13	13	NUM
eurjchem-2553	69	4	(	(	PUNCT
eurjchem-2553	69	5	3.5	3.5	NUM
eurjchem-2553	69	6	%	%	NOUN
eurjchem-2553	69	7	)	)	PUNCT
eurjchem-2553	69	8	the	the	DET
eurjchem-2553	69	9	vaccination	vaccination	NOUN
eurjchem-2553	69	10	certificate	certificate	NOUN
eurjchem-2553	69	11	issued	issue	VERB
eurjchem-2553	69	12	by	by	ADP
eurjchem-2553	69	13	the	the	DET
eurjchem-2553	69	14	ministry	ministry	PROPN
eurjchem-2553	69	15	of	of	ADP
eurjchem-2553	69	16	health	health	PROPN
eurjchem-2553	69	17	and	and	CCONJ
eurjchem-2553	69	18	family	family	NOUN
eurjchem-2553	69	19	welfare	welfare	NOUN
eurjchem-2553	69	20	of	of	ADP
eurjchem-2553	69	21	india	india	PROPN
eurjchem-2553	69	22	validated	validate	VERB
eurjchem-2553	69	23	the	the	DET
eurjchem-2553	69	24	type	type	NOUN
eurjchem-2553	69	25	and	and	CCONJ
eurjchem-2553	69	26	dose	dose	NOUN
eurjchem-2553	69	27	of	of	ADP
eurjchem-2553	69	28	vaccinations	vaccination	NOUN
eurjchem-2553	69	29	.	.	PUNCT
eurjchem-2553	70	1	for	for	ADP
eurjchem-2553	70	2	the	the	DET
eurjchem-2553	70	3	purpose	purpose	NOUN
eurjchem-2553	70	4	of	of	ADP
eurjchem-2553	70	5	the	the	DET
eurjchem-2553	70	6	analysis	analysis	NOUN
eurjchem-2553	70	7	,	,	PUNCT
eurjchem-2553	70	8	participants	participant	NOUN
eurjchem-2553	70	9	were	be	AUX
eurjchem-2553	70	10	categorized	categorize	VERB
eurjchem-2553	70	11	into	into	ADP
eurjchem-2553	70	12	three	three	NUM
eurjchem-2553	70	13	groups	group	NOUN
eurjchem-2553	70	14	.	.	PUNCT
eurjchem-2553	71	1	group	group	NOUN
eurjchem-2553	71	2	1	1	NUM
eurjchem-2553	71	3	,	,	PUNCT
eurjchem-2553	71	4	those	those	PRON
eurjchem-2553	71	5	who	who	PRON
eurjchem-2553	71	6	had	have	VERB
eurjchem-2553	71	7	a	a	DET
eurjchem-2553	71	8	history	history	NOUN
eurjchem-2553	71	9	of	of	ADP
eurjchem-2553	71	10	sars	sar	NOUN
eurjchem-2553	71	11	-	-	PUNCT
eurjchem-2553	71	12	cov-2	cov-2	PART
eurjchem-2553	71	13	infection	infection	NOUN
eurjchem-2553	71	14	and	and	CCONJ
eurjchem-2553	71	15	were	be	AUX
eurjchem-2553	71	16	vaccinated	vaccinate	VERB
eurjchem-2553	71	17	(	(	PUNCT
eurjchem-2553	71	18	n	n	NOUN
eurjchem-2553	71	19	=	=	SYM
eurjchem-2553	71	20	161	161	NUM
eurjchem-2553	71	21	)	)	PUNCT
eurjchem-2553	71	22	.	.	PUNCT
eurjchem-2553	72	1	group	group	NOUN
eurjchem-2553	72	2	2	2	NUM
eurjchem-2553	72	3	were	be	AUX
eurjchem-2553	72	4	those	those	PRON
eurjchem-2553	72	5	who	who	PRON
eurjchem-2553	72	6	had	have	VERB
eurjchem-2553	72	7	no	no	DET
eurjchem-2553	72	8	history	history	NOUN
eurjchem-2553	72	9	of	of	ADP
eurjchem-2553	72	10	sars	sar	NOUN
eurjchem-2553	72	11	-	-	PUNCT
eurjchem-2553	72	12	cov-2	cov-2	PART
eurjchem-2553	72	13	infection	infection	NOUN
eurjchem-2553	72	14	and	and	CCONJ
eurjchem-2553	72	15	received	receive	VERB
eurjchem-2553	72	16	vaccines	vaccine	NOUN
eurjchem-2553	72	17	(	(	PUNCT
eurjchem-2553	72	18	n	n	NOUN
eurjchem-2553	72	19	=	=	SYM
eurjchem-2553	72	20	210	210	NUM
eurjchem-2553	72	21	)	)	PUNCT
eurjchem-2553	72	22	.	.	PUNCT
eurjchem-2553	73	1	group	group	NOUN
eurjchem-2553	73	2	3	3	NUM
eurjchem-2553	73	3	,	,	PUNCT
eurjchem-2553	73	4	those	those	PRON
eurjchem-2553	73	5	who	who	PRON
eurjchem-2553	73	6	had	have	AUX
eurjchem-2553	73	7	received	receive	VERB
eurjchem-2553	73	8	3	3	NUM
eurjchem-2553	73	9	doses	dose	NOUN
eurjchem-2553	73	10	of	of	ADP
eurjchem-2553	73	11	the	the	DET
eurjchem-2553	73	12	covishieldtm	covishieldtm	ADJ
eurjchem-2553	73	13	vaccine	vaccine	NOUN
eurjchem-2553	73	14	at	at	ADP
eurjchem-2553	73	15	different	different	ADJ
eurjchem-2553	73	16	time	time	NOUN
eurjchem-2553	73	17	points	point	NOUN
eurjchem-2553	73	18	(	(	PUNCT
eurjchem-2553	73	19	n	n	NOUN
eurjchem-2553	73	20	=	=	SYM
eurjchem-2553	73	21	114	114	NUM
eurjchem-2553	73	22	)	)	PUNCT
eurjchem-2553	73	23	,	,	PUNCT
eurjchem-2553	73	24	also	also	ADV
eurjchem-2553	73	25	,	,	PUNCT
eurjchem-2553	73	26	the	the	DET
eurjchem-2553	73	27	primary	primary	ADJ
eurjchem-2553	73	28	objective	objective	NOUN
eurjchem-2553	73	29	of	of	ADP
eurjchem-2553	73	30	this	this	DET
eurjchem-2553	73	31	study	study	NOUN
eurjchem-2553	73	32	was	be	AUX
eurjchem-2553	73	33	to	to	PART
eurjchem-2553	73	34	systematically	systematically	ADV
eurjchem-2553	73	35	review	review	VERB
eurjchem-2553	73	36	and	and	CCONJ
eurjchem-2553	73	37	analyze	analyze	VERB
eurjchem-2553	73	38	the	the	DET
eurjchem-2553	73	39	longitudinal	longitudinal	ADJ
eurjchem-2553	73	40	cohort	cohort	NOUN
eurjchem-2553	73	41	study	study	NOUN
eurjchem-2553	73	42	,	,	PUNCT
eurjchem-2553	73	43	including	include	VERB
eurjchem-2553	73	44	the	the	DET
eurjchem-2553	73	45	measurement	measurement	NOUN
eurjchem-2553	73	46	of	of	ADP
eurjchem-2553	73	47	igg	igg	PROPN
eurjchem-2553	73	48	neutralization	neutralization	NOUN
eurjchem-2553	73	49	activity	activity	NOUN
eurjchem-2553	73	50	of	of	ADP
eurjchem-2553	73	51	the	the	DET
eurjchem-2553	73	52	same	same	ADJ
eurjchem-2553	73	53	individuals	individual	NOUN
eurjchem-2553	73	54	(	(	PUNCT
eurjchem-2553	73	55	53	53	NUM
eurjchem-2553	73	56	)	)	PUNCT
eurjchem-2553	73	57	after	after	ADP
eurjchem-2553	73	58	three	three	NUM
eurjchem-2553	73	59	doses	dose	NOUN
eurjchem-2553	73	60	of	of	ADP
eurjchem-2553	73	61	the	the	DET
eurjchem-2553	73	62	vaccine	vaccine	NOUN
eurjchem-2553	73	63	and	and	CCONJ
eurjchem-2553	73	64	also	also	ADV
eurjchem-2553	73	65	involved	involve	VERB
eurjchem-2553	73	66	in	in	ADP
eurjchem-2553	73	67	the	the	DET
eurjchem-2553	73	68	previous	previous	ADJ
eurjchem-2553	73	69	[	[	X
eurjchem-2553	73	70	10	10	NUM
eurjchem-2553	73	71	]	]	PUNCT
eurjchem-2553	73	72	and	and	CCONJ
eurjchem-2553	73	73	the	the	DET
eurjchem-2553	73	74	present	present	ADJ
eurjchem-2553	73	75	study	study	NOUN
eurjchem-2553	73	76	.	.	PUNCT
eurjchem-2553	74	1	2.2	2.2	NUM
eurjchem-2553	74	2	.	.	PUNCT
eurjchem-2553	74	3	sample	sample	NOUN
eurjchem-2553	74	4	collection	collection	NOUN
eurjchem-2553	74	5	and	and	CCONJ
eurjchem-2553	74	6	evaluation	evaluation	NOUN
eurjchem-2553	74	7	of	of	ADP
eurjchem-2553	74	8	sars	sar	NOUN
eurjchem-2553	74	9	-	-	PUNCT
eurjchem-2553	74	10	cov-2	cov-2	ADP
eurjchem-2553	74	11	specific	specific	ADJ
eurjchem-2553	74	12	neutralizing	neutralizing	ADJ
eurjchem-2553	74	13	antibodies	antibody	NOUN
eurjchem-2553	74	14	in	in	ADP
eurjchem-2553	74	15	serum	serum	NOUN
eurjchem-2553	74	16	and	and	CCONJ
eurjchem-2553	74	17	measurements	measurement	NOUN
eurjchem-2553	74	18	after	after	ADP
eurjchem-2553	74	19	completion	completion	NOUN
eurjchem-2553	74	20	of	of	ADP
eurjchem-2553	74	21	a	a	DET
eurjchem-2553	74	22	consent	consent	NOUN
eurjchem-2553	74	23	form	form	NOUN
eurjchem-2553	74	24	,	,	PUNCT
eurjchem-2553	74	25	venous	venous	ADJ
eurjchem-2553	74	26	blood	blood	NOUN
eurjchem-2553	74	27	samples	sample	NOUN
eurjchem-2553	74	28	were	be	AUX
eurjchem-2553	74	29	taken	take	VERB
eurjchem-2553	74	30	in	in	ADP
eurjchem-2553	74	31	5	5	NUM
eurjchem-2553	74	32	ml	ml	NOUN
eurjchem-2553	74	33	vacutainer	vacutainer	ADJ
eurjchem-2553	74	34	tubes	tube	NOUN
eurjchem-2553	74	35	from	from	ADP
eurjchem-2553	74	36	all	all	DET
eurjchem-2553	74	37	participants	participant	NOUN
eurjchem-2553	74	38	.	.	PUNCT
eurjchem-2553	75	1	blood	blood	NOUN
eurjchem-2553	75	2	was	be	AUX
eurjchem-2553	75	3	spun	spin	VERB
eurjchem-2553	75	4	at	at	ADP
eurjchem-2553	75	5	4000	4000	NUM
eurjchem-2553	75	6	rpm	rpm	NOUN
eurjchem-2553	75	7	for	for	ADP
eurjchem-2553	75	8	10	10	NUM
eurjchem-2553	75	9	minutes	minute	NOUN
eurjchem-2553	75	10	at	at	ADP
eurjchem-2553	75	11	room	room	NOUN
eurjchem-2553	75	12	temperature	temperature	NOUN
eurjchem-2553	75	13	to	to	PART
eurjchem-2553	75	14	collect	collect	VERB
eurjchem-2553	75	15	and	and	CCONJ
eurjchem-2553	75	16	test	test	VERB
eurjchem-2553	75	17	the	the	DET
eurjchem-2553	75	18	serum	serum	NOUN
eurjchem-2553	75	19	.	.	PUNCT
eurjchem-2553	76	1	the	the	DET
eurjchem-2553	76	2	serum	serum	NOUN
eurjchem-2553	76	3	samples	sample	NOUN
eurjchem-2553	76	4	were	be	AUX
eurjchem-2553	76	5	aliquoted	aliquote	VERB
eurjchem-2553	76	6	and	and	CCONJ
eurjchem-2553	76	7	processed	process	VERB
eurjchem-2553	76	8	.	.	PUNCT
eurjchem-2553	77	1	according	accord	VERB
eurjchem-2553	77	2	to	to	ADP
eurjchem-2553	77	3	the	the	DET
eurjchem-2553	77	4	manufacturer	manufacturer	NOUN
eurjchem-2553	77	5	's	's	PART
eurjchem-2553	77	6	instructions	instruction	NOUN
eurjchem-2553	77	7	,	,	PUNCT
eurjchem-2553	77	8	serum	serum	NOUN
eurjchem-2553	77	9	samples	sample	NOUN
eurjchem-2553	77	10	were	be	AUX
eurjchem-2553	77	11	tested	test	VERB
eurjchem-2553	77	12	for	for	ADP
eurjchem-2553	77	13	sars	sar	NOUN
eurjchem-2553	77	14	-	-	PUNCT
eurjchem-2553	77	15	cov-2specific	cov-2specific	ADJ
eurjchem-2553	77	16	nab	nab	NOUN
eurjchem-2553	77	17	using	use	VERB
eurjchem-2553	77	18	the	the	DET
eurjchem-2553	77	19	covid-19	covid-19	PROPN
eurjchem-2553	77	20	neutralizing	neutralize	VERB
eurjchem-2553	77	21	antibody	antibody	NOUN
eurjchem-2553	77	22	microlisa	microlisa	NOUN
eurjchem-2553	77	23	test	test	NOUN
eurjchem-2553	77	24	kit	kit	NOUN
eurjchem-2553	77	25	supplied	supply	VERB
eurjchem-2553	77	26	by	by	ADP
eurjchem-2553	77	27	j.	j.	PROPN
eurjchem-2553	77	28	mitra	mitra	PROPN
eurjchem-2553	77	29	&	&	CCONJ
eurjchem-2553	77	30	co.	co.	PROPN
eurjchem-2553	77	31	pvt	pvt	PROPN
eurjchem-2553	77	32	.	.	PROPN
eurjchem-2553	77	33	ltd	ltd	PROPN
eurjchem-2553	77	34	.	.	PROPN
eurjchem-2553	77	35	,	,	PUNCT
eurjchem-2553	77	36	new	new	PROPN
eurjchem-2553	77	37	delhi	delhi	PROPN
eurjchem-2553	77	38	,	,	PUNCT
eurjchem-2553	77	39	india	india	PROPN
eurjchem-2553	77	40	(	(	PUNCT
eurjchem-2553	77	41	lot	lot	NOUN
eurjchem-2553	77	42	no	no	INTJ
eurjchem-2553	77	43	.	.	PUNCT
eurjchem-2553	77	44	ecn010522	ecn010522	NOUN
eurjchem-2553	77	45	)	)	PUNCT
eurjchem-2553	78	1	[	[	X
eurjchem-2553	78	2	13	13	NUM
eurjchem-2553	78	3	]	]	PUNCT
eurjchem-2553	78	4	.	.	PUNCT
eurjchem-2553	79	1	the	the	DET
eurjchem-2553	79	2	assay	assay	PROPN
eurjchem-2553	79	3	kit	kit	NOUN
eurjchem-2553	79	4	was	be	AUX
eurjchem-2553	79	5	created	create	VERB
eurjchem-2553	79	6	to	to	PART
eurjchem-2553	79	7	identify	identify	VERB
eurjchem-2553	79	8	neutralizing	neutralize	VERB
eurjchem-2553	79	9	antibodies	antibody	NOUN
eurjchem-2553	79	10	made	make	VERB
eurjchem-2553	79	11	against	against	ADP
eurjchem-2553	79	12	sars	sar	NOUN
eurjchem-2553	79	13	-	-	PUNCT
eurjchem-2553	79	14	cov-2	cov-2	NOUN
eurjchem-2553	79	15	in	in	ADP
eurjchem-2553	79	16	human	human	ADJ
eurjchem-2553	79	17	serum	serum	NOUN
eurjchem-2553	79	18	/	/	SYM
eurjchem-2553	79	19	plasma	plasma	NOUN
eurjchem-2553	79	20	in	in	ADP
eurjchem-2553	79	21	an	an	DET
eurjchem-2553	79	22	in	in	ADP
eurjchem-2553	79	23	vitro	vitro	X
eurjchem-2553	79	24	semiquantitative	semiquantitative	ADJ
eurjchem-2553	79	25	manner	manner	NOUN
eurjchem-2553	79	26	to	to	PART
eurjchem-2553	79	27	prevent	prevent	VERB
eurjchem-2553	79	28	the	the	DET
eurjchem-2553	79	29	interaction	interaction	NOUN
eurjchem-2553	79	30	between	between	ADP
eurjchem-2553	79	31	the	the	DET
eurjchem-2553	79	32	viral	viral	ADJ
eurjchem-2553	79	33	spike	spike	ADJ
eurjchem-2553	79	34	glycoprotein	glycoprotein	NOUN
eurjchem-2553	79	35	receptor	receptor	NOUN
eurjchem-2553	79	36	binding	bind	VERB
eurjchem-2553	79	37	domain	domain	NOUN
eurjchem-2553	79	38	(	(	PUNCT
eurjchem-2553	79	39	rbd	rbd	NOUN
eurjchem-2553	79	40	)	)	PUNCT
eurjchem-2553	79	41	and	and	CCONJ
eurjchem-2553	79	42	the	the	DET
eurjchem-2553	79	43	cell	cell	NOUN
eurjchem-2553	79	44	surface	surface	NOUN
eurjchem-2553	79	45	receptor	receptor	NOUN
eurjchem-2553	79	46	angiotensin	angiotensin	NOUN
eurjchem-2553	79	47	converting	convert	VERB
eurjchem-2553	79	48	enzyme-2	enzyme-2	PROPN
eurjchem-2553	79	49	[	[	X
eurjchem-2553	79	50	14	14	NUM
eurjchem-2553	79	51	]	]	PUNCT
eurjchem-2553	79	52	.	.	PUNCT
eurjchem-2553	80	1	following	follow	VERB
eurjchem-2553	80	2	incubation	incubation	NOUN
eurjchem-2553	80	3	,	,	PUNCT
eurjchem-2553	80	4	the	the	DET
eurjchem-2553	80	5	unbound	unbound	NOUN
eurjchem-2553	80	6	hrp	hrp	PROPN
eurjchem-2553	80	7	-	-	PUNCT
eurjchem-2553	80	8	rbd	rbd	NOUN
eurjchem-2553	80	9	neutralizing	neutralize	VERB
eurjchem-2553	80	10	antibody	antibody	NOUN
eurjchem-2553	80	11	complex	complex	NOUN
eurjchem-2553	80	12	was	be	AUX
eurjchem-2553	80	13	removed	remove	VERB
eurjchem-2553	80	14	from	from	ADP
eurjchem-2553	80	15	the	the	DET
eurjchem-2553	80	16	wells	well	NOUN
eurjchem-2553	80	17	with	with	ADP
eurjchem-2553	80	18	25×	25×	NUM
eurjchem-2553	80	19	wash	wash	NOUN
eurjchem-2553	80	20	buffer	buffer	NOUN
eurjchem-2553	80	21	by	by	ADP
eurjchem-2553	80	22	five	five	NUM
eurjchem-2553	80	23	washes	wash	NOUN
eurjchem-2553	80	24	of	of	ADP
eurjchem-2553	80	25	the	the	DET
eurjchem-2553	80	26	working	work	VERB
eurjchem-2553	80	27	wash	wash	NOUN
eurjchem-2553	80	28	buffer	buffer	NOUN
eurjchem-2553	80	29	solution	solution	NOUN
eurjchem-2553	80	30	.	.	PUNCT
eurjchem-2553	81	1	using	use	VERB
eurjchem-2553	81	2	the	the	DET
eurjchem-2553	81	3	euphoria	euphoria	NOUN
eurjchem-2553	81	4	4.1	4.1	NUM
eurjchem-2553	81	5	fully	fully	ADV
eurjchem-2553	81	6	automated	automate	VERB
eurjchem-2553	81	7	elisa	elisa	NOUN
eurjchem-2553	81	8	processor	processor	NOUN
eurjchem-2553	81	9	,	,	PUNCT
eurjchem-2553	81	10	the	the	DET
eurjchem-2553	81	11	optical	optical	ADJ
eurjchem-2553	81	12	density	density	NOUN
eurjchem-2553	81	13	(	(	PUNCT
eurjchem-2553	81	14	od	od	NOUN
eurjchem-2553	81	15	)	)	PUNCT
eurjchem-2553	81	16	was	be	AUX
eurjchem-2553	81	17	measured	measure	VERB
eurjchem-2553	81	18	at	at	ADP
eurjchem-2553	81	19	a	a	DET
eurjchem-2553	81	20	wavelength	wavelength	NOUN
eurjchem-2553	81	21	of	of	ADP
eurjchem-2553	81	22	450	450	NUM
eurjchem-2553	81	23	nm	nm	NOUN
eurjchem-2553	81	24	(	(	PUNCT
eurjchem-2553	81	25	alto	alto	NOUN
eurjchem-2553	81	26	,	,	PUNCT
eurjchem-2553	81	27	santacruz	santacruz	PROPN
eurjchem-2553	81	28	bambolin	bambolin	PROPN
eurjchem-2553	81	29	complex	complex	PROPN
eurjchem-2553	81	30	,	,	PUNCT
eurjchem-2553	81	31	goa	goa	PROPN
eurjchem-2553	81	32	,	,	PUNCT
eurjchem-2553	81	33	india	india	PROPN
eurjchem-2553	81	34	)	)	PUNCT
eurjchem-2553	81	35	.	.	PUNCT
eurjchem-2553	82	1	by	by	ADP
eurjchem-2553	82	2	computing	compute	VERB
eurjchem-2553	82	3	the	the	DET
eurjchem-2553	82	4	inhibition	inhibition	NOUN
eurjchem-2553	82	5	rates	rate	NOUN
eurjchem-2553	82	6	for	for	ADP
eurjchem-2553	82	7	samples	sample	NOUN
eurjchem-2553	82	8	according	accord	VERB
eurjchem-2553	82	9	to	to	ADP
eurjchem-2553	82	10	the	the	DET
eurjchem-2553	82	11	suggested	suggest	VERB
eurjchem-2553	82	12	positive	positive	ADJ
eurjchem-2553	82	13	and	and	CCONJ
eurjchem-2553	82	14	negative	negative	ADJ
eurjchem-2553	82	15	cut	cut	NOUN
eurjchem-2553	82	16	-	-	PUNCT
eurjchem-2553	82	17	offs	off	NOUN
eurjchem-2553	82	18	,	,	PUNCT
eurjchem-2553	82	19	the	the	DET
eurjchem-2553	82	20	test	test	NOUN
eurjchem-2553	82	21	findings	finding	NOUN
eurjchem-2553	82	22	were	be	AUX
eurjchem-2553	82	23	interpreted	interpret	VERB
eurjchem-2553	82	24	as	as	ADP
eurjchem-2553	82	25	follows	follow	VERB
eurjchem-2553	82	26	.	.	PUNCT
eurjchem-2553	83	1	%	%	NOUN
eurjchem-2553	83	2	inhibition	inhibition	NOUN
eurjchem-2553	83	3	=	=	PUNCT
eurjchem-2553	83	4	(	(	PUNCT
eurjchem-2553	83	5	1	1	NUM
eurjchem-2553	83	6	–	–	PUNCT
eurjchem-2553	83	7	sample	sample	NOUN
eurjchem-2553	83	8	o.d./negative	o.d./negative	PROPN
eurjchem-2553	83	9	control	control	PROPN
eurjchem-2553	83	10	o.d	o.d	PROPN
eurjchem-2553	83	11	.	.	PROPN
eurjchem-2553	83	12	)	)	PUNCT
eurjchem-2553	84	1	×	×	NOUN
eurjchem-2553	84	2	100	100	NUM
eurjchem-2553	84	3	(	(	PUNCT
eurjchem-2553	84	4	1	1	X
eurjchem-2553	84	5	)	)	PUNCT
eurjchem-2553	84	6	neutralizing	neutralize	VERB
eurjchem-2553	84	7	antibody	antibody	NOUN
eurjchem-2553	84	8	levels	level	NOUN
eurjchem-2553	84	9	of	of	ADP
eurjchem-2553	84	10	more	more	ADJ
eurjchem-2553	84	11	than	than	ADP
eurjchem-2553	84	12	30	30	NUM
eurjchem-2553	84	13	%	%	NOUN
eurjchem-2553	84	14	were	be	AUX
eurjchem-2553	84	15	considered	consider	VERB
eurjchem-2553	84	16	positive	positive	ADJ
eurjchem-2553	84	17	,	,	PUNCT
eurjchem-2553	84	18	as	as	ADP
eurjchem-2553	84	19	per	per	ADP
eurjchem-2553	84	20	the	the	DET
eurjchem-2553	84	21	manufacturer	manufacturer	NOUN
eurjchem-2553	84	22	’s	’s	PART
eurjchem-2553	84	23	recommenddations	recommenddation	NOUN
eurjchem-2553	84	24	(	(	PUNCT
eurjchem-2553	84	25	sars	sar	NOUN
eurjchem-2553	84	26	-	-	PUNCT
eurjchem-2553	84	27	cov-2	cov-2	NOUN
eurjchem-2553	84	28	neutralizing	neutralize	VERB
eurjchem-2553	84	29	antibody	antibody	NOUN
eurjchem-2553	84	30	present	present	ADJ
eurjchem-2553	84	31	)	)	PUNCT
eurjchem-2553	84	32	.	.	PUNCT
eurjchem-2553	85	1	serum	serum	NOUN
eurjchem-2553	85	2	samples	sample	NOUN
eurjchem-2553	85	3	from	from	ADP
eurjchem-2553	85	4	non	non	ADJ
eurjchem-2553	85	5	-	-	ADJ
eurjchem-2553	85	6	immunized	immunized	ADJ
eurjchem-2553	85	7	and	and	CCONJ
eurjchem-2553	85	8	positively	positively	ADV
eurjchem-2553	85	9	identified	identify	VERB
eurjchem-2553	85	10	noninfected	noninfected	ADJ
eurjchem-2553	85	11	people	people	NOUN
eurjchem-2553	85	12	were	be	AUX
eurjchem-2553	85	13	also	also	ADV
eurjchem-2553	85	14	used	use	VERB
eurjchem-2553	85	15	to	to	PART
eurjchem-2553	85	16	validate	validate	VERB
eurjchem-2553	85	17	the	the	DET
eurjchem-2553	85	18	results	result	NOUN
eurjchem-2553	85	19	under	under	ADP
eurjchem-2553	85	20	the	the	DET
eurjchem-2553	85	21	manufacturer	manufacturer	NOUN
eurjchem-2553	85	22	’s	’s	PART
eurjchem-2553	85	23	negative	negative	ADJ
eurjchem-2553	85	24	cut	cut	VERB
eurjchem-2553	85	25	-	-	PUNCT
eurjchem-2553	85	26	off	off	ADP
eurjchem-2553	85	27	control	control	NOUN
eurjchem-2553	85	28	.	.	PUNCT
eurjchem-2553	86	1	the	the	DET
eurjchem-2553	86	2	assay	assay	PROPN
eurjchem-2553	86	3	kit	kit	NOUN
eurjchem-2553	86	4	was	be	AUX
eurjchem-2553	86	5	targeted	target	VERB
eurjchem-2553	86	6	to	to	PART
eurjchem-2553	86	7	detect	detect	VERB
eurjchem-2553	86	8	neutralizing	neutralize	VERB
eurjchem-2553	86	9	antibodies	antibody	NOUN
eurjchem-2553	86	10	generated	generate	VERB
eurjchem-2553	86	11	against	against	ADP
eurjchem-2553	86	12	sars	sar	NOUN
eurjchem-2553	86	13	-	-	PUNCT
eurjchem-2553	86	14	cov-2	cov-2	NOUN
eurjchem-2553	86	15	in	in	ADP
eurjchem-2553	86	16	human	human	ADJ
eurjchem-2553	86	17	serum	serum	NOUN
eurjchem-2553	86	18	or	or	CCONJ
eurjchem-2553	86	19	plasma	plasma	NOUN
eurjchem-2553	86	20	in	in	ADP
eurjchem-2553	86	21	an	an	DET
eurjchem-2553	86	22	in	in	ADP
eurjchem-2553	86	23	vitro	vitro	X
eurjchem-2553	86	24	semiquantitative	semiquantitative	ADJ
eurjchem-2553	86	25	manner	manner	NOUN
eurjchem-2553	86	26	,	,	PUNCT
eurjchem-2553	86	27	preventing	prevent	VERB
eurjchem-2553	86	28	the	the	DET
eurjchem-2553	86	29	interaction	interaction	NOUN
eurjchem-2553	86	30	between	between	ADP
eurjchem-2553	86	31	the	the	DET
eurjchem-2553	86	32	viral	viral	ADJ
eurjchem-2553	86	33	spike	spike	ADJ
eurjchem-2553	86	34	glycoprotein	glycoprotein	NOUN
eurjchem-2553	86	35	’s	’s	PART
eurjchem-2553	86	36	receptor	receptor	NOUN
eurjchem-2553	86	37	binding	bind	VERB
eurjchem-2553	86	38	domain	domain	NOUN
eurjchem-2553	86	39	(	(	PUNCT
eurjchem-2553	86	40	rbd	rbd	NOUN
eurjchem-2553	86	41	)	)	PUNCT
eurjchem-2553	86	42	and	and	CCONJ
eurjchem-2553	86	43	the	the	DET
eurjchem-2553	86	44	cell	cell	NOUN
eurjchem-2553	86	45	surface	surface	NOUN
eurjchem-2553	86	46	receptor	receptor	NOUN
eurjchem-2553	86	47	angiotensin	angiotensin	NOUN
eurjchem-2553	86	48	converting	convert	VERB
eurjchem-2553	86	49	enzyme-2	enzyme-2	NUM
eurjchem-2553	86	50	(	(	PUNCT
eurjchem-2553	86	51	ace2	ace2	PROPN
eurjchem-2553	86	52	)	)	PUNCT
eurjchem-2553	86	53	.	.	PUNCT
eurjchem-2553	87	1	the	the	DET
eurjchem-2553	87	2	detection	detection	NOUN
eurjchem-2553	87	3	protocols	protocol	NOUN
eurjchem-2553	87	4	and	and	CCONJ
eurjchem-2553	87	5	routines	routine	NOUN
eurjchem-2553	87	6	adhered	adhere	VERB
eurjchem-2553	87	7	to	to	ADP
eurjchem-2553	87	8	the	the	DET
eurjchem-2553	87	9	manufacturer	manufacturer	NOUN
eurjchem-2553	87	10	’s	’s	PART
eurjchem-2553	87	11	instructions	instruction	NOUN
eurjchem-2553	87	12	(	(	PUNCT
eurjchem-2553	87	13	https://jmitra.co.in/wp-content/uploads/2021/10/	https://jmitra.co.in/wp-content/uploads/2021/10/	NOUN
eurjchem-2553	87	14	instruction-manual-covid-19-neutralizing-antibodiesmicrolisa.pdf	instruction-manual-covid-19-neutralizing-antibodiesmicrolisa.pdf	PROPN
eurjchem-2553	87	15	)	)	PUNCT
eurjchem-2553	88	1	[	[	X
eurjchem-2553	88	2	15	15	NUM
eurjchem-2553	88	3	]	]	PUNCT
eurjchem-2553	88	4	.	.	PUNCT
eurjchem-2553	89	1	the	the	DET
eurjchem-2553	89	2	test	test	NOUN
eurjchem-2553	89	3	evaluation	evaluation	NOUN
eurjchem-2553	89	4	was	be	AUX
eurjchem-2553	89	5	carried	carry	VERB
eurjchem-2553	89	6	out	out	ADP
eurjchem-2553	89	7	following	follow	VERB
eurjchem-2553	89	8	the	the	DET
eurjchem-2553	89	9	recommended	recommend	VERB
eurjchem-2553	89	10	positive	positive	ADJ
eurjchem-2553	89	11	and	and	CCONJ
eurjchem-2553	89	12	negative	negative	ADJ
eurjchem-2553	89	13	cut	cut	NOUN
eurjchem-2553	89	14	-	-	PUNCT
eurjchem-2553	89	15	offs	off	NOUN
eurjchem-2553	89	16	,	,	PUNCT
eurjchem-2553	89	17	and	and	CCONJ
eurjchem-2553	89	18	the	the	DET
eurjchem-2553	89	19	test	test	NOUN
eurjchem-2553	89	20	results	result	NOUN
eurjchem-2553	89	21	were	be	AUX
eurjchem-2553	89	22	interpreted	interpret	VERB
eurjchem-2553	89	23	by	by	ADP
eurjchem-2553	89	24	calculating	calculate	VERB
eurjchem-2553	89	25	the	the	DET
eurjchem-2553	89	26	inhibition	inhibition	NOUN
eurjchem-2553	89	27	rates	rate	NOUN
eurjchem-2553	89	28	for	for	ADP
eurjchem-2553	89	29	the	the	DET
eurjchem-2553	89	30	samples	sample	NOUN
eurjchem-2553	89	31	as	as	SCONJ
eurjchem-2553	89	32	follows	follow	VERB
eurjchem-2553	89	33	:	:	PUNCT
eurjchem-2553	89	34	according	accord	VERB
eurjchem-2553	89	35	to	to	ADP
eurjchem-2553	89	36	the	the	DET
eurjchem-2553	89	37	manufacturer	manufacturer	NOUN
eurjchem-2553	89	38	’s	’s	PART
eurjchem-2553	89	39	instructions	instruction	NOUN
eurjchem-2553	89	40	,	,	PUNCT
eurjchem-2553	89	41	neutralizing	neutralize	VERB
eurjchem-2553	89	42	antibody	antibody	NOUN
eurjchem-2553	89	43	levels	level	NOUN
eurjchem-2553	89	44	higher	high	ADJ
eurjchem-2553	89	45	than	than	ADP
eurjchem-2553	89	46	>	>	SYM
eurjchem-2553	89	47	30	30	NUM
eurjchem-2553	89	48	%	%	NOUN
eurjchem-2553	89	49	were	be	AUX
eurjchem-2553	89	50	considered	consider	VERB
eurjchem-2553	89	51	as	as	ADP
eurjchem-2553	89	52	positive	positive	ADJ
eurjchem-2553	89	53	(	(	PUNCT
eurjchem-2553	89	54	sars	sar	NOUN
eurjchem-2553	89	55	-	-	PUNCT
eurjchem-2553	89	56	cov-2	cov-2	NOUN
eurjchem-2553	89	57	neutralizing	neutralize	VERB
eurjchem-2553	89	58	antibody	antibody	NOUN
eurjchem-2553	89	59	present	present	ADJ
eurjchem-2553	89	60	)	)	PUNCT
eurjchem-2553	89	61	.	.	PUNCT
eurjchem-2553	90	1	in	in	ADP
eurjchem-2553	90	2	addition	addition	NOUN
eurjchem-2553	90	3	to	to	ADP
eurjchem-2553	90	4	the	the	DET
eurjchem-2553	90	5	negative	negative	ADJ
eurjchem-2553	90	6	cutoff	cutoff	NOUN
eurjchem-2553	90	7	control	control	NOUN
eurjchem-2553	90	8	provided	provide	VERB
eurjchem-2553	90	9	by	by	ADP
eurjchem-2553	90	10	the	the	DET
eurjchem-2553	90	11	manufacturer	manufacturer	NOUN
eurjchem-2553	90	12	,	,	PUNCT
eurjchem-2553	90	13	serum	serum	NOUN
eurjchem-2553	90	14	samples	sample	NOUN
eurjchem-2553	90	15	from	from	ADP
eurjchem-2553	90	16	nonimmunized	nonimmunize	VERB
eurjchem-2553	90	17	and	and	CCONJ
eurjchem-2553	90	18	confirmed	confirm	VERB
eurjchem-2553	90	19	noninfected	noninfected	ADJ
eurjchem-2553	90	20	subjects	subject	NOUN
eurjchem-2553	90	21	were	be	AUX
eurjchem-2553	90	22	also	also	ADV
eurjchem-2553	90	23	used	use	VERB
eurjchem-2553	90	24	to	to	PART
eurjchem-2553	90	25	ratify	ratify	VERB
eurjchem-2553	90	26	the	the	DET
eurjchem-2553	90	27	results	result	NOUN
eurjchem-2553	90	28	.	.	PUNCT
eurjchem-2553	91	1	2.3	2.3	NUM
eurjchem-2553	91	2	.	.	PUNCT
eurjchem-2553	92	1	statistical	statistical	ADJ
eurjchem-2553	92	2	analysis	analysis	NOUN
eurjchem-2553	92	3	for	for	ADP
eurjchem-2553	92	4	categorical	categorical	ADJ
eurjchem-2553	92	5	variables	variable	NOUN
eurjchem-2553	92	6	,	,	PUNCT
eurjchem-2553	92	7	descriptive	descriptive	ADJ
eurjchem-2553	92	8	statistics	statistic	NOUN
eurjchem-2553	92	9	are	be	AUX
eurjchem-2553	92	10	presented	present	VERB
eurjchem-2553	92	11	as	as	ADP
eurjchem-2553	92	12	frequencies	frequency	NOUN
eurjchem-2553	92	13	and	and	CCONJ
eurjchem-2553	92	14	percentages	percentage	NOUN
eurjchem-2553	92	15	,	,	PUNCT
eurjchem-2553	92	16	and	and	CCONJ
eurjchem-2553	92	17	for	for	ADP
eurjchem-2553	92	18	continuous	continuous	ADJ
eurjchem-2553	92	19	variables	variable	NOUN
eurjchem-2553	92	20	,	,	PUNCT
eurjchem-2553	92	21	such	such	ADJ
eurjchem-2553	92	22	as	as	ADP
eurjchem-2553	92	23	means	mean	NOUN
eurjchem-2553	92	24	(	(	PUNCT
eurjchem-2553	92	25	standard	standard	ADJ
eurjchem-2553	92	26	deviation	deviation	NOUN
eurjchem-2553	92	27	,	,	PUNCT
eurjchem-2553	92	28	sd	sd	NOUN
eurjchem-2553	92	29	)	)	PUNCT
eurjchem-2553	92	30	,	,	PUNCT
eurjchem-2553	92	31	and	and	CCONJ
eurjchem-2553	92	32	medians	median	NOUN
eurjchem-2553	92	33	(	(	PUNCT
eurjchem-2553	92	34	interquartile	interquartile	NOUN
eurjchem-2553	92	35	range	range	PROPN
eurjchem-2553	92	36	,	,	PUNCT
eurjchem-2553	92	37	iqr	iqr	NOUN
eurjchem-2553	92	38	)	)	PUNCT
eurjchem-2553	92	39	.	.	PUNCT
eurjchem-2553	93	1	here	here	ADV
eurjchem-2553	93	2	,	,	PUNCT
eurjchem-2553	93	3	we	we	PRON
eurjchem-2553	93	4	describe	describe	VERB
eurjchem-2553	93	5	the	the	DET
eurjchem-2553	93	6	dynamics	dynamic	NOUN
eurjchem-2553	93	7	of	of	ADP
eurjchem-2553	93	8	the	the	DET
eurjchem-2553	93	9	humoral	humoral	ADJ
eurjchem-2553	93	10	immune	immune	ADJ
eurjchem-2553	93	11	response	response	NOUN
eurjchem-2553	93	12	of	of	ADP
eurjchem-2553	93	13	sars	sar	NOUN
eurjchem-2553	93	14	-	-	PUNCT
eurjchem-2553	93	15	cov-2	cov-2	NOUN
eurjchem-2553	93	16	up	up	ADP
eurjchem-2553	93	17	to	to	PART
eurjchem-2553	93	18	one	one	NUM
eurjchem-2553	93	19	year	year	NOUN
eurjchem-2553	93	20	after	after	ADP
eurjchem-2553	93	21	vaccination	vaccination	NOUN
eurjchem-2553	93	22	and	and	CCONJ
eurjchem-2553	93	23	examined	examine	VERB
eurjchem-2553	93	24	the	the	DET
eurjchem-2553	93	25	igg	igg	PROPN
eurjchem-2553	93	26	neutralization	neutralization	NOUN
eurjchem-2553	93	27	potential	potential	NOUN
eurjchem-2553	93	28	of	of	ADP
eurjchem-2553	93	29	the	the	DET
eurjchem-2553	93	30	vaccine	vaccine	NOUN
eurjchem-2553	93	31	using	use	VERB
eurjchem-2553	93	32	validated	validate	VERB
eurjchem-2553	93	33	serological	serological	ADJ
eurjchem-2553	93	34	assays	assay	NOUN
eurjchem-2553	93	35	on	on	ADP
eurjchem-2553	93	36	a	a	DET
eurjchem-2553	93	37	substantial	substantial	ADJ
eurjchem-2553	93	38	cohort	cohort	NOUN
eurjchem-2553	93	39	of	of	ADP
eurjchem-2553	93	40	healthcare	healthcare	NOUN
eurjchem-2553	93	41	workers	worker	NOUN
eurjchem-2553	93	42	who	who	PRON
eurjchem-2553	93	43	have	have	AUX
eurjchem-2553	93	44	recovered	recover	VERB
eurjchem-2553	93	45	from	from	ADP
eurjchem-2553	93	46	covid-19	covid-19	PROPN
eurjchem-2553	93	47	and	and	CCONJ
eurjchem-2553	93	48	received	receive	VERB
eurjchem-2553	93	49	the	the	DET
eurjchem-2553	93	50	vaccine	vaccine	NOUN
eurjchem-2553	93	51	and	and	CCONJ
eurjchem-2553	93	52	received	receive	VERB
eurjchem-2553	93	53	the	the	DET
eurjchem-2553	93	54	vaccine	vaccine	NOUN
eurjchem-2553	93	55	without	without	ADP
eurjchem-2553	93	56	infection	infection	NOUN
eurjchem-2553	93	57	.	.	PUNCT
eurjchem-2553	94	1	three	three	NUM
eurjchem-2553	94	2	tests	test	NOUN
eurjchem-2553	94	3	,	,	PUNCT
eurjchem-2553	94	4	chi	chi	NOUN
eurjchem-2553	94	5	-	-	PUNCT
eurjchem-2553	94	6	square	square	ADJ
eurjchem-2553	94	7	,	,	PUNCT
eurjchem-2553	94	8	one	one	NUM
eurjchem-2553	94	9	-	-	PUNCT
eurjchem-2553	94	10	way	way	NOUN
eurjchem-2553	94	11	anova	anova	PROPN
eurjchem-2553	94	12	,	,	PUNCT
eurjchem-2553	94	13	and	and	CCONJ
eurjchem-2553	94	14	student	student	NOUN
eurjchem-2553	94	15	t	t	PROPN
eurjchem-2553	94	16	-	-	PUNCT
eurjchem-2553	94	17	tests	test	NOUN
eurjchem-2553	94	18	were	be	AUX
eurjchem-2553	94	19	applied	apply	VERB
eurjchem-2553	94	20	.	.	PUNCT
eurjchem-2553	95	1	when	when	SCONJ
eurjchem-2553	95	2	the	the	DET
eurjchem-2553	95	3	third	third	ADJ
eurjchem-2553	95	4	booster	booster	NOUN
eurjchem-2553	95	5	dose	dose	NOUN
eurjchem-2553	95	6	of	of	ADP
eurjchem-2553	95	7	the	the	DET
eurjchem-2553	95	8	vaccine	vaccine	NOUN
eurjchem-2553	95	9	had	have	AUX
eurjchem-2553	95	10	been	be	AUX
eurjchem-2553	95	11	administered	administer	VERB
eurjchem-2553	95	12	,	,	PUNCT
eurjchem-2553	95	13	we	we	PRON
eurjchem-2553	95	14	assessed	assess	VERB
eurjchem-2553	95	15	the	the	DET
eurjchem-2553	95	16	differences	difference	NOUN
eurjchem-2553	95	17	in	in	ADP
eurjchem-2553	95	18	nab	nab	ADJ
eurjchem-2553	95	19	titer	titer	NOUN
eurjchem-2553	95	20	values	value	NOUN
eurjchem-2553	95	21	after	after	ADP
eurjchem-2553	95	22	one	one	NUM
eurjchem-2553	95	23	year	year	NOUN
eurjchem-2553	95	24	of	of	ADP
eurjchem-2553	95	25	vaccination	vaccination	NOUN
eurjchem-2553	95	26	.	.	PUNCT
eurjchem-2553	96	1	furthermore	furthermore	ADV
eurjchem-2553	96	2	,	,	PUNCT
eurjchem-2553	96	3	a	a	DET
eurjchem-2553	96	4	two	two	NUM
eurjchem-2553	96	5	-	-	PUNCT
eurjchem-2553	96	6	tailed	tail	VERB
eurjchem-2553	96	7	t	t	NOUN
eurjchem-2553	96	8	-	-	PUNCT
eurjchem-2553	96	9	test	test	NOUN
eurjchem-2553	96	10	was	be	AUX
eurjchem-2553	96	11	used	use	VERB
eurjchem-2553	96	12	to	to	PART
eurjchem-2553	96	13	compare	compare	VERB
eurjchem-2553	96	14	neutralization	neutralization	NOUN
eurjchem-2553	96	15	titers	titer	NOUN
eurjchem-2553	96	16	of	of	ADP
eurjchem-2553	96	17	the	the	DET
eurjchem-2553	96	18	same	same	ADJ
eurjchem-2553	96	19	person	person	NOUN
eurjchem-2553	96	20	's	's	PART
eurjchem-2553	96	21	serum	serum	NOUN
eurjchem-2553	96	22	variables	variable	NOUN
eurjchem-2553	96	23	related	relate	VERB
eurjchem-2553	96	24	to	to	ADP
eurjchem-2553	96	25	anti	anti	ADJ
eurjchem-2553	96	26	-	-	ADJ
eurjchem-2553	96	27	spike	spike	ADJ
eurjchem-2553	96	28	antibody	antibody	NOUN
eurjchem-2553	96	29	titers	titer	NOUN
eurjchem-2553	96	30	following	follow	VERB
eurjchem-2553	96	31	three	three	NUM
eurjchem-2553	96	32	doses	dose	NOUN
eurjchem-2553	96	33	of	of	ADP
eurjchem-2553	96	34	the	the	DET
eurjchem-2553	96	35	vaccine	vaccine	NOUN
eurjchem-2553	96	36	chadox1	chadox1	NOUN
eurjchem-2553	96	37	-	-	PUNCT
eurjchem-2553	96	38	ncov	ncov	NOUN
eurjchem-2553	96	39	(	(	PUNCT
eurjchem-2553	96	40	covishieldtm	covishieldtm	NOUN
eurjchem-2553	96	41	)	)	PUNCT
eurjchem-2553	96	42	.	.	PUNCT
eurjchem-2553	97	1	following	follow	VERB
eurjchem-2553	97	2	the	the	DET
eurjchem-2553	97	3	first	first	ADJ
eurjchem-2553	97	4	dose	dose	NOUN
eurjchem-2553	97	5	of	of	ADP
eurjchem-2553	97	6	the	the	DET
eurjchem-2553	97	7	vaccine	vaccine	NOUN
eurjchem-2553	97	8	(	(	PUNCT
eurjchem-2553	97	9	3	3	NUM
eurjchem-2553	97	10	months	month	NOUN
eurjchem-2553	97	11	after	after	ADP
eurjchem-2553	97	12	immunization	immunization	NOUN
eurjchem-2553	97	13	)	)	PUNCT
eurjchem-2553	97	14	and	and	CCONJ
eurjchem-2553	97	15	the	the	DET
eurjchem-2553	97	16	second	second	ADJ
eurjchem-2553	97	17	dose	dose	NOUN
eurjchem-2553	97	18	of	of	ADP
eurjchem-2553	97	19	the	the	DET
eurjchem-2553	97	20	vaccine	vaccine	NOUN
eurjchem-2553	97	21	(	(	PUNCT
eurjchem-2553	97	22	6	6	NUM
eurjchem-2553	97	23	months	month	NOUN
eurjchem-2553	97	24	after	after	ADP
eurjchem-2553	97	25	immunization	immunization	NOUN
eurjchem-2553	97	26	)	)	PUNCT
eurjchem-2553	97	27	,	,	PUNCT
eurjchem-2553	97	28	the	the	DET
eurjchem-2553	97	29	correlation	correlation	NOUN
eurjchem-2553	97	30	with	with	ADP
eurjchem-2553	97	31	our	our	PRON
eurjchem-2553	97	32	prior	prior	ADJ
eurjchem-2553	97	33	nab	nab	ADJ
eurjchem-2553	97	34	titer	titer	NOUN
eurjchem-2553	97	35	was	be	AUX
eurjchem-2553	97	36	evaluated	evaluate	VERB
eurjchem-2553	97	37	using	use	VERB
eurjchem-2553	97	38	generalized	generalized	ADJ
eurjchem-2553	97	39	linear	linear	ADJ
eurjchem-2553	97	40	models	model	NOUN
eurjchem-2553	97	41	,	,	PUNCT
eurjchem-2553	97	42	respectively	respectively	ADV
eurjchem-2553	97	43	.	.	PUNCT
eurjchem-2553	98	1	this	this	DET
eurjchem-2553	98	2	set	set	NOUN
eurjchem-2553	98	3	of	of	ADP
eurjchem-2553	98	4	analyses	analysis	NOUN
eurjchem-2553	98	5	had	have	VERB
eurjchem-2553	98	6	a	a	DET
eurjchem-2553	98	7	2	2	NUM
eurjchem-2553	98	8	-	-	PUNCT
eurjchem-2553	98	9	tailed	tail	VERB
eurjchem-2553	98	10	p	p	NOUN
eurjchem-2553	98	11	<	<	X
eurjchem-2553	98	12	0.001	0.001	NUM
eurjchem-2553	98	13	level	level	NOUN
eurjchem-2553	98	14	of	of	ADP
eurjchem-2553	98	15	significance	significance	NOUN
eurjchem-2553	98	16	with	with	ADP
eurjchem-2553	98	17	98.69	98.69	NUM
eurjchem-2553	98	18	%	%	NOUN
eurjchem-2553	98	19	inhibition	inhibition	NOUN
eurjchem-2553	98	20	.	.	PUNCT
eurjchem-2553	99	1	stata	stata	PROPN
eurjchem-2553	99	2	16	16	NUM
eurjchem-2553	99	3	mp	mp	PROPN
eurjchem-2553	99	4	was	be	AUX
eurjchem-2553	99	5	used	use	VERB
eurjchem-2553	99	6	to	to	PART
eurjchem-2553	99	7	perform	perform	VERB
eurjchem-2553	99	8	all	all	DET
eurjchem-2553	99	9	statistical	statistical	ADJ
eurjchem-2553	99	10	analyzes	analyze	NOUN
eurjchem-2553	99	11	(	(	PUNCT
eurjchem-2553	99	12	stata	stata	PROPN
eurjchem-2553	99	13	corp	corp	PROPN
eurjchem-2553	99	14	.	.	PROPN
eurjchem-2553	99	15	,	,	PUNCT
eurjchem-2553	99	16	college	college	NOUN
eurjchem-2553	99	17	station	station	NOUN
eurjchem-2553	99	18	,	,	PUNCT
eurjchem-2553	99	19	tx	tx	PROPN
eurjchem-2553	99	20	)	)	PUNCT
eurjchem-2553	99	21	.	.	PUNCT
eurjchem-2553	100	1	the	the	DET
eurjchem-2553	100	2	graphpad	graphpad	NOUN
eurjchem-2553	100	3	prism	prism	NOUN
eurjchem-2553	100	4	(	(	PUNCT
eurjchem-2553	100	5	version	version	NOUN
eurjchem-2553	100	6	9.5.1	9.5.1	NUM
eurjchem-2553	100	7	)	)	PUNCT
eurjchem-2553	100	8	tool	tool	NOUN
eurjchem-2553	100	9	was	be	AUX
eurjchem-2553	100	10	used	use	VERB
eurjchem-2553	100	11	to	to	PART
eurjchem-2553	100	12	analyze	analyze	VERB
eurjchem-2553	100	13	and	and	CCONJ
eurjchem-2553	100	14	visualize	visualize	VERB
eurjchem-2553	100	15	all	all	DET
eurjchem-2553	100	16	additional	additional	ADJ
eurjchem-2553	100	17	data	datum	NOUN
eurjchem-2553	100	18	.	.	PUNCT
eurjchem-2553	101	1	3	3	X
eurjchem-2553	101	2	.	.	NOUN
eurjchem-2553	101	3	results	result	VERB
eurjchem-2553	101	4	3.1	3.1	NUM
eurjchem-2553	101	5	.	.	PUNCT
eurjchem-2553	102	1	characteristics	characteristic	NOUN
eurjchem-2553	102	2	of	of	ADP
eurjchem-2553	102	3	participants	participant	NOUN
eurjchem-2553	102	4	healthcare	healthcare	PROPN
eurjchem-2553	102	5	professionals	professional	NOUN
eurjchem-2553	102	6	including	include	VERB
eurjchem-2553	102	7	physicians	physician	NOUN
eurjchem-2553	102	8	,	,	PUNCT
eurjchem-2553	102	9	nurses	nurse	NOUN
eurjchem-2553	102	10	,	,	PUNCT
eurjchem-2553	102	11	paramedics	paramedic	NOUN
eurjchem-2553	102	12	technicians	technician	NOUN
eurjchem-2553	102	13	,	,	PUNCT
eurjchem-2553	102	14	housekeeping	housekeeping	NOUN
eurjchem-2553	102	15	personnel	personnel	NOUN
eurjchem-2553	102	16	,	,	PUNCT
eurjchem-2553	102	17	and	and	CCONJ
eurjchem-2553	102	18	office	office	NOUN
eurjchem-2553	102	19	assistants	assistant	NOUN
eurjchem-2553	102	20	,	,	PUNCT
eurjchem-2553	102	21	were	be	AUX
eurjchem-2553	102	22	included	include	VERB
eurjchem-2553	102	23	in	in	ADP
eurjchem-2553	102	24	this	this	DET
eurjchem-2553	102	25	study	study	NOUN
eurjchem-2553	102	26	with	with	ADP
eurjchem-2553	102	27	their	their	PRON
eurjchem-2553	102	28	consent	consent	NOUN
eurjchem-2553	102	29	.	.	PUNCT
eurjchem-2553	103	1	as	as	SCONJ
eurjchem-2553	103	2	indicated	indicate	VERB
eurjchem-2553	103	3	in	in	ADP
eurjchem-2553	103	4	table	table	NOUN
eurjchem-2553	103	5	1	1	NUM
eurjchem-2553	103	6	,	,	PUNCT
eurjchem-2553	103	7	214	214	NUM
eurjchem-2553	103	8	women	woman	NOUN
eurjchem-2553	103	9	(	(	PUNCT
eurjchem-2553	103	10	57.7	57.7	NUM
eurjchem-2553	103	11	%	%	NOUN
eurjchem-2553	103	12	;	;	PUNCT
eurjchem-2553	103	13	median	median	ADJ
eurjchem-2553	103	14	age	age	NOUN
eurjchem-2553	103	15	31	31	NUM
eurjchem-2553	103	16	-	-	SYM
eurjchem-2553	103	17	41	41	NUM
eurjchem-2553	103	18	years	year	NOUN
eurjchem-2553	103	19	)	)	PUNCT
eurjchem-2553	103	20	and	and	CCONJ
eurjchem-2553	103	21	157	157	NUM
eurjchem-2553	103	22	male	male	NOUN
eurjchem-2553	103	23	(	(	PUNCT
eurjchem-2553	103	24	42	42	NUM
eurjchem-2553	103	25	%	%	NOUN
eurjchem-2553	103	26	;	;	PUNCT
eurjchem-2553	103	27	median	median	ADJ
eurjchem-2553	103	28	age	age	NOUN
eurjchem-2553	103	29	31	31	NUM
eurjchem-2553	103	30	-	-	SYM
eurjchem-2553	103	31	45	45	NUM
eurjchem-2553	103	32	years	year	NOUN
eurjchem-2553	103	33	)	)	PUNCT
eurjchem-2553	103	34	out	out	ADP
eurjchem-2553	103	35	of	of	ADP
eurjchem-2553	103	36	371	371	NUM
eurjchem-2553	103	37	participants	participant	NOUN
eurjchem-2553	103	38	who	who	PRON
eurjchem-2553	103	39	had	have	AUX
eurjchem-2553	103	40	given	give	VERB
eurjchem-2553	103	41	blood	blood	NOUN
eurjchem-2553	103	42	samples	sample	NOUN
eurjchem-2553	103	43	after	after	ADP
eurjchem-2553	103	44	365	365	NUM
eurjchem-2553	103	45	days	day	NOUN
eurjchem-2553	103	46	of	of	ADP
eurjchem-2553	103	47	their	their	PRON
eurjchem-2553	103	48	vaccine	vaccine	NOUN
eurjchem-2553	103	49	administration	administration	NOUN
eurjchem-2553	103	50	were	be	AUX
eurjchem-2553	103	51	included	include	VERB
eurjchem-2553	103	52	in	in	ADP
eurjchem-2553	103	53	this	this	DET
eurjchem-2553	103	54	study	study	NOUN
eurjchem-2553	103	55	(	(	PUNCT
eurjchem-2553	103	56	figure	figure	NOUN
eurjchem-2553	103	57	3	3	NUM
eurjchem-2553	103	58	)	)	PUNCT
eurjchem-2553	103	59	.	.	PUNCT
eurjchem-2553	104	1	a	a	DET
eurjchem-2553	104	2	total	total	NOUN
eurjchem-2553	104	3	of	of	ADP
eurjchem-2553	104	4	161	161	NUM
eurjchem-2553	104	5	(	(	PUNCT
eurjchem-2553	104	6	43.4	43.4	NUM
eurjchem-2553	104	7	%	%	NOUN
eurjchem-2553	104	8	)	)	PUNCT
eurjchem-2553	104	9	participants	participant	NOUN
eurjchem-2553	104	10	had	have	VERB
eurjchem-2553	104	11	covid-19	covid-19	PROPN
eurjchem-2553	104	12	infection	infection	NOUN
eurjchem-2553	104	13	and	and	CCONJ
eurjchem-2553	104	14	recovered	recover	VERB
eurjchem-2553	104	15	during	during	ADP
eurjchem-2553	104	16	the	the	DET
eurjchem-2553	104	17	post	post	NOUN
eurjchem-2553	104	18	vaccination	vaccination	NOUN
eurjchem-2553	104	19	analysis	analysis	NOUN
eurjchem-2553	104	20	period	period	NOUN
eurjchem-2553	104	21	,	,	PUNCT
eurjchem-2553	104	22	while	while	SCONJ
eurjchem-2553	104	23	210	210	NUM
eurjchem-2553	104	24	(	(	PUNCT
eurjchem-2553	104	25	56.6	56.6	NUM
eurjchem-2553	104	26	%	%	NOUN
eurjchem-2553	104	27	)	)	PUNCT
eurjchem-2553	104	28	participants	participant	NOUN
eurjchem-2553	104	29	did	do	AUX
eurjchem-2553	104	30	not	not	PART
eurjchem-2553	104	31	have	have	VERB
eurjchem-2553	104	32	covid-19	covid-19	PROPN
eurjchem-2553	104	33	infection	infection	NOUN
eurjchem-2553	104	34	.	.	PUNCT
eurjchem-2553	105	1	https://jmitra.co.in/wp-content/uploads/2021/10/%20instruction-manual-covid-19-neutralizing-antibodies-microlisa.pdf	https://jmitra.co.in/wp-content/uploads/2021/10/%20instruction-manual-covid-19-neutralizing-antibodies-microlisa.pdf	PRON
eurjchem-2553	105	2	https://jmitra.co.in/wp-content/uploads/2021/10/%20instruction-manual-covid-19-neutralizing-antibodies-microlisa.pdf	https://jmitra.co.in/wp-content/uploads/2021/10/%20instruction-manual-covid-19-neutralizing-antibodies-microlisa.pdf	PRON
eurjchem-2553	105	3	https://jmitra.co.in/wp-content/uploads/2021/10/%20instruction-manual-covid-19-neutralizing-antibodies-microlisa.pdf	https://jmitra.co.in/wp-content/uploads/2021/10/%20instruction-manual-covid-19-neutralizing-antibodies-microlisa.pdf	PROPN
eurjchem-2553	105	4	jagadeesan	jagadeesan	NOUN
eurjchem-2553	105	5	et	et	PROPN
eurjchem-2553	105	6	al	al	PROPN
eurjchem-2553	105	7	.	.	PUNCT
eurjchem-2553	105	8	/	/	SYM
eurjchem-2553	105	9	european	european	PROPN
eurjchem-2553	105	10	journal	journal	PROPN
eurjchem-2553	105	11	of	of	ADP
eurjchem-2553	105	12	chemistry	chemistry	NOUN
eurjchem-2553	105	13	15	15	NUM
eurjchem-2553	105	14	(	(	PUNCT
eurjchem-2553	105	15	3	3	NUM
eurjchem-2553	105	16	)	)	PUNCT
eurjchem-2553	105	17	(	(	PUNCT
eurjchem-2553	105	18	2024	2024	NUM
eurjchem-2553	105	19	)	)	PUNCT
eurjchem-2553	105	20	274	274	NUM
eurjchem-2553	105	21	-	-	SYM
eurjchem-2553	105	22	281	281	NUM
eurjchem-2553	105	23	277	277	NUM
eurjchem-2553	105	24	2024	2024	NUM
eurjchem-2553	105	25	–	–	PUNCT
eurjchem-2553	105	26	european	european	ADJ
eurjchem-2553	105	27	journal	journal	NOUN
eurjchem-2553	105	28	of	of	ADP
eurjchem-2553	105	29	chemistry	chemistry	NOUN
eurjchem-2553	105	30	–	–	PUNCT
eurjchem-2553	105	31	cc	cc	NOUN
eurjchem-2553	105	32	by	by	ADP
eurjchem-2553	105	33	nc	nc	PROPN
eurjchem-2553	105	34	–	–	PUNCT
eurjchem-2553	105	35	doi	doi	PROPN
eurjchem-2553	105	36	:	:	PUNCT
eurjchem-2553	105	37	10.5155	10.5155	NUM
eurjchem-2553	105	38	/	/	SYM
eurjchem-2553	105	39	eurjchem.15.3.274	eurjchem.15.3.274	ADV
eurjchem-2553	105	40	-	-	SYM
eurjchem-2553	105	41	281.2553	281.2553	NUM
eurjchem-2553	105	42	figure	figure	NOUN
eurjchem-2553	105	43	3	3	NUM
eurjchem-2553	105	44	.	.	NOUN
eurjchem-2553	105	45	flow	flow	NOUN
eurjchem-2553	105	46	diagram	diagram	NOUN
eurjchem-2553	105	47	showing	show	VERB
eurjchem-2553	105	48	the	the	DET
eurjchem-2553	105	49	selection	selection	NOUN
eurjchem-2553	105	50	process	process	NOUN
eurjchem-2553	105	51	for	for	SCONJ
eurjchem-2553	105	52	studies	study	NOUN
eurjchem-2553	105	53	to	to	PART
eurjchem-2553	105	54	include	include	VERB
eurjchem-2553	105	55	.	.	PUNCT
eurjchem-2553	106	1	figure	figure	VERB
eurjchem-2553	106	2	4	4	NUM
eurjchem-2553	106	3	.	.	PUNCT
eurjchem-2553	106	4	neutralization	neutralization	NOUN
eurjchem-2553	106	5	efficacy	efficacy	NOUN
eurjchem-2553	106	6	after	after	ADP
eurjchem-2553	106	7	three	three	NUM
eurjchem-2553	106	8	doses	dose	NOUN
eurjchem-2553	106	9	vaccination	vaccination	NOUN
eurjchem-2553	106	10	among	among	ADP
eurjchem-2553	106	11	the	the	DET
eurjchem-2553	106	12	hcw	hcw	PROPN
eurjchem-2553	106	13	.	.	PUNCT
eurjchem-2553	107	1	comparison	comparison	NOUN
eurjchem-2553	107	2	of	of	ADP
eurjchem-2553	107	3	nab	nab	ADJ
eurjchem-2553	107	4	titer	titer	NOUN
eurjchem-2553	107	5	between	between	ADP
eurjchem-2553	107	6	covid	covid	PROPN
eurjchem-2553	107	7	recovered	recover	VERB
eurjchem-2553	107	8	+	+	CCONJ
eurjchem-2553	107	9	vaccinated	vaccinated	ADJ
eurjchem-2553	107	10	(	(	PUNCT
eurjchem-2553	107	11	red	red	ADJ
eurjchem-2553	107	12	,	,	PUNCT
eurjchem-2553	107	13	n	n	NOUN
eurjchem-2553	107	14	=	=	SYM
eurjchem-2553	107	15	164	164	NUM
eurjchem-2553	107	16	)	)	PUNCT
eurjchem-2553	107	17	and	and	CCONJ
eurjchem-2553	107	18	vaccinated	vaccinated	ADJ
eurjchem-2553	107	19	cases	case	NOUN
eurjchem-2553	107	20	(	(	PUNCT
eurjchem-2553	107	21	green	green	ADJ
eurjchem-2553	107	22	,	,	PUNCT
eurjchem-2553	107	23	n	n	NOUN
eurjchem-2553	107	24	=	=	NUM
eurjchem-2553	107	25	207	207	NUM
eurjchem-2553	107	26	)	)	PUNCT
eurjchem-2553	107	27	.	.	PUNCT
eurjchem-2553	108	1	administrated	administrate	VERB
eurjchem-2553	108	2	with	with	ADP
eurjchem-2553	108	3	three	three	NUM
eurjchem-2553	108	4	doses	dose	NOUN
eurjchem-2553	108	5	of	of	ADP
eurjchem-2553	108	6	vaccine	vaccine	NOUN
eurjchem-2553	108	7	(	(	PUNCT
eurjchem-2553	108	8	sera	sera	NOUN
eurjchem-2553	108	9	collected	collect	VERB
eurjchem-2553	108	10	12	12	NUM
eurjchem-2553	108	11	months	month	NOUN
eurjchem-2553	108	12	after	after	ADP
eurjchem-2553	108	13	the	the	DET
eurjchem-2553	108	14	third	third	ADJ
eurjchem-2553	108	15	(	(	PUNCT
eurjchem-2553	108	16	booster	booster	NOUN
eurjchem-2553	108	17	)	)	PUNCT
eurjchem-2553	108	18	dose	dose	NOUN
eurjchem-2553	108	19	of	of	ADP
eurjchem-2553	108	20	covishieldtm	covishieldtm	NOUN
eurjchem-2553	108	21	)	)	PUNCT
eurjchem-2553	108	22	.	.	PUNCT
eurjchem-2553	109	1	the	the	DET
eurjchem-2553	109	2	participants	participant	NOUN
eurjchem-2553	109	3	were	be	AUX
eurjchem-2553	109	4	all	all	PRON
eurjchem-2553	109	5	of	of	ADP
eurjchem-2553	109	6	indian	indian	ADJ
eurjchem-2553	109	7	nationality	nationality	NOUN
eurjchem-2553	109	8	.	.	PUNCT
eurjchem-2553	110	1	none	none	NOUN
eurjchem-2553	110	2	of	of	ADP
eurjchem-2553	110	3	the	the	DET
eurjchem-2553	110	4	participants	participant	NOUN
eurjchem-2553	110	5	experienced	experience	VERB
eurjchem-2553	110	6	any	any	PRON
eurjchem-2553	110	7	of	of	ADP
eurjchem-2553	110	8	the	the	DET
eurjchem-2553	110	9	following	follow	VERB
eurjchem-2553	110	10	symptoms	symptom	NOUN
eurjchem-2553	110	11	prior	prior	ADV
eurjchem-2553	110	12	to	to	ADP
eurjchem-2553	110	13	vaccination	vaccination	NOUN
eurjchem-2553	110	14	:	:	PUNCT
eurjchem-2553	110	15	cough	cough	NOUN
eurjchem-2553	110	16	,	,	PUNCT
eurjchem-2553	110	17	fever	fever	NOUN
eurjchem-2553	110	18	,	,	PUNCT
eurjchem-2553	110	19	sore	sore	ADJ
eurjchem-2553	110	20	throat	throat	NOUN
eurjchem-2553	110	21	,	,	PUNCT
eurjchem-2553	110	22	exhaustion	exhaustion	NOUN
eurjchem-2553	110	23	,	,	PUNCT
eurjchem-2553	110	24	diarrhea	diarrhea	NOUN
eurjchem-2553	110	25	,	,	PUNCT
eurjchem-2553	110	26	difficulty	difficulty	NOUN
eurjchem-2553	110	27	breathing	breathing	NOUN
eurjchem-2553	110	28	,	,	PUNCT
eurjchem-2553	110	29	fatigue	fatigue	NOUN
eurjchem-2553	110	30	,	,	PUNCT
eurjchem-2553	110	31	muscle	muscle	NOUN
eurjchem-2553	110	32	aches	ache	VERB
eurjchem-2553	110	33	,	,	PUNCT
eurjchem-2553	110	34	or	or	CCONJ
eurjchem-2553	110	35	change	change	NOUN
eurjchem-2553	110	36	or	or	CCONJ
eurjchem-2553	110	37	loss	loss	NOUN
eurjchem-2553	110	38	of	of	ADP
eurjchem-2553	110	39	sense	sense	NOUN
eurjchem-2553	110	40	of	of	ADP
eurjchem-2553	110	41	taste	taste	NOUN
eurjchem-2553	110	42	or	or	CCONJ
eurjchem-2553	110	43	smell	smell	NOUN
eurjchem-2553	110	44	.	.	PUNCT
eurjchem-2553	111	1	our	our	PRON
eurjchem-2553	111	2	study	study	NOUN
eurjchem-2553	111	3	group	group	NOUN
eurjchem-2553	111	4	was	be	AUX
eurjchem-2553	111	5	further	far	ADV
eurjchem-2553	111	6	divided	divide	VERB
eurjchem-2553	111	7	according	accord	VERB
eurjchem-2553	111	8	to	to	ADP
eurjchem-2553	111	9	participants	participant	NOUN
eurjchem-2553	111	10	whose	whose	DET
eurjchem-2553	111	11	samples	sample	NOUN
eurjchem-2553	111	12	were	be	AUX
eurjchem-2553	111	13	used	use	VERB
eurjchem-2553	111	14	in	in	ADP
eurjchem-2553	111	15	previous	previous	ADJ
eurjchem-2553	111	16	and	and	CCONJ
eurjchem-2553	111	17	current	current	ADJ
eurjchem-2553	111	18	studies	study	NOUN
eurjchem-2553	111	19	.	.	PUNCT
eurjchem-2553	112	1	after	after	ADP
eurjchem-2553	112	2	12	12	NUM
eurjchem-2553	112	3	months	month	NOUN
eurjchem-2553	112	4	of	of	ADP
eurjchem-2553	112	5	vaccination	vaccination	NOUN
eurjchem-2553	112	6	,	,	PUNCT
eurjchem-2553	112	7	their	their	PRON
eurjchem-2553	112	8	nab	nab	ADJ
eurjchem-2553	112	9	titer	titer	NOUN
eurjchem-2553	112	10	had	have	VERB
eurjchem-2553	112	11	significantly	significantly	ADV
eurjchem-2553	112	12	(	(	PUNCT
eurjchem-2553	112	13	p	p	X
eurjchem-2553	112	14	<	<	X
eurjchem-2553	112	15	0.001	0.001	NUM
eurjchem-2553	112	16	)	)	PUNCT
eurjchem-2553	112	17	increased	increase	VERB
eurjchem-2553	112	18	compared	compare	VERB
eurjchem-2553	112	19	to	to	ADP
eurjchem-2553	112	20	their	their	PRON
eurjchem-2553	112	21	nab	nab	ADJ
eurjchem-2553	112	22	titer	titer	NOUN
eurjchem-2553	112	23	of	of	ADP
eurjchem-2553	112	24	the	the	DET
eurjchem-2553	112	25	previous	previous	ADJ
eurjchem-2553	112	26	study	study	NOUN
eurjchem-2553	112	27	(	(	PUNCT
eurjchem-2553	112	28	figures	figure	NOUN
eurjchem-2553	112	29	4	4	NUM
eurjchem-2553	112	30	-	-	SYM
eurjchem-2553	112	31	7	7	NUM
eurjchem-2553	112	32	)	)	PUNCT
eurjchem-2553	112	33	.	.	PUNCT
eurjchem-2553	113	1	flow	flow	VERB
eurjchem-2553	113	2	chart	chart	NOUN
eurjchem-2553	113	3	of	of	ADP
eurjchem-2553	113	4	survey	survey	NOUN
eurjchem-2553	113	5	recruitment	recruitment	NOUN
eurjchem-2553	113	6	and	and	CCONJ
eurjchem-2553	113	7	serum	serum	NOUN
eurjchem-2553	113	8	sampling	sample	VERB
eurjchem-2553	113	9	among	among	ADP
eurjchem-2553	113	10	healthcare	healthcare	NOUN
eurjchem-2553	113	11	workers	worker	NOUN
eurjchem-2553	113	12	(	(	PUNCT
eurjchem-2553	113	13	hcw	hcw	PROPN
eurjchem-2553	113	14	)	)	PUNCT
eurjchem-2553	113	15	at	at	ADP
eurjchem-2553	113	16	sri	sri	PROPN
eurjchem-2553	113	17	jayadeva	jayadeva	PROPN
eurjchem-2553	113	18	institute	institute	PROPN
eurjchem-2553	113	19	of	of	ADP
eurjchem-2553	113	20	cardiovascular	cardiovascular	ADJ
eurjchem-2553	113	21	sciences	science	NOUN
eurjchem-2553	113	22	and	and	CCONJ
eurjchem-2553	113	23	research	research	NOUN
eurjchem-2553	113	24	.	.	PUNCT
eurjchem-2553	114	1	first	first	ADJ
eurjchem-2553	114	2	-	-	PUNCT
eurjchem-2553	114	3	line	line	NOUN
eurjchem-2553	114	4	serological	serological	ADJ
eurjchem-2553	114	5	screening	screening	NOUN
eurjchem-2553	114	6	was	be	AUX
eurjchem-2553	114	7	performed	perform	VERB
eurjchem-2553	114	8	using	use	VERB
eurjchem-2553	114	9	elisa	elisa	NOUN
eurjchem-2553	114	10	assay	assay	PROPN
eurjchem-2553	114	11	:	:	PUNCT
eurjchem-2553	114	12	detecting	detect	VERB
eurjchem-2553	114	13	antireceptor	antireceptor	NOUN
eurjchem-2553	114	14	binding	bind	VERB
eurjchem-2553	114	15	domain	domain	NOUN
eurjchem-2553	114	16	(	(	PUNCT
eurjchem-2553	114	17	rbd	rbd	NOUN
eurjchem-2553	114	18	)	)	PUNCT
eurjchem-2553	114	19	antibodies	antibody	NOUN
eurjchem-2553	114	20	and	and	CCONJ
eurjchem-2553	114	21	novel	novel	ADJ
eurjchem-2553	114	22	coronavirus	coronavirus	NOUN
eurjchem-2553	114	23	covid-19	covid-19	PROPN
eurjchem-2553	114	24	igg	igg	PROPN
eurjchem-2553	114	25	elisa	elisa	PROPN
eurjchem-2553	114	26	detecting	detect	VERB
eurjchem-2553	114	27	the	the	DET
eurjchem-2553	114	28	anti	anti	ADJ
eurjchem-2553	114	29	-	-	ADJ
eurjchem-2553	114	30	nucleocapsid	nucleocapsid	ADJ
eurjchem-2553	114	31	protein	protein	NOUN
eurjchem-2553	114	32	(	(	PUNCT
eurjchem-2553	114	33	n	n	CCONJ
eurjchem-2553	114	34	)	)	PUNCT
eurjchem-2553	114	35	igg	igg	PROPN
eurjchem-2553	114	36	.	.	PROPN
eurjchem-2553	115	1	3.2	3.2	NUM
eurjchem-2553	115	2	.	.	PUNCT
eurjchem-2553	116	1	covid-19	covid-19	PROPN
eurjchem-2553	116	2	vaccine	vaccine	NOUN
eurjchem-2553	116	3	cohort	cohort	VERB
eurjchem-2553	116	4	several	several	ADJ
eurjchem-2553	116	5	studies	study	NOUN
eurjchem-2553	116	6	have	have	AUX
eurjchem-2553	116	7	found	find	VERB
eurjchem-2553	116	8	that	that	SCONJ
eurjchem-2553	116	9	certain	certain	ADJ
eurjchem-2553	116	10	vaccinations	vaccination	NOUN
eurjchem-2553	116	11	,	,	PUNCT
eurjchem-2553	116	12	including	include	VERB
eurjchem-2553	116	13	mrna-1273	mrna-1273	NOUN
eurjchem-2553	116	14	,	,	PUNCT
eurjchem-2553	116	15	nvxcov2373	nvxcov2373	PROPN
eurjchem-2553	116	16	,	,	PUNCT
eurjchem-2553	116	17	bnt162b2	bnt162b2	NOUN
eurjchem-2553	116	18	,	,	PUNCT
eurjchem-2553	116	19	and	and	CCONJ
eurjchem-2553	116	20	chadox1	chadox1	ADJ
eurjchem-2553	116	21	-	-	PUNCT
eurjchem-2553	116	22	ncov19	ncov19	NOUN
eurjchem-2553	116	23	,	,	PUNCT
eurjchem-2553	116	24	are	be	AUX
eurjchem-2553	116	25	less	less	ADV
eurjchem-2553	116	26	effective	effective	ADJ
eurjchem-2553	116	27	at	at	ADP
eurjchem-2553	116	28	neutralizing	neutralize	VERB
eurjchem-2553	116	29	b.1.1.7	b.1.1.7	PROPN
eurjchem-2553	116	30	,	,	PUNCT
eurjchem-2553	116	31	b.1.351	b.1.351	NOUN
eurjchem-2553	116	32	,	,	PUNCT
eurjchem-2553	116	33	and	and	CCONJ
eurjchem-2553	116	34	b.1.1.28	b.1.1.28	PROPN
eurjchem-2553	116	35	p1	p1	NOUN
eurjchem-2553	116	36	variants	variant	NOUN
eurjchem-2553	116	37	.	.	PUNCT
eurjchem-2553	117	1	indian	indian	ADJ
eurjchem-2553	117	2	citizens	citizen	NOUN
eurjchem-2553	117	3	have	have	AUX
eurjchem-2553	117	4	received	receive	VERB
eurjchem-2553	117	5	more	more	ADJ
eurjchem-2553	117	6	than	than	ADP
eurjchem-2553	117	7	2,137	2,137	NUM
eurjchem-2553	117	8	million	million	NUM
eurjchem-2553	117	9	doses	dose	NOUN
eurjchem-2553	117	10	of	of	ADP
eurjchem-2553	117	11	the	the	DET
eurjchem-2553	117	12	two	two	NUM
eurjchem-2553	117	13	approved	approve	VERB
eurjchem-2553	117	14	vaccines	vaccine	NOUN
eurjchem-2553	117	15	covishield	covishield	NOUN
eurjchem-2553	117	16	(	(	PUNCT
eurjchem-2553	117	17	astrazeneca	astrazeneca	NOUN
eurjchem-2553	117	18	-	-	PUNCT
eurjchem-2553	117	19	oxford	oxford	PROPN
eurjchem-2553	117	20	)	)	PUNCT
eurjchem-2553	117	21	and	and	CCONJ
eurjchem-2553	117	22	covaxintm	covaxintm	PROPN
eurjchem-2553	117	23	(	(	PUNCT
eurjchem-2553	117	24	bbv152	bbv152	PROPN
eurjchem-2553	117	25	)	)	PUNCT
eurjchem-2553	117	26	.	.	PUNCT
eurjchem-2553	118	1	most	most	ADJ
eurjchem-2553	118	2	of	of	ADP
eurjchem-2553	118	3	the	the	DET
eurjchem-2553	118	4	immunization	immunization	NOUN
eurjchem-2553	118	5	programs	program	NOUN
eurjchem-2553	118	6	in	in	ADP
eurjchem-2553	118	7	india	india	PROPN
eurjchem-2553	118	8	consist	consist	NOUN
eurjchem-2553	118	9	of	of	ADP
eurjchem-2553	118	10	covishield	covishield	NOUN
eurjchem-2553	118	11	.	.	PUNCT
eurjchem-2553	119	1	therefore	therefore	ADV
eurjchem-2553	119	2	,	,	PUNCT
eurjchem-2553	119	3	understanding	understand	VERB
eurjchem-2553	119	4	the	the	DET
eurjchem-2553	119	5	capacity	capacity	NOUN
eurjchem-2553	119	6	of	of	ADP
eurjchem-2553	119	7	the	the	DET
eurjchem-2553	119	8	covishield	covishield	NOUN
eurjchem-2553	119	9	vaccine	vaccine	NOUN
eurjchem-2553	119	10	to	to	PART
eurjchem-2553	119	11	counteract	counteract	VERB
eurjchem-2553	119	12	this	this	DET
eurjchem-2553	119	13	newly	newly	ADV
eurjchem-2553	119	14	discovered	discover	VERB
eurjchem-2553	119	15	variant	variant	NOUN
eurjchem-2553	119	16	is	be	AUX
eurjchem-2553	119	17	crucial	crucial	ADJ
eurjchem-2553	119	18	[	[	X
eurjchem-2553	119	19	9	9	NUM
eurjchem-2553	119	20	]	]	PUNCT
eurjchem-2553	119	21	.	.	PUNCT
eurjchem-2553	120	1	we	we	PRON
eurjchem-2553	120	2	evaluated	evaluate	VERB
eurjchem-2553	120	3	the	the	DET
eurjchem-2553	120	4	covishield	covishield	NOUN
eurjchem-2553	120	5	vaccination	vaccination	NOUN
eurjchem-2553	120	6	recipient	recipient	NOUN
eurjchem-2553	120	7	sera	sera	NOUN
eurjchem-2553	120	8	24	24	NUM
eurjchem-2553	120	9	months	month	NOUN
eurjchem-2553	120	10	after	after	ADP
eurjchem-2553	120	11	the	the	DET
eurjchem-2553	120	12	second	second	ADJ
eurjchem-2553	120	13	dose	dose	NOUN
eurjchem-2553	120	14	of	of	ADP
eurjchem-2553	120	15	covishield	covishield	NOUN
eurjchem-2553	120	16	and	and	CCONJ
eurjchem-2553	120	17	12	12	NUM
eurjchem-2553	120	18	months	month	NOUN
eurjchem-2553	120	19	after	after	ADP
eurjchem-2553	120	20	the	the	DET
eurjchem-2553	120	21	third	third	ADJ
eurjchem-2553	120	22	dose	dose	NOUN
eurjchem-2553	120	23	(	(	PUNCT
eurjchem-2553	120	24	booster	booster	NOUN
eurjchem-2553	120	25	)	)	PUNCT
eurjchem-2553	120	26	of	of	ADP
eurjchem-2553	120	27	covishield	covishield	NOUN
eurjchem-2553	120	28	for	for	ADP
eurjchem-2553	120	29	their	their	PRON
eurjchem-2553	120	30	ability	ability	NOUN
eurjchem-2553	120	31	to	to	PART
eurjchem-2553	120	32	neutralize	neutralize	VERB
eurjchem-2553	120	33	the	the	DET
eurjchem-2553	120	34	covishield	covishield	NOUN
eurjchem-2553	120	35	vaccine	vaccine	NOUN
eurjchem-2553	120	36	(	(	PUNCT
eurjchem-2553	120	37	n	n	NOUN
eurjchem-2553	120	38	=	=	NUM
eurjchem-2553	120	39	371	371	NUM
eurjchem-2553	120	40	)	)	PUNCT
eurjchem-2553	120	41	.	.	PUNCT
eurjchem-2553	121	1	278	278	NUM
eurjchem-2553	121	2	jagadeesan	jagadeesan	NOUN
eurjchem-2553	121	3	et	et	PROPN
eurjchem-2553	121	4	al	al	PROPN
eurjchem-2553	121	5	.	.	PUNCT
eurjchem-2553	121	6	/	/	SYM
eurjchem-2553	121	7	european	european	PROPN
eurjchem-2553	121	8	journal	journal	PROPN
eurjchem-2553	121	9	of	of	ADP
eurjchem-2553	121	10	chemistry	chemistry	NOUN
eurjchem-2553	121	11	15	15	NUM
eurjchem-2553	121	12	(	(	PUNCT
eurjchem-2553	121	13	3	3	NUM
eurjchem-2553	121	14	)	)	PUNCT
eurjchem-2553	121	15	(	(	PUNCT
eurjchem-2553	121	16	2024	2024	NUM
eurjchem-2553	121	17	)	)	PUNCT
eurjchem-2553	121	18	274	274	NUM
eurjchem-2553	121	19	-	-	SYM
eurjchem-2553	121	20	281	281	NUM
eurjchem-2553	121	21	2024	2024	NUM
eurjchem-2553	121	22	–	–	PUNCT
eurjchem-2553	121	23	european	european	ADJ
eurjchem-2553	121	24	journal	journal	NOUN
eurjchem-2553	121	25	of	of	ADP
eurjchem-2553	121	26	chemistry	chemistry	NOUN
eurjchem-2553	121	27	–	–	PUNCT
eurjchem-2553	121	28	cc	cc	NOUN
eurjchem-2553	121	29	by	by	ADP
eurjchem-2553	121	30	nc	nc	PROPN
eurjchem-2553	121	31	–	–	PUNCT
eurjchem-2553	121	32	doi	doi	PROPN
eurjchem-2553	121	33	:	:	PUNCT
eurjchem-2553	121	34	10.5155	10.5155	NUM
eurjchem-2553	121	35	/	/	SYM
eurjchem-2553	121	36	eurjchem.15.3.274	eurjchem.15.3.274	ADV
eurjchem-2553	121	37	-	-	SYM
eurjchem-2553	121	38	281.2553	281.2553	NUM
eurjchem-2553	121	39	figure	figure	NOUN
eurjchem-2553	121	40	5	5	NUM
eurjchem-2553	121	41	.	.	PUNCT
eurjchem-2553	121	42	anti	anti	ADJ
eurjchem-2553	121	43	-	-	ADJ
eurjchem-2553	121	44	sars	sars	ADJ
eurjchem-2553	121	45	-	-	PUNCT
eurjchem-2553	121	46	cov-2	cov-2	NOUN
eurjchem-2553	121	47	antibody	antibody	NOUN
eurjchem-2553	121	48	responses	response	NOUN
eurjchem-2553	121	49	to	to	ADP
eurjchem-2553	121	50	vaccines	vaccine	NOUN
eurjchem-2553	121	51	for	for	ADP
eurjchem-2553	121	52	371	371	NUM
eurjchem-2553	121	53	participants	participant	NOUN
eurjchem-2553	121	54	a	a	DET
eurjchem-2553	121	55	(	(	PUNCT
eurjchem-2553	121	56	n	n	NOUN
eurjchem-2553	121	57	=	=	SYM
eurjchem-2553	121	58	207	207	NUM
eurjchem-2553	121	59	)	)	PUNCT
eurjchem-2553	121	60	and	and	CCONJ
eurjchem-2553	121	61	b	b	X
eurjchem-2553	121	62	(	(	PUNCT
eurjchem-2553	121	63	n	n	NOUN
eurjchem-2553	121	64	=	=	NOUN
eurjchem-2553	121	65	164	164	NUM
eurjchem-2553	121	66	)	)	PUNCT
eurjchem-2553	121	67	.	.	PUNCT
eurjchem-2553	122	1	heat	heat	NOUN
eurjchem-2553	122	2	maps	map	NOUN
eurjchem-2553	122	3	showing	show	VERB
eurjchem-2553	122	4	the	the	DET
eurjchem-2553	122	5	kinetics	kinetic	NOUN
eurjchem-2553	122	6	of	of	ADP
eurjchem-2553	122	7	anti	anti	ADJ
eurjchem-2553	122	8	-	-	ADJ
eurjchem-2553	122	9	sars	sar	NOUN
eurjchem-2553	122	10	-	-	PUNCT
eurjchem-2553	122	11	cov-2	cov-2	NOUN
eurjchem-2553	122	12	neutralizing	neutralize	VERB
eurjchem-2553	122	13	antibodies	antibody	NOUN
eurjchem-2553	122	14	(	(	PUNCT
eurjchem-2553	122	15	anti	anti	ADJ
eurjchem-2553	122	16	-	-	ADJ
eurjchem-2553	122	17	sars	sar	NOUN
eurjchem-2553	122	18	-	-	PUNCT
eurjchem-2553	122	19	cov-2	cov-2	NOUN
eurjchem-2553	122	20	igg	igg	PROPN
eurjchem-2553	122	21	antibodies	antibodie	VERB
eurjchem-2553	122	22	)	)	PUNCT
eurjchem-2553	122	23	.	.	PUNCT
eurjchem-2553	123	1	figure	figure	VERB
eurjchem-2553	123	2	6	6	NUM
eurjchem-2553	123	3	.	.	PUNCT
eurjchem-2553	124	1	binding	bind	VERB
eurjchem-2553	124	2	igg	igg	PROPN
eurjchem-2553	124	3	levels	level	NOUN
eurjchem-2553	124	4	to	to	PART
eurjchem-2553	124	5	spike	spike	NOUN
eurjchem-2553	124	6	rbd	rbd	NOUN
eurjchem-2553	124	7	were	be	AUX
eurjchem-2553	124	8	measured	measure	VERB
eurjchem-2553	124	9	by	by	ADP
eurjchem-2553	124	10	elisa	elisa	NOUN
eurjchem-2553	124	11	using	use	VERB
eurjchem-2553	124	12	serially	serially	ADV
eurjchem-2553	124	13	diluted	dilute	VERB
eurjchem-2553	124	14	sera	sera	NOUN
eurjchem-2553	124	15	from	from	ADP
eurjchem-2553	124	16	naive	naive	ADJ
eurjchem-2553	124	17	and	and	CCONJ
eurjchem-2553	124	18	previously	previously	ADV
eurjchem-2553	124	19	infected	infect	VERB
eurjchem-2553	124	20	individuals	individual	NOUN
eurjchem-2553	124	21	collected	collect	VERB
eurjchem-2553	124	22	from	from	ADP
eurjchem-2553	124	23	3	3	NUM
eurjchem-2553	124	24	months	month	NOUN
eurjchem-2553	124	25	after	after	ADP
eurjchem-2553	124	26	dose	dose	NOUN
eurjchem-2553	124	27	1	1	NUM
eurjchem-2553	124	28	,	,	PUNCT
eurjchem-2553	124	29	6	6	NUM
eurjchem-2553	124	30	months	month	NOUN
eurjchem-2553	124	31	after	after	ADP
eurjchem-2553	124	32	dose	dose	NOUN
eurjchem-2553	124	33	2	2	NUM
eurjchem-2553	124	34	,	,	PUNCT
eurjchem-2553	124	35	and	and	CCONJ
eurjchem-2553	124	36	12	12	NUM
eurjchem-2553	124	37	months	month	NOUN
eurjchem-2553	124	38	after	after	ADP
eurjchem-2553	124	39	the	the	DET
eurjchem-2553	124	40	3rd	3rd	PROPN
eurjchem-2553	124	41	dose	dose	NOUN
eurjchem-2553	124	42	of	of	ADP
eurjchem-2553	124	43	covishield	covishield	ADJ
eurjchem-2553	124	44	vaccine	vaccine	NOUN
eurjchem-2553	124	45	.	.	PUNCT
eurjchem-2553	125	1	*	*	PUNCT
eurjchem-2553	125	2	*	*	PUNCT
eurjchem-2553	125	3	*	*	PUNCT
eurjchem-2553	125	4	p	p	X
eurjchem-2553	125	5	<	<	X
eurjchem-2553	125	6	0.001	0.001	NUM
eurjchem-2553	125	7	,	,	PUNCT
eurjchem-2553	125	8	calculated	calculate	VERB
eurjchem-2553	125	9	with	with	ADP
eurjchem-2553	125	10	oneway	oneway	PROPN
eurjchem-2553	125	11	anova	anova	PROPN
eurjchem-2553	125	12	test	test	NOUN
eurjchem-2553	125	13	using	use	VERB
eurjchem-2553	125	14	the	the	DET
eurjchem-2553	125	15	graphpad	graphpad	NOUN
eurjchem-2553	125	16	prism	prism	NOUN
eurjchem-2553	125	17	version	version	NOUN
eurjchem-2553	125	18	9.0.0	9.0.0	NUM
eurjchem-2553	125	19	software	software	NOUN
eurjchem-2553	125	20	.	.	PUNCT
eurjchem-2553	126	1	the	the	DET
eurjchem-2553	126	2	covid-19	covid-19	PROPN
eurjchem-2553	126	3	-	-	PUNCT
eurjchem-2553	126	4	positive	positive	ADJ
eurjchem-2553	126	5	recovered	recover	VERB
eurjchem-2553	126	6	and	and	CCONJ
eurjchem-2553	126	7	vaccinated	vaccinated	ADJ
eurjchem-2553	126	8	subjects	subject	NOUN
eurjchem-2553	126	9	were	be	AUX
eurjchem-2553	126	10	(	(	PUNCT
eurjchem-2553	126	11	n	n	X
eurjchem-2553	126	12	=	=	SYM
eurjchem-2553	126	13	164	164	NUM
eurjchem-2553	126	14	)	)	PUNCT
eurjchem-2553	126	15	and	and	CCONJ
eurjchem-2553	126	16	vaccinated	vaccinate	VERB
eurjchem-2553	126	17	(	(	PUNCT
eurjchem-2553	126	18	n	n	NOUN
eurjchem-2553	126	19	=	=	NUM
eurjchem-2553	126	20	207	207	NUM
eurjchem-2553	126	21	)	)	PUNCT
eurjchem-2553	126	22	.	.	PUNCT
eurjchem-2553	127	1	for	for	ADP
eurjchem-2553	127	2	both	both	DET
eurjchem-2553	127	3	types	type	NOUN
eurjchem-2553	127	4	of	of	ADP
eurjchem-2553	127	5	sera	sera	NOUN
eurjchem-2553	127	6	,	,	PUNCT
eurjchem-2553	127	7	the	the	DET
eurjchem-2553	127	8	neutralizing	neutralize	VERB
eurjchem-2553	127	9	-	-	PUNCT
eurjchem-2553	127	10	antibody	antibody	NOUN
eurjchem-2553	127	11	(	(	PUNCT
eurjchem-2553	127	12	nab	nab	NOUN
eurjchem-2553	127	13	)	)	PUNCT
eurjchem-2553	127	14	titer	titer	NOUN
eurjchem-2553	127	15	was	be	AUX
eurjchem-2553	127	16	measured	measure	VERB
eurjchem-2553	127	17	.	.	PUNCT
eurjchem-2553	128	1	the	the	DET
eurjchem-2553	128	2	results	result	NOUN
eurjchem-2553	128	3	demonstrated	demonstrate	VERB
eurjchem-2553	128	4	that	that	DET
eurjchem-2553	128	5	sera	sera	NOUN
eurjchem-2553	128	6	of	of	ADP
eurjchem-2553	128	7	covid-19	covid-19	PROPN
eurjchem-2553	128	8	-	-	PUNCT
eurjchem-2553	128	9	positive	positive	ADJ
eurjchem-2553	128	10	recovered	recovered	ADJ
eurjchem-2553	128	11	subjects	subject	NOUN
eurjchem-2553	128	12	(	(	PUNCT
eurjchem-2553	128	13	n	n	NOUN
eurjchem-2553	128	14	=	=	SYM
eurjchem-2553	128	15	164	164	NUM
eurjchem-2553	128	16	,	,	PUNCT
eurjchem-2553	128	17	red	red	ADJ
eurjchem-2553	128	18	color	color	NOUN
eurjchem-2553	128	19	)	)	PUNCT
eurjchem-2553	128	20	who	who	PRON
eurjchem-2553	128	21	received	receive	VERB
eurjchem-2553	128	22	three	three	NUM
eurjchem-2553	128	23	doses	dose	NOUN
eurjchem-2553	128	24	of	of	ADP
eurjchem-2553	128	25	covishield	covishield	NOUN
eurjchem-2553	128	26	have	have	VERB
eurjchem-2553	128	27	a	a	DET
eurjchem-2553	128	28	higher	high	ADJ
eurjchem-2553	128	29	antibody	antibody	NOUN
eurjchem-2553	128	30	response	response	NOUN
eurjchem-2553	128	31	compared	compare	VERB
eurjchem-2553	128	32	to	to	ADP
eurjchem-2553	128	33	the	the	DET
eurjchem-2553	128	34	covid-19	covid-19	PROPN
eurjchem-2553	128	35	naive	naive	ADJ
eurjchem-2553	128	36	vaccine	vaccine	NOUN
eurjchem-2553	128	37	(	(	PUNCT
eurjchem-2553	128	38	n	n	NOUN
eurjchem-2553	128	39	=	=	SYM
eurjchem-2553	128	40	207	207	NUM
eurjchem-2553	128	41	,	,	PUNCT
eurjchem-2553	128	42	green	green	ADJ
eurjchem-2553	128	43	color	color	NOUN
eurjchem-2553	128	44	)	)	PUNCT
eurjchem-2553	128	45	with	with	ADP
eurjchem-2553	128	46	a	a	DET
eurjchem-2553	128	47	significant	significant	ADJ
eurjchem-2553	128	48	difference	difference	NOUN
eurjchem-2553	128	49	(	(	PUNCT
eurjchem-2553	128	50	p	p	X
eurjchem-2553	128	51	<	<	X
eurjchem-2553	128	52	0.0001	0.0001	NUM
eurjchem-2553	128	53	)	)	PUNCT
eurjchem-2553	128	54	in	in	ADP
eurjchem-2553	128	55	nab	nab	ADJ
eurjchem-2553	128	56	titer	titer	NOUN
eurjchem-2553	128	57	against	against	ADP
eurjchem-2553	128	58	sars	sar	NOUN
eurjchem-2553	128	59	-	-	PUNCT
eurjchem-2553	128	60	cov-2	cov-2	PART
eurjchem-2553	128	61	infection	infection	NOUN
eurjchem-2553	128	62	(	(	PUNCT
eurjchem-2553	128	63	figure	figure	NOUN
eurjchem-2553	128	64	4	4	NUM
eurjchem-2553	128	65	and	and	CCONJ
eurjchem-2553	128	66	5	5	NUM
eurjchem-2553	128	67	)	)	PUNCT
eurjchem-2553	128	68	.	.	PUNCT
eurjchem-2553	129	1	for	for	ADP
eurjchem-2553	129	2	the	the	DET
eurjchem-2553	129	3	371	371	NUM
eurjchem-2553	129	4	participants	participant	NOUN
eurjchem-2553	129	5	,	,	PUNCT
eurjchem-2553	129	6	we	we	PRON
eurjchem-2553	129	7	successfully	successfully	ADV
eurjchem-2553	129	8	performed	perform	VERB
eurjchem-2553	129	9	analyses	analysis	NOUN
eurjchem-2553	129	10	of	of	ADP
eurjchem-2553	129	11	neutralizing	neutralize	VERB
eurjchem-2553	129	12	igg	igg	PROPN
eurjchem-2553	129	13	anti	anti	PROPN
eurjchem-2553	129	14	-	-	ADJ
eurjchem-2553	129	15	sarscov-2	sarscov-2	NUM
eurjchem-2553	129	16	antibodies	antibodie	VERB
eurjchem-2553	129	17	after	after	ADP
eurjchem-2553	129	18	vaccination	vaccination	NOUN
eurjchem-2553	129	19	and	and	CCONJ
eurjchem-2553	129	20	then	then	ADV
eurjchem-2553	129	21	profiled	profile	VERB
eurjchem-2553	129	22	the	the	DET
eurjchem-2553	129	23	kinetics	kinetic	NOUN
eurjchem-2553	129	24	of	of	ADP
eurjchem-2553	129	25	the	the	DET
eurjchem-2553	129	26	antibodies	antibody	NOUN
eurjchem-2553	129	27	.	.	PUNCT
eurjchem-2553	130	1	figure	figure	NOUN
eurjchem-2553	130	2	5	5	NUM
eurjchem-2553	130	3	shows	show	VERB
eurjchem-2553	130	4	the	the	DET
eurjchem-2553	130	5	trends	trend	NOUN
eurjchem-2553	130	6	in	in	ADP
eurjchem-2553	130	7	antibodies	antibody	NOUN
eurjchem-2553	130	8	for	for	ADP
eurjchem-2553	130	9	each	each	DET
eurjchem-2553	130	10	individual	individual	NOUN
eurjchem-2553	130	11	based	base	VERB
eurjchem-2553	130	12	on	on	ADP
eurjchem-2553	130	13	the	the	DET
eurjchem-2553	130	14	time	time	NOUN
eurjchem-2553	130	15	and	and	CCONJ
eurjchem-2553	130	16	dosage	dosage	NOUN
eurjchem-2553	130	17	of	of	ADP
eurjchem-2553	130	18	vaccination	vaccination	NOUN
eurjchem-2553	130	19	,	,	PUNCT
eurjchem-2553	130	20	represented	represent	VERB
eurjchem-2553	130	21	by	by	ADP
eurjchem-2553	130	22	heat	heat	NOUN
eurjchem-2553	130	23	maps	map	NOUN
eurjchem-2553	130	24	.	.	PUNCT
eurjchem-2553	131	1	it	it	PRON
eurjchem-2553	131	2	's	be	AUX
eurjchem-2553	131	3	interesting	interesting	ADJ
eurjchem-2553	131	4	to	to	PART
eurjchem-2553	131	5	note	note	VERB
eurjchem-2553	131	6	that	that	SCONJ
eurjchem-2553	131	7	following	follow	VERB
eurjchem-2553	131	8	the	the	DET
eurjchem-2553	131	9	third	third	ADJ
eurjchem-2553	131	10	treatment	treatment	NOUN
eurjchem-2553	131	11	(	(	PUNCT
eurjchem-2553	131	12	12	12	NUM
eurjchem-2553	131	13	months	month	NOUN
eurjchem-2553	131	14	)	)	PUNCT
eurjchem-2553	131	15	,	,	PUNCT
eurjchem-2553	131	16	the	the	DET
eurjchem-2553	131	17	seropositivity	seropositivity	NOUN
eurjchem-2553	131	18	rate	rate	NOUN
eurjchem-2553	131	19	increased	increase	VERB
eurjchem-2553	131	20	significantly	significantly	ADV
eurjchem-2553	131	21	to	to	ADP
eurjchem-2553	131	22	100	100	NUM
eurjchem-2553	131	23	%	%	NOUN
eurjchem-2553	131	24	(	(	PUNCT
eurjchem-2553	131	25	371/371	371/371	NUM
eurjchem-2553	131	26	)	)	PUNCT
eurjchem-2553	131	27	and	and	CCONJ
eurjchem-2553	131	28	the	the	DET
eurjchem-2553	131	29	igg	igg	PROPN
eurjchem-2553	131	30	antibodies	antibodies	PROPN
eurjchem-2553	131	31	produced	produce	VERB
eurjchem-2553	131	32	a	a	DET
eurjchem-2553	131	33	strong	strong	ADJ
eurjchem-2553	131	34	response	response	NOUN
eurjchem-2553	131	35	.	.	PUNCT
eurjchem-2553	132	1	after	after	ADP
eurjchem-2553	132	2	the	the	DET
eurjchem-2553	132	3	third	third	ADJ
eurjchem-2553	132	4	dosage	dosage	NOUN
eurjchem-2553	132	5	of	of	ADP
eurjchem-2553	132	6	vaccination	vaccination	NOUN
eurjchem-2553	132	7	,	,	PUNCT
eurjchem-2553	132	8	compared	compare	VERB
eurjchem-2553	132	9	to	to	ADP
eurjchem-2553	132	10	the	the	DET
eurjchem-2553	132	11	first	first	ADJ
eurjchem-2553	132	12	and	and	CCONJ
eurjchem-2553	132	13	second	second	ADJ
eurjchem-2553	132	14	doses	dose	NOUN
eurjchem-2553	132	15	,	,	PUNCT
eurjchem-2553	132	16	the	the	DET
eurjchem-2553	132	17	levels	level	NOUN
eurjchem-2553	132	18	of	of	ADP
eurjchem-2553	132	19	these	these	DET
eurjchem-2553	132	20	igg	igg	PROPN
eurjchem-2553	132	21	antibodies	antibody	NOUN
eurjchem-2553	132	22	increased	increase	VERB
eurjchem-2553	132	23	once	once	ADV
eurjchem-2553	132	24	more	more	ADV
eurjchem-2553	132	25	and	and	CCONJ
eurjchem-2553	132	26	continued	continue	VERB
eurjchem-2553	132	27	to	to	PART
eurjchem-2553	132	28	rise	rise	VERB
eurjchem-2553	132	29	for	for	ADP
eurjchem-2553	132	30	twelve	twelve	NUM
eurjchem-2553	132	31	months	month	NOUN
eurjchem-2553	132	32	.	.	PUNCT
eurjchem-2553	133	1	furthermore	furthermore	ADV
eurjchem-2553	133	2	,	,	PUNCT
eurjchem-2553	133	3	we	we	PRON
eurjchem-2553	133	4	measured	measure	VERB
eurjchem-2553	133	5	the	the	DET
eurjchem-2553	133	6	sars	sar	NOUN
eurjchem-2553	133	7	-	-	PUNCT
eurjchem-2553	133	8	cov-2	cov-2	NOUN
eurjchem-2553	133	9	antibody	antibody	NOUN
eurjchem-2553	133	10	,	,	PUNCT
eurjchem-2553	133	11	immunoglobulin	immunoglobulin	NOUN
eurjchem-2553	133	12	(	(	PUNCT
eurjchem-2553	133	13	ig	ig	PROPN
eurjchem-2553	133	14	)	)	PUNCT
eurjchem-2553	133	15	g	g	PROPN
eurjchem-2553	133	16	s	s	NOUN
eurjchem-2553	133	17	against	against	ADP
eurjchem-2553	133	18	full	full	ADJ
eurjchem-2553	133	19	spike	spike	NOUN
eurjchem-2553	133	20	and	and	CCONJ
eurjchem-2553	133	21	rbd	rbd	NOUN
eurjchem-2553	133	22	antigens	antigen	NOUN
eurjchem-2553	133	23	from	from	ADP
eurjchem-2553	133	24	the	the	DET
eurjchem-2553	133	25	previously	previously	ADV
eurjchem-2553	133	26	infected	infect	VERB
eurjchem-2553	133	27	and	and	CCONJ
eurjchem-2553	133	28	recovered	recovered	ADJ
eurjchem-2553	133	29	participants	participant	NOUN
eurjchem-2553	133	30	,	,	PUNCT
eurjchem-2553	133	31	and	and	CCONJ
eurjchem-2553	133	32	only	only	ADV
eurjchem-2553	133	33	vaccinated	vaccinate	VERB
eurjchem-2553	133	34	individuals	individual	NOUN
eurjchem-2553	133	35	of	of	ADP
eurjchem-2553	133	36	those	those	DET
eurjchem-2553	133	37	antibody	antibody	NOUN
eurjchem-2553	133	38	neutralization	neutralization	NOUN
eurjchem-2553	133	39	titer	titer	NOUN
eurjchem-2553	133	40	studies	study	NOUN
eurjchem-2553	133	41	were	be	AUX
eurjchem-2553	133	42	done	do	VERB
eurjchem-2553	133	43	in	in	ADP
eurjchem-2553	133	44	the	the	DET
eurjchem-2553	133	45	previous	previous	ADJ
eurjchem-2553	133	46	and	and	CCONJ
eurjchem-2553	133	47	present	present	ADJ
eurjchem-2553	133	48	investigation	investigation	NOUN
eurjchem-2553	133	49	(	(	PUNCT
eurjchem-2553	133	50	figure	figure	NOUN
eurjchem-2553	133	51	6	6	NUM
eurjchem-2553	133	52	)	)	PUNCT
eurjchem-2553	133	53	to	to	PART
eurjchem-2553	133	54	understand	understand	VERB
eurjchem-2553	133	55	the	the	DET
eurjchem-2553	133	56	antibody	antibody	NOUN
eurjchem-2553	133	57	response	response	NOUN
eurjchem-2553	133	58	following	follow	VERB
eurjchem-2553	133	59	the	the	DET
eurjchem-2553	133	60	doses	dose	NOUN
eurjchem-2553	133	61	1	1	NUM
eurjchem-2553	133	62	and	and	CCONJ
eurjchem-2553	133	63	2	2	NUM
eurjchem-2553	133	64	and	and	CCONJ
eurjchem-2553	133	65	3	3	NUM
eurjchem-2553	133	66	of	of	ADP
eurjchem-2553	133	67	covishield	covishield	ADJ
eurjchem-2553	133	68	vaccines	vaccine	NOUN
eurjchem-2553	133	69	(	(	PUNCT
eurjchem-2553	133	70	table	table	NOUN
eurjchem-2553	133	71	2	2	NUM
eurjchem-2553	133	72	)	)	PUNCT
eurjchem-2553	133	73	.	.	PUNCT
eurjchem-2553	134	1	the	the	DET
eurjchem-2553	134	2	predominant	predominant	ADJ
eurjchem-2553	134	3	response	response	NOUN
eurjchem-2553	134	4	was	be	AUX
eurjchem-2553	134	5	found	find	VERB
eurjchem-2553	134	6	for	for	SCONJ
eurjchem-2553	134	7	the	the	DET
eurjchem-2553	134	8	igg	igg	PROPN
eurjchem-2553	134	9	antibodies	antibodie	VERB
eurjchem-2553	134	10	in	in	ADP
eurjchem-2553	134	11	both	both	CCONJ
eurjchem-2553	134	12	naive	naive	ADJ
eurjchem-2553	134	13	and	and	CCONJ
eurjchem-2553	134	14	previously	previously	ADV
eurjchem-2553	134	15	infected	infect	VERB
eurjchem-2553	134	16	participants	participant	NOUN
eurjchem-2553	134	17	after	after	ADP
eurjchem-2553	134	18	doses	dose	NOUN
eurjchem-2553	134	19	1	1	NUM
eurjchem-2553	134	20	,	,	PUNCT
eurjchem-2553	134	21	2	2	NUM
eurjchem-2553	134	22	,	,	PUNCT
eurjchem-2553	134	23	and	and	CCONJ
eurjchem-2553	135	1	3	3	X
eurjchem-2553	135	2	.	.	PUNCT
eurjchem-2553	136	1	among	among	ADP
eurjchem-2553	136	2	naive	naive	ADJ
eurjchem-2553	136	3	individuals	individual	NOUN
eurjchem-2553	136	4	,	,	PUNCT
eurjchem-2553	136	5	igg	igg	PROPN
eurjchem-2553	136	6	antibodies	antibody	NOUN
eurjchem-2553	136	7	were	be	AUX
eurjchem-2553	136	8	higher	high	ADJ
eurjchem-2553	136	9	after	after	SCONJ
eurjchem-2553	136	10	the	the	DET
eurjchem-2553	136	11	booster	booster	NOUN
eurjchem-2553	136	12	dose	dose	NOUN
eurjchem-2553	136	13	(	(	PUNCT
eurjchem-2553	136	14	3rd	3rd	NOUN
eurjchem-2553	136	15	)	)	PUNCT
eurjchem-2553	136	16	than	than	ADP
eurjchem-2553	136	17	after	after	ADP
eurjchem-2553	136	18	the	the	DET
eurjchem-2553	136	19	first	first	ADJ
eurjchem-2553	136	20	dose	dose	NOUN
eurjchem-2553	136	21	(	(	PUNCT
eurjchem-2553	136	22	figure	figure	NOUN
eurjchem-2553	136	23	6	6	NUM
eurjchem-2553	136	24	)	)	PUNCT
eurjchem-2553	136	25	.	.	PUNCT
eurjchem-2553	137	1	however	however	ADV
eurjchem-2553	137	2	,	,	PUNCT
eurjchem-2553	137	3	igg	igg	PROPN
eurjchem-2553	137	4	levels	level	NOUN
eurjchem-2553	137	5	in	in	ADP
eurjchem-2553	137	6	the	the	DET
eurjchem-2553	137	7	previously	previously	ADV
eurjchem-2553	137	8	infected	infect	VERB
eurjchem-2553	137	9	individuals	individual	NOUN
eurjchem-2553	137	10	were	be	AUX
eurjchem-2553	137	11	comparable	comparable	ADJ
eurjchem-2553	137	12	with	with	ADP
eurjchem-2553	137	13	those	those	PRON
eurjchem-2553	137	14	in	in	ADP
eurjchem-2553	137	15	the	the	DET
eurjchem-2553	137	16	naive	naive	ADJ
eurjchem-2553	137	17	individuals	individual	NOUN
eurjchem-2553	137	18	after	after	ADP
eurjchem-2553	137	19	dose	dose	NOUN
eurjchem-2553	137	20	2	2	NUM
eurjchem-2553	137	21	,	,	PUNCT
eurjchem-2553	137	22	and	and	CCONJ
eurjchem-2553	137	23	were	be	AUX
eurjchem-2553	137	24	unchanged	unchanged	ADJ
eurjchem-2553	137	25	after	after	ADP
eurjchem-2553	137	26	dose	dose	NOUN
eurjchem-2553	137	27	3	3	NUM
eurjchem-2553	137	28	.	.	PUNCT
eurjchem-2553	137	29	jagadeesan	jagadeesan	NOUN
eurjchem-2553	137	30	et	et	PROPN
eurjchem-2553	137	31	al	al	PROPN
eurjchem-2553	137	32	.	.	PUNCT
eurjchem-2553	137	33	/	/	SYM
eurjchem-2553	137	34	european	european	PROPN
eurjchem-2553	137	35	journal	journal	PROPN
eurjchem-2553	137	36	of	of	ADP
eurjchem-2553	137	37	chemistry	chemistry	NOUN
eurjchem-2553	137	38	15	15	NUM
eurjchem-2553	137	39	(	(	PUNCT
eurjchem-2553	137	40	3	3	NUM
eurjchem-2553	137	41	)	)	PUNCT
eurjchem-2553	137	42	(	(	PUNCT
eurjchem-2553	137	43	2024	2024	NUM
eurjchem-2553	137	44	)	)	PUNCT
eurjchem-2553	137	45	274	274	NUM
eurjchem-2553	137	46	-	-	SYM
eurjchem-2553	137	47	281	281	NUM
eurjchem-2553	137	48	279	279	NUM
eurjchem-2553	137	49	2024	2024	NUM
eurjchem-2553	137	50	–	–	PUNCT
eurjchem-2553	137	51	european	european	ADJ
eurjchem-2553	137	52	journal	journal	NOUN
eurjchem-2553	137	53	of	of	ADP
eurjchem-2553	137	54	chemistry	chemistry	NOUN
eurjchem-2553	137	55	–	–	PUNCT
eurjchem-2553	137	56	cc	cc	NOUN
eurjchem-2553	137	57	by	by	ADP
eurjchem-2553	137	58	nc	nc	PROPN
eurjchem-2553	137	59	–	–	PUNCT
eurjchem-2553	137	60	doi	doi	PROPN
eurjchem-2553	137	61	:	:	PUNCT
eurjchem-2553	137	62	10.5155	10.5155	NUM
eurjchem-2553	137	63	/	/	SYM
eurjchem-2553	137	64	eurjchem.15.3.274	eurjchem.15.3.274	ADJ
eurjchem-2553	137	65	-	-	SYM
eurjchem-2553	137	66	281.2553	281.2553	NUM
eurjchem-2553	137	67	table	table	NOUN
eurjchem-2553	137	68	2	2	NUM
eurjchem-2553	137	69	.	.	PUNCT
eurjchem-2553	137	70	participants	participant	NOUN
eurjchem-2553	137	71	who	who	PRON
eurjchem-2553	137	72	received	receive	VERB
eurjchem-2553	137	73	the	the	DET
eurjchem-2553	137	74	first	first	ADJ
eurjchem-2553	137	75	,	,	PUNCT
eurjchem-2553	137	76	second	second	ADJ
eurjchem-2553	137	77	,	,	PUNCT
eurjchem-2553	137	78	and	and	CCONJ
eurjchem-2553	137	79	third	third	ADJ
eurjchem-2553	137	80	doses	dose	NOUN
eurjchem-2553	137	81	of	of	ADP
eurjchem-2553	137	82	covishieldtm	covishieldtm	ADJ
eurjchem-2553	137	83	vaccine	vaccine	NOUN
eurjchem-2553	137	84	(	(	PUNCT
eurjchem-2553	137	85	n	n	NOUN
eurjchem-2553	137	86	=	=	NUM
eurjchem-2553	137	87	371	371	NUM
eurjchem-2553	137	88	)	)	PUNCT
eurjchem-2553	137	89	.	.	PUNCT
eurjchem-2553	138	1	covid	covid	PROPN
eurjchem-2553	138	2	test	test	NOUN
eurjchem-2553	138	3	result	result	NOUN
eurjchem-2553	138	4	vaccine	vaccine	NOUN
eurjchem-2553	138	5	n	n	PRON
eurjchem-2553	138	6	mean	mean	VERB
eurjchem-2553	138	7	sd	sd	ADP
eurjchem-2553	138	8	median	median	ADJ
eurjchem-2553	138	9	minimum	minimum	ADJ
eurjchem-2553	138	10	maximum	maximum	ADJ
eurjchem-2553	138	11	p	p	NOUN
eurjchem-2553	138	12	value	value	NOUN
eurjchem-2553	138	13	+	+	NOUN
eurjchem-2553	138	14	ve	ve	AUX
eurjchem-2553	138	15	dose	dose	VERB
eurjchem-2553	138	16	1	1	NUM
eurjchem-2553	138	17	27	27	NUM
eurjchem-2553	138	18	60.3	60.3	NUM
eurjchem-2553	138	19	31.290	31.290	NUM
eurjchem-2553	138	20	64.0	64.0	NUM
eurjchem-2553	138	21	7.30	7.30	NUM
eurjchem-2553	138	22	99.60	99.60	NUM
eurjchem-2553	139	1	p	p	NOUN
eurjchem-2553	139	2	<	<	X
eurjchem-2553	139	3	0.001	0.001	NUM
eurjchem-2553	139	4	dose	dose	NOUN
eurjchem-2553	139	5	2	2	NUM
eurjchem-2553	139	6	39	39	NUM
eurjchem-2553	139	7	80.4	80.4	NUM
eurjchem-2553	139	8	20.240	20.240	NUM
eurjchem-2553	139	9	86.4	86.4	NUM
eurjchem-2553	139	10	35.30	35.30	NUM
eurjchem-2553	139	11	99.50	99.50	NUM
eurjchem-2553	139	12	dose	dose	NOUN
eurjchem-2553	139	13	3	3	NUM
eurjchem-2553	139	14	48	48	NUM
eurjchem-2553	139	15	91.6	91.6	NUM
eurjchem-2553	139	16	7.554	7.554	NUM
eurjchem-2553	139	17	94.1	94.1	NUM
eurjchem-2553	139	18	57.45	57.45	NUM
eurjchem-2553	139	19	97.91	97.91	NUM
eurjchem-2553	139	20	-ve	-ve	NOUN
eurjchem-2553	139	21	dose	dose	VERB
eurjchem-2553	139	22	1	1	NUM
eurjchem-2553	139	23	45	45	NUM
eurjchem-2553	139	24	71.7	71.7	NUM
eurjchem-2553	139	25	26.848	26.848	NUM
eurjchem-2553	139	26	81.5	81.5	NUM
eurjchem-2553	139	27	9.53	9.53	NUM
eurjchem-2553	139	28	99.17	99.17	NUM
eurjchem-2553	140	1	p	p	X
eurjchem-2553	140	2	<	<	X
eurjchem-2553	140	3	0.001	0.001	NUM
eurjchem-2553	140	4	dose	dose	VERB
eurjchem-2553	140	5	2	2	NUM
eurjchem-2553	140	6	52	52	NUM
eurjchem-2553	140	7	82.4	82.4	NUM
eurjchem-2553	140	8	19.529	19.529	NUM
eurjchem-2553	140	9	91.8	91.8	NUM
eurjchem-2553	140	10	32.00	32.00	NUM
eurjchem-2553	140	11	99.70	99.70	NUM
eurjchem-2553	140	12	dose	dose	NOUN
eurjchem-2553	140	13	3	3	NUM
eurjchem-2553	140	14	66	66	NUM
eurjchem-2553	140	15	90.3	90.3	NUM
eurjchem-2553	140	16	8.904	8.904	NUM
eurjchem-2553	140	17	92.6	92.6	NUM
eurjchem-2553	140	18	48.37	48.37	NUM
eurjchem-2553	140	19	98.69	98.69	NUM
eurjchem-2553	140	20	table	table	NOUN
eurjchem-2553	140	21	3	3	NUM
eurjchem-2553	140	22	.	.	PUNCT
eurjchem-2553	140	23	analysis	analysis	NOUN
eurjchem-2553	140	24	of	of	ADP
eurjchem-2553	140	25	sars	sar	NOUN
eurjchem-2553	140	26	-	-	PUNCT
eurjchem-2553	140	27	cov-2	cov-2	NOUN
eurjchem-2553	140	28	live	live	ADJ
eurjchem-2553	140	29	virus	virus	NOUN
eurjchem-2553	140	30	neutralizing	neutralize	VERB
eurjchem-2553	140	31	antibody	antibody	NOUN
eurjchem-2553	140	32	titers	titer	NOUN
eurjchem-2553	140	33	(	(	PUNCT
eurjchem-2553	140	34	n	n	NOUN
eurjchem-2553	140	35	=	=	SYM
eurjchem-2553	140	36	53	53	NUM
eurjchem-2553	140	37	)	)	PUNCT
eurjchem-2553	140	38	.	.	PUNCT
eurjchem-2553	141	1	vaccine	vaccine	NOUN
eurjchem-2553	142	1	n	n	PRON
eurjchem-2553	142	2	mean	mean	VERB
eurjchem-2553	142	3	sd	sd	ADP
eurjchem-2553	142	4	median	median	ADJ
eurjchem-2553	142	5	minimum	minimum	ADJ
eurjchem-2553	142	6	maximum	maximum	ADJ
eurjchem-2553	142	7	p	p	NOUN
eurjchem-2553	142	8	value	value	NOUN
eurjchem-2553	142	9	dose	dose	VERB
eurjchem-2553	142	10	1	1	NUM
eurjchem-2553	142	11	53	53	NUM
eurjchem-2553	142	12	68.0	68.0	NUM
eurjchem-2553	142	13	27.466	27.466	NUM
eurjchem-2553	142	14	69.5	69.5	NUM
eurjchem-2553	142	15	7.30	7.30	NUM
eurjchem-2553	142	16	99.17	99.17	NUM
eurjchem-2553	142	17	p	p	NOUN
eurjchem-2553	142	18	<	<	X
eurjchem-2553	142	19	0.001	0.001	NUM
eurjchem-2553	142	20	dose	dose	VERB
eurjchem-2553	142	21	2	2	NUM
eurjchem-2553	142	22	53	53	NUM
eurjchem-2553	142	23	82.9	82.9	NUM
eurjchem-2553	142	24	18.074	18.074	NUM
eurjchem-2553	142	25	91.6	91.6	NUM
eurjchem-2553	142	26	35.30	35.30	NUM
eurjchem-2553	142	27	99.50	99.50	NUM
eurjchem-2553	142	28	dose	dose	NOUN
eurjchem-2553	142	29	3	3	NUM
eurjchem-2553	142	30	53	53	NUM
eurjchem-2553	142	31	90.0	90.0	NUM
eurjchem-2553	142	32	9.271	9.271	NUM
eurjchem-2553	142	33	92.4	92.4	NUM
eurjchem-2553	142	34	48.37	48.37	NUM
eurjchem-2553	142	35	98.69	98.69	NUM
eurjchem-2553	142	36	figure	figure	NOUN
eurjchem-2553	142	37	7	7	NUM
eurjchem-2553	142	38	.	.	PUNCT
eurjchem-2553	142	39	geometric	geometric	ADJ
eurjchem-2553	142	40	mean	mean	NOUN
eurjchem-2553	142	41	(	(	PUNCT
eurjchem-2553	142	42	gm	gm	PROPN
eurjchem-2553	142	43	)	)	PUNCT
eurjchem-2553	142	44	with	with	ADP
eurjchem-2553	142	45	95	95	NUM
eurjchem-2553	142	46	%	%	NOUN
eurjchem-2553	142	47	confidence	confidence	NOUN
eurjchem-2553	142	48	interval	interval	NOUN
eurjchem-2553	142	49	(	(	PUNCT
eurjchem-2553	142	50	ci	ci	NOUN
eurjchem-2553	142	51	)	)	PUNCT
eurjchem-2553	142	52	for	for	ADP
eurjchem-2553	142	53	the	the	DET
eurjchem-2553	142	54	nab	nab	ADJ
eurjchem-2553	142	55	titers	titer	NOUN
eurjchem-2553	142	56	in	in	ADP
eurjchem-2553	142	57	hcw	hcw	PROPN
eurjchem-2553	142	58	3	3	NUM
eurjchem-2553	142	59	months	month	NOUN
eurjchem-2553	142	60	after	after	ADP
eurjchem-2553	142	61	the	the	DET
eurjchem-2553	142	62	1st	1st	PROPN
eurjchem-2553	142	63	dose	dose	NOUN
eurjchem-2553	142	64	covishield	covishield	NOUN
eurjchem-2553	142	65	,	,	PUNCT
eurjchem-2553	142	66	6	6	NUM
eurjchem-2553	142	67	months	month	NOUN
eurjchem-2553	142	68	after	after	ADP
eurjchem-2553	142	69	the	the	DET
eurjchem-2553	142	70	2nd	2nd	PROPN
eurjchem-2553	142	71	dose	dose	NOUN
eurjchem-2553	142	72	of	of	ADP
eurjchem-2553	142	73	covishieldtm	covishieldtm	NOUN
eurjchem-2553	142	74	and	and	CCONJ
eurjchem-2553	142	75	12	12	NUM
eurjchem-2553	142	76	months	month	NOUN
eurjchem-2553	142	77	after	after	ADP
eurjchem-2553	142	78	the	the	DET
eurjchem-2553	142	79	3rd	3rd	PROPN
eurjchem-2553	142	80	dose	dose	NOUN
eurjchem-2553	142	81	(	(	PUNCT
eurjchem-2553	142	82	booster	booster	NOUN
eurjchem-2553	142	83	)	)	PUNCT
eurjchem-2553	142	84	of	of	ADP
eurjchem-2553	142	85	covishield	covishield	NOUN
eurjchem-2553	142	86	(	(	PUNCT
eurjchem-2553	142	87	*	*	PUNCT
eurjchem-2553	142	88	*	*	PUNCT
eurjchem-2553	142	89	*	*	PUNCT
eurjchem-2553	142	90	p	p	X
eurjchem-2553	142	91	<	<	X
eurjchem-2553	142	92	0.001	0.001	NUM
eurjchem-2553	142	93	)	)	PUNCT
eurjchem-2553	142	94	.	.	PUNCT
eurjchem-2553	143	1	3.3	3.3	NUM
eurjchem-2553	143	2	.	.	PUNCT
eurjchem-2553	144	1	analysis	analysis	NOUN
eurjchem-2553	144	2	of	of	ADP
eurjchem-2553	144	3	neutralization	neutralization	NOUN
eurjchem-2553	144	4	titers	titer	NOUN
eurjchem-2553	144	5	of	of	ADP
eurjchem-2553	144	6	the	the	DET
eurjchem-2553	144	7	same	same	ADJ
eurjchem-2553	144	8	individual	individual	NOUN
eurjchem-2553	144	9	’s	’s	PART
eurjchem-2553	144	10	sera	sera	NOUN
eurjchem-2553	144	11	variables	variable	NOUN
eurjchem-2553	144	12	associated	associate	VERB
eurjchem-2553	144	13	with	with	ADP
eurjchem-2553	144	14	anti	anti	ADJ
eurjchem-2553	144	15	-	-	ADJ
eurjchem-2553	144	16	spike	spike	ADJ
eurjchem-2553	144	17	anti	anti	ADJ
eurjchem-2553	144	18	-	-	ADJ
eurjchem-2553	144	19	body	body	ADJ
eurjchem-2553	144	20	titers	titer	NOUN
eurjchem-2553	144	21	after	after	ADP
eurjchem-2553	144	22	three	three	NUM
eurjchem-2553	144	23	doses	dose	NOUN
eurjchem-2553	144	24	of	of	ADP
eurjchem-2553	144	25	vaccine	vaccine	NOUN
eurjchem-2553	144	26	chadox1	chadox1	NOUN
eurjchem-2553	144	27	-	-	PUNCT
eurjchem-2553	144	28	ncov	ncov	NOUN
eurjchem-2553	144	29	(	(	PUNCT
eurjchem-2553	144	30	covishield	covishield	NOUN
eurjchem-2553	144	31	™	™	PROPN
eurjchem-2553	144	32	)	)	PUNCT
eurjchem-2553	144	33	114	114	NUM
eurjchem-2553	144	34	participants	participant	NOUN
eurjchem-2553	144	35	never	never	ADV
eurjchem-2553	144	36	achieved	achieve	VERB
eurjchem-2553	144	37	positive	positive	ADJ
eurjchem-2553	144	38	conversion	conversion	NOUN
eurjchem-2553	144	39	after	after	ADP
eurjchem-2553	144	40	vaccination	vaccination	NOUN
eurjchem-2553	144	41	during	during	ADP
eurjchem-2553	144	42	the	the	DET
eurjchem-2553	144	43	three	three	NUM
eurjchem-2553	144	44	-	-	PUNCT
eurjchem-2553	144	45	dose	dose	NOUN
eurjchem-2553	144	46	regimen	regiman	NOUN
eurjchem-2553	144	47	.	.	PUNCT
eurjchem-2553	145	1	their	their	PRON
eurjchem-2553	145	2	igg	igg	PROPN
eurjchem-2553	145	3	response	response	NOUN
eurjchem-2553	145	4	was	be	AUX
eurjchem-2553	145	5	maximum	maximum	ADJ
eurjchem-2553	145	6	after	after	ADP
eurjchem-2553	145	7	the	the	DET
eurjchem-2553	145	8	third	third	ADJ
eurjchem-2553	145	9	dose	dose	NOUN
eurjchem-2553	145	10	.	.	PUNCT
eurjchem-2553	146	1	in	in	ADP
eurjchem-2553	146	2	particular	particular	ADJ
eurjchem-2553	146	3	,	,	PUNCT
eurjchem-2553	146	4	participants	participant	NOUN
eurjchem-2553	146	5	who	who	PRON
eurjchem-2553	146	6	had	have	AUX
eurjchem-2553	146	7	achieved	achieve	VERB
eurjchem-2553	146	8	positive	positive	ADJ
eurjchem-2553	146	9	conversion	conversion	NOUN
eurjchem-2553	146	10	after	after	SCONJ
eurjchem-2553	146	11	the	the	DET
eurjchem-2553	146	12	second	second	ADJ
eurjchem-2553	146	13	dose	dose	NOUN
eurjchem-2553	146	14	did	do	AUX
eurjchem-2553	146	15	not	not	PART
eurjchem-2553	146	16	again	again	ADV
eurjchem-2553	146	17	exhibit	exhibit	VERB
eurjchem-2553	146	18	positive	positive	ADJ
eurjchem-2553	146	19	conversion	conversion	NOUN
eurjchem-2553	146	20	after	after	ADP
eurjchem-2553	146	21	the	the	DET
eurjchem-2553	146	22	third	third	ADJ
eurjchem-2553	146	23	dose	dose	NOUN
eurjchem-2553	146	24	(	(	PUNCT
eurjchem-2553	146	25	figure	figure	NOUN
eurjchem-2553	146	26	7	7	NUM
eurjchem-2553	146	27	)	)	PUNCT
eurjchem-2553	146	28	.	.	PUNCT
eurjchem-2553	147	1	the	the	DET
eurjchem-2553	147	2	igg	igg	PROPN
eurjchem-2553	147	3	(	(	PUNCT
eurjchem-2553	147	4	anti	anti	ADJ
eurjchem-2553	147	5	-	-	ADJ
eurjchem-2553	147	6	rbd	rbd	ADJ
eurjchem-2553	147	7	/	/	SYM
eurjchem-2553	147	8	s	s	NOUN
eurjchem-2553	147	9	)	)	PUNCT
eurjchem-2553	147	10	titer	titer	NOUN
eurjchem-2553	147	11	was	be	AUX
eurjchem-2553	147	12	significantly	significantly	ADV
eurjchem-2553	147	13	higher	high	ADJ
eurjchem-2553	147	14	in	in	ADP
eurjchem-2553	147	15	vaccinated	vaccinated	ADJ
eurjchem-2553	147	16	individuals	individual	NOUN
eurjchem-2553	147	17	after	after	ADP
eurjchem-2553	147	18	one	one	NUM
eurjchem-2553	147	19	or	or	CCONJ
eurjchem-2553	147	20	two	two	NUM
eurjchem-2553	147	21	vaccine	vaccine	NOUN
eurjchem-2553	147	22	doses	dose	NOUN
eurjchem-2553	147	23	,	,	PUNCT
eurjchem-2553	147	24	compared	compare	VERB
eurjchem-2553	147	25	with	with	ADP
eurjchem-2553	147	26	the	the	DET
eurjchem-2553	147	27	baseline	baseline	ADJ
eurjchem-2553	147	28	values	value	NOUN
eurjchem-2553	147	29	of	of	ADP
eurjchem-2553	147	30	individuals	individual	NOUN
eurjchem-2553	147	31	who	who	PRON
eurjchem-2553	147	32	had	have	AUX
eurjchem-2553	147	33	developed	develop	VERB
eurjchem-2553	147	34	an	an	DET
eurjchem-2553	147	35	immunity	immunity	NOUN
eurjchem-2553	147	36	response	response	NOUN
eurjchem-2553	147	37	after	after	ADP
eurjchem-2553	147	38	a	a	DET
eurjchem-2553	147	39	previous	previous	ADJ
eurjchem-2553	147	40	sars	sar	NOUN
eurjchem-2553	147	41	-	-	PUNCT
eurjchem-2553	147	42	cov-2	cov-2	NOUN
eurjchem-2553	147	43	infection	infection	NOUN
eurjchem-2553	147	44	.	.	PUNCT
eurjchem-2553	148	1	the	the	DET
eurjchem-2553	148	2	gm	gm	PROPN
eurjchem-2553	148	3	of	of	ADP
eurjchem-2553	148	4	igg	igg	PROPN
eurjchem-2553	148	5	(	(	PUNCT
eurjchem-2553	148	6	anti	anti	ADJ
eurjchem-2553	148	7	-	-	ADJ
eurjchem-2553	148	8	rbd	rbd	ADJ
eurjchem-2553	148	9	/	/	SYM
eurjchem-2553	148	10	s	s	PROPN
eurjchem-2553	148	11	)	)	PUNCT
eurjchem-2553	148	12	,	,	PUNCT
eurjchem-2553	148	13	after	after	SCONJ
eurjchem-2553	148	14	one	one	NUM
eurjchem-2553	148	15	vaccine	vaccine	NOUN
eurjchem-2553	148	16	dose	dose	VERB
eurjchem-2553	148	17	from	from	ADP
eurjchem-2553	148	18	vaccinated	vaccinate	VERB
eurjchem-2553	148	19	individuals	individual	NOUN
eurjchem-2553	148	20	was	be	AUX
eurjchem-2553	148	21	significantly	significantly	ADV
eurjchem-2553	148	22	higher	high	ADJ
eurjchem-2553	148	23	(	(	PUNCT
eurjchem-2553	148	24	p	p	X
eurjchem-2553	148	25	<	<	X
eurjchem-2553	148	26	0.001	0.001	NUM
eurjchem-2553	148	27	)	)	PUNCT
eurjchem-2553	148	28	than	than	SCONJ
eurjchem-2553	148	29	gm	gm	PROPN
eurjchem-2553	148	30	found	find	VERB
eurjchem-2553	148	31	at	at	ADP
eurjchem-2553	148	32	the	the	DET
eurjchem-2553	148	33	point	point	NOUN
eurjchem-2553	148	34	of	of	ADP
eurjchem-2553	148	35	recruitment	recruitment	NOUN
eurjchem-2553	148	36	for	for	ADP
eurjchem-2553	148	37	individuals	individual	NOUN
eurjchem-2553	148	38	that	that	PRON
eurjchem-2553	148	39	had	have	VERB
eurjchem-2553	148	40	a	a	DET
eurjchem-2553	148	41	previous	previous	ADJ
eurjchem-2553	148	42	infection	infection	NOUN
eurjchem-2553	148	43	.	.	PUNCT
eurjchem-2553	149	1	the	the	DET
eurjchem-2553	149	2	main	main	ADJ
eurjchem-2553	149	3	objective	objective	NOUN
eurjchem-2553	149	4	of	of	ADP
eurjchem-2553	149	5	the	the	DET
eurjchem-2553	149	6	current	current	ADJ
eurjchem-2553	149	7	study	study	NOUN
eurjchem-2553	149	8	was	be	AUX
eurjchem-2553	149	9	to	to	PART
eurjchem-2553	149	10	compare	compare	VERB
eurjchem-2553	149	11	the	the	DET
eurjchem-2553	149	12	spike	spike	ADJ
eurjchem-2553	149	13	neutralization	neutralization	NOUN
eurjchem-2553	149	14	activity	activity	NOUN
eurjchem-2553	149	15	(	(	PUNCT
eurjchem-2553	149	16	n	n	NOUN
eurjchem-2553	149	17	=	=	SYM
eurjchem-2553	149	18	53	53	NUM
eurjchem-2553	149	19	)	)	PUNCT
eurjchem-2553	149	20	after	after	ADP
eurjchem-2553	149	21	determining	determine	VERB
eurjchem-2553	149	22	the	the	DET
eurjchem-2553	149	23	serostatus	serostatus	NOUN
eurjchem-2553	149	24	of	of	ADP
eurjchem-2553	149	25	sars	sar	NOUN
eurjchem-2553	149	26	-	-	PUNCT
eurjchem-2553	149	27	cov-2	cov-2	NOUN
eurjchem-2553	149	28	among	among	ADP
eurjchem-2553	149	29	covishield	covishield	NOUN
eurjchem-2553	149	30	vaccination	vaccination	NOUN
eurjchem-2553	149	31	recipients	recipient	NOUN
eurjchem-2553	149	32	(	(	PUNCT
eurjchem-2553	149	33	table	table	NOUN
eurjchem-2553	149	34	3	3	NUM
eurjchem-2553	149	35	)	)	PUNCT
eurjchem-2553	149	36	.	.	PUNCT
eurjchem-2553	150	1	the	the	DET
eurjchem-2553	150	2	igg	igg	PROPN
eurjchem-2553	150	3	antibodies	antibody	NOUN
eurjchem-2553	150	4	remained	remain	VERB
eurjchem-2553	150	5	detectable	detectable	ADJ
eurjchem-2553	150	6	in	in	ADP
eurjchem-2553	150	7	all	all	DET
eurjchem-2553	150	8	participants	participant	NOUN
eurjchem-2553	150	9	for	for	ADP
eurjchem-2553	150	10	the	the	DET
eurjchem-2553	150	11	study	study	NOUN
eurjchem-2553	150	12	duration	duration	NOUN
eurjchem-2553	150	13	.	.	PUNCT
eurjchem-2553	151	1	3.4	3.4	NUM
eurjchem-2553	151	2	.	.	PUNCT
eurjchem-2553	151	3	present	present	ADJ
eurjchem-2553	151	4	study	study	NOUN
eurjchem-2553	151	5	findings	finding	NOUN
eurjchem-2553	151	6	and	and	CCONJ
eurjchem-2553	151	7	further	further	ADJ
eurjchem-2553	151	8	implications	implication	NOUN
eurjchem-2553	151	9	for	for	ADP
eurjchem-2553	151	10	practice	practice	NOUN
eurjchem-2553	151	11	and	and	CCONJ
eurjchem-2553	151	12	research	research	VERB
eurjchem-2553	151	13	our	our	PRON
eurjchem-2553	151	14	prospective	prospective	ADJ
eurjchem-2553	151	15	longitudinal	longitudinal	ADJ
eurjchem-2553	151	16	study	study	NOUN
eurjchem-2553	151	17	assesses	assesse	NOUN
eurjchem-2553	151	18	over	over	ADP
eurjchem-2553	151	19	more	more	ADJ
eurjchem-2553	151	20	than	than	ADP
eurjchem-2553	151	21	one	one	NUM
eurjchem-2553	151	22	year	year	NOUN
eurjchem-2553	151	23	:	:	PUNCT
eurjchem-2553	151	24	the	the	DET
eurjchem-2553	151	25	anti	anti	ADJ
eurjchem-2553	151	26	-	-	ADJ
eurjchem-2553	151	27	sars	sars	ADJ
eurjchem-2553	151	28	-	-	PUNCT
eurjchem-2553	151	29	cov-2	cov-2	NOUN
eurjchem-2553	151	30	antibody	antibody	NOUN
eurjchem-2553	151	31	,	,	PUNCT
eurjchem-2553	151	32	persistence	persistence	NOUN
eurjchem-2553	151	33	against	against	ADP
eurjchem-2553	151	34	anti	anti	ADJ
eurjchem-2553	151	35	-	-	ADJ
eurjchem-2553	151	36	rbd	rbd	ADJ
eurjchem-2553	151	37	after	after	ADP
eurjchem-2553	151	38	primary	primary	ADJ
eurjchem-2553	151	39	infection	infection	NOUN
eurjchem-2553	151	40	,	,	PUNCT
eurjchem-2553	151	41	the	the	DET
eurjchem-2553	151	42	neutralizing	neutralizing	ADJ
eurjchem-2553	151	43	capacity	capacity	NOUN
eurjchem-2553	151	44	of	of	ADP
eurjchem-2553	151	45	these	these	DET
eurjchem-2553	151	46	antibodies	antibody	NOUN
eurjchem-2553	151	47	against	against	ADP
eurjchem-2553	151	48	live	live	ADJ
eurjchem-2553	151	49	virus	virus	NOUN
eurjchem-2553	151	50	variants	variant	NOUN
eurjchem-2553	151	51	of	of	ADP
eurjchem-2553	151	52	concern	concern	NOUN
eurjchem-2553	151	53	the	the	DET
eurjchem-2553	151	54	influence	influence	NOUN
eurjchem-2553	151	55	of	of	ADP
eurjchem-2553	151	56	host	host	NOUN
eurjchem-2553	151	57	factors	factor	NOUN
eurjchem-2553	151	58	on	on	ADP
eurjchem-2553	151	59	antibody	antibody	NOUN
eurjchem-2553	151	60	kinetics	kinetic	NOUN
eurjchem-2553	151	61	,	,	PUNCT
eurjchem-2553	151	62	the	the	DET
eurjchem-2553	151	63	impact	impact	NOUN
eurjchem-2553	151	64	of	of	ADP
eurjchem-2553	151	65	vaccination	vaccination	NOUN
eurjchem-2553	151	66	on	on	ADP
eurjchem-2553	151	67	humoral	humoral	ADJ
eurjchem-2553	151	68	responses	response	NOUN
eurjchem-2553	151	69	against	against	ADP
eurjchem-2553	151	70	sars	sar	NOUN
eurjchem-2553	151	71	-	-	PUNCT
eurjchem-2553	151	72	cov-2	cov-2	NOUN
eurjchem-2553	151	73	variants	variant	NOUN
eurjchem-2553	151	74	after	after	ADP
eurjchem-2553	151	75	covid-19	covid-19	PROPN
eurjchem-2553	151	76	,	,	PUNCT
eurjchem-2553	151	77	and	and	CCONJ
eurjchem-2553	151	78	long	long	ADJ
eurjchem-2553	151	79	-	-	PUNCT
eurjchem-2553	151	80	term	term	NOUN
eurjchem-2553	151	81	risk	risk	NOUN
eurjchem-2553	151	82	of	of	ADP
eurjchem-2553	151	83	reinfection	reinfection	NOUN
eurjchem-2553	151	84	during	during	ADP
eurjchem-2553	151	85	sarscov-2	sarscov-2	NUM
eurjchem-2553	151	86	variants	variant	NOUN
eurjchem-2553	151	87	spread	spread	VERB
eurjchem-2553	151	88	.	.	PUNCT
eurjchem-2553	152	1	we	we	PRON
eurjchem-2553	152	2	found	find	VERB
eurjchem-2553	152	3	that	that	SCONJ
eurjchem-2553	152	4	vaccination	vaccination	NOUN
eurjchem-2553	152	5	with	with	ADP
eurjchem-2553	152	6	covishieldtm	covishieldtm	VERB
eurjchem-2553	152	7	increases	increase	VERB
eurjchem-2553	152	8	anti	anti	ADJ
eurjchem-2553	152	9	-	-	ADJ
eurjchem-2553	152	10	rbd	rbd	ADJ
eurjchem-2553	152	11	igg	igg	PROPN
eurjchem-2553	152	12	to	to	ADP
eurjchem-2553	152	13	a	a	DET
eurjchem-2553	152	14	level	level	NOUN
eurjchem-2553	152	15	that	that	PRON
eurjchem-2553	152	16	strongly	strongly	ADV
eurjchem-2553	152	17	neutralizes	neutralize	VERB
eurjchem-2553	152	18	sars	sar	NOUN
eurjchem-2553	152	19	-	-	PUNCT
eurjchem-2553	152	20	cov-2	cov-2	PART
eurjchem-2553	152	21	variants	variant	NOUN
eurjchem-2553	152	22	regardless	regardless	ADV
eurjchem-2553	152	23	of	of	ADP
eurjchem-2553	152	24	prevaccine	prevaccine	ADJ
eurjchem-2553	152	25	igg	igg	PROPN
eurjchem-2553	152	26	levels	level	NOUN
eurjchem-2553	152	27	and	and	CCONJ
eurjchem-2553	152	28	dose	dose	NOUN
eurjchem-2553	152	29	-	-	PUNCT
eurjchem-2553	152	30	dependant	dependant	ADJ
eurjchem-2553	152	31	manner	manner	NOUN
eurjchem-2553	152	32	.	.	PUNCT
eurjchem-2553	153	1	furthermore	furthermore	ADV
eurjchem-2553	153	2	,	,	PUNCT
eurjchem-2553	153	3	this	this	DET
eurjchem-2553	153	4	study	study	NOUN
eurjchem-2553	153	5	offered	offer	VERB
eurjchem-2553	153	6	a	a	DET
eurjchem-2553	153	7	unique	unique	ADJ
eurjchem-2553	153	8	opportunity	opportunity	NOUN
eurjchem-2553	153	9	to	to	PART
eurjchem-2553	153	10	evaluate	evaluate	VERB
eurjchem-2553	153	11	the	the	DET
eurjchem-2553	153	12	risk	risk	NOUN
eurjchem-2553	153	13	of	of	ADP
eurjchem-2553	153	14	reinfection	reinfection	NOUN
eurjchem-2553	153	15	following	follow	VERB
eurjchem-2553	153	16	previous	previous	ADJ
eurjchem-2553	153	17	covid-19	covid-19	PROPN
eurjchem-2553	153	18	with	with	ADP
eurjchem-2553	153	19	a	a	DET
eurjchem-2553	153	20	longitudinal	longitudinal	ADJ
eurjchem-2553	153	21	follow	follow	NOUN
eurjchem-2553	153	22	-	-	PUNCT
eurjchem-2553	153	23	up	up	NOUN
eurjchem-2553	153	24	of	of	ADP
eurjchem-2553	153	25	convalescent	convalescent	NOUN
eurjchem-2553	153	26	and	and	CCONJ
eurjchem-2553	153	27	recovered	recover	VERB
eurjchem-2553	153	28	individuals	individual	NOUN
eurjchem-2553	153	29	during	during	ADP
eurjchem-2553	153	30	the	the	DET
eurjchem-2553	153	31	same	same	ADJ
eurjchem-2553	153	32	period	period	NOUN
eurjchem-2553	153	33	,	,	PUNCT
eurjchem-2553	153	34	which	which	PRON
eurjchem-2553	153	35	includes	include	VERB
eurjchem-2553	153	36	the	the	DET
eurjchem-2553	153	37	three	three	NUM
eurjchem-2553	153	38	covid-19	covid-19	PROPN
eurjchem-2553	153	39	waves	wave	NOUN
eurjchem-2553	153	40	experienced	experience	VERB
eurjchem-2553	153	41	in	in	ADP
eurjchem-2553	153	42	india	india	PROPN
eurjchem-2553	153	43	.	.	PUNCT
eurjchem-2553	154	1	analysis	analysis	NOUN
eurjchem-2553	154	2	of	of	ADP
eurjchem-2553	154	3	clinical	clinical	ADJ
eurjchem-2553	154	4	and	and	CCONJ
eurjchem-2553	154	5	virological	virological	ADJ
eurjchem-2553	154	6	data	datum	NOUN
eurjchem-2553	154	7	revealed	reveal	VERB
eurjchem-2553	154	8	that	that	SCONJ
eurjchem-2553	154	9	the	the	DET
eurjchem-2553	154	10	risk	risk	NOUN
eurjchem-2553	154	11	of	of	ADP
eurjchem-2553	154	12	reinfection	reinfection	NOUN
eurjchem-2553	154	13	was	be	AUX
eurjchem-2553	154	14	reduced	reduce	VERB
eurjchem-2553	154	15	by	by	ADP
eurjchem-2553	154	16	96.7	96.7	NUM
eurjchem-2553	154	17	%	%	NOUN
eurjchem-2553	154	18	over	over	ADP
eurjchem-2553	154	19	one	one	NUM
eurjchem-2553	154	20	year	year	NOUN
eurjchem-2553	154	21	.	.	PUNCT
eurjchem-2553	155	1	4	4	X
eurjchem-2553	155	2	.	.	X
eurjchem-2553	155	3	discussions	discussion	NOUN
eurjchem-2553	155	4	the	the	DET
eurjchem-2553	155	5	severe	severe	ADJ
eurjchem-2553	155	6	acute	acute	ADJ
eurjchem-2553	155	7	respiratory	respiratory	ADJ
eurjchem-2553	155	8	syndrome	syndrome	NOUN
eurjchem-2553	155	9	coronavirus-2	coronavirus-2	NUM
eurjchem-2553	155	10	is	be	AUX
eurjchem-2553	155	11	the	the	DET
eurjchem-2553	155	12	cause	cause	NOUN
eurjchem-2553	155	13	behind	behind	ADP
eurjchem-2553	155	14	the	the	DET
eurjchem-2553	155	15	highly	highly	ADV
eurjchem-2553	155	16	contagious	contagious	ADJ
eurjchem-2553	155	17	respiratory	respiratory	ADJ
eurjchem-2553	155	18	ailment	ailment	NOUN
eurjchem-2553	155	19	known	know	VERB
eurjchem-2553	155	20	as	as	ADP
eurjchem-2553	155	21	coronavirus	coronavirus	NOUN
eurjchem-2553	155	22	disease	disease	NOUN
eurjchem-2553	155	23	of	of	ADP
eurjchem-2553	155	24	2019	2019	NUM
eurjchem-2553	155	25	(	(	PUNCT
eurjchem-2553	155	26	covid-19	covid-19	PROPN
eurjchem-2553	155	27	)	)	PUNCT
eurjchem-2553	155	28	(	(	PUNCT
eurjchem-2553	155	29	sars	sar	NOUN
eurjchem-2553	155	30	-	-	PUNCT
eurjchem-2553	155	31	cov2	cov2	PROPN
eurjchem-2553	155	32	)	)	PUNCT
eurjchem-2553	156	1	[	[	X
eurjchem-2553	156	2	16	16	NUM
eurjchem-2553	156	3	]	]	PUNCT
eurjchem-2553	156	4	.	.	PUNCT
eurjchem-2553	157	1	through	through	ADP
eurjchem-2553	157	2	the	the	DET
eurjchem-2553	157	3	angiotensin	angiotensin	NOUN
eurjchem-2553	157	4	-	-	PUNCT
eurjchem-2553	157	5	converting	convert	VERB
eurjchem-2553	157	6	enzyme	enzyme	NOUN
eurjchem-2553	157	7	2	2	NUM
eurjchem-2553	157	8	(	(	PUNCT
eurjchem-2553	157	9	ace2	ace2	NOUN
eurjchem-2553	157	10	)	)	PUNCT
eurjchem-2553	157	11	receptor	receptor	NOUN
eurjchem-2553	157	12	,	,	PUNCT
eurjchem-2553	157	13	sars	sar	NOUN
eurjchem-2553	157	14	-	-	PUNCT
eurjchem-2553	157	15	cov-2	cov-2	NOUN
eurjchem-2553	157	16	infects	infect	VERB
eurjchem-2553	157	17	alveolar	alveolar	ADJ
eurjchem-2553	157	18	epithelial	epithelial	ADJ
eurjchem-2553	157	19	cells	cell	NOUN
eurjchem-2553	157	20	and	and	CCONJ
eurjchem-2553	157	21	primarily	primarily	ADV
eurjchem-2553	157	22	alveolar	alveolar	ADJ
eurjchem-2553	157	23	epithelial	epithelial	ADJ
eurjchem-2553	157	24	type	type	NOUN
eurjchem-2553	157	25	2	2	NUM
eurjchem-2553	157	26	cells	cell	NOUN
eurjchem-2553	157	27	[	[	X
eurjchem-2553	157	28	14	14	NUM
eurjchem-2553	157	29	]	]	PUNCT
eurjchem-2553	157	30	.	.	PUNCT
eurjchem-2553	158	1	the	the	DET
eurjchem-2553	158	2	innate	innate	ADJ
eurjchem-2553	158	3	immune	immune	ADJ
eurjchem-2553	158	4	system	system	NOUN
eurjchem-2553	158	5	is	be	AUX
eurjchem-2553	158	6	also	also	ADV
eurjchem-2553	158	7	activated	activate	VERB
eurjchem-2553	158	8	by	by	ADP
eurjchem-2553	158	9	sars	sar	NOUN
eurjchem-2553	158	10	-	-	PUNCT
eurjchem-2553	158	11	cov-2	cov-2	NUM
eurjchem-2553	158	12	;	;	PUNCT
eurjchem-2553	158	13	macrophage	macrophage	ADJ
eurjchem-2553	158	14	stimulation	stimulation	NOUN
eurjchem-2553	158	15	results	result	NOUN
eurjchem-2553	158	16	in	in	ADP
eurjchem-2553	158	17	an	an	DET
eurjchem-2553	158	18	overproduction	overproduction	NOUN
eurjchem-2553	158	19	of	of	ADP
eurjchem-2553	158	20	pro	pro	ADJ
eurjchem-2553	158	21	-	-	ADJ
eurjchem-2553	158	22	inflammatory	inflammatory	ADJ
eurjchem-2553	158	23	cytokines	cytokine	NOUN
eurjchem-2553	158	24	,	,	PUNCT
eurjchem-2553	158	25	such	such	ADJ
eurjchem-2553	158	26	as	as	ADP
eurjchem-2553	158	27	il-6	il-6	NUM
eurjchem-2553	158	28	,	,	PUNCT
eurjchem-2553	158	29	and	and	CCONJ
eurjchem-2553	158	30	the	the	DET
eurjchem-2553	158	31	"	"	PUNCT
eurjchem-2553	158	32	cytokine	cytokine	ADJ
eurjchem-2553	158	33	storm	storm	NOUN
eurjchem-2553	158	34	"	"	PUNCT
eurjchem-2553	158	35	,	,	PUNCT
eurjchem-2553	158	36	which	which	PRON
eurjchem-2553	158	37	causes	cause	VERB
eurjchem-2553	158	38	multiple	multiple	ADJ
eurjchem-2553	158	39	organ	organ	NOUN
eurjchem-2553	158	40	failure	failure	NOUN
eurjchem-2553	158	41	and	and	CCONJ
eurjchem-2553	158	42	the	the	DET
eurjchem-2553	158	43	systemic	systemic	ADJ
eurjchem-2553	158	44	inflammatory	inflammatory	ADJ
eurjchem-2553	158	45	response	response	NOUN
eurjchem-2553	158	46	syndrome	syndrome	NOUN
eurjchem-2553	158	47	[	[	X
eurjchem-2553	158	48	17	17	NUM
eurjchem-2553	158	49	]	]	PUNCT
eurjchem-2553	158	50	.	.	PUNCT
eurjchem-2553	159	1	understanding	understand	VERB
eurjchem-2553	159	2	the	the	DET
eurjchem-2553	159	3	covid-19	covid-19	PROPN
eurjchem-2553	159	4	pandemic	pandemic	NOUN
eurjchem-2553	159	5	critically	critically	ADV
eurjchem-2553	159	6	depends	depend	VERB
eurjchem-2553	159	7	on	on	ADP
eurjchem-2553	159	8	the	the	DET
eurjchem-2553	159	9	duration	duration	NOUN
eurjchem-2553	159	10	that	that	PRON
eurjchem-2553	159	11	adaptive	adaptive	ADJ
eurjchem-2553	159	12	immunity	immunity	NOUN
eurjchem-2553	159	13	against	against	ADP
eurjchem-2553	159	14	sars	sar	NOUN
eurjchem-2553	159	15	-	-	PUNCT
eurjchem-2553	159	16	cov-2	cov-2	NOUN
eurjchem-2553	159	17	lasts	last	VERB
eurjchem-2553	159	18	as	as	ADV
eurjchem-2553	159	19	well	well	ADV
eurjchem-2553	159	20	as	as	ADP
eurjchem-2553	159	21	how	how	SCONJ
eurjchem-2553	159	22	effectively	effectively	ADV
eurjchem-2553	159	23	it	it	PRON
eurjchem-2553	159	24	works	work	VERB
eurjchem-2553	159	25	after	after	ADP
eurjchem-2553	159	26	the	the	DET
eurjchem-2553	159	27	primary	primary	ADJ
eurjchem-2553	159	28	infection	infection	NOUN
eurjchem-2553	159	29	[	[	X
eurjchem-2553	159	30	18	18	NUM
eurjchem-2553	159	31	]	]	PUNCT
eurjchem-2553	159	32	.	.	PUNCT
eurjchem-2553	160	1	the	the	DET
eurjchem-2553	160	2	ability	ability	NOUN
eurjchem-2553	160	3	to	to	PART
eurjchem-2553	160	4	determine	determine	VERB
eurjchem-2553	160	5	the	the	DET
eurjchem-2553	160	6	occurrence	occurrence	NOUN
eurjchem-2553	160	7	of	of	ADP
eurjchem-2553	160	8	covid-19	covid-19	PROPN
eurjchem-2553	160	9	,	,	PUNCT
eurjchem-2553	160	10	quickly	quickly	ADV
eurjchem-2553	160	11	identify	identify	VERB
eurjchem-2553	160	12	asymptomatic	asymptomatic	ADJ
eurjchem-2553	160	13	patients	patient	NOUN
eurjchem-2553	160	14	,	,	PUNCT
eurjchem-2553	160	15	and	and	CCONJ
eurjchem-2553	160	16	assess	assess	VERB
eurjchem-2553	160	17	covid-19	covid-19	PROPN
eurjchem-2553	160	18	patients	patient	NOUN
eurjchem-2553	160	19	after	after	SCONJ
eurjchem-2553	160	20	therapy	therapy	NOUN
eurjchem-2553	160	21	is	be	AUX
eurjchem-2553	160	22	made	make	VERB
eurjchem-2553	160	23	possible	possible	ADJ
eurjchem-2553	160	24	by	by	ADP
eurjchem-2553	160	25	antibody	antibody	NOUN
eurjchem-2553	160	26	testing	testing	NOUN
eurjchem-2553	160	27	against	against	ADP
eurjchem-2553	160	28	sars	sar	NOUN
eurjchem-2553	160	29	-	-	PUNCT
eurjchem-2553	160	30	cov-2	cov-2	NOUN
eurjchem-2553	160	31	[	[	NOUN
eurjchem-2553	160	32	19	19	NUM
eurjchem-2553	160	33	]	]	PUNCT
eurjchem-2553	160	34	.	.	PUNCT
eurjchem-2553	161	1	monitoring	monitor	VERB
eurjchem-2553	161	2	the	the	DET
eurjchem-2553	161	3	existence	existence	NOUN
eurjchem-2553	161	4	of	of	ADP
eurjchem-2553	161	5	antibodies	antibody	NOUN
eurjchem-2553	161	6	against	against	ADP
eurjchem-2553	161	7	sars	sar	NOUN
eurjchem-2553	161	8	-	-	PUNCT
eurjchem-2553	161	9	cov-2	cov-2	PART
eurjchem-2553	161	10	following	follow	VERB
eurjchem-2553	161	11	vaccination	vaccination	NOUN
eurjchem-2553	161	12	is	be	AUX
eurjchem-2553	161	13	another	another	DET
eurjchem-2553	161	14	function	function	NOUN
eurjchem-2553	161	15	of	of	ADP
eurjchem-2553	161	16	antibody	antibody	NOUN
eurjchem-2553	161	17	testing	testing	NOUN
eurjchem-2553	161	18	in	in	ADP
eurjchem-2553	161	19	the	the	DET
eurjchem-2553	161	20	covid-19	covid-19	PROPN
eurjchem-2553	161	21	vaccine	vaccine	NOUN
eurjchem-2553	161	22	era	era	NOUN
eurjchem-2553	161	23	[	[	X
eurjchem-2553	161	24	20	20	NUM
eurjchem-2553	161	25	]	]	PUNCT
eurjchem-2553	161	26	.	.	PUNCT
eurjchem-2553	162	1	the	the	DET
eurjchem-2553	162	2	two	two	NUM
eurjchem-2553	162	3	main	main	ADJ
eurjchem-2553	162	4	categories	category	NOUN
eurjchem-2553	162	5	of	of	ADP
eurjchem-2553	162	6	the	the	DET
eurjchem-2553	162	7	280	280	NUM
eurjchem-2553	162	8	jagadeesan	jagadeesan	NOUN
eurjchem-2553	162	9	et	et	PROPN
eurjchem-2553	162	10	al	al	PROPN
eurjchem-2553	162	11	.	.	PUNCT
eurjchem-2553	162	12	/	/	SYM
eurjchem-2553	162	13	european	european	PROPN
eurjchem-2553	162	14	journal	journal	PROPN
eurjchem-2553	162	15	of	of	ADP
eurjchem-2553	162	16	chemistry	chemistry	NOUN
eurjchem-2553	162	17	15	15	NUM
eurjchem-2553	162	18	(	(	PUNCT
eurjchem-2553	162	19	3	3	NUM
eurjchem-2553	162	20	)	)	PUNCT
eurjchem-2553	162	21	(	(	PUNCT
eurjchem-2553	162	22	2024	2024	NUM
eurjchem-2553	162	23	)	)	PUNCT
eurjchem-2553	162	24	274	274	NUM
eurjchem-2553	162	25	-	-	SYM
eurjchem-2553	162	26	281	281	NUM
eurjchem-2553	162	27	2024	2024	NUM
eurjchem-2553	162	28	–	–	PUNCT
eurjchem-2553	162	29	european	european	ADJ
eurjchem-2553	162	30	journal	journal	NOUN
eurjchem-2553	162	31	of	of	ADP
eurjchem-2553	162	32	chemistry	chemistry	NOUN
eurjchem-2553	162	33	–	–	PUNCT
eurjchem-2553	162	34	cc	cc	NOUN
eurjchem-2553	162	35	by	by	ADP
eurjchem-2553	162	36	nc	nc	PROPN
eurjchem-2553	162	37	–	–	PUNCT
eurjchem-2553	162	38	doi	doi	PROPN
eurjchem-2553	162	39	:	:	PUNCT
eurjchem-2553	162	40	10.5155	10.5155	NUM
eurjchem-2553	162	41	/	/	SYM
eurjchem-2553	162	42	eurjchem.15.3.274	eurjchem.15.3.274	ADJ
eurjchem-2553	162	43	-	-	SYM
eurjchem-2553	162	44	281.2553	281.2553	NUM
eurjchem-2553	162	45	antibody	antibody	NOUN
eurjchem-2553	162	46	test	test	NOUN
eurjchem-2553	162	47	are	be	AUX
eurjchem-2553	162	48	binding	bind	VERB
eurjchem-2553	162	49	and	and	CCONJ
eurjchem-2553	162	50	neutralizing	neutralize	VERB
eurjchem-2553	162	51	antibody	antibody	NOUN
eurjchem-2553	162	52	assays	assay	NOUN
eurjchem-2553	162	53	.	.	PUNCT
eurjchem-2553	163	1	antibodies	antibodie	VERB
eurjchem-2553	163	2	(	(	PUNCT
eurjchem-2553	163	3	igg	igg	PROPN
eurjchem-2553	163	4	,	,	PUNCT
eurjchem-2553	163	5	igm	igm	PROPN
eurjchem-2553	163	6	,	,	PUNCT
eurjchem-2553	163	7	or	or	CCONJ
eurjchem-2553	163	8	total	total	NOUN
eurjchem-2553	163	9	)	)	PUNCT
eurjchem-2553	163	10	against	against	ADP
eurjchem-2553	163	11	the	the	DET
eurjchem-2553	163	12	spike	spike	ADJ
eurjchem-2553	163	13	protein	protein	NOUN
eurjchem-2553	163	14	receptor	receptor	NOUN
eurjchem-2553	163	15	-	-	PUNCT
eurjchem-2553	163	16	binding	bind	VERB
eurjchem-2553	163	17	domain	domain	NOUN
eurjchem-2553	163	18	(	(	PUNCT
eurjchem-2553	163	19	rbd	rbd	NOUN
eurjchem-2553	163	20	)	)	PUNCT
eurjchem-2553	163	21	,	,	PUNCT
eurjchem-2553	163	22	partial	partial	ADJ
eurjchem-2553	163	23	spike	spike	ADJ
eurjchem-2553	163	24	protein	protein	NOUN
eurjchem-2553	163	25	(	(	PUNCT
eurjchem-2553	163	26	s1	s1	NOUN
eurjchem-2553	163	27	subunit	subunit	NOUN
eurjchem-2553	163	28	,	,	PUNCT
eurjchem-2553	163	29	s2	s2	NOUN
eurjchem-2553	163	30	subunit	subunit	NOUN
eurjchem-2553	163	31	)	)	PUNCT
eurjchem-2553	163	32	,	,	PUNCT
eurjchem-2553	163	33	or	or	CCONJ
eurjchem-2553	163	34	nucleocapsid	nucleocapsid	ADJ
eurjchem-2553	163	35	protein	protein	NOUN
eurjchem-2553	163	36	can	can	AUX
eurjchem-2553	163	37	be	be	AUX
eurjchem-2553	163	38	found	find	VERB
eurjchem-2553	163	39	using	use	VERB
eurjchem-2553	163	40	binding	bind	VERB
eurjchem-2553	163	41	antibody	antibody	NOUN
eurjchem-2553	163	42	assays	assay	NOUN
eurjchem-2553	163	43	(	(	PUNCT
eurjchem-2553	163	44	n	n	CCONJ
eurjchem-2553	163	45	)	)	PUNCT
eurjchem-2553	163	46	.	.	PUNCT
eurjchem-2553	164	1	the	the	DET
eurjchem-2553	164	2	presence	presence	NOUN
eurjchem-2553	164	3	of	of	ADP
eurjchem-2553	164	4	functional	functional	ADJ
eurjchem-2553	164	5	antibodies	antibody	NOUN
eurjchem-2553	164	6	to	to	PART
eurjchem-2553	164	7	stop	stop	VERB
eurjchem-2553	164	8	sars	sar	NOUN
eurjchem-2553	164	9	-	-	PUNCT
eurjchem-2553	164	10	cov-2	cov-2	PART
eurjchem-2553	164	11	infection	infection	NOUN
eurjchem-2553	164	12	is	be	AUX
eurjchem-2553	164	13	identified	identify	VERB
eurjchem-2553	164	14	by	by	ADP
eurjchem-2553	164	15	the	the	DET
eurjchem-2553	164	16	neutralizing	neutralize	VERB
eurjchem-2553	164	17	antibody	antibody	NOUN
eurjchem-2553	164	18	assay	assay	VERB
eurjchem-2553	165	1	[	[	X
eurjchem-2553	165	2	21	21	NUM
eurjchem-2553	165	3	]	]	PUNCT
eurjchem-2553	165	4	.	.	PUNCT
eurjchem-2553	166	1	our	our	PRON
eurjchem-2553	166	2	results	result	NOUN
eurjchem-2553	166	3	demonstrated	demonstrate	VERB
eurjchem-2553	166	4	that	that	SCONJ
eurjchem-2553	166	5	robust	robust	ADJ
eurjchem-2553	166	6	seropositive	seropositive	ADJ
eurjchem-2553	166	7	rates	rate	NOUN
eurjchem-2553	166	8	were	be	AUX
eurjchem-2553	166	9	observed	observe	VERB
eurjchem-2553	166	10	after	after	ADP
eurjchem-2553	166	11	the	the	DET
eurjchem-2553	166	12	first	first	ADJ
eurjchem-2553	166	13	and	and	CCONJ
eurjchem-2553	166	14	second	second	ADJ
eurjchem-2553	166	15	vaccinations	vaccination	NOUN
eurjchem-2553	166	16	of	of	ADP
eurjchem-2553	166	17	covishield	covishield	NOUN
eurjchem-2553	166	18	.	.	PUNCT
eurjchem-2553	167	1	corresponding	correspond	VERB
eurjchem-2553	167	2	well	well	NOUN
eurjchem-2553	167	3	with	with	ADP
eurjchem-2553	167	4	these	these	DET
eurjchem-2553	167	5	findings	finding	NOUN
eurjchem-2553	167	6	,	,	PUNCT
eurjchem-2553	167	7	our	our	PRON
eurjchem-2553	167	8	previous	previous	ADJ
eurjchem-2553	167	9	study	study	NOUN
eurjchem-2553	167	10	reported	report	VERB
eurjchem-2553	167	11	that	that	SCONJ
eurjchem-2553	167	12	seropositive	seropositive	ADJ
eurjchem-2553	167	13	rates	rate	NOUN
eurjchem-2553	167	14	after	after	ADP
eurjchem-2553	167	15	the	the	DET
eurjchem-2553	167	16	first	first	ADJ
eurjchem-2553	167	17	and	and	CCONJ
eurjchem-2553	167	18	second	second	ADJ
eurjchem-2553	167	19	vaccinations	vaccination	NOUN
eurjchem-2553	167	20	of	of	ADP
eurjchem-2553	167	21	covishield	covishield	ADJ
eurjchem-2553	167	22	vaccine	vaccine	NOUN
eurjchem-2553	167	23	were	be	AUX
eurjchem-2553	167	24	significantly	significantly	ADV
eurjchem-2553	167	25	high	high	ADJ
eurjchem-2553	167	26	(	(	PUNCT
eurjchem-2553	167	27	92	92	NUM
eurjchem-2553	167	28	-	-	SYM
eurjchem-2553	167	29	98.5	98.5	NUM
eurjchem-2553	167	30	%	%	NOUN
eurjchem-2553	167	31	)	)	PUNCT
eurjchem-2553	168	1	[	[	X
eurjchem-2553	168	2	9	9	NUM
eurjchem-2553	168	3	]	]	PUNCT
eurjchem-2553	168	4	.	.	PUNCT
eurjchem-2553	169	1	the	the	DET
eurjchem-2553	169	2	humoral	humoral	ADJ
eurjchem-2553	169	3	immune	immune	ADJ
eurjchem-2553	169	4	response	response	NOUN
eurjchem-2553	169	5	after	after	ADP
eurjchem-2553	169	6	vaccination	vaccination	NOUN
eurjchem-2553	169	7	could	could	AUX
eurjchem-2553	169	8	differ	differ	VERB
eurjchem-2553	169	9	according	accord	VERB
eurjchem-2553	169	10	to	to	ADP
eurjchem-2553	169	11	age	age	NOUN
eurjchem-2553	169	12	,	,	PUNCT
eurjchem-2553	169	13	sex	sex	NOUN
eurjchem-2553	169	14	,	,	PUNCT
eurjchem-2553	169	15	and	and	CCONJ
eurjchem-2553	169	16	ethnicity	ethnicity	NOUN
eurjchem-2553	169	17	.	.	PUNCT
eurjchem-2553	170	1	this	this	DET
eurjchem-2553	170	2	study	study	NOUN
eurjchem-2553	170	3	demonstrated	demonstrate	VERB
eurjchem-2553	170	4	that	that	SCONJ
eurjchem-2553	170	5	age	age	NOUN
eurjchem-2553	170	6	and	and	CCONJ
eurjchem-2553	170	7	gender	gender	NOUN
eurjchem-2553	170	8	did	do	AUX
eurjchem-2553	170	9	not	not	PART
eurjchem-2553	170	10	statistically	statistically	ADV
eurjchem-2553	170	11	affect	affect	VERB
eurjchem-2553	170	12	antibody	antibody	NOUN
eurjchem-2553	170	13	response	response	NOUN
eurjchem-2553	170	14	after	after	ADP
eurjchem-2553	170	15	the	the	DET
eurjchem-2553	170	16	second	second	ADJ
eurjchem-2553	170	17	and	and	CCONJ
eurjchem-2553	170	18	third	third	ADJ
eurjchem-2553	170	19	(	(	PUNCT
eurjchem-2553	170	20	booster	booster	NOUN
eurjchem-2553	170	21	)	)	PUNCT
eurjchem-2553	170	22	vaccinations	vaccination	NOUN
eurjchem-2553	170	23	,	,	PUNCT
eurjchem-2553	170	24	and	and	CCONJ
eurjchem-2553	170	25	our	our	PRON
eurjchem-2553	170	26	previous	previous	ADJ
eurjchem-2553	170	27	studies	study	NOUN
eurjchem-2553	170	28	showed	show	VERB
eurjchem-2553	170	29	conflicting	conflicting	ADJ
eurjchem-2553	170	30	results	result	NOUN
eurjchem-2553	170	31	for	for	ADP
eurjchem-2553	170	32	vaccine	vaccine	NOUN
eurjchem-2553	170	33	response	response	NOUN
eurjchem-2553	170	34	by	by	ADP
eurjchem-2553	170	35	age	age	NOUN
eurjchem-2553	170	36	and	and	CCONJ
eurjchem-2553	170	37	gender	gender	NOUN
eurjchem-2553	170	38	.	.	PUNCT
eurjchem-2553	171	1	the	the	DET
eurjchem-2553	171	2	causes	cause	NOUN
eurjchem-2553	171	3	driving	drive	VERB
eurjchem-2553	171	4	this	this	DET
eurjchem-2553	171	5	"	"	PUNCT
eurjchem-2553	171	6	antigenic	antigenic	ADJ
eurjchem-2553	171	7	shift	shift	NOUN
eurjchem-2553	171	8	"	"	PUNCT
eurjchem-2553	171	9	are	be	AUX
eurjchem-2553	171	10	likely	likely	ADJ
eurjchem-2553	171	11	to	to	PART
eurjchem-2553	171	12	become	become	VERB
eurjchem-2553	171	13	stronger	strong	ADJ
eurjchem-2553	171	14	when	when	SCONJ
eurjchem-2553	171	15	most	most	ADJ
eurjchem-2553	171	16	of	of	ADP
eurjchem-2553	171	17	the	the	DET
eurjchem-2553	171	18	population	population	NOUN
eurjchem-2553	171	19	develops	develop	VERB
eurjchem-2553	171	20	resistance	resistance	NOUN
eurjchem-2553	171	21	to	to	ADP
eurjchem-2553	171	22	the	the	DET
eurjchem-2553	171	23	virus	virus	NOUN
eurjchem-2553	171	24	through	through	ADP
eurjchem-2553	171	25	infection	infection	NOUN
eurjchem-2553	171	26	,	,	PUNCT
eurjchem-2553	171	27	vaccination	vaccination	NOUN
eurjchem-2553	171	28	,	,	PUNCT
eurjchem-2553	171	29	or	or	CCONJ
eurjchem-2553	171	30	both	both	PRON
eurjchem-2553	171	31	.	.	PUNCT
eurjchem-2553	172	1	the	the	DET
eurjchem-2553	172	2	sars	sar	NOUN
eurjchem-2553	172	3	cov-2	cov-2	PART
eurjchem-2553	172	4	neutralizing	neutralize	VERB
eurjchem-2553	172	5	antibody	antibody	NOUN
eurjchem-2553	172	6	developed	develop	VERB
eurjchem-2553	172	7	after	after	ADP
eurjchem-2553	172	8	immunization	immunization	NOUN
eurjchem-2553	172	9	and	and	CCONJ
eurjchem-2553	172	10	is	be	AUX
eurjchem-2553	172	11	retained	retain	VERB
eurjchem-2553	172	12	in	in	ADP
eurjchem-2553	172	13	the	the	DET
eurjchem-2553	172	14	blood	blood	NOUN
eurjchem-2553	172	15	for	for	ADP
eurjchem-2553	172	16	several	several	ADJ
eurjchem-2553	172	17	months	month	NOUN
eurjchem-2553	172	18	depending	depend	VERB
eurjchem-2553	172	19	on	on	ADP
eurjchem-2553	172	20	several	several	ADJ
eurjchem-2553	172	21	physiological	physiological	ADJ
eurjchem-2553	172	22	factors	factor	NOUN
eurjchem-2553	172	23	.	.	PUNCT
eurjchem-2553	173	1	according	accord	VERB
eurjchem-2553	173	2	to	to	ADP
eurjchem-2553	173	3	floriane	floriane	NOUN
eurjchem-2553	173	4	et	et	PROPN
eurjchem-2553	173	5	al	al	PROPN
eurjchem-2553	173	6	.	.	PROPN
eurjchem-2553	173	7	,	,	PUNCT
eurjchem-2553	173	8	a	a	DET
eurjchem-2553	173	9	study	study	NOUN
eurjchem-2553	173	10	that	that	PRON
eurjchem-2553	173	11	examined	examine	VERB
eurjchem-2553	173	12	antibody	antibody	NOUN
eurjchem-2553	173	13	responses	response	VERB
eurjchem-2553	173	14	up	up	ADP
eurjchem-2553	173	15	to	to	PART
eurjchem-2553	173	16	13	13	NUM
eurjchem-2553	173	17	months	month	NOUN
eurjchem-2553	173	18	after	after	ADP
eurjchem-2553	173	19	sars	sar	NOUN
eurjchem-2553	173	20	-	-	PUNCT
eurjchem-2553	173	21	cov-2	cov-2	PART
eurjchem-2553	173	22	infection	infection	NOUN
eurjchem-2553	173	23	and	and	CCONJ
eurjchem-2553	173	24	the	the	DET
eurjchem-2553	173	25	risk	risk	NOUN
eurjchem-2553	173	26	of	of	ADP
eurjchem-2553	173	27	reinfection	reinfection	NOUN
eurjchem-2553	173	28	,	,	PUNCT
eurjchem-2553	173	29	the	the	DET
eurjchem-2553	173	30	slight	slight	ADJ
eurjchem-2553	173	31	antibody	antibody	NOUN
eurjchem-2553	173	32	decline	decline	NOUN
eurjchem-2553	173	33	seen	see	VERB
eurjchem-2553	173	34	in	in	ADP
eurjchem-2553	173	35	convalescent	convalescent	NOUN
eurjchem-2553	173	36	individuals	individual	NOUN
eurjchem-2553	173	37	does	do	AUX
eurjchem-2553	173	38	not	not	PART
eurjchem-2553	173	39	actually	actually	ADV
eurjchem-2553	173	40	reflect	reflect	VERB
eurjchem-2553	173	41	a	a	DET
eurjchem-2553	173	42	waning	waning	NOUN
eurjchem-2553	173	43	of	of	ADP
eurjchem-2553	173	44	humoral	humoral	ADJ
eurjchem-2553	173	45	immunity	immunity	NOUN
eurjchem-2553	173	46	but	but	CCONJ
eurjchem-2553	173	47	rather	rather	ADV
eurjchem-2553	173	48	a	a	DET
eurjchem-2553	173	49	contraction	contraction	NOUN
eurjchem-2553	173	50	of	of	ADP
eurjchem-2553	173	51	the	the	DET
eurjchem-2553	173	52	immune	immune	ADJ
eurjchem-2553	173	53	response	response	NOUN
eurjchem-2553	173	54	,	,	PUNCT
eurjchem-2553	173	55	while	while	SCONJ
eurjchem-2553	173	56	antibody	antibody	NOUN
eurjchem-2553	173	57	affinity	affinity	NOUN
eurjchem-2553	173	58	maturation	maturation	NOUN
eurjchem-2553	173	59	and	and	CCONJ
eurjchem-2553	173	60	anti	anti	ADJ
eurjchem-2553	173	61	-	-	ADJ
eurjchem-2553	173	62	s	s	X
eurjchem-2553	173	63	memory	memory	NOUN
eurjchem-2553	173	64	b	b	PROPN
eurjchem-2553	173	65	cells	cell	NOUN
eurjchem-2553	173	66	persist	persist	VERB
eurjchem-2553	174	1	[	[	X
eurjchem-2553	174	2	22	22	NUM
eurjchem-2553	174	3	]	]	PUNCT
eurjchem-2553	174	4	.	.	PUNCT
eurjchem-2553	175	1	according	accord	VERB
eurjchem-2553	175	2	to	to	ADP
eurjchem-2553	175	3	a	a	DET
eurjchem-2553	175	4	recent	recent	ADJ
eurjchem-2553	175	5	study	study	NOUN
eurjchem-2553	175	6	by	by	ADP
eurjchem-2553	175	7	wang	wang	PROPN
eurjchem-2553	175	8	et	et	PROPN
eurjchem-2553	175	9	al	al	PROPN
eurjchem-2553	175	10	.	.	PROPN
eurjchem-2553	175	11	,	,	PUNCT
eurjchem-2553	175	12	memory	memory	NOUN
eurjchem-2553	175	13	b	b	PROPN
eurjchem-2553	175	14	cell	cell	NOUN
eurjchem-2553	175	15	clones	clone	NOUN
eurjchem-2553	175	16	that	that	PRON
eurjchem-2553	175	17	express	express	VERB
eurjchem-2553	175	18	strong	strong	ADJ
eurjchem-2553	175	19	and	and	CCONJ
eurjchem-2553	175	20	broad	broad	ADJ
eurjchem-2553	175	21	anti	anti	ADJ
eurjchem-2553	175	22	-	-	ADJ
eurjchem-2553	175	23	s	s	ADJ
eurjchem-2553	175	24	antibodies	antibody	NOUN
eurjchem-2553	175	25	are	be	AUX
eurjchem-2553	175	26	selectively	selectively	ADV
eurjchem-2553	175	27	preserved	preserve	VERB
eurjchem-2553	175	28	in	in	ADP
eurjchem-2553	175	29	the	the	DET
eurjchem-2553	175	30	repertoire	repertoire	NOUN
eurjchem-2553	175	31	for	for	ADP
eurjchem-2553	175	32	at	at	ADV
eurjchem-2553	175	33	least	least	ADV
eurjchem-2553	175	34	a	a	PRON
eurjchem-2553	175	35	year	year	NOUN
eurjchem-2553	175	36	after	after	ADP
eurjchem-2553	175	37	infection	infection	NOUN
eurjchem-2553	175	38	and	and	CCONJ
eurjchem-2553	175	39	persist	persist	VERB
eurjchem-2553	175	40	after	after	ADP
eurjchem-2553	175	41	vaccination	vaccination	NOUN
eurjchem-2553	175	42	[	[	X
eurjchem-2553	175	43	23	23	NUM
eurjchem-2553	175	44	]	]	PUNCT
eurjchem-2553	175	45	.	.	PUNCT
eurjchem-2553	176	1	these	these	DET
eurjchem-2553	176	2	findings	finding	NOUN
eurjchem-2553	176	3	provide	provide	VERB
eurjchem-2553	176	4	highly	highly	ADV
eurjchem-2553	176	5	encouraging	encouraging	ADJ
eurjchem-2553	176	6	evidence	evidence	NOUN
eurjchem-2553	176	7	for	for	ADP
eurjchem-2553	176	8	the	the	DET
eurjchem-2553	176	9	longevity	longevity	NOUN
eurjchem-2553	176	10	of	of	ADP
eurjchem-2553	176	11	humoral	humoral	ADJ
eurjchem-2553	176	12	responses	response	NOUN
eurjchem-2553	176	13	induced	induce	VERB
eurjchem-2553	176	14	by	by	ADP
eurjchem-2553	176	15	covid-19	covid-19	PROPN
eurjchem-2553	176	16	and	and	CCONJ
eurjchem-2553	176	17	imply	imply	VERB
eurjchem-2553	176	18	that	that	DET
eurjchem-2553	176	19	long	long	ADJ
eurjchem-2553	176	20	-	-	PUNCT
eurjchem-2553	176	21	term	term	NOUN
eurjchem-2553	176	22	protection	protection	NOUN
eurjchem-2553	176	23	against	against	ADP
eurjchem-2553	176	24	sars	sar	NOUN
eurjchem-2553	176	25	-	-	PUNCT
eurjchem-2553	176	26	cov-2	cov-2	PART
eurjchem-2553	176	27	infection	infection	NOUN
eurjchem-2553	176	28	may	may	AUX
eurjchem-2553	176	29	be	be	AUX
eurjchem-2553	176	30	possible	possible	ADJ
eurjchem-2553	176	31	[	[	X
eurjchem-2553	176	32	24,25	24,25	NUM
eurjchem-2553	176	33	]	]	PUNCT
eurjchem-2553	176	34	.	.	PUNCT
eurjchem-2553	177	1	in	in	ADP
eurjchem-2553	177	2	conclusion	conclusion	NOUN
eurjchem-2553	177	3	,	,	PUNCT
eurjchem-2553	177	4	our	our	PRON
eurjchem-2553	177	5	study	study	NOUN
eurjchem-2553	177	6	provides	provide	VERB
eurjchem-2553	177	7	crucial	crucial	ADJ
eurjchem-2553	177	8	information	information	NOUN
eurjchem-2553	177	9	on	on	ADP
eurjchem-2553	177	10	the	the	DET
eurjchem-2553	177	11	persistence	persistence	NOUN
eurjchem-2553	177	12	of	of	ADP
eurjchem-2553	177	13	circulating	circulate	VERB
eurjchem-2553	177	14	antibodies	antibody	NOUN
eurjchem-2553	177	15	against	against	ADP
eurjchem-2553	177	16	sars	sar	NOUN
eurjchem-2553	177	17	-	-	PUNCT
eurjchem-2553	177	18	cov-2	cov-2	NOUN
eurjchem-2553	177	19	more	more	ADJ
eurjchem-2553	177	20	than	than	ADP
eurjchem-2553	177	21	one	one	NUM
eurjchem-2553	177	22	year	year	NOUN
eurjchem-2553	177	23	after	after	ADP
eurjchem-2553	177	24	covid-19	covid-19	PROPN
eurjchem-2553	177	25	vaccination	vaccination	NOUN
eurjchem-2553	177	26	,	,	PUNCT
eurjchem-2553	177	27	and	and	CCONJ
eurjchem-2553	177	28	on	on	ADP
eurjchem-2553	177	29	the	the	DET
eurjchem-2553	177	30	long	long	ADJ
eurjchem-2553	177	31	-	-	PUNCT
eurjchem-2553	177	32	term	term	NOUN
eurjchem-2553	177	33	risk	risk	NOUN
eurjchem-2553	177	34	of	of	ADP
eurjchem-2553	177	35	re	re	NOUN
eurjchem-2553	177	36	-	-	NOUN
eurjchem-2553	177	37	infection	infection	NOUN
eurjchem-2553	177	38	.	.	PUNCT
eurjchem-2553	178	1	the	the	DET
eurjchem-2553	178	2	sars	sar	NOUN
eurjchem-2553	178	3	-	-	PUNCT
eurjchem-2553	178	4	cov-2	cov-2	PART
eurjchem-2553	178	5	vaccine	vaccine	NOUN
eurjchem-2553	178	6	may	may	AUX
eurjchem-2553	178	7	improve	improve	VERB
eurjchem-2553	178	8	protection	protection	NOUN
eurjchem-2553	178	9	by	by	ADP
eurjchem-2553	178	10	raising	raise	VERB
eurjchem-2553	178	11	the	the	DET
eurjchem-2553	178	12	levels	level	NOUN
eurjchem-2553	178	13	of	of	ADP
eurjchem-2553	178	14	cross	cross	ADJ
eurjchem-2553	178	15	-	-	ADJ
eurjchem-2553	178	16	neutralizing	neutralizing	ADJ
eurjchem-2553	178	17	antibodies	antibody	NOUN
eurjchem-2553	178	18	,	,	PUNCT
eurjchem-2553	178	19	particularly	particularly	ADV
eurjchem-2553	178	20	against	against	ADP
eurjchem-2553	178	21	versions	version	NOUN
eurjchem-2553	178	22	with	with	ADP
eurjchem-2553	178	23	antibody	antibody	NOUN
eurjchem-2553	178	24	escape	escape	NOUN
eurjchem-2553	178	25	mutations	mutation	NOUN
eurjchem-2553	178	26	like	like	ADP
eurjchem-2553	178	27	b1.351	b1.351	NOUN
eurjchem-2553	178	28	.	.	PUNCT
eurjchem-2553	179	1	the	the	DET
eurjchem-2553	179	2	interpretation	interpretation	NOUN
eurjchem-2553	179	3	of	of	ADP
eurjchem-2553	179	4	serological	serological	ADJ
eurjchem-2553	179	5	results	result	NOUN
eurjchem-2553	179	6	and	and	CCONJ
eurjchem-2553	179	7	the	the	DET
eurjchem-2553	179	8	future	future	ADJ
eurjchem-2553	179	9	calculation	calculation	NOUN
eurjchem-2553	179	10	of	of	ADP
eurjchem-2553	179	11	a	a	DET
eurjchem-2553	179	12	protective	protective	ADJ
eurjchem-2553	179	13	anti	anti	ADJ
eurjchem-2553	179	14	-	-	ADJ
eurjchem-2553	179	15	rbd	rbd	ADJ
eurjchem-2553	179	16	igg	igg	PROPN
eurjchem-2553	179	17	level	level	NOUN
eurjchem-2553	179	18	may	may	AUX
eurjchem-2553	179	19	benefit	benefit	VERB
eurjchem-2553	179	20	greatly	greatly	ADV
eurjchem-2553	179	21	from	from	ADP
eurjchem-2553	179	22	the	the	DET
eurjchem-2553	179	23	high	high	ADJ
eurjchem-2553	179	24	association	association	NOUN
eurjchem-2553	179	25	between	between	ADP
eurjchem-2553	179	26	antibody	antibody	NOUN
eurjchem-2553	179	27	levels	level	NOUN
eurjchem-2553	179	28	and	and	CCONJ
eurjchem-2553	179	29	their	their	PRON
eurjchem-2553	179	30	neutralizing	neutralizing	ADJ
eurjchem-2553	179	31	capacity	capacity	NOUN
eurjchem-2553	179	32	against	against	ADP
eurjchem-2553	179	33	variations	variation	NOUN
eurjchem-2553	179	34	[	[	X
eurjchem-2553	179	35	26	26	NUM
eurjchem-2553	179	36	]	]	PUNCT
eurjchem-2553	179	37	.	.	PUNCT
eurjchem-2553	180	1	furthermore	furthermore	ADV
eurjchem-2553	180	2	,	,	PUNCT
eurjchem-2553	180	3	our	our	PRON
eurjchem-2553	180	4	findings	finding	NOUN
eurjchem-2553	180	5	demonstrate	demonstrate	VERB
eurjchem-2553	180	6	that	that	SCONJ
eurjchem-2553	180	7	even	even	ADV
eurjchem-2553	180	8	repeated	repeat	VERB
eurjchem-2553	180	9	booster	booster	NOUN
eurjchem-2553	180	10	shots	shot	NOUN
eurjchem-2553	180	11	can	can	AUX
eurjchem-2553	180	12	significantly	significantly	ADV
eurjchem-2553	180	13	boost	boost	VERB
eurjchem-2553	180	14	a	a	DET
eurjchem-2553	180	15	strong	strong	ADJ
eurjchem-2553	180	16	humoral	humoral	ADJ
eurjchem-2553	180	17	immune	immune	ADJ
eurjchem-2553	180	18	response	response	NOUN
eurjchem-2553	180	19	to	to	PART
eurjchem-2553	180	20	protect	protect	VERB
eurjchem-2553	180	21	against	against	ADP
eurjchem-2553	180	22	sars	sar	NOUN
eurjchem-2553	180	23	-	-	PUNCT
eurjchem-2553	180	24	cov-2	cov-2	PART
eurjchem-2553	180	25	infection	infection	NOUN
eurjchem-2553	180	26	.	.	PUNCT
eurjchem-2553	181	1	a	a	DET
eurjchem-2553	181	2	twelvemonth	twelvemonth	NOUN
eurjchem-2553	181	3	study	study	NOUN
eurjchem-2553	181	4	of	of	ADP
eurjchem-2553	181	5	polyfunctional	polyfunctional	ADJ
eurjchem-2553	181	6	cd4	cd4	PROPN
eurjchem-2553	181	7	+	+	PROPN
eurjchem-2553	181	8	and	and	CCONJ
eurjchem-2553	181	9	cd8	cd8	PROPN
eurjchem-2553	181	10	+	+	PROPN
eurjchem-2553	181	11	t	t	PROPN
eurjchem-2553	181	12	-	-	PUNCT
eurjchem-2553	181	13	cells	cell	NOUN
eurjchem-2553	181	14	following	follow	VERB
eurjchem-2553	181	15	the	the	DET
eurjchem-2553	181	16	covishieldtm	covishieldtm	ADJ
eurjchem-2553	181	17	booster	booster	NOUN
eurjchem-2553	181	18	is	be	AUX
eurjchem-2553	181	19	also	also	ADV
eurjchem-2553	181	20	being	be	AUX
eurjchem-2553	181	21	investigated	investigate	VERB
eurjchem-2553	181	22	.	.	PUNCT
eurjchem-2553	182	1	acknowledgements	acknowledgement	NOUN
eurjchem-2553	182	2	we	we	PRON
eurjchem-2553	182	3	thank	thank	VERB
eurjchem-2553	182	4	the	the	DET
eurjchem-2553	182	5	director	director	NOUN
eurjchem-2553	182	6	of	of	ADP
eurjchem-2553	182	7	the	the	DET
eurjchem-2553	182	8	institute	institute	PROPN
eurjchem-2553	182	9	and	and	CCONJ
eurjchem-2553	182	10	ethical	ethical	ADJ
eurjchem-2553	182	11	committee	committee	NOUN
eurjchem-2553	182	12	members	member	NOUN
eurjchem-2553	182	13	of	of	ADP
eurjchem-2553	182	14	sri	sri	PROPN
eurjchem-2553	182	15	jayadeva	jayadeva	PROPN
eurjchem-2553	182	16	institute	institute	PROPN
eurjchem-2553	182	17	of	of	ADP
eurjchem-2553	182	18	cardiovascular	cardiovascular	ADJ
eurjchem-2553	182	19	sciences	science	NOUN
eurjchem-2553	182	20	and	and	CCONJ
eurjchem-2553	182	21	research	research	NOUN
eurjchem-2553	182	22	centre	centre	NOUN
eurjchem-2553	182	23	for	for	ADP
eurjchem-2553	182	24	their	their	PRON
eurjchem-2553	182	25	numerous	numerous	ADJ
eurjchem-2553	182	26	contributions	contribution	NOUN
eurjchem-2553	182	27	.	.	PUNCT
eurjchem-2553	183	1	we	we	PRON
eurjchem-2553	183	2	would	would	AUX
eurjchem-2553	183	3	like	like	VERB
eurjchem-2553	183	4	to	to	PART
eurjchem-2553	183	5	acknowledge	acknowledge	VERB
eurjchem-2553	183	6	all	all	DET
eurjchem-2553	183	7	healthcare	healthcare	NOUN
eurjchem-2553	183	8	workers	worker	NOUN
eurjchem-2553	183	9	of	of	ADP
eurjchem-2553	183	10	sri	sri	PROPN
eurjchem-2553	183	11	jayadeva	jayadeva	PROPN
eurjchem-2553	183	12	institute	institute	PROPN
eurjchem-2553	183	13	of	of	ADP
eurjchem-2553	183	14	cardiovascular	cardiovascular	ADJ
eurjchem-2553	183	15	sciences	science	NOUN
eurjchem-2553	183	16	and	and	CCONJ
eurjchem-2553	183	17	research	research	NOUN
eurjchem-2553	183	18	centre	centre	NOUN
eurjchem-2553	183	19	for	for	ADP
eurjchem-2553	183	20	their	their	PRON
eurjchem-2553	183	21	participation	participation	NOUN
eurjchem-2553	183	22	in	in	ADP
eurjchem-2553	183	23	the	the	DET
eurjchem-2553	183	24	present	present	ADJ
eurjchem-2553	183	25	study	study	NOUN
eurjchem-2553	183	26	and	and	CCONJ
eurjchem-2553	183	27	their	their	PRON
eurjchem-2553	183	28	donation	donation	NOUN
eurjchem-2553	183	29	of	of	ADP
eurjchem-2553	183	30	blood	blood	NOUN
eurjchem-2553	183	31	samples	sample	NOUN
eurjchem-2553	183	32	for	for	ADP
eurjchem-2553	183	33	the	the	DET
eurjchem-2553	183	34	evaluation	evaluation	NOUN
eurjchem-2553	183	35	of	of	ADP
eurjchem-2553	183	36	the	the	DET
eurjchem-2553	183	37	humoral	humoral	ADJ
eurjchem-2553	183	38	immunity	immunity	NOUN
eurjchem-2553	183	39	response	response	NOUN
eurjchem-2553	183	40	after	after	ADP
eurjchem-2553	183	41	vaccination	vaccination	NOUN
eurjchem-2553	183	42	.	.	PUNCT
eurjchem-2553	184	1	the	the	DET
eurjchem-2553	184	2	authors	author	NOUN
eurjchem-2553	184	3	acknowledge	acknowledge	VERB
eurjchem-2553	184	4	the	the	DET
eurjchem-2553	184	5	patients	patient	NOUN
eurjchem-2553	184	6	and	and	CCONJ
eurjchem-2553	184	7	staff	staff	NOUN
eurjchem-2553	184	8	,	,	PUNCT
eurjchem-2553	184	9	colleagues	colleague	NOUN
eurjchem-2553	184	10	,	,	PUNCT
eurjchem-2553	184	11	technologists	technologist	NOUN
eurjchem-2553	184	12	of	of	ADP
eurjchem-2553	184	13	department	department	NOUN
eurjchem-2553	184	14	of	of	ADP
eurjchem-2553	184	15	microbiology	microbiology	NOUN
eurjchem-2553	184	16	who	who	PRON
eurjchem-2553	184	17	contributed	contribute	VERB
eurjchem-2553	184	18	to	to	ADP
eurjchem-2553	184	19	the	the	DET
eurjchem-2553	184	20	support	support	NOUN
eurjchem-2553	184	21	of	of	ADP
eurjchem-2553	184	22	the	the	DET
eurjchem-2553	184	23	present	present	ADJ
eurjchem-2553	184	24	study	study	NOUN
eurjchem-2553	184	25	.	.	PUNCT
eurjchem-2553	185	1	disclosure	disclosure	NOUN
eurjchem-2553	185	2	statement	statement	NOUN
eurjchem-2553	185	3	conflict	conflict	NOUN
eurjchem-2553	185	4	of	of	ADP
eurjchem-2553	185	5	interest	interest	NOUN
eurjchem-2553	185	6	:	:	PUNCT
eurjchem-2553	185	7	the	the	DET
eurjchem-2553	185	8	authors	author	NOUN
eurjchem-2553	185	9	declare	declare	VERB
eurjchem-2553	185	10	that	that	SCONJ
eurjchem-2553	185	11	they	they	PRON
eurjchem-2553	185	12	have	have	VERB
eurjchem-2553	185	13	no	no	DET
eurjchem-2553	185	14	conflict	conflict	NOUN
eurjchem-2553	185	15	of	of	ADP
eurjchem-2553	185	16	interest	interest	NOUN
eurjchem-2553	185	17	.	.	PUNCT
eurjchem-2553	186	1	ethical	ethical	ADJ
eurjchem-2553	186	2	approval	approval	NOUN
eurjchem-2553	186	3	:	:	PUNCT
eurjchem-2553	186	4	the	the	DET
eurjchem-2553	186	5	study	study	NOUN
eurjchem-2553	186	6	was	be	AUX
eurjchem-2553	186	7	approved	approve	VERB
eurjchem-2553	186	8	by	by	ADP
eurjchem-2553	186	9	the	the	DET
eurjchem-2553	186	10	institutional	institutional	ADJ
eurjchem-2553	186	11	ethics	ethic	NOUN
eurjchem-2553	186	12	committee	committee	PROPN
eurjchem-2553	186	13	of	of	ADP
eurjchem-2553	186	14	the	the	DET
eurjchem-2553	186	15	sri	sri	PROPN
eurjchem-2553	186	16	jayadeva	jayadeva	PROPN
eurjchem-2553	186	17	institute	institute	PROPN
eurjchem-2553	186	18	of	of	ADP
eurjchem-2553	186	19	cardiovascular	cardiovascular	ADJ
eurjchem-2553	186	20	sciences	sciences	PROPN
eurjchem-2553	186	21	and	and	CCONJ
eurjchem-2553	186	22	research	research	NOUN
eurjchem-2553	186	23	centre	centre	NOUN
eurjchem-2553	186	24	(	(	PUNCT
eurjchem-2553	186	25	sjicr	sjicr	PROPN
eurjchem-2553	186	26	-	-	PUNCT
eurjchem-2553	186	27	ec	ec	PROPN
eurjchem-2553	186	28	)	)	PUNCT
eurjchem-2553	186	29	,	,	PUNCT
eurjchem-2553	186	30	bengaluru	bengaluru	PROPN
eurjchem-2553	186	31	.	.	PUNCT
eurjchem-2553	187	1	(	(	PUNCT
eurjchem-2553	187	2	ihec	ihec	ADJ
eurjchem-2553	187	3	number	number	NOUN
eurjchem-2553	187	4	-	-	PUNCT
eurjchem-2553	187	5	sjicr	sjicr	NOUN
eurjchem-2553	187	6	/	/	SYM
eurjchem-2553	187	7	ec/202324/003	ec/202324/003	PROPN
eurjchem-2553	187	8	)	)	PUNCT
eurjchem-2553	187	9	.	.	PUNCT
eurjchem-2553	188	1	written	write	VERB
eurjchem-2553	188	2	and	and	CCONJ
eurjchem-2553	188	3	informed	informed	ADJ
eurjchem-2553	188	4	consent	consent	NOUN
eurjchem-2553	188	5	was	be	AUX
eurjchem-2553	188	6	obtained	obtain	VERB
eurjchem-2553	188	7	from	from	ADP
eurjchem-2553	188	8	all	all	DET
eurjchem-2553	188	9	participants	participant	NOUN
eurjchem-2553	188	10	enrolled	enrol	VERB
eurjchem-2553	188	11	in	in	ADP
eurjchem-2553	188	12	the	the	DET
eurjchem-2553	188	13	study	study	NOUN
eurjchem-2553	188	14	before	before	ADP
eurjchem-2553	188	15	the	the	DET
eurjchem-2553	188	16	collection	collection	NOUN
eurjchem-2553	188	17	of	of	ADP
eurjchem-2553	188	18	specimens	specimens	PROPN
eurjchem-2553	188	19	.	.	PUNCT
eurjchem-2553	189	1	credit	credit	NOUN
eurjchem-2553	189	2	authorship	authorship	NOUN
eurjchem-2553	189	3	contribution	contribution	NOUN
eurjchem-2553	189	4	statement	statement	NOUN
eurjchem-2553	189	5	conceptualization	conceptualization	NOUN
eurjchem-2553	189	6	:	:	PUNCT
eurjchem-2553	189	7	naveena	naveena	PROPN
eurjchem-2553	189	8	jagadeesan	jagadeesan	PROPN
eurjchem-2553	189	9	,	,	PUNCT
eurjchem-2553	189	10	kavitha	kavitha	PROPN
eurjchem-2553	189	11	karur	karur	PROPN
eurjchem-2553	189	12	,	,	PUNCT
eurjchem-2553	189	13	nandini	nandini	PROPN
eurjchem-2553	189	14	puttamasthi	puttamasthi	PROPN
eurjchem-2553	189	15	gowda	gowda	PROPN
eurjchem-2553	189	16	;	;	PUNCT
eurjchem-2553	189	17	methodology	methodology	NOUN
eurjchem-2553	189	18	:	:	PUNCT
eurjchem-2553	189	19	naveena	naveena	PROPN
eurjchem-2553	189	20	jagadeesan	jagadeesan	PROPN
eurjchem-2553	189	21	,	,	PUNCT
eurjchem-2553	189	22	kavitha	kavitha	PROPN
eurjchem-2553	189	23	karur	karur	PROPN
eurjchem-2553	189	24	,	,	PUNCT
eurjchem-2553	189	25	nandini	nandini	PROPN
eurjchem-2553	189	26	puttamasthi	puttamasthi	PROPN
eurjchem-2553	189	27	gowda	gowda	PROPN
eurjchem-2553	189	28	;	;	PUNCT
eurjchem-2553	189	29	software	software	NOUN
eurjchem-2553	189	30	:	:	PUNCT
eurjchem-2553	189	31	praveen	praveen	PROPN
eurjchem-2553	189	32	kumar	kumar	PROPN
eurjchem-2553	189	33	,	,	PUNCT
eurjchem-2553	189	34	harsha	harsha	PROPN
eurjchem-2553	189	35	tumkur	tumkur	PROPN
eurjchem-2553	189	36	kumar	kumar	PROPN
eurjchem-2553	189	37	;	;	PUNCT
eurjchem-2553	189	38	validation	validation	NOUN
eurjchem-2553	189	39	:	:	PUNCT
eurjchem-2553	189	40	naveena	naveena	PROPN
eurjchem-2553	189	41	jagadeesan	jagadeesan	PROPN
eurjchem-2553	189	42	,	,	PUNCT
eurjchem-2553	189	43	kavitha	kavitha	PROPN
eurjchem-2553	189	44	karur	karur	PROPN
eurjchem-2553	189	45	,	,	PUNCT
eurjchem-2553	189	46	nandini	nandini	PROPN
eurjchem-2553	189	47	puttamasthi	puttamasthi	PROPN
eurjchem-2553	189	48	gowda	gowda	PROPN
eurjchem-2553	189	49	;	;	PUNCT
eurjchem-2553	189	50	formal	formal	ADJ
eurjchem-2553	189	51	analysis	analysis	NOUN
eurjchem-2553	189	52	:	:	PUNCT
eurjchem-2553	189	53	naveena	naveena	NOUN
eurjchem-2553	189	54	jagadeesan	jagadeesan	PROPN
eurjchem-2553	189	55	,	,	PUNCT
eurjchem-2553	189	56	kavitha	kavitha	PROPN
eurjchem-2553	189	57	karur	karur	PROPN
eurjchem-2553	189	58	,	,	PUNCT
eurjchem-2553	189	59	nandini	nandini	PROPN
eurjchem-2553	189	60	puttamasthi	puttamasthi	PROPN
eurjchem-2553	189	61	gowda	gowda	PROPN
eurjchem-2553	189	62	,	,	PUNCT
eurjchem-2553	189	63	prapulla	prapulla	NOUN
eurjchem-2553	189	64	kumari	kumari	PROPN
eurjchem-2553	189	65	,	,	PUNCT
eurjchem-2553	189	66	manjunath	manjunath	PROPN
eurjchem-2553	189	67	cholenalli	cholenalli	PROPN
eurjchem-2553	189	68	nanjappa	nanjappa	PROPN
eurjchem-2553	189	69	;	;	PUNCT
eurjchem-2553	189	70	investigation	investigation	NOUN
eurjchem-2553	189	71	:	:	PUNCT
eurjchem-2553	189	72	naveena	naveena	PROPN
eurjchem-2553	189	73	jagadeesan	jagadeesan	NOUN
eurjchem-2553	189	74	;	;	PUNCT
eurjchem-2553	189	75	resources	resource	NOUN
eurjchem-2553	189	76	:	:	PUNCT
eurjchem-2553	189	77	naveena	naveena	PROPN
eurjchem-2553	189	78	jagadeesan	jagadeesan	PROPN
eurjchem-2553	189	79	,	,	PUNCT
eurjchem-2553	189	80	kavitha	kavitha	PROPN
eurjchem-2553	189	81	karur	karur	PROPN
eurjchem-2553	189	82	,	,	PUNCT
eurjchem-2553	189	83	nandini	nandini	PROPN
eurjchem-2553	189	84	puttamasthi	puttamasthi	PROPN
eurjchem-2553	189	85	gowda	gowda	PROPN
eurjchem-2553	189	86	,	,	PUNCT
eurjchem-2553	189	87	prapulla	prapulla	NOUN
eurjchem-2553	189	88	kumari	kumari	PROPN
eurjchem-2553	189	89	;	;	PUNCT
eurjchem-2553	189	90	data	datum	NOUN
eurjchem-2553	189	91	curation	curation	NOUN
eurjchem-2553	189	92	:	:	PUNCT
eurjchem-2553	189	93	naveena	naveena	PROPN
eurjchem-2553	189	94	jagadeesan	jagadeesan	PROPN
eurjchem-2553	189	95	,	,	PUNCT
eurjchem-2553	189	96	praveen	praveen	PROPN
eurjchem-2553	189	97	kumar	kumar	PROPN
eurjchem-2553	189	98	,	,	PUNCT
eurjchem-2553	189	99	harsha	harsha	PROPN
eurjchem-2553	189	100	tumkur	tumkur	PROPN
eurjchem-2553	189	101	kumar	kumar	PROPN
eurjchem-2553	189	102	;	;	PUNCT
eurjchem-2553	189	103	writing	write	VERB
eurjchem-2553	189	104	original	original	ADJ
eurjchem-2553	189	105	draft	draft	NOUN
eurjchem-2553	189	106	:	:	PUNCT
eurjchem-2553	189	107	naveena	naveena	NOUN
eurjchem-2553	189	108	jagadeesan	jagadeesan	PROPN
eurjchem-2553	189	109	,	,	PUNCT
eurjchem-2553	189	110	praveen	praveen	PROPN
eurjchem-2553	189	111	kumar	kumar	PROPN
eurjchem-2553	189	112	;	;	PUNCT
eurjchem-2553	189	113	writing	write	VERB
eurjchem-2553	189	114	review	review	NOUN
eurjchem-2553	189	115	and	and	CCONJ
eurjchem-2553	189	116	editing	editing	NOUN
eurjchem-2553	189	117	:	:	PUNCT
eurjchem-2553	189	118	naveena	naveena	NOUN
eurjchem-2553	189	119	jagadeesan	jagadeesan	NOUN
eurjchem-2553	189	120	;	;	PUNCT
eurjchem-2553	189	121	visualization	visualization	NOUN
eurjchem-2553	189	122	:	:	PUNCT
eurjchem-2553	189	123	naveena	naveena	PROPN
eurjchem-2553	189	124	jagadeesan	jagadeesan	PROPN
eurjchem-2553	189	125	,	,	PUNCT
eurjchem-2553	189	126	praveen	praveen	PROPN
eurjchem-2553	189	127	kumar	kumar	PROPN
eurjchem-2553	189	128	,	,	PUNCT
eurjchem-2553	189	129	kavitha	kavitha	PROPN
eurjchem-2553	189	130	karur	karur	PROPN
eurjchem-2553	189	131	,	,	PUNCT
eurjchem-2553	189	132	harsha	harsha	PROPN
eurjchem-2553	189	133	tumkur	tumkur	PROPN
eurjchem-2553	189	134	kumar	kumar	PROPN
eurjchem-2553	189	135	;	;	PUNCT
eurjchem-2553	189	136	supervision	supervision	NOUN
eurjchem-2553	189	137	:	:	PUNCT
eurjchem-2553	189	138	naveena	naveena	PROPN
eurjchem-2553	189	139	jagadeesan	jagadeesan	PROPN
eurjchem-2553	189	140	,	,	PUNCT
eurjchem-2553	189	141	manjunath	manjunath	PROPN
eurjchem-2553	189	142	cholenalli	cholenalli	PROPN
eurjchem-2553	189	143	nanjappa	nanjappa	PROPN
eurjchem-2553	189	144	;	;	PUNCT
eurjchem-2553	189	145	project	project	NOUN
eurjchem-2553	189	146	administration	administration	NOUN
eurjchem-2553	189	147	:	:	PUNCT
eurjchem-2553	189	148	naveena	naveena	PROPN
eurjchem-2553	189	149	jagadeesan	jagadeesan	PROPN
eurjchem-2553	189	150	.	.	PUNCT
eurjchem-2553	190	1	funding	fund	VERB
eurjchem-2553	190	2	the	the	DET
eurjchem-2553	190	3	work	work	NOUN
eurjchem-2553	190	4	was	be	AUX
eurjchem-2553	190	5	supported	support	VERB
eurjchem-2553	190	6	by	by	ADP
eurjchem-2553	190	7	the	the	DET
eurjchem-2553	190	8	sri	sri	PROPN
eurjchem-2553	190	9	jayadeva	jayadeva	PROPN
eurjchem-2553	190	10	institute	institute	PROPN
eurjchem-2553	190	11	of	of	ADP
eurjchem-2553	190	12	cardiovascular	cardiovascular	ADJ
eurjchem-2553	190	13	sciences	sciences	PROPN
eurjchem-2553	190	14	and	and	CCONJ
eurjchem-2553	190	15	research	research	NOUN
eurjchem-2553	190	16	centre	centre	NOUN
eurjchem-2553	190	17	,	,	PUNCT
eurjchem-2553	190	18	banneraghatta	banneraghatta	NOUN
eurjchem-2553	190	19	road	road	NOUN
eurjchem-2553	190	20	,	,	PUNCT
eurjchem-2553	190	21	bengaluru	bengaluru	PROPN
eurjchem-2553	190	22	,	,	PUNCT
eurjchem-2553	190	23	karnataka	karnataka	PROPN
eurjchem-2553	190	24	,	,	PUNCT
eurjchem-2553	190	25	india	india	PROPN
eurjchem-2553	190	26	.	.	PUNCT
eurjchem-2553	191	1	orcid	orcid	PROPN
eurjchem-2553	191	2	and	and	CCONJ
eurjchem-2553	191	3	email	email	NOUN
eurjchem-2553	191	4	naveena	naveena	NOUN
eurjchem-2553	191	5	jagadeesan	jagadeesan	PROPN
eurjchem-2553	191	6	drnaveenaj@gmail.com	drnaveenaj@gmail.com	X
eurjchem-2553	192	1	drnaveenajmicro@gmail.com	drnaveenajmicro@gmail.com	X
eurjchem-2553	192	2	https://orcid.org/0000-0001-7286-7154	https://orcid.org/0000-0001-7286-7154	PROPN
eurjchem-2553	192	3	praveen	praveen	PROPN
eurjchem-2553	192	4	kumar	kumar	PROPN
eurjchem-2553	193	1	drpraveengenesis@gmail.com	drpraveengenesis@gmail.com	PROPN
eurjchem-2553	194	1	praveenbiochemku@gmail.com	praveenbiochemku@gmail.com	X
eurjchem-2553	195	1	https://orcid.org/0000-0002-8034-6348	https://orcid.org/0000-0002-8034-6348	ADJ
eurjchem-2553	195	2	nandini	nandini	PROPN
eurjchem-2553	195	3	puttamasthi	puttamasthi	PROPN
eurjchem-2553	195	4	gowda	gowda	VERB
eurjchem-2553	195	5	nandhiniputtaswamy@gmail.com	nandhiniputtaswamy@gmail.com	X
eurjchem-2553	196	1	https://orcid.org/0009-0004-6196-5890	https://orcid.org/0009-0004-6196-5890	PROPN
eurjchem-2553	196	2	kavitha	kavitha	PROPN
eurjchem-2553	196	3	karur	karur	PROPN
eurjchem-2553	196	4	kavitha.karur@gmail.com	kavitha.karur@gmail.com	PROPN
eurjchem-2553	196	5	https://orcid.org/0000-0001-5518-9945	https://orcid.org/0000-0001-5518-9945	PROPN
eurjchem-2553	196	6	manjunath	manjunath	PROPN
eurjchem-2553	196	7	cholenalli	cholenalli	PROPN
eurjchem-2553	196	8	nanjappa	nanjappa	NOUN
eurjchem-2553	197	1	drcnmanjunath@gmail.com	drcnmanjunath@gmail.com	X
eurjchem-2553	198	1	https://orcid.org/0000-0002-5336-2131	https://orcid.org/0000-0002-5336-2131	INTJ
eurjchem-2553	198	2	prapulla	prapulla	NOUN
eurjchem-2553	198	3	kumari	kumari	PROPN
eurjchem-2553	198	4	nprapullasr@gmail.com	nprapullasr@gmail.com	PROPN
eurjchem-2553	198	5	https://orcid.org/0009-0006-0423-1713	https://orcid.org/0009-0006-0423-1713	PROPN
eurjchem-2553	198	6	harsha	harsha	PROPN
eurjchem-2553	198	7	tumkur	tumkur	PROPN
eurjchem-2553	198	8	kumar	kumar	PROPN
eurjchem-2553	198	9	dr.harshatk@gmail.com	dr.harshatk@gmail.com	PROPN
eurjchem-2553	198	10	https://orcid.org/0009-0006-3195-8539	https://orcid.org/0009-0006-3195-8539	PART
eurjchem-2553	198	11	references	reference	NOUN
eurjchem-2553	198	12	[	[	X
eurjchem-2553	198	13	1	1	NUM
eurjchem-2553	198	14	]	]	PUNCT
eurjchem-2553	198	15	.	.	PUNCT
eurjchem-2553	199	1	kumar	kumar	PROPN
eurjchem-2553	199	2	,	,	PUNCT
eurjchem-2553	199	3	p.	p.	PROPN
eurjchem-2553	199	4	;	;	PUNCT
eurjchem-2553	199	5	mahantheshappa	mahantheshappa	PROPN
eurjchem-2553	199	6	,	,	PUNCT
eurjchem-2553	199	7	s.	s.	PROPN
eurjchem-2553	199	8	s.	s.	PROPN
eurjchem-2553	199	9	;	;	PUNCT
eurjchem-2553	199	10	balasubramaniyan	balasubramaniyan	PROPN
eurjchem-2553	199	11	,	,	PUNCT
eurjchem-2553	199	12	s.	s.	PROPN
eurjchem-2553	199	13	;	;	PUNCT
eurjchem-2553	199	14	satyanarayan	satyanarayan	ADJ
eurjchem-2553	199	15	,	,	PUNCT
eurjchem-2553	199	16	n.	n.	PROPN
eurjchem-2553	199	17	d.	d.	PROPN
eurjchem-2553	199	18	;	;	PUNCT
eurjchem-2553	199	19	achur	achur	NOUN
eurjchem-2553	199	20	,	,	PUNCT
eurjchem-2553	199	21	r.	r.	PROPN
eurjchem-2553	199	22	quinoline	quinoline	PROPN
eurjchem-2553	199	23	analogue	analogue	NOUN
eurjchem-2553	199	24	as	as	ADP
eurjchem-2553	199	25	a	a	DET
eurjchem-2553	199	26	potential	potential	ADJ
eurjchem-2553	199	27	inhibitor	inhibitor	NOUN
eurjchem-2553	199	28	of	of	ADP
eurjchem-2553	199	29	sars	sar	NOUN
eurjchem-2553	199	30	-	-	PUNCT
eurjchem-2553	199	31	cov-2	cov-2	NOUN
eurjchem-2553	199	32	main	main	ADJ
eurjchem-2553	199	33	protease	protease	NOUN
eurjchem-2553	199	34	:	:	PUNCT
eurjchem-2553	199	35	admet	admet	PROPN
eurjchem-2553	199	36	prediction	prediction	NOUN
eurjchem-2553	199	37	,	,	PUNCT
eurjchem-2553	199	38	molecular	molecular	ADJ
eurjchem-2553	199	39	docking	docking	NOUN
eurjchem-2553	199	40	and	and	CCONJ
eurjchem-2553	199	41	dynamics	dynamic	NOUN
eurjchem-2553	199	42	simulation	simulation	NOUN
eurjchem-2553	199	43	analysis	analysis	NOUN
eurjchem-2553	199	44	.	.	PUNCT
eurjchem-2553	200	1	eur	eur	PROPN
eurjchem-2553	200	2	.	.	PUNCT
eurjchem-2553	201	1	j.	j.	PROPN
eurjchem-2553	201	2	chem	chem	PROPN
eurjchem-2553	201	3	.	.	PUNCT
eurjchem-2553	202	1	2023	2023	NUM
eurjchem-2553	202	2	,	,	PUNCT
eurjchem-2553	202	3	14	14	NUM
eurjchem-2553	202	4	,	,	PUNCT
eurjchem-2553	202	5	30	30	NUM
eurjchem-2553	202	6	–	–	PUNCT
eurjchem-2553	202	7	38	38	NUM
eurjchem-2553	202	8	.	.	PUNCT
eurjchem-2553	203	1	[	[	X
eurjchem-2553	203	2	2	2	NUM
eurjchem-2553	203	3	]	]	PUNCT
eurjchem-2553	203	4	.	.	PUNCT
eurjchem-2553	204	1	mathieu	mathieu	PROPN
eurjchem-2553	204	2	,	,	PUNCT
eurjchem-2553	204	3	e.	e.	PROPN
eurjchem-2553	204	4	;	;	PUNCT
eurjchem-2553	204	5	ritchie	ritchie	PROPN
eurjchem-2553	204	6	,	,	PUNCT
eurjchem-2553	204	7	h.	h.	PROPN
eurjchem-2553	204	8	;	;	PUNCT
eurjchem-2553	204	9	rodés	rodés	NOUN
eurjchem-2553	204	10	-	-	PUNCT
eurjchem-2553	204	11	guirao	guirao	PROPN
eurjchem-2553	204	12	,	,	PUNCT
eurjchem-2553	204	13	l.	l.	PROPN
eurjchem-2553	204	14	;	;	PUNCT
eurjchem-2553	204	15	appel	appel	PROPN
eurjchem-2553	204	16	,	,	PUNCT
eurjchem-2553	204	17	c.	c.	PROPN
eurjchem-2553	204	18	;	;	PUNCT
eurjchem-2553	204	19	giattino	giattino	NOUN
eurjchem-2553	204	20	,	,	PUNCT
eurjchem-2553	204	21	c.	c.	PROPN
eurjchem-2553	204	22	;	;	PUNCT
eurjchem-2553	204	23	hasell	hasell	INTJ
eurjchem-2553	204	24	,	,	PUNCT
eurjchem-2553	204	25	j.	j.	PROPN
eurjchem-2553	204	26	;	;	PUNCT
eurjchem-2553	204	27	macdonald	macdonald	PROPN
eurjchem-2553	204	28	,	,	PUNCT
eurjchem-2553	204	29	b.	b.	PROPN
eurjchem-2553	204	30	;	;	PUNCT
eurjchem-2553	204	31	dattani	dattani	PROPN
eurjchem-2553	204	32	,	,	PUNCT
eurjchem-2553	204	33	s.	s.	PROPN
eurjchem-2553	204	34	;	;	PUNCT
eurjchem-2553	204	35	beltekian	beltekian	PROPN
eurjchem-2553	204	36	,	,	PUNCT
eurjchem-2553	204	37	d.	d.	PROPN
eurjchem-2553	204	38	;	;	PUNCT
eurjchem-2553	204	39	ortiz	ortiz	PROPN
eurjchem-2553	204	40	-	-	PUNCT
eurjchem-2553	204	41	ospina	ospina	PROPN
eurjchem-2553	204	42	,	,	PUNCT
eurjchem-2553	204	43	e.	e.	PROPN
eurjchem-2553	204	44	;	;	PUNCT
eurjchem-2553	204	45	roser	roser	PROPN
eurjchem-2553	204	46	,	,	PUNCT
eurjchem-2553	204	47	m.	m.	NOUN
eurjchem-2553	204	48	coronavirus	coronavirus	PROPN
eurjchem-2553	204	49	(	(	PUNCT
eurjchem-2553	204	50	covid-19	covid-19	PROPN
eurjchem-2553	204	51	)	)	PUNCT
eurjchem-2553	204	52	vaccinations	vaccination	NOUN
eurjchem-2553	204	53	.	.	PUNCT
eurjchem-2553	205	1	https://ourworldindata.org/	https://ourworldindata.org/	PROPN
eurjchem-2553	205	2	covid	covid	NOUN
eurjchem-2553	205	3	-	-	NOUN
eurjchem-2553	205	4	vaccinations	vaccination	NOUN
eurjchem-2553	205	5	(	(	PUNCT
eurjchem-2553	205	6	accessed	access	VERB
eurjchem-2553	205	7	january	january	PROPN
eurjchem-2553	205	8	20	20	NUM
eurjchem-2553	205	9	,	,	PUNCT
eurjchem-2553	205	10	2024	2024	NUM
eurjchem-2553	205	11	)	)	PUNCT
eurjchem-2553	205	12	.	.	PUNCT
eurjchem-2553	206	1	[	[	X
eurjchem-2553	206	2	3	3	NUM
eurjchem-2553	206	3	]	]	PUNCT
eurjchem-2553	206	4	.	.	PUNCT
eurjchem-2553	207	1	ritchie	ritchie	PROPN
eurjchem-2553	207	2	,	,	PUNCT
eurjchem-2553	207	3	h.	h.	PROPN
eurjchem-2553	207	4	;	;	PUNCT
eurjchem-2553	207	5	samborska	samborska	PROPN
eurjchem-2553	207	6	,	,	PUNCT
eurjchem-2553	207	7	v.	v.	PROPN
eurjchem-2553	207	8	;	;	PUNCT
eurjchem-2553	207	9	ahuja	ahuja	PROPN
eurjchem-2553	207	10	,	,	PUNCT
eurjchem-2553	207	11	n.	n.	PROPN
eurjchem-2553	207	12	;	;	PUNCT
eurjchem-2553	207	13	ortiz	ortiz	PROPN
eurjchem-2553	207	14	-	-	PUNCT
eurjchem-2553	207	15	ospina	ospina	PROPN
eurjchem-2553	207	16	,	,	PUNCT
eurjchem-2553	207	17	e.	e.	PROPN
eurjchem-2553	207	18	;	;	PUNCT
eurjchem-2553	207	19	roser	roser	PROPN
eurjchem-2553	207	20	,	,	PUNCT
eurjchem-2553	207	21	m.	m.	NOUN
eurjchem-2553	207	22	global	global	ADJ
eurjchem-2553	207	23	education	education	NOUN
eurjchem-2553	207	24	.	.	PUNCT
eurjchem-2553	208	1	https://ourworldindata.org/global-education	https://ourworldindata.org/global-education	NOUN
eurjchem-2553	208	2	(	(	PUNCT
eurjchem-2553	208	3	accessed	access	VERB
eurjchem-2553	208	4	january	january	PROPN
eurjchem-2553	208	5	20	20	NUM
eurjchem-2553	208	6	,	,	PUNCT
eurjchem-2553	208	7	2024	2024	NUM
eurjchem-2553	208	8	)	)	PUNCT
eurjchem-2553	208	9	.	.	PUNCT
eurjchem-2553	209	1	[	[	X
eurjchem-2553	209	2	4	4	NUM
eurjchem-2553	209	3	]	]	PUNCT
eurjchem-2553	209	4	.	.	PUNCT
eurjchem-2553	210	1	feikin	feikin	PROPN
eurjchem-2553	210	2	,	,	PUNCT
eurjchem-2553	210	3	d.	d.	PROPN
eurjchem-2553	210	4	r.	r.	PROPN
eurjchem-2553	210	5	;	;	PUNCT
eurjchem-2553	210	6	higdon	higdon	PROPN
eurjchem-2553	210	7	,	,	PUNCT
eurjchem-2553	210	8	m.	m.	NOUN
eurjchem-2553	210	9	m.	m.	NOUN
eurjchem-2553	210	10	;	;	PUNCT
eurjchem-2553	210	11	abu	abu	PROPN
eurjchem-2553	210	12	-	-	PUNCT
eurjchem-2553	210	13	raddad	raddad	PROPN
eurjchem-2553	210	14	,	,	PUNCT
eurjchem-2553	210	15	l.	l.	PROPN
eurjchem-2553	210	16	j.	j.	PROPN
eurjchem-2553	210	17	;	;	PUNCT
eurjchem-2553	210	18	andrews	andrews	PROPN
eurjchem-2553	210	19	,	,	PUNCT
eurjchem-2553	210	20	n.	n.	PROPN
eurjchem-2553	210	21	;	;	PUNCT
eurjchem-2553	210	22	araos	araos	PROPN
eurjchem-2553	210	23	,	,	PUNCT
eurjchem-2553	210	24	r.	r.	PROPN
eurjchem-2553	210	25	;	;	PUNCT
eurjchem-2553	210	26	goldberg	goldberg	PROPN
eurjchem-2553	210	27	,	,	PUNCT
eurjchem-2553	210	28	y.	y.	PROPN
eurjchem-2553	210	29	;	;	PUNCT
eurjchem-2553	210	30	groome	groome	NOUN
eurjchem-2553	210	31	,	,	PUNCT
eurjchem-2553	210	32	m.	m.	NOUN
eurjchem-2553	210	33	j.	j.	PROPN
eurjchem-2553	210	34	;	;	PUNCT
eurjchem-2553	210	35	huppert	huppert	PROPN
eurjchem-2553	210	36	,	,	PUNCT
eurjchem-2553	210	37	a.	a.	NOUN
eurjchem-2553	210	38	;	;	PUNCT
eurjchem-2553	210	39	o’brien	o’brien	PROPN
eurjchem-2553	210	40	,	,	PUNCT
eurjchem-2553	210	41	k.	k.	PROPN
eurjchem-2553	210	42	l.	l.	PROPN
eurjchem-2553	210	43	;	;	PUNCT
eurjchem-2553	210	44	smith	smith	PROPN
eurjchem-2553	210	45	,	,	PUNCT
eurjchem-2553	210	46	p.	p.	PROPN
eurjchem-2553	210	47	g.	g.	PROPN
eurjchem-2553	210	48	;	;	PUNCT
eurjchem-2553	210	49	wilder	wilder	X
eurjchem-2553	210	50	-	-	PUNCT
eurjchem-2553	210	51	smith	smith	NOUN
eurjchem-2553	210	52	,	,	PUNCT
eurjchem-2553	210	53	a.	a.	NOUN
eurjchem-2553	210	54	;	;	PUNCT
eurjchem-2553	210	55	zeger	zeger	PROPN
eurjchem-2553	210	56	,	,	PUNCT
eurjchem-2553	210	57	s.	s.	PROPN
eurjchem-2553	210	58	;	;	PUNCT
eurjchem-2553	210	59	deloria	deloria	PROPN
eurjchem-2553	210	60	knoll	knoll	PROPN
eurjchem-2553	210	61	,	,	PUNCT
eurjchem-2553	210	62	m.	m.	NOUN
eurjchem-2553	210	63	;	;	PUNCT
eurjchem-2553	210	64	patel	patel	PROPN
eurjchem-2553	210	65	,	,	PUNCT
eurjchem-2553	210	66	m.	m.	PROPN
eurjchem-2553	210	67	k.	k.	PROPN
eurjchem-2553	210	68	duration	duration	PROPN
eurjchem-2553	210	69	of	of	ADP
eurjchem-2553	210	70	effectiveness	effectiveness	NOUN
eurjchem-2553	210	71	of	of	ADP
eurjchem-2553	210	72	vaccines	vaccine	NOUN
eurjchem-2553	210	73	against	against	ADP
eurjchem-2553	210	74	sars	sar	NOUN
eurjchem-2553	210	75	-	-	PUNCT
eurjchem-2553	210	76	cov-2	cov-2	PART
eurjchem-2553	210	77	infection	infection	NOUN
eurjchem-2553	210	78	and	and	CCONJ
eurjchem-2553	210	79	covid-19	covid-19	PROPN
eurjchem-2553	210	80	disease	disease	NOUN
eurjchem-2553	210	81	:	:	PUNCT
eurjchem-2553	210	82	results	result	NOUN
eurjchem-2553	210	83	of	of	ADP
eurjchem-2553	210	84	a	a	DET
eurjchem-2553	210	85	systematic	systematic	ADJ
eurjchem-2553	210	86	review	review	NOUN
eurjchem-2553	210	87	and	and	CCONJ
eurjchem-2553	210	88	meta	meta	NOUN
eurjchem-2553	210	89	-	-	PUNCT
eurjchem-2553	210	90	regression	regression	NOUN
eurjchem-2553	210	91	.	.	PUNCT
eurjchem-2553	211	1	lancet	lancet	NOUN
eurjchem-2553	211	2	2022	2022	NUM
eurjchem-2553	211	3	,	,	PUNCT
eurjchem-2553	211	4	399	399	NUM
eurjchem-2553	211	5	,	,	PUNCT
eurjchem-2553	211	6	924–944	924–944	NUM
eurjchem-2553	211	7	.	.	PUNCT
eurjchem-2553	212	1	[	[	X
eurjchem-2553	212	2	5	5	NUM
eurjchem-2553	212	3	]	]	PUNCT
eurjchem-2553	212	4	.	.	PUNCT
eurjchem-2553	213	1	kong	kong	PROPN
eurjchem-2553	213	2	,	,	PUNCT
eurjchem-2553	213	3	d.	d.	PROPN
eurjchem-2553	213	4	z.	z.	PROPN
eurjchem-2553	213	5	;	;	PUNCT
eurjchem-2553	213	6	liang	liang	PROPN
eurjchem-2553	213	7	,	,	PUNCT
eurjchem-2553	213	8	n.	n.	PROPN
eurjchem-2553	213	9	;	;	PUNCT
eurjchem-2553	213	10	yang	yang	PROPN
eurjchem-2553	213	11	,	,	PUNCT
eurjchem-2553	213	12	g.	g.	PROPN
eurjchem-2553	213	13	l.	l.	PROPN
eurjchem-2553	213	14	;	;	PUNCT
eurjchem-2553	213	15	zhang	zhang	PROPN
eurjchem-2553	213	16	,	,	PUNCT
eurjchem-2553	213	17	z.	z.	PROPN
eurjchem-2553	213	18	;	;	PUNCT
eurjchem-2553	213	19	liu	liu	PROPN
eurjchem-2553	213	20	,	,	PUNCT
eurjchem-2553	213	21	y.	y.	PROPN
eurjchem-2553	213	22	;	;	PUNCT
eurjchem-2553	213	23	yang	yang	PROPN
eurjchem-2553	213	24	,	,	PUNCT
eurjchem-2553	213	25	y.	y.	PROPN
eurjchem-2553	213	26	;	;	PUNCT
eurjchem-2553	213	27	liu	liu	PROPN
eurjchem-2553	213	28	,	,	PUNCT
eurjchem-2553	213	29	y.	y.	PROPN
eurjchem-2553	213	30	x.	x.	PROPN
eurjchem-2553	213	31	;	;	PUNCT
eurjchem-2553	213	32	wang	wang	PROPN
eurjchem-2553	213	33	,	,	PUNCT
eurjchem-2553	213	34	q.	q.	PROPN
eurjchem-2553	213	35	g.	g.	PROPN
eurjchem-2553	213	36	;	;	PUNCT
eurjchem-2553	213	37	zhang	zhang	PROPN
eurjchem-2553	213	38	,	,	PUNCT
eurjchem-2553	213	39	f.	f.	PROPN
eurjchem-2553	213	40	;	;	PUNCT
eurjchem-2553	213	41	zhang	zhang	PROPN
eurjchem-2553	213	42	,	,	PUNCT
eurjchem-2553	213	43	h.	h.	PROPN
eurjchem-2553	213	44	y.	y.	PROPN
eurjchem-2553	213	45	;	;	PUNCT
eurjchem-2553	213	46	nikolova	nikolova	PROPN
eurjchem-2553	213	47	,	,	PUNCT
eurjchem-2553	213	48	d.	d.	PROPN
eurjchem-2553	213	49	;	;	PUNCT
eurjchem-2553	213	50	jakobsen	jakobsen	PROPN
eurjchem-2553	213	51	,	,	PUNCT
eurjchem-2553	213	52	j.	j.	PROPN
eurjchem-2553	213	53	c.	c.	PROPN
eurjchem-2553	213	54	;	;	PUNCT
eurjchem-2553	213	55	gluud	gluud	PROPN
eurjchem-2553	213	56	,	,	PUNCT
eurjchem-2553	213	57	c.	c.	PROPN
eurjchem-2553	213	58	;	;	PUNCT
eurjchem-2553	213	59	liu	liu	PROPN
eurjchem-2553	213	60	,	,	PUNCT
eurjchem-2553	214	1	j.	j.	PROPN
eurjchem-2553	214	2	p.	p.	PROPN
eurjchem-2553	214	3	acupuncture	acupuncture	NOUN
eurjchem-2553	214	4	for	for	ADP
eurjchem-2553	214	5	chronic	chronic	ADJ
eurjchem-2553	214	6	hepatitis	hepatitis	PROPN
eurjchem-2553	214	7	b.	b.	PROPN
eurjchem-2553	214	8	cochrane	cochrane	PROPN
eurjchem-2553	214	9	libr	libr	PROPN
eurjchem-2553	214	10	.	.	PUNCT
eurjchem-2553	215	1	2019	2019	NUM
eurjchem-2553	215	2	.	.	PUNCT
eurjchem-2553	216	1	https://doi.org/10.1002/14651858.cd013107.pub2	https://doi.org/10.1002/14651858.cd013107.pub2	X
eurjchem-2553	216	2	mailto:drnaveenaj@gmail.com	mailto:drnaveenaj@gmail.com	PROPN
eurjchem-2553	216	3	mailto:drnaveenajmicro@gmail.com	mailto:drnaveenajmicro@gmail.com	PROPN
eurjchem-2553	216	4	https://orcid.org/0000-0001-7286-7154	https://orcid.org/0000-0001-7286-7154	PROPN
eurjchem-2553	217	1	mailto:drpraveengenesis@gmail.com	mailto:drpraveengenesis@gmail.com	PROPN
eurjchem-2553	217	2	mailto:praveenbiochemku@gmail.com	mailto:praveenbiochemku@gmail.com	X
eurjchem-2553	218	1	https://orcid.org/0000-0002-8034-6348	https://orcid.org/0000-0002-8034-6348	PROPN
eurjchem-2553	218	2	mailto:nandhiniputtaswamy@gmail.com	mailto:nandhiniputtaswamy@gmail.com	X
eurjchem-2553	218	3	https://orcid.org/0009-0004-6196-5890	https://orcid.org/0009-0004-6196-5890	NOUN
eurjchem-2553	218	4	mailto:kavitha.karur@gmail.com	mailto:kavitha.karur@gmail.com	NOUN
eurjchem-2553	218	5	https://orcid.org/0000-0001-5518-9945	https://orcid.org/0000-0001-5518-9945	ADV
eurjchem-2553	218	6	mailto:drcnmanjunath@gmail.com	mailto:drcnmanjunath@gmail.com	X
eurjchem-2553	219	1	https://orcid.org/0000-0002-5336-2131	https://orcid.org/0000-0002-5336-2131	PROPN
eurjchem-2553	219	2	mailto:nprapullasr@gmail.com	mailto:nprapullasr@gmail.com	X
eurjchem-2553	219	3	https://orcid.org/0009-0006-0423-1713	https://orcid.org/0009-0006-0423-1713	PROPN
eurjchem-2553	219	4	mailto:dr.harshatk@gmail.com	mailto:dr.harshatk@gmail.com	PROPN
eurjchem-2553	219	5	https://orcid.org/0009-0006-3195-8539	https://orcid.org/0009-0006-3195-8539	PROPN
eurjchem-2553	219	6	https://ourworldindata.org/%20covid-vaccinations	https://ourworldindata.org/%20covid-vaccination	NOUN
eurjchem-2553	219	7	https://ourworldindata.org/%20covid-vaccinations	https://ourworldindata.org/%20covid-vaccinations	ADP
eurjchem-2553	219	8	https://ourworldindata.org/global-education	https://ourworldindata.org/global-education	NOUN
eurjchem-2553	219	9	https://doi.org/10.1002/14651858.cd013107.pub2	https://doi.org/10.1002/14651858.cd013107.pub2	NOUN
eurjchem-2553	219	10	jagadeesan	jagadeesan	NOUN
eurjchem-2553	219	11	et	et	PROPN
eurjchem-2553	219	12	al	al	PROPN
eurjchem-2553	219	13	.	.	PUNCT
eurjchem-2553	219	14	/	/	SYM
eurjchem-2553	219	15	european	european	PROPN
eurjchem-2553	219	16	journal	journal	PROPN
eurjchem-2553	219	17	of	of	ADP
eurjchem-2553	219	18	chemistry	chemistry	NOUN
eurjchem-2553	219	19	15	15	NUM
eurjchem-2553	219	20	(	(	PUNCT
eurjchem-2553	219	21	3	3	NUM
eurjchem-2553	219	22	)	)	PUNCT
eurjchem-2553	219	23	(	(	PUNCT
eurjchem-2553	219	24	2024	2024	NUM
eurjchem-2553	219	25	)	)	PUNCT
eurjchem-2553	219	26	274	274	NUM
eurjchem-2553	219	27	-	-	SYM
eurjchem-2553	219	28	281	281	NUM
eurjchem-2553	219	29	281	281	NUM
eurjchem-2553	219	30	2024	2024	NUM
eurjchem-2553	219	31	–	–	PUNCT
eurjchem-2553	219	32	european	european	ADJ
eurjchem-2553	219	33	journal	journal	NOUN
eurjchem-2553	219	34	of	of	ADP
eurjchem-2553	219	35	chemistry	chemistry	NOUN
eurjchem-2553	219	36	–	–	PUNCT
eurjchem-2553	219	37	cc	cc	NOUN
eurjchem-2553	219	38	by	by	ADP
eurjchem-2553	219	39	nc	nc	PROPN
eurjchem-2553	219	40	–	–	PUNCT
eurjchem-2553	219	41	doi	doi	PROPN
eurjchem-2553	219	42	:	:	PUNCT
eurjchem-2553	219	43	10.5155	10.5155	NUM
eurjchem-2553	219	44	/	/	SYM
eurjchem-2553	219	45	eurjchem.15.3.274	eurjchem.15.3.274	NOUN
eurjchem-2553	219	46	-	-	SYM
eurjchem-2553	219	47	281.2553	281.2553	NUM
eurjchem-2553	219	48	[	[	X
eurjchem-2553	219	49	6	6	NUM
eurjchem-2553	219	50	]	]	PUNCT
eurjchem-2553	219	51	.	.	PUNCT
eurjchem-2553	220	1	wang	wang	PROPN
eurjchem-2553	220	2	,	,	PUNCT
eurjchem-2553	220	3	k.	k.	PROPN
eurjchem-2553	220	4	;	;	PUNCT
eurjchem-2553	220	5	jia	jia	PROPN
eurjchem-2553	220	6	,	,	PUNCT
eurjchem-2553	220	7	z.	z.	PROPN
eurjchem-2553	220	8	;	;	PUNCT
eurjchem-2553	220	9	bao	bao	PROPN
eurjchem-2553	220	10	,	,	PUNCT
eurjchem-2553	220	11	l.	l.	PROPN
eurjchem-2553	220	12	;	;	PUNCT
eurjchem-2553	220	13	wang	wang	PROPN
eurjchem-2553	220	14	,	,	PUNCT
eurjchem-2553	220	15	l.	l.	PROPN
eurjchem-2553	220	16	;	;	PUNCT
eurjchem-2553	220	17	cao	cao	PROPN
eurjchem-2553	220	18	,	,	PUNCT
eurjchem-2553	220	19	l.	l.	PROPN
eurjchem-2553	220	20	;	;	PUNCT
eurjchem-2553	220	21	chi	chi	PROPN
eurjchem-2553	220	22	,	,	PUNCT
eurjchem-2553	220	23	h.	h.	PROPN
eurjchem-2553	220	24	;	;	PUNCT
eurjchem-2553	220	25	hu	hu	PROPN
eurjchem-2553	220	26	,	,	PUNCT
eurjchem-2553	220	27	y.	y.	PROPN
eurjchem-2553	220	28	;	;	PUNCT
eurjchem-2553	220	29	li	li	PROPN
eurjchem-2553	220	30	,	,	PUNCT
eurjchem-2553	220	31	q.	q.	PROPN
eurjchem-2553	220	32	;	;	PUNCT
eurjchem-2553	220	33	zhou	zhou	PROPN
eurjchem-2553	220	34	,	,	PUNCT
eurjchem-2553	220	35	y.	y.	PROPN
eurjchem-2553	220	36	;	;	PUNCT
eurjchem-2553	220	37	jiang	jiang	PROPN
eurjchem-2553	220	38	,	,	PUNCT
eurjchem-2553	220	39	y.	y.	PROPN
eurjchem-2553	220	40	;	;	PUNCT
eurjchem-2553	220	41	zhu	zhu	PROPN
eurjchem-2553	220	42	,	,	PUNCT
eurjchem-2553	220	43	q.	q.	PROPN
eurjchem-2553	220	44	;	;	PUNCT
eurjchem-2553	220	45	deng	deng	PROPN
eurjchem-2553	220	46	,	,	PUNCT
eurjchem-2553	220	47	y.	y.	PROPN
eurjchem-2553	220	48	;	;	PUNCT
eurjchem-2553	220	49	liu	liu	PROPN
eurjchem-2553	220	50	,	,	PUNCT
eurjchem-2553	220	51	p.	p.	PROPN
eurjchem-2553	220	52	;	;	PUNCT
eurjchem-2553	220	53	wang	wang	PROPN
eurjchem-2553	220	54	,	,	PUNCT
eurjchem-2553	220	55	n.	n.	PROPN
eurjchem-2553	220	56	;	;	PUNCT
eurjchem-2553	220	57	wang	wang	PROPN
eurjchem-2553	220	58	,	,	PUNCT
eurjchem-2553	220	59	l.	l.	PROPN
eurjchem-2553	220	60	;	;	PUNCT
eurjchem-2553	220	61	liu	liu	PROPN
eurjchem-2553	220	62	,	,	PUNCT
eurjchem-2553	220	63	m.	m.	NOUN
eurjchem-2553	220	64	;	;	PUNCT
eurjchem-2553	220	65	li	li	PROPN
eurjchem-2553	220	66	,	,	PUNCT
eurjchem-2553	220	67	y.	y.	PROPN
eurjchem-2553	220	68	;	;	PUNCT
eurjchem-2553	220	69	zhu	zhu	PROPN
eurjchem-2553	220	70	,	,	PUNCT
eurjchem-2553	220	71	b.	b.	PROPN
eurjchem-2553	220	72	;	;	PUNCT
eurjchem-2553	220	73	fan	fan	PROPN
eurjchem-2553	220	74	,	,	PUNCT
eurjchem-2553	220	75	k.	k.	PROPN
eurjchem-2553	220	76	;	;	PUNCT
eurjchem-2553	220	77	fu	fu	PROPN
eurjchem-2553	220	78	,	,	PUNCT
eurjchem-2553	220	79	w.	w.	PROPN
eurjchem-2553	220	80	;	;	PUNCT
eurjchem-2553	220	81	yang	yang	PROPN
eurjchem-2553	220	82	,	,	PUNCT
eurjchem-2553	220	83	p.	p.	PROPN
eurjchem-2553	220	84	;	;	PUNCT
eurjchem-2553	220	85	pei	pei	PROPN
eurjchem-2553	220	86	,	,	PUNCT
eurjchem-2553	220	87	x.	x.	PROPN
eurjchem-2553	220	88	;	;	PUNCT
eurjchem-2553	220	89	cui	cui	PROPN
eurjchem-2553	220	90	,	,	PUNCT
eurjchem-2553	220	91	z.	z.	PROPN
eurjchem-2553	220	92	;	;	PUNCT
eurjchem-2553	220	93	qin	qin	PROPN
eurjchem-2553	220	94	,	,	PUNCT
eurjchem-2553	220	95	l.	l.	PROPN
eurjchem-2553	220	96	;	;	PUNCT
eurjchem-2553	220	97	ge	ge	PROPN
eurjchem-2553	220	98	,	,	PUNCT
eurjchem-2553	220	99	p.	p.	PROPN
eurjchem-2553	220	100	;	;	PUNCT
eurjchem-2553	220	101	wu	wu	PROPN
eurjchem-2553	220	102	,	,	PUNCT
eurjchem-2553	220	103	j.	j.	PROPN
eurjchem-2553	220	104	;	;	PUNCT
eurjchem-2553	220	105	liu	liu	PROPN
eurjchem-2553	220	106	,	,	PUNCT
eurjchem-2553	220	107	s.	s.	PROPN
eurjchem-2553	220	108	;	;	PUNCT
eurjchem-2553	220	109	chen	chen	PROPN
eurjchem-2553	220	110	,	,	PUNCT
eurjchem-2553	220	111	y.	y.	PROPN
eurjchem-2553	220	112	;	;	PUNCT
eurjchem-2553	220	113	huang	huang	PROPN
eurjchem-2553	220	114	,	,	PUNCT
eurjchem-2553	220	115	w.	w.	PROPN
eurjchem-2553	220	116	;	;	PUNCT
eurjchem-2553	220	117	wang	wang	PROPN
eurjchem-2553	220	118	,	,	PUNCT
eurjchem-2553	220	119	q.	q.	PROPN
eurjchem-2553	220	120	;	;	PUNCT
eurjchem-2553	220	121	qin	qin	X
eurjchem-2553	220	122	,	,	PUNCT
eurjchem-2553	220	123	c.-f	c.-f	NOUN
eurjchem-2553	220	124	.	.	PUNCT
eurjchem-2553	220	125	;	;	PUNCT
eurjchem-2553	220	126	wang	wang	PROPN
eurjchem-2553	220	127	,	,	PUNCT
eurjchem-2553	220	128	y.	y.	PROPN
eurjchem-2553	220	129	;	;	PUNCT
eurjchem-2553	220	130	qin	qin	PROPN
eurjchem-2553	220	131	,	,	PUNCT
eurjchem-2553	220	132	c.	c.	PROPN
eurjchem-2553	220	133	;	;	PUNCT
eurjchem-2553	220	134	wang	wang	PROPN
eurjchem-2553	220	135	,	,	PUNCT
eurjchem-2553	220	136	x.	x.	PROPN
eurjchem-2553	220	137	memory	memory	NOUN
eurjchem-2553	220	138	b	b	PROPN
eurjchem-2553	220	139	cell	cell	NOUN
eurjchem-2553	220	140	repertoire	repertoire	NOUN
eurjchem-2553	220	141	from	from	ADP
eurjchem-2553	220	142	triple	triple	ADJ
eurjchem-2553	220	143	vaccinees	vaccinee	NOUN
eurjchem-2553	220	144	against	against	ADP
eurjchem-2553	220	145	diverse	diverse	ADJ
eurjchem-2553	220	146	sarscov-2	sarscov-2	NUM
eurjchem-2553	220	147	variants	variant	NOUN
eurjchem-2553	220	148	.	.	PUNCT
eurjchem-2553	221	1	nature	nature	NOUN
eurjchem-2553	221	2	2022	2022	NUM
eurjchem-2553	221	3	,	,	PUNCT
eurjchem-2553	221	4	603	603	NUM
eurjchem-2553	221	5	,	,	PUNCT
eurjchem-2553	221	6	919–925	919–925	NUM
eurjchem-2553	221	7	.	.	PUNCT
eurjchem-2553	222	1	[	[	X
eurjchem-2553	222	2	7	7	NUM
eurjchem-2553	222	3	]	]	PUNCT
eurjchem-2553	222	4	.	.	PUNCT
eurjchem-2553	223	1	soleimanpour	soleimanpour	PROPN
eurjchem-2553	223	2	,	,	PUNCT
eurjchem-2553	223	3	s.	s.	PROPN
eurjchem-2553	223	4	;	;	PUNCT
eurjchem-2553	223	5	yaghoubi	yaghoubi	NOUN
eurjchem-2553	223	6	,	,	PUNCT
eurjchem-2553	223	7	a.	a.	NOUN
eurjchem-2553	223	8	covid-19	covid-19	PROPN
eurjchem-2553	223	9	vaccine	vaccine	NOUN
eurjchem-2553	223	10	:	:	PUNCT
eurjchem-2553	223	11	where	where	SCONJ
eurjchem-2553	223	12	are	be	AUX
eurjchem-2553	223	13	we	we	PRON
eurjchem-2553	223	14	now	now	ADV
eurjchem-2553	223	15	and	and	CCONJ
eurjchem-2553	223	16	where	where	SCONJ
eurjchem-2553	223	17	should	should	AUX
eurjchem-2553	223	18	we	we	PRON
eurjchem-2553	223	19	go	go	VERB
eurjchem-2553	223	20	?	?	PUNCT
eurjchem-2553	224	1	expert	expert	NOUN
eurjchem-2553	224	2	rev	rev	VERB
eurjchem-2553	224	3	.	.	PROPN
eurjchem-2553	224	4	vaccines	vaccine	NOUN
eurjchem-2553	224	5	2021	2021	NUM
eurjchem-2553	224	6	,	,	PUNCT
eurjchem-2553	224	7	20	20	NUM
eurjchem-2553	224	8	,	,	PUNCT
eurjchem-2553	224	9	23–44	23–44	NUM
eurjchem-2553	224	10	.	.	PUNCT
eurjchem-2553	225	1	[	[	X
eurjchem-2553	225	2	8	8	NUM
eurjchem-2553	225	3	]	]	PUNCT
eurjchem-2553	225	4	.	.	PUNCT
eurjchem-2553	226	1	wang	wang	PROPN
eurjchem-2553	226	2	,	,	PUNCT
eurjchem-2553	226	3	w.	w.	PROPN
eurjchem-2553	226	4	;	;	PUNCT
eurjchem-2553	226	5	wu	wu	PROPN
eurjchem-2553	226	6	,	,	PUNCT
eurjchem-2553	226	7	j.	j.	PROPN
eurjchem-2553	226	8	;	;	PUNCT
eurjchem-2553	226	9	zhao	zhao	PROPN
eurjchem-2553	226	10	,	,	PUNCT
eurjchem-2553	226	11	z.	z.	PROPN
eurjchem-2553	226	12	;	;	PUNCT
eurjchem-2553	226	13	li	li	PROPN
eurjchem-2553	226	14	,	,	PUNCT
eurjchem-2553	226	15	q.	q.	PROPN
eurjchem-2553	226	16	;	;	PUNCT
eurjchem-2553	226	17	huo	huo	PROPN
eurjchem-2553	226	18	,	,	PUNCT
eurjchem-2553	226	19	b.	b.	PROPN
eurjchem-2553	226	20	;	;	PUNCT
eurjchem-2553	226	21	sun	sun	NOUN
eurjchem-2553	226	22	,	,	PUNCT
eurjchem-2553	226	23	x.	x.	PROPN
eurjchem-2553	226	24	;	;	PUNCT
eurjchem-2553	226	25	han	han	PROPN
eurjchem-2553	226	26	,	,	PUNCT
eurjchem-2553	226	27	d.	d.	PROPN
eurjchem-2553	226	28	;	;	PUNCT
eurjchem-2553	226	29	liu	liu	PROPN
eurjchem-2553	226	30	,	,	PUNCT
eurjchem-2553	226	31	m.	m.	NOUN
eurjchem-2553	226	32	;	;	PUNCT
eurjchem-2553	226	33	cai	cai	X
eurjchem-2553	226	34	,	,	PUNCT
eurjchem-2553	226	35	l.	l.	PROPN
eurjchem-2553	226	36	c.	c.	PROPN
eurjchem-2553	226	37	;	;	PUNCT
eurjchem-2553	226	38	peng	peng	PROPN
eurjchem-2553	226	39	,	,	PUNCT
eurjchem-2553	226	40	y.	y.	PROPN
eurjchem-2553	226	41	;	;	PUNCT
eurjchem-2553	226	42	bai	bai	PROPN
eurjchem-2553	226	43	,	,	PUNCT
eurjchem-2553	226	44	j.	j.	PROPN
eurjchem-2553	226	45	;	;	PUNCT
eurjchem-2553	226	46	gao	gao	PROPN
eurjchem-2553	226	47	,	,	PUNCT
eurjchem-2553	226	48	z.	z.	PROPN
eurjchem-2553	226	49	ultrasensitive	ultrasensitive	ADJ
eurjchem-2553	226	50	automatic	automatic	ADJ
eurjchem-2553	226	51	detection	detection	NOUN
eurjchem-2553	226	52	of	of	ADP
eurjchem-2553	226	53	small	small	ADJ
eurjchem-2553	226	54	molecules	molecule	NOUN
eurjchem-2553	226	55	by	by	ADP
eurjchem-2553	226	56	membrane	membrane	NOUN
eurjchem-2553	226	57	imaging	imaging	NOUN
eurjchem-2553	226	58	of	of	ADP
eurjchem-2553	226	59	single	single	ADJ
eurjchem-2553	226	60	molecule	molecule	NOUN
eurjchem-2553	226	61	assays	assay	NOUN
eurjchem-2553	226	62	.	.	PUNCT
eurjchem-2553	227	1	acs	acs	PROPN
eurjchem-2553	227	2	appl	appl	PROPN
eurjchem-2553	227	3	.	.	PUNCT
eurjchem-2553	228	1	mater	mater	PROPN
eurjchem-2553	228	2	.	.	PUNCT
eurjchem-2553	229	1	interfaces	interface	NOUN
eurjchem-2553	229	2	2022	2022	NUM
eurjchem-2553	229	3	,	,	PUNCT
eurjchem-2553	229	4	14	14	NUM
eurjchem-2553	229	5	,	,	PUNCT
eurjchem-2553	229	6	54914–54923	54914–54923	NUM
eurjchem-2553	229	7	.	.	PUNCT
eurjchem-2553	230	1	[	[	X
eurjchem-2553	230	2	9	9	NUM
eurjchem-2553	230	3	]	]	PUNCT
eurjchem-2553	230	4	.	.	PUNCT
eurjchem-2553	231	1	speiser	speiser	PROPN
eurjchem-2553	231	2	,	,	PUNCT
eurjchem-2553	231	3	d.	d.	PROPN
eurjchem-2553	231	4	e.	e.	PROPN
eurjchem-2553	231	5	;	;	PUNCT
eurjchem-2553	231	6	bachmann	bachmann	PROPN
eurjchem-2553	231	7	,	,	PUNCT
eurjchem-2553	231	8	m.	m.	PROPN
eurjchem-2553	231	9	f.	f.	PROPN
eurjchem-2553	231	10	covid-19	covid-19	PROPN
eurjchem-2553	231	11	:	:	PUNCT
eurjchem-2553	231	12	mechanisms	mechanism	NOUN
eurjchem-2553	231	13	of	of	ADP
eurjchem-2553	231	14	vaccination	vaccination	NOUN
eurjchem-2553	231	15	and	and	CCONJ
eurjchem-2553	231	16	immunity	immunity	NOUN
eurjchem-2553	231	17	.	.	PUNCT
eurjchem-2553	232	1	vaccines	vaccine	NOUN
eurjchem-2553	232	2	(	(	PUNCT
eurjchem-2553	232	3	basel	basel	PROPN
eurjchem-2553	232	4	)	)	PUNCT
eurjchem-2553	232	5	2020	2020	NUM
eurjchem-2553	232	6	,	,	PUNCT
eurjchem-2553	232	7	8	8	NUM
eurjchem-2553	232	8	,	,	PUNCT
eurjchem-2553	232	9	404	404	NUM
eurjchem-2553	232	10	.	.	PUNCT
eurjchem-2553	233	1	[	[	X
eurjchem-2553	233	2	10	10	NUM
eurjchem-2553	233	3	]	]	PUNCT
eurjchem-2553	233	4	.	.	PUNCT
eurjchem-2553	233	5	naveena	naveena	PROPN
eurjchem-2553	233	6	,	,	PUNCT
eurjchem-2553	233	7	j.	j.	PROPN
eurjchem-2553	233	8	;	;	PUNCT
eurjchem-2553	233	9	nandhini	nandhini	PROPN
eurjchem-2553	233	10	,	,	PUNCT
eurjchem-2553	233	11	m.	m.	NOUN
eurjchem-2553	233	12	p.	p.	PROPN
eurjchem-2553	233	13	;	;	PUNCT
eurjchem-2553	233	14	kavitha	kavitha	PROPN
eurjchem-2553	233	15	,	,	PUNCT
eurjchem-2553	233	16	k.	k.	PROPN
eurjchem-2553	233	17	;	;	PUNCT
eurjchem-2553	233	18	manjunath	manjunath	PROPN
eurjchem-2553	233	19	,	,	PUNCT
eurjchem-2553	233	20	c.	c.	PROPN
eurjchem-2553	233	21	n.	n.	PROPN
eurjchem-2553	233	22	;	;	PUNCT
eurjchem-2553	233	23	cherukumudi	cherukumudi	PROPN
eurjchem-2553	233	24	,	,	PUNCT
eurjchem-2553	233	25	a.	a.	NOUN
eurjchem-2553	233	26	;	;	PUNCT
eurjchem-2553	233	27	prapulla	prapulla	NOUN
eurjchem-2553	233	28	,	,	PUNCT
eurjchem-2553	233	29	n.	n.	NOUN
eurjchem-2553	233	30	neutralising	neutralise	VERB
eurjchem-2553	233	31	antibodies	antibody	NOUN
eurjchem-2553	233	32	in	in	ADP
eurjchem-2553	233	33	healthcare	healthcare	NOUN
eurjchem-2553	233	34	workers	worker	NOUN
eurjchem-2553	233	35	after	after	ADP
eurjchem-2553	233	36	two	two	NUM
eurjchem-2553	233	37	doses	dose	NOUN
eurjchem-2553	233	38	of	of	ADP
eurjchem-2553	233	39	covishield	covishield	ADJ
eurjchem-2553	233	40	vaccine	vaccine	NOUN
eurjchem-2553	233	41	at	at	ADP
eurjchem-2553	233	42	three	three	NUM
eurjchem-2553	233	43	months	month	NOUN
eurjchem-2553	233	44	and	and	CCONJ
eurjchem-2553	233	45	six	six	NUM
eurjchem-2553	233	46	months	month	NOUN
eurjchem-2553	233	47	:	:	PUNCT
eurjchem-2553	233	48	a	a	DET
eurjchem-2553	233	49	single	single	ADJ
eurjchem-2553	233	50	-	-	PUNCT
eurjchem-2553	233	51	centre	centre	NOUN
eurjchem-2553	233	52	observational	observational	ADJ
eurjchem-2553	233	53	study	study	NOUN
eurjchem-2553	233	54	.	.	PUNCT
eurjchem-2553	234	1	j.	j.	PROPN
eurjchem-2553	234	2	clin	clin	PROPN
eurjchem-2553	234	3	.	.	PUNCT
eurjchem-2553	235	1	diagn	diagn	PROPN
eurjchem-2553	235	2	.	.	PUNCT
eurjchem-2553	236	1	res	re	NOUN
eurjchem-2553	236	2	.	.	PUNCT
eurjchem-2553	236	3	2022	2022	NUM
eurjchem-2553	236	4	.	.	PUNCT
eurjchem-2553	237	1	https://doi.org/10.7860/jcdr/2022/56189.16758	https://doi.org/10.7860/jcdr/2022/56189.16758	PRON
eurjchem-2553	238	1	[	[	X
eurjchem-2553	238	2	11	11	NUM
eurjchem-2553	238	3	]	]	PUNCT
eurjchem-2553	238	4	.	.	PUNCT
eurjchem-2553	239	1	yadav	yadav	PROPN
eurjchem-2553	239	2	,	,	PUNCT
eurjchem-2553	239	3	p.	p.	PROPN
eurjchem-2553	239	4	d.	d.	PROPN
eurjchem-2553	239	5	;	;	PUNCT
eurjchem-2553	239	6	mohandas	mohandas	PROPN
eurjchem-2553	239	7	,	,	PUNCT
eurjchem-2553	239	8	s.	s.	PROPN
eurjchem-2553	239	9	;	;	PUNCT
eurjchem-2553	239	10	shete	shete	PROPN
eurjchem-2553	239	11	,	,	PUNCT
eurjchem-2553	239	12	a.	a.	NOUN
eurjchem-2553	239	13	m.	m.	NOUN
eurjchem-2553	239	14	;	;	PUNCT
eurjchem-2553	239	15	nyayanit	nyayanit	NOUN
eurjchem-2553	239	16	,	,	PUNCT
eurjchem-2553	239	17	d.	d.	PROPN
eurjchem-2553	239	18	a.	a.	PROPN
eurjchem-2553	239	19	;	;	PUNCT
eurjchem-2553	239	20	gupta	gupta	PROPN
eurjchem-2553	239	21	,	,	PUNCT
eurjchem-2553	239	22	n.	n.	NOUN
eurjchem-2553	239	23	;	;	PUNCT
eurjchem-2553	239	24	patil	patil	PROPN
eurjchem-2553	239	25	,	,	PUNCT
eurjchem-2553	239	26	d.	d.	PROPN
eurjchem-2553	239	27	y.	y.	PROPN
eurjchem-2553	239	28	;	;	PUNCT
eurjchem-2553	239	29	sapkal	sapkal	NOUN
eurjchem-2553	239	30	,	,	PUNCT
eurjchem-2553	239	31	g.	g.	PROPN
eurjchem-2553	239	32	n.	n.	PROPN
eurjchem-2553	239	33	;	;	PUNCT
eurjchem-2553	239	34	potdar	potdar	PRON
eurjchem-2553	239	35	,	,	PUNCT
eurjchem-2553	239	36	v.	v.	PROPN
eurjchem-2553	239	37	;	;	PUNCT
eurjchem-2553	239	38	kadam	kadam	PROPN
eurjchem-2553	239	39	,	,	PUNCT
eurjchem-2553	239	40	m.	m.	NOUN
eurjchem-2553	239	41	;	;	PUNCT
eurjchem-2553	239	42	kumar	kumar	PROPN
eurjchem-2553	239	43	,	,	PUNCT
eurjchem-2553	239	44	a.	a.	PROPN
eurjchem-2553	239	45	;	;	PUNCT
eurjchem-2553	239	46	kumar	kumar	PROPN
eurjchem-2553	239	47	,	,	PUNCT
eurjchem-2553	239	48	s.	s.	PROPN
eurjchem-2553	239	49	;	;	PUNCT
eurjchem-2553	239	50	suryavanshi	suryavanshi	PROPN
eurjchem-2553	239	51	,	,	PUNCT
eurjchem-2553	239	52	d.	d.	PROPN
eurjchem-2553	239	53	;	;	PUNCT
eurjchem-2553	239	54	mote	mote	PROPN
eurjchem-2553	239	55	,	,	PUNCT
eurjchem-2553	239	56	c.	c.	PROPN
eurjchem-2553	239	57	s.	s.	PROPN
eurjchem-2553	239	58	;	;	PUNCT
eurjchem-2553	239	59	abraham	abraham	PROPN
eurjchem-2553	239	60	,	,	PUNCT
eurjchem-2553	239	61	p.	p.	NOUN
eurjchem-2553	239	62	;	;	PUNCT
eurjchem-2553	239	63	panda	panda	NOUN
eurjchem-2553	239	64	,	,	PUNCT
eurjchem-2553	239	65	s.	s.	PROPN
eurjchem-2553	239	66	;	;	PUNCT
eurjchem-2553	239	67	bhargava	bhargava	PROPN
eurjchem-2553	239	68	,	,	PUNCT
eurjchem-2553	239	69	b.	b.	PROPN
eurjchem-2553	239	70	sars	sars	PROPN
eurjchem-2553	239	71	cov-2	cov-2	PART
eurjchem-2553	239	72	variant	variant	NOUN
eurjchem-2553	239	73	b.1.617.1	b.1.617.1	NOUN
eurjchem-2553	239	74	is	be	AUX
eurjchem-2553	239	75	highly	highly	ADV
eurjchem-2553	239	76	pathogenic	pathogenic	ADJ
eurjchem-2553	239	77	in	in	ADP
eurjchem-2553	239	78	hamsters	hamster	NOUN
eurjchem-2553	239	79	than	than	ADP
eurjchem-2553	239	80	b.1	b.1	NOUN
eurjchem-2553	239	81	variant	variant	NOUN
eurjchem-2553	239	82	.	.	PUNCT
eurjchem-2553	240	1	biorxiv	biorxiv	NOUN
eurjchem-2553	240	2	2021	2021	NUM
eurjchem-2553	240	3	.	.	PUNCT
eurjchem-2553	241	1	https://doi.org/10.1101/2021.05.05.442760	https://doi.org/10.1101/2021.05.05.442760	PROPN
eurjchem-2553	241	2	[	[	X
eurjchem-2553	241	3	12	12	NUM
eurjchem-2553	241	4	]	]	PUNCT
eurjchem-2553	241	5	.	.	PUNCT
eurjchem-2553	242	1	india	india	PROPN
eurjchem-2553	242	2	:	:	PUNCT
eurjchem-2553	243	1	covid-19	covid-19	PROPN
eurjchem-2553	243	2	vaccines	vaccine	NOUN
eurjchem-2553	243	3	administered	administer	VERB
eurjchem-2553	243	4	by	by	ADP
eurjchem-2553	243	5	vaccine	vaccine	NOUN
eurjchem-2553	243	6	type	type	NOUN
eurjchem-2553	243	7	2022	2022	NUM
eurjchem-2553	243	8	.	.	PUNCT
eurjchem-2553	244	1	https://www.statista.com/statistics/1248301/india-covid-19vaccines-administered-by-vaccine-type(accessed	https://www.statista.com/statistics/1248301/india-covid-19vaccines-administered-by-vaccine-type(accesse	VERB
eurjchem-2553	244	2	january	january	PROPN
eurjchem-2553	244	3	20	20	NUM
eurjchem-2553	244	4	,	,	PUNCT
eurjchem-2553	244	5	2024	2024	NUM
eurjchem-2553	244	6	)	)	PUNCT
eurjchem-2553	244	7	.	.	PUNCT
eurjchem-2553	245	1	[	[	X
eurjchem-2553	245	2	13	13	NUM
eurjchem-2553	245	3	]	]	PUNCT
eurjchem-2553	245	4	.	.	PUNCT
eurjchem-2553	245	5	jain	jain	PROPN
eurjchem-2553	245	6	,	,	PUNCT
eurjchem-2553	245	7	a.	a.	PROPN
eurjchem-2553	245	8	;	;	PUNCT
eurjchem-2553	245	9	negi	negi	PROPN
eurjchem-2553	245	10	,	,	PUNCT
eurjchem-2553	245	11	g.	g.	PROPN
eurjchem-2553	245	12	;	;	PUNCT
eurjchem-2553	245	13	kaur	kaur	PROPN
eurjchem-2553	245	14	,	,	PUNCT
eurjchem-2553	245	15	d.	d.	PROPN
eurjchem-2553	245	16	;	;	PUNCT
eurjchem-2553	245	17	vivekanandhan	vivekanandhan	ADV
eurjchem-2553	245	18	;	;	PUNCT
eurjchem-2553	245	19	saxena	saxena	PROPN
eurjchem-2553	245	20	,	,	PUNCT
eurjchem-2553	245	21	v.	v.	ADP
eurjchem-2553	245	22	utility	utility	NOUN
eurjchem-2553	245	23	of	of	ADP
eurjchem-2553	245	24	covid19	covid19	NOUN
eurjchem-2553	245	25	seropositive	seropositive	ADJ
eurjchem-2553	245	26	plasma	plasma	NOUN
eurjchem-2553	245	27	as	as	ADP
eurjchem-2553	245	28	convalescent	convalescent	NOUN
eurjchem-2553	245	29	plasma	plasma	NOUN
eurjchem-2553	245	30	:	:	PUNCT
eurjchem-2553	245	31	an	an	DET
eurjchem-2553	245	32	immune	immune	ADJ
eurjchem-2553	245	33	and	and	CCONJ
eurjchem-2553	245	34	neutralization	neutralization	NOUN
eurjchem-2553	245	35	antibody	antibody	NOUN
eurjchem-2553	245	36	seroprevalence	seroprevalence	NOUN
eurjchem-2553	245	37	analysis	analysis	NOUN
eurjchem-2553	245	38	in	in	ADP
eurjchem-2553	245	39	blood	blood	NOUN
eurjchem-2553	245	40	donors	donor	NOUN
eurjchem-2553	245	41	for	for	ADP
eurjchem-2553	245	42	future	future	ADJ
eurjchem-2553	245	43	potential	potential	ADJ
eurjchem-2553	245	44	pandemic	pandemic	ADJ
eurjchem-2553	245	45	readiness	readiness	NOUN
eurjchem-2553	245	46	.	.	PUNCT
eurjchem-2553	246	1	cureus	cureus	NOUN
eurjchem-2553	246	2	2024	2024	NUM
eurjchem-2553	246	3	.	.	PUNCT
eurjchem-2553	247	1	https://doi.org/10.7759/cureus.57149	https://doi.org/10.7759/cureus.57149	PROPN
eurjchem-2553	248	1	[	[	X
eurjchem-2553	248	2	14	14	NUM
eurjchem-2553	248	3	]	]	PUNCT
eurjchem-2553	248	4	.	.	PUNCT
eurjchem-2553	249	1	zhao	zhao	NOUN
eurjchem-2553	249	2	,	,	PUNCT
eurjchem-2553	249	3	t.	t.	PROPN
eurjchem-2553	249	4	;	;	PUNCT
eurjchem-2553	249	5	shen	shen	PROPN
eurjchem-2553	249	6	,	,	PUNCT
eurjchem-2553	249	7	j.	j.	PROPN
eurjchem-2553	249	8	;	;	PUNCT
eurjchem-2553	249	9	zhu	zhu	PROPN
eurjchem-2553	249	10	,	,	PUNCT
eurjchem-2553	249	11	y.	y.	PROPN
eurjchem-2553	249	12	;	;	PUNCT
eurjchem-2553	249	13	tian	tian	ADJ
eurjchem-2553	249	14	,	,	PUNCT
eurjchem-2553	249	15	x.	x.	PROPN
eurjchem-2553	249	16	;	;	PUNCT
eurjchem-2553	249	17	wen	wen	PROPN
eurjchem-2553	249	18	,	,	PUNCT
eurjchem-2553	249	19	g.	g.	PROPN
eurjchem-2553	249	20	;	;	PUNCT
eurjchem-2553	249	21	wei	wei	PROPN
eurjchem-2553	249	22	,	,	PUNCT
eurjchem-2553	249	23	y.	y.	PROPN
eurjchem-2553	249	24	;	;	PUNCT
eurjchem-2553	249	25	xu	xu	PROPN
eurjchem-2553	249	26	,	,	PUNCT
eurjchem-2553	249	27	b.	b.	PROPN
eurjchem-2553	249	28	;	;	PUNCT
eurjchem-2553	249	29	fu	fu	PROPN
eurjchem-2553	249	30	,	,	PUNCT
eurjchem-2553	249	31	c.	c.	PROPN
eurjchem-2553	249	32	;	;	PUNCT
eurjchem-2553	249	33	xie	xie	PROPN
eurjchem-2553	249	34	,	,	PUNCT
eurjchem-2553	249	35	z.	z.	PROPN
eurjchem-2553	249	36	;	;	PUNCT
eurjchem-2553	249	37	xi	xi	PROPN
eurjchem-2553	249	38	,	,	PUNCT
eurjchem-2553	249	39	y.	y.	PROPN
eurjchem-2553	249	40	;	;	PUNCT
eurjchem-2553	249	41	li	li	PROPN
eurjchem-2553	249	42	,	,	PUNCT
eurjchem-2553	249	43	z.	z.	PROPN
eurjchem-2553	249	44	;	;	PUNCT
eurjchem-2553	249	45	peng	peng	PROPN
eurjchem-2553	249	46	,	,	PUNCT
eurjchem-2553	249	47	j.	j.	PROPN
eurjchem-2553	249	48	;	;	PUNCT
eurjchem-2553	249	49	wu	wu	PROPN
eurjchem-2553	249	50	,	,	PUNCT
eurjchem-2553	249	51	y.	y.	PROPN
eurjchem-2553	249	52	;	;	PUNCT
eurjchem-2553	249	53	tang	tang	PROPN
eurjchem-2553	249	54	,	,	PUNCT
eurjchem-2553	249	55	x.	x.	PROPN
eurjchem-2553	249	56	;	;	PUNCT
eurjchem-2553	249	57	wan	wan	PROPN
eurjchem-2553	249	58	,	,	PUNCT
eurjchem-2553	249	59	c.	c.	PROPN
eurjchem-2553	249	60	;	;	PUNCT
eurjchem-2553	249	61	pan	pan	PROPN
eurjchem-2553	249	62	,	,	PUNCT
eurjchem-2553	249	63	l.	l.	PROPN
eurjchem-2553	249	64	;	;	PUNCT
eurjchem-2553	249	65	li	li	PROPN
eurjchem-2553	249	66	,	,	PUNCT
eurjchem-2553	249	67	z.	z.	PROPN
eurjchem-2553	249	68	;	;	PUNCT
eurjchem-2553	249	69	qin	qin	PROPN
eurjchem-2553	249	70	,	,	PUNCT
eurjchem-2553	249	71	d.	d.	PROPN
eurjchem-2553	249	72	immunogenicity	immunogenicity	NOUN
eurjchem-2553	249	73	of	of	ADP
eurjchem-2553	249	74	inactivated	inactivated	ADJ
eurjchem-2553	249	75	sars	sar	NOUN
eurjchem-2553	249	76	-	-	PUNCT
eurjchem-2553	249	77	cov-2	cov-2	NOUN
eurjchem-2553	249	78	vaccines	vaccine	NOUN
eurjchem-2553	249	79	in	in	ADP
eurjchem-2553	249	80	patients	patient	NOUN
eurjchem-2553	249	81	with	with	ADP
eurjchem-2553	249	82	rheumatoid	rheumatoid	NOUN
eurjchem-2553	249	83	arthritis	arthritis	NOUN
eurjchem-2553	249	84	:	:	PUNCT
eurjchem-2553	249	85	a	a	DET
eurjchem-2553	249	86	case	case	NOUN
eurjchem-2553	249	87	series	series	NOUN
eurjchem-2553	249	88	.	.	PUNCT
eurjchem-2553	250	1	front	front	ADJ
eurjchem-2553	250	2	.	.	PUNCT
eurjchem-2553	251	1	public	public	ADJ
eurjchem-2553	251	2	health	health	NOUN
eurjchem-2553	251	3	2022	2022	NUM
eurjchem-2553	251	4	,	,	PUNCT
eurjchem-2553	251	5	10	10	NUM
eurjchem-2553	251	6	.	.	PUNCT
eurjchem-2553	252	1	[	[	X
eurjchem-2553	252	2	15	15	NUM
eurjchem-2553	252	3	]	]	PUNCT
eurjchem-2553	252	4	.	.	PUNCT
eurjchem-2553	253	1	covid	covid	PROPN
eurjchem-2553	253	2	19	19	NUM
eurjchem-2553	253	3	ag	ag	PROPN
eurjchem-2553	253	4	microlisa	microlisa	NOUN
eurjchem-2553	253	5	.	.	PUNCT
eurjchem-2553	254	1	https://jmitra.co.in/product-details/covid19ag-microlisa-elisa-test-kit/	https://jmitra.co.in/product-details/covid19ag-microlisa-elisa-test-kit/	PROPN
eurjchem-2553	254	2	(	(	PUNCT
eurjchem-2553	254	3	accessed	access	VERB
eurjchem-2553	254	4	january	january	PROPN
eurjchem-2553	254	5	20	20	NUM
eurjchem-2553	254	6	,	,	PUNCT
eurjchem-2553	254	7	2024	2024	NUM
eurjchem-2553	254	8	)	)	PUNCT
eurjchem-2553	254	9	.	.	PUNCT
eurjchem-2553	255	1	[	[	X
eurjchem-2553	255	2	16	16	NUM
eurjchem-2553	255	3	]	]	PUNCT
eurjchem-2553	255	4	.	.	PUNCT
eurjchem-2553	256	1	cleemput	cleemput	PROPN
eurjchem-2553	256	2	,	,	PUNCT
eurjchem-2553	256	3	s.	s.	PROPN
eurjchem-2553	256	4	;	;	PUNCT
eurjchem-2553	256	5	dumon	dumon	PROPN
eurjchem-2553	256	6	,	,	PUNCT
eurjchem-2553	256	7	w.	w.	PROPN
eurjchem-2553	256	8	;	;	PUNCT
eurjchem-2553	256	9	fonseca	fonseca	PROPN
eurjchem-2553	256	10	,	,	PUNCT
eurjchem-2553	256	11	v.	v.	ADV
eurjchem-2553	256	12	;	;	PUNCT
eurjchem-2553	256	13	abdool	abdool	NOUN
eurjchem-2553	256	14	karim	karim	PROPN
eurjchem-2553	256	15	,	,	PUNCT
eurjchem-2553	256	16	w.	w.	PROPN
eurjchem-2553	256	17	;	;	PUNCT
eurjchem-2553	256	18	giovanetti	giovanetti	PROPN
eurjchem-2553	256	19	,	,	PUNCT
eurjchem-2553	256	20	m.	m.	NOUN
eurjchem-2553	256	21	;	;	PUNCT
eurjchem-2553	256	22	alcantara	alcantara	PROPN
eurjchem-2553	256	23	,	,	PUNCT
eurjchem-2553	256	24	l.	l.	PROPN
eurjchem-2553	256	25	c.	c.	PROPN
eurjchem-2553	256	26	;	;	PUNCT
eurjchem-2553	256	27	deforche	deforche	PROPN
eurjchem-2553	256	28	,	,	PUNCT
eurjchem-2553	256	29	k.	k.	PROPN
eurjchem-2553	256	30	;	;	PUNCT
eurjchem-2553	256	31	de	de	PROPN
eurjchem-2553	256	32	oliveira	oliveira	PROPN
eurjchem-2553	256	33	,	,	PUNCT
eurjchem-2553	256	34	t.	t.	NOUN
eurjchem-2553	256	35	genome	genome	NOUN
eurjchem-2553	256	36	detective	detective	NOUN
eurjchem-2553	256	37	coronavirus	coronavirus	NOUN
eurjchem-2553	256	38	typing	type	VERB
eurjchem-2553	256	39	tool	tool	NOUN
eurjchem-2553	256	40	for	for	ADP
eurjchem-2553	256	41	rapid	rapid	ADJ
eurjchem-2553	256	42	identification	identification	NOUN
eurjchem-2553	256	43	and	and	CCONJ
eurjchem-2553	256	44	characterization	characterization	NOUN
eurjchem-2553	256	45	of	of	ADP
eurjchem-2553	256	46	novel	novel	ADJ
eurjchem-2553	256	47	coronavirus	coronavirus	NOUN
eurjchem-2553	256	48	genomes	genome	NOUN
eurjchem-2553	256	49	.	.	PUNCT
eurjchem-2553	257	1	bioinformatics	bioinformatic	NOUN
eurjchem-2553	257	2	2020	2020	NUM
eurjchem-2553	257	3	,	,	PUNCT
eurjchem-2553	257	4	36	36	NUM
eurjchem-2553	257	5	,	,	PUNCT
eurjchem-2553	257	6	3552–3555	3552–3555	NUM
eurjchem-2553	257	7	.	.	PUNCT
eurjchem-2553	258	1	[	[	X
eurjchem-2553	258	2	17	17	NUM
eurjchem-2553	258	3	]	]	PUNCT
eurjchem-2553	258	4	.	.	PUNCT
eurjchem-2553	259	1	kruglikov	kruglikov	PROPN
eurjchem-2553	259	2	,	,	PUNCT
eurjchem-2553	259	3	i.	i.	PROPN
eurjchem-2553	259	4	l.	l.	PROPN
eurjchem-2553	259	5	;	;	PUNCT
eurjchem-2553	259	6	scherer	scherer	PROPN
eurjchem-2553	259	7	,	,	PUNCT
eurjchem-2553	259	8	p.	p.	PROPN
eurjchem-2553	259	9	e.	e.	PROPN
eurjchem-2553	260	1	the	the	DET
eurjchem-2553	260	2	role	role	NOUN
eurjchem-2553	260	3	of	of	ADP
eurjchem-2553	260	4	adipocytes	adipocyte	NOUN
eurjchem-2553	260	5	and	and	CCONJ
eurjchem-2553	260	6	adipocyte	adipocyte	NOUN
eurjchem-2553	260	7	-	-	PUNCT
eurjchem-2553	260	8	like	like	ADJ
eurjchem-2553	260	9	cells	cell	NOUN
eurjchem-2553	260	10	in	in	ADP
eurjchem-2553	260	11	the	the	DET
eurjchem-2553	260	12	severity	severity	NOUN
eurjchem-2553	260	13	of	of	ADP
eurjchem-2553	260	14	covid-19	covid-19	PROPN
eurjchem-2553	260	15	infections	infection	NOUN
eurjchem-2553	260	16	.	.	PUNCT
eurjchem-2553	261	1	obesity	obesity	NOUN
eurjchem-2553	261	2	(	(	PUNCT
eurjchem-2553	261	3	silver	silver	NOUN
eurjchem-2553	261	4	spring	spring	NOUN
eurjchem-2553	261	5	)	)	PUNCT
eurjchem-2553	261	6	2020	2020	NUM
eurjchem-2553	261	7	,	,	PUNCT
eurjchem-2553	261	8	28	28	NUM
eurjchem-2553	261	9	,	,	PUNCT
eurjchem-2553	261	10	1187–1190	1187–1190	NUM
eurjchem-2553	261	11	.	.	PUNCT
eurjchem-2553	262	1	[	[	X
eurjchem-2553	262	2	18	18	NUM
eurjchem-2553	262	3	]	]	PUNCT
eurjchem-2553	262	4	.	.	PUNCT
eurjchem-2553	263	1	rabaan	rabaan	PROPN
eurjchem-2553	263	2	,	,	PUNCT
eurjchem-2553	263	3	a.	a.	NOUN
eurjchem-2553	263	4	a.	a.	PROPN
eurjchem-2553	263	5	;	;	PUNCT
eurjchem-2553	263	6	al	al	PROPN
eurjchem-2553	263	7	-	-	PUNCT
eurjchem-2553	263	8	ahmed	ahmed	PROPN
eurjchem-2553	263	9	,	,	PUNCT
eurjchem-2553	263	10	s.	s.	PROPN
eurjchem-2553	263	11	h.	h.	PROPN
eurjchem-2553	263	12	;	;	PUNCT
eurjchem-2553	263	13	muhammad	muhammad	PROPN
eurjchem-2553	263	14	,	,	PUNCT
eurjchem-2553	263	15	j.	j.	PROPN
eurjchem-2553	263	16	;	;	PUNCT
eurjchem-2553	263	17	khan	khan	PROPN
eurjchem-2553	263	18	,	,	PUNCT
eurjchem-2553	263	19	a.	a.	PROPN
eurjchem-2553	263	20	;	;	PUNCT
eurjchem-2553	263	21	sule	sule	NOUN
eurjchem-2553	263	22	,	,	PUNCT
eurjchem-2553	263	23	a.	a.	NOUN
eurjchem-2553	263	24	a.	a.	PROPN
eurjchem-2553	263	25	;	;	PUNCT
eurjchem-2553	263	26	tirupathi	tirupathi	PROPN
eurjchem-2553	263	27	,	,	PUNCT
eurjchem-2553	263	28	r.	r.	PROPN
eurjchem-2553	263	29	;	;	PUNCT
eurjchem-2553	263	30	mutair	mutair	NOUN
eurjchem-2553	263	31	,	,	PUNCT
eurjchem-2553	263	32	a.	a.	NOUN
eurjchem-2553	263	33	a.	a.	NOUN
eurjchem-2553	263	34	;	;	PUNCT
eurjchem-2553	263	35	alhumaid	alhumaid	VERB
eurjchem-2553	263	36	,	,	PUNCT
eurjchem-2553	263	37	s.	s.	PROPN
eurjchem-2553	263	38	;	;	PUNCT
eurjchem-2553	263	39	al	al	PROPN
eurjchem-2553	263	40	-	-	PUNCT
eurjchem-2553	263	41	omari	omari	PROPN
eurjchem-2553	263	42	,	,	PUNCT
eurjchem-2553	263	43	a.	a.	NOUN
eurjchem-2553	263	44	;	;	PUNCT
eurjchem-2553	263	45	dhawan	dhawan	NOUN
eurjchem-2553	263	46	,	,	PUNCT
eurjchem-2553	263	47	m.	m.	NOUN
eurjchem-2553	263	48	;	;	PUNCT
eurjchem-2553	263	49	tiwari	tiwari	PROPN
eurjchem-2553	263	50	,	,	PUNCT
eurjchem-2553	263	51	r.	r.	PROPN
eurjchem-2553	263	52	;	;	PUNCT
eurjchem-2553	263	53	sharun	sharun	NOUN
eurjchem-2553	263	54	,	,	PUNCT
eurjchem-2553	263	55	k.	k.	PROPN
eurjchem-2553	263	56	;	;	PUNCT
eurjchem-2553	263	57	mohapatra	mohapatra	PROPN
eurjchem-2553	263	58	,	,	PUNCT
eurjchem-2553	263	59	r.	r.	PROPN
eurjchem-2553	263	60	k.	k.	PROPN
eurjchem-2553	263	61	;	;	PUNCT
eurjchem-2553	263	62	mitra	mitra	PROPN
eurjchem-2553	263	63	,	,	PUNCT
eurjchem-2553	263	64	s.	s.	PROPN
eurjchem-2553	263	65	;	;	PUNCT
eurjchem-2553	263	66	bilal	bilal	PROPN
eurjchem-2553	263	67	,	,	PUNCT
eurjchem-2553	263	68	m.	m.	NOUN
eurjchem-2553	263	69	;	;	PUNCT
eurjchem-2553	263	70	alyami	alyami	NOUN
eurjchem-2553	263	71	,	,	PUNCT
eurjchem-2553	263	72	s.	s.	PROPN
eurjchem-2553	263	73	a.	a.	PROPN
eurjchem-2553	263	74	;	;	PUNCT
eurjchem-2553	263	75	emran	emran	PROPN
eurjchem-2553	263	76	,	,	PUNCT
eurjchem-2553	263	77	t.	t.	PROPN
eurjchem-2553	263	78	b.	b.	PROPN
eurjchem-2553	263	79	;	;	PUNCT
eurjchem-2553	263	80	moni	moni	PROPN
eurjchem-2553	263	81	,	,	PUNCT
eurjchem-2553	263	82	m.	m.	NOUN
eurjchem-2553	263	83	a.	a.	NOUN
eurjchem-2553	263	84	;	;	PUNCT
eurjchem-2553	263	85	dhama	dhama	PROPN
eurjchem-2553	263	86	,	,	PUNCT
eurjchem-2553	263	87	k.	k.	PROPN
eurjchem-2553	263	88	role	role	NOUN
eurjchem-2553	263	89	of	of	ADP
eurjchem-2553	263	90	inflammatory	inflammatory	ADJ
eurjchem-2553	263	91	cytokines	cytokine	NOUN
eurjchem-2553	263	92	in	in	ADP
eurjchem-2553	263	93	covid-19	covid-19	PROPN
eurjchem-2553	263	94	patients	patient	NOUN
eurjchem-2553	263	95	:	:	PUNCT
eurjchem-2553	263	96	a	a	DET
eurjchem-2553	263	97	review	review	NOUN
eurjchem-2553	263	98	on	on	ADP
eurjchem-2553	263	99	molecular	molecular	ADJ
eurjchem-2553	263	100	mechanisms	mechanism	NOUN
eurjchem-2553	263	101	,	,	PUNCT
eurjchem-2553	263	102	immune	immune	ADJ
eurjchem-2553	263	103	functions	function	NOUN
eurjchem-2553	263	104	,	,	PUNCT
eurjchem-2553	263	105	immunopathology	immunopathology	NOUN
eurjchem-2553	263	106	and	and	CCONJ
eurjchem-2553	263	107	immunomodulatory	immunomodulatory	ADJ
eurjchem-2553	263	108	drugs	drug	NOUN
eurjchem-2553	263	109	to	to	PART
eurjchem-2553	263	110	counter	counter	VERB
eurjchem-2553	263	111	cytokine	cytokine	NOUN
eurjchem-2553	263	112	storm	storm	NOUN
eurjchem-2553	263	113	.	.	PUNCT
eurjchem-2553	264	1	vaccines	vaccine	NOUN
eurjchem-2553	264	2	(	(	PUNCT
eurjchem-2553	264	3	basel	basel	PROPN
eurjchem-2553	264	4	)	)	PUNCT
eurjchem-2553	264	5	2021	2021	NUM
eurjchem-2553	264	6	,	,	PUNCT
eurjchem-2553	264	7	9	9	NUM
eurjchem-2553	264	8	,	,	PUNCT
eurjchem-2553	264	9	436	436	NUM
eurjchem-2553	264	10	.	.	PUNCT
eurjchem-2553	265	1	[	[	X
eurjchem-2553	265	2	19	19	NUM
eurjchem-2553	265	3	]	]	PUNCT
eurjchem-2553	265	4	.	.	PUNCT
eurjchem-2553	266	1	gallais	gallais	PROPN
eurjchem-2553	266	2	,	,	PUNCT
eurjchem-2553	266	3	f.	f.	PROPN
eurjchem-2553	266	4	;	;	PUNCT
eurjchem-2553	266	5	gantner	gantner	NOUN
eurjchem-2553	266	6	,	,	PUNCT
eurjchem-2553	266	7	p.	p.	PROPN
eurjchem-2553	266	8	;	;	PUNCT
eurjchem-2553	266	9	bruel	bruel	PROPN
eurjchem-2553	266	10	,	,	PUNCT
eurjchem-2553	266	11	t.	t.	PROPN
eurjchem-2553	266	12	;	;	PUNCT
eurjchem-2553	266	13	velay	velay	NOUN
eurjchem-2553	266	14	,	,	PUNCT
eurjchem-2553	266	15	a.	a.	NOUN
eurjchem-2553	266	16	;	;	PUNCT
eurjchem-2553	266	17	planas	planas	PROPN
eurjchem-2553	266	18	,	,	PUNCT
eurjchem-2553	266	19	d.	d.	PROPN
eurjchem-2553	266	20	;	;	PUNCT
eurjchem-2553	266	21	wendling	wendle	VERB
eurjchem-2553	266	22	,	,	PUNCT
eurjchem-2553	266	23	m.-j	m.-j	PROPN
eurjchem-2553	266	24	.	.	PUNCT
eurjchem-2553	266	25	;	;	PUNCT
eurjchem-2553	267	1	bayer	bayer	PROPN
eurjchem-2553	267	2	,	,	PUNCT
eurjchem-2553	267	3	s.	s.	PROPN
eurjchem-2553	267	4	;	;	PUNCT
eurjchem-2553	267	5	solis	solis	PROPN
eurjchem-2553	267	6	,	,	PUNCT
eurjchem-2553	267	7	m.	m.	NOUN
eurjchem-2553	267	8	;	;	PUNCT
eurjchem-2553	267	9	laugel	laugel	PROPN
eurjchem-2553	267	10	,	,	PUNCT
eurjchem-2553	267	11	e.	e.	PROPN
eurjchem-2553	267	12	;	;	PUNCT
eurjchem-2553	267	13	reix	reix	NOUN
eurjchem-2553	267	14	,	,	PUNCT
eurjchem-2553	267	15	n.	n.	NOUN
eurjchem-2553	267	16	;	;	PUNCT
eurjchem-2553	267	17	schneider	schneider	PROPN
eurjchem-2553	267	18	,	,	PUNCT
eurjchem-2553	267	19	a.	a.	NOUN
eurjchem-2553	267	20	;	;	PUNCT
eurjchem-2553	267	21	glady	glady	PROPN
eurjchem-2553	267	22	,	,	PUNCT
eurjchem-2553	267	23	l.	l.	PROPN
eurjchem-2553	267	24	;	;	PUNCT
eurjchem-2553	267	25	panaget	panaget	PROPN
eurjchem-2553	267	26	,	,	PUNCT
eurjchem-2553	267	27	b.	b.	PROPN
eurjchem-2553	267	28	;	;	PUNCT
eurjchem-2553	267	29	collongues	collongue	NOUN
eurjchem-2553	267	30	,	,	PUNCT
eurjchem-2553	267	31	n.	n.	NOUN
eurjchem-2553	267	32	;	;	PUNCT
eurjchem-2553	267	33	partisani	partisani	NOUN
eurjchem-2553	267	34	,	,	PUNCT
eurjchem-2553	267	35	m.	m.	NOUN
eurjchem-2553	267	36	;	;	PUNCT
eurjchem-2553	267	37	lessinger	lessinger	ADJ
eurjchem-2553	267	38	,	,	PUNCT
eurjchem-2553	267	39	j.-m	j.-m	NOUN
eurjchem-2553	267	40	.	.	PUNCT
eurjchem-2553	267	41	;	;	PUNCT
eurjchem-2553	267	42	fontanet	fontanet	PROPN
eurjchem-2553	267	43	,	,	PUNCT
eurjchem-2553	267	44	a.	a.	NOUN
eurjchem-2553	267	45	;	;	PUNCT
eurjchem-2553	267	46	rey	rey	PROPN
eurjchem-2553	267	47	,	,	PUNCT
eurjchem-2553	267	48	d.	d.	PROPN
eurjchem-2553	267	49	;	;	PUNCT
eurjchem-2553	267	50	hansmann	hansmann	PROPN
eurjchem-2553	267	51	,	,	PUNCT
eurjchem-2553	267	52	y.	y.	PROPN
eurjchem-2553	267	53	;	;	PUNCT
eurjchem-2553	267	54	kling	kle	VERB
eurjchem-2553	267	55	-	-	PUNCT
eurjchem-2553	267	56	pillitteri	pillitteri	NOUN
eurjchem-2553	267	57	,	,	PUNCT
eurjchem-2553	267	58	l.	l.	PROPN
eurjchem-2553	267	59	;	;	PUNCT
eurjchem-2553	267	60	schwartz	schwartz	PROPN
eurjchem-2553	267	61	,	,	PUNCT
eurjchem-2553	267	62	o.	o.	PROPN
eurjchem-2553	267	63	;	;	PUNCT
eurjchem-2553	267	64	de	de	PROPN
eurjchem-2553	267	65	sèze	sèze	PROPN
eurjchem-2553	267	66	,	,	PUNCT
eurjchem-2553	267	67	j.	j.	PROPN
eurjchem-2553	267	68	;	;	PUNCT
eurjchem-2553	267	69	meyer	meyer	PROPN
eurjchem-2553	267	70	,	,	PUNCT
eurjchem-2553	267	71	n.	n.	PROPN
eurjchem-2553	267	72	;	;	PUNCT
eurjchem-2553	267	73	gonzalez	gonzalez	PROPN
eurjchem-2553	267	74	,	,	PUNCT
eurjchem-2553	267	75	m.	m.	NOUN
eurjchem-2553	267	76	;	;	PUNCT
eurjchem-2553	267	77	schmidt	schmidt	NOUN
eurjchem-2553	267	78	-	-	PUNCT
eurjchem-2553	267	79	mutter	mutter	PROPN
eurjchem-2553	267	80	,	,	PUNCT
eurjchem-2553	267	81	c.	c.	NOUN
eurjchem-2553	267	82	;	;	PUNCT
eurjchem-2553	267	83	fafi	fafi	PROPN
eurjchem-2553	267	84	-	-	PUNCT
eurjchem-2553	267	85	kremer	kremer	PROPN
eurjchem-2553	267	86	,	,	PUNCT
eurjchem-2553	267	87	s.	s.	PROPN
eurjchem-2553	267	88	evolution	evolution	NOUN
eurjchem-2553	267	89	of	of	ADP
eurjchem-2553	267	90	antibody	antibody	NOUN
eurjchem-2553	267	91	responses	response	VERB
eurjchem-2553	267	92	up	up	ADP
eurjchem-2553	267	93	to	to	PART
eurjchem-2553	267	94	13	13	NUM
eurjchem-2553	267	95	months	month	NOUN
eurjchem-2553	267	96	after	after	ADP
eurjchem-2553	267	97	sars	sar	NOUN
eurjchem-2553	267	98	-	-	PUNCT
eurjchem-2553	267	99	cov-2	cov-2	PART
eurjchem-2553	267	100	infection	infection	NOUN
eurjchem-2553	267	101	and	and	CCONJ
eurjchem-2553	267	102	risk	risk	NOUN
eurjchem-2553	267	103	of	of	ADP
eurjchem-2553	267	104	reinfection	reinfection	NOUN
eurjchem-2553	267	105	.	.	PUNCT
eurjchem-2553	268	1	ebiomedicine	ebiomedicine	ADJ
eurjchem-2553	268	2	2021	2021	NUM
eurjchem-2553	268	3	,	,	PUNCT
eurjchem-2553	268	4	71	71	NUM
eurjchem-2553	268	5	,	,	PUNCT
eurjchem-2553	268	6	103561	103561	NUM
eurjchem-2553	268	7	.	.	PUNCT
eurjchem-2553	269	1	[	[	X
eurjchem-2553	269	2	20	20	NUM
eurjchem-2553	269	3	]	]	PUNCT
eurjchem-2553	269	4	.	.	PUNCT
eurjchem-2553	270	1	bchetnia	bchetnia	PROPN
eurjchem-2553	270	2	,	,	PUNCT
eurjchem-2553	270	3	m.	m.	NOUN
eurjchem-2553	270	4	;	;	PUNCT
eurjchem-2553	270	5	girard	girard	PROPN
eurjchem-2553	270	6	,	,	PUNCT
eurjchem-2553	270	7	c.	c.	PROPN
eurjchem-2553	270	8	;	;	PUNCT
eurjchem-2553	270	9	duchaine	duchaine	PROPN
eurjchem-2553	270	10	,	,	PUNCT
eurjchem-2553	270	11	c.	c.	PROPN
eurjchem-2553	270	12	;	;	PUNCT
eurjchem-2553	270	13	laprise	laprise	PROPN
eurjchem-2553	270	14	,	,	PUNCT
eurjchem-2553	270	15	c.	c.	PROPN
eurjchem-2553	270	16	the	the	DET
eurjchem-2553	270	17	outbreak	outbreak	NOUN
eurjchem-2553	270	18	of	of	ADP
eurjchem-2553	270	19	the	the	DET
eurjchem-2553	270	20	novel	novel	ADJ
eurjchem-2553	270	21	severe	severe	ADJ
eurjchem-2553	270	22	acute	acute	ADJ
eurjchem-2553	270	23	respiratory	respiratory	ADJ
eurjchem-2553	270	24	syndrome	syndrome	NOUN
eurjchem-2553	270	25	coronavirus	coronavirus	NOUN
eurjchem-2553	270	26	2	2	NUM
eurjchem-2553	270	27	(	(	PUNCT
eurjchem-2553	270	28	sars	sar	NOUN
eurjchem-2553	270	29	-	-	PUNCT
eurjchem-2553	270	30	cov2	cov2	PROPN
eurjchem-2553	270	31	):	):	PUNCT
eurjchem-2553	270	32	a	a	DET
eurjchem-2553	270	33	review	review	NOUN
eurjchem-2553	270	34	of	of	ADP
eurjchem-2553	270	35	the	the	DET
eurjchem-2553	270	36	current	current	ADJ
eurjchem-2553	270	37	global	global	ADJ
eurjchem-2553	270	38	status	status	NOUN
eurjchem-2553	270	39	.	.	PUNCT
eurjchem-2553	271	1	j.	j.	PROPN
eurjchem-2553	271	2	infect	infect	PROPN
eurjchem-2553	271	3	.	.	PUNCT
eurjchem-2553	272	1	public	public	ADJ
eurjchem-2553	272	2	health	health	NOUN
eurjchem-2553	272	3	2020	2020	NUM
eurjchem-2553	272	4	,	,	PUNCT
eurjchem-2553	272	5	13	13	NUM
eurjchem-2553	272	6	,	,	PUNCT
eurjchem-2553	272	7	1601–1610	1601–1610	NUM
eurjchem-2553	272	8	.	.	PUNCT
eurjchem-2553	273	1	[	[	X
eurjchem-2553	273	2	21	21	NUM
eurjchem-2553	273	3	]	]	PUNCT
eurjchem-2553	273	4	.	.	PUNCT
eurjchem-2553	274	1	vandenberg	vandenberg	PROPN
eurjchem-2553	274	2	,	,	PUNCT
eurjchem-2553	274	3	o.	o.	PROPN
eurjchem-2553	274	4	;	;	PUNCT
eurjchem-2553	274	5	martiny	martiny	PROPN
eurjchem-2553	274	6	,	,	PUNCT
eurjchem-2553	274	7	d.	d.	PROPN
eurjchem-2553	274	8	;	;	PUNCT
eurjchem-2553	274	9	rochas	rochas	PROPN
eurjchem-2553	274	10	,	,	PUNCT
eurjchem-2553	274	11	o.	o.	PROPN
eurjchem-2553	274	12	;	;	PUNCT
eurjchem-2553	274	13	van	van	PROPN
eurjchem-2553	274	14	belkum	belkum	NOUN
eurjchem-2553	274	15	,	,	PUNCT
eurjchem-2553	274	16	a.	a.	NOUN
eurjchem-2553	274	17	;	;	PUNCT
eurjchem-2553	274	18	kozlakidis	kozlakidis	PROPN
eurjchem-2553	274	19	,	,	PUNCT
eurjchem-2553	274	20	z.	z.	PROPN
eurjchem-2553	274	21	considerations	consideration	NOUN
eurjchem-2553	274	22	for	for	ADP
eurjchem-2553	274	23	diagnostic	diagnostic	ADJ
eurjchem-2553	274	24	covid-19	covid-19	PROPN
eurjchem-2553	274	25	tests	test	NOUN
eurjchem-2553	274	26	.	.	PUNCT
eurjchem-2553	275	1	nat	nat	PROPN
eurjchem-2553	275	2	.	.	PUNCT
eurjchem-2553	276	1	rev	rev	PROPN
eurjchem-2553	276	2	.	.	PROPN
eurjchem-2553	276	3	microbiol	microbiol	PROPN
eurjchem-2553	276	4	.	.	PUNCT
eurjchem-2553	277	1	2021	2021	NUM
eurjchem-2553	277	2	,	,	PUNCT
eurjchem-2553	277	3	19	19	NUM
eurjchem-2553	277	4	,	,	PUNCT
eurjchem-2553	277	5	171–183	171–183	NUM
eurjchem-2553	277	6	.	.	PUNCT
eurjchem-2553	278	1	[	[	X
eurjchem-2553	278	2	22	22	NUM
eurjchem-2553	278	3	]	]	PUNCT
eurjchem-2553	278	4	.	.	PUNCT
eurjchem-2553	278	5	alter	alter	PROPN
eurjchem-2553	278	6	,	,	PUNCT
eurjchem-2553	278	7	g.	g.	NOUN
eurjchem-2553	278	8	;	;	PUNCT
eurjchem-2553	278	9	seder	seder	NOUN
eurjchem-2553	278	10	,	,	PUNCT
eurjchem-2553	278	11	r.	r.	VERB
eurjchem-2553	278	12	the	the	DET
eurjchem-2553	278	13	power	power	NOUN
eurjchem-2553	278	14	of	of	ADP
eurjchem-2553	278	15	antibody	antibody	NOUN
eurjchem-2553	278	16	-	-	PUNCT
eurjchem-2553	278	17	based	base	VERB
eurjchem-2553	278	18	surveillance	surveillance	NOUN
eurjchem-2553	278	19	.	.	PUNCT
eurjchem-2553	279	1	n.	n.	PROPN
eurjchem-2553	279	2	engl	engl	PROPN
eurjchem-2553	279	3	.	.	PUNCT
eurjchem-2553	280	1	j.	j.	PROPN
eurjchem-2553	280	2	med	med	PROPN
eurjchem-2553	280	3	.	.	PUNCT
eurjchem-2553	281	1	2020	2020	NUM
eurjchem-2553	281	2	,	,	PUNCT
eurjchem-2553	281	3	383	383	NUM
eurjchem-2553	281	4	,	,	PUNCT
eurjchem-2553	281	5	1782–1784	1782–1784	NUM
eurjchem-2553	281	6	.	.	PUNCT
eurjchem-2553	282	1	[	[	X
eurjchem-2553	282	2	23	23	NUM
eurjchem-2553	282	3	]	]	PUNCT
eurjchem-2553	282	4	.	.	PUNCT
eurjchem-2553	283	1	dan	dan	PROPN
eurjchem-2553	283	2	,	,	PUNCT
eurjchem-2553	283	3	j.	j.	PROPN
eurjchem-2553	283	4	m.	m.	PROPN
eurjchem-2553	283	5	;	;	PUNCT
eurjchem-2553	283	6	mateus	mateus	PROPN
eurjchem-2553	283	7	,	,	PUNCT
eurjchem-2553	283	8	j.	j.	PROPN
eurjchem-2553	283	9	;	;	PUNCT
eurjchem-2553	283	10	kato	kato	PROPN
eurjchem-2553	283	11	,	,	PUNCT
eurjchem-2553	283	12	y.	y.	PROPN
eurjchem-2553	283	13	;	;	PUNCT
eurjchem-2553	283	14	hastie	hastie	PROPN
eurjchem-2553	283	15	,	,	PUNCT
eurjchem-2553	283	16	k.	k.	PROPN
eurjchem-2553	283	17	m.	m.	PROPN
eurjchem-2553	283	18	;	;	PUNCT
eurjchem-2553	283	19	yu	yu	PROPN
eurjchem-2553	283	20	,	,	PUNCT
eurjchem-2553	283	21	e.	e.	PROPN
eurjchem-2553	283	22	d.	d.	PROPN
eurjchem-2553	283	23	;	;	PUNCT
eurjchem-2553	283	24	faliti	faliti	PROPN
eurjchem-2553	283	25	,	,	PUNCT
eurjchem-2553	283	26	c.	c.	PROPN
eurjchem-2553	283	27	e.	e.	PROPN
eurjchem-2553	283	28	;	;	PUNCT
eurjchem-2553	283	29	grifoni	grifoni	PROPN
eurjchem-2553	283	30	,	,	PUNCT
eurjchem-2553	283	31	a.	a.	NOUN
eurjchem-2553	283	32	;	;	PUNCT
eurjchem-2553	283	33	ramirez	ramirez	PROPN
eurjchem-2553	283	34	,	,	PUNCT
eurjchem-2553	283	35	s.	s.	PROPN
eurjchem-2553	283	36	i.	i.	PROPN
eurjchem-2553	283	37	;	;	PUNCT
eurjchem-2553	283	38	haupt	haupt	PROPN
eurjchem-2553	283	39	,	,	PUNCT
eurjchem-2553	283	40	s.	s.	PROPN
eurjchem-2553	283	41	;	;	PUNCT
eurjchem-2553	283	42	frazier	frazier	PROPN
eurjchem-2553	283	43	,	,	PUNCT
eurjchem-2553	283	44	a.	a.	NOUN
eurjchem-2553	283	45	;	;	PUNCT
eurjchem-2553	283	46	nakao	nakao	PROPN
eurjchem-2553	283	47	,	,	PUNCT
eurjchem-2553	283	48	c.	c.	PROPN
eurjchem-2553	283	49	;	;	PUNCT
eurjchem-2553	283	50	rayaprolu	rayaprolu	PROPN
eurjchem-2553	283	51	,	,	PUNCT
eurjchem-2553	283	52	v.	v.	PROPN
eurjchem-2553	283	53	;	;	PUNCT
eurjchem-2553	283	54	rawlings	rawlings	PROPN
eurjchem-2553	283	55	,	,	PUNCT
eurjchem-2553	283	56	s.	s.	PROPN
eurjchem-2553	283	57	a.	a.	PROPN
eurjchem-2553	283	58	;	;	PUNCT
eurjchem-2553	283	59	peters	peters	PROPN
eurjchem-2553	283	60	,	,	PUNCT
eurjchem-2553	283	61	b.	b.	PROPN
eurjchem-2553	283	62	;	;	PUNCT
eurjchem-2553	283	63	krammer	krammer	PROPN
eurjchem-2553	283	64	,	,	PUNCT
eurjchem-2553	283	65	f.	f.	PROPN
eurjchem-2553	283	66	;	;	PUNCT
eurjchem-2553	283	67	simon	simon	PROPN
eurjchem-2553	283	68	,	,	PUNCT
eurjchem-2553	283	69	v.	v.	PROPN
eurjchem-2553	283	70	;	;	PUNCT
eurjchem-2553	283	71	saphire	saphire	PROPN
eurjchem-2553	283	72	,	,	PUNCT
eurjchem-2553	283	73	e.	e.	PROPN
eurjchem-2553	283	74	o.	o.	PROPN
eurjchem-2553	283	75	;	;	PUNCT
eurjchem-2553	283	76	smith	smith	PROPN
eurjchem-2553	283	77	,	,	PUNCT
eurjchem-2553	283	78	d.	d.	PROPN
eurjchem-2553	283	79	m.	m.	PROPN
eurjchem-2553	283	80	;	;	PUNCT
eurjchem-2553	283	81	weiskopf	weiskopf	ADV
eurjchem-2553	283	82	,	,	PUNCT
eurjchem-2553	283	83	d.	d.	PROPN
eurjchem-2553	283	84	;	;	PUNCT
eurjchem-2553	283	85	sette	sette	PROPN
eurjchem-2553	283	86	,	,	PUNCT
eurjchem-2553	283	87	a.	a.	PROPN
eurjchem-2553	283	88	;	;	PUNCT
eurjchem-2553	283	89	crotty	crotty	PROPN
eurjchem-2553	283	90	,	,	PUNCT
eurjchem-2553	283	91	s.	s.	PROPN
eurjchem-2553	283	92	immunological	immunological	ADJ
eurjchem-2553	283	93	memory	memory	NOUN
eurjchem-2553	283	94	to	to	ADP
eurjchem-2553	283	95	sars	sar	NOUN
eurjchem-2553	283	96	-	-	PUNCT
eurjchem-2553	283	97	cov-2	cov-2	NOUN
eurjchem-2553	283	98	assessed	assess	VERB
eurjchem-2553	283	99	for	for	ADP
eurjchem-2553	283	100	up	up	ADP
eurjchem-2553	283	101	to	to	PART
eurjchem-2553	283	102	8	8	NUM
eurjchem-2553	283	103	months	month	NOUN
eurjchem-2553	283	104	after	after	ADP
eurjchem-2553	283	105	infection	infection	NOUN
eurjchem-2553	283	106	.	.	PUNCT
eurjchem-2553	284	1	science	science	NOUN
eurjchem-2553	284	2	2021	2021	NUM
eurjchem-2553	284	3	,	,	PUNCT
eurjchem-2553	284	4	371	371	NUM
eurjchem-2553	284	5	.	.	PUNCT
eurjchem-2553	285	1	[	[	X
eurjchem-2553	285	2	24	24	NUM
eurjchem-2553	285	3	]	]	PUNCT
eurjchem-2553	285	4	.	.	PUNCT
eurjchem-2553	286	1	wang	wang	PROPN
eurjchem-2553	286	2	,	,	PUNCT
eurjchem-2553	286	3	z.	z.	PROPN
eurjchem-2553	286	4	;	;	PUNCT
eurjchem-2553	286	5	muecksch	muecksch	PROPN
eurjchem-2553	286	6	,	,	PUNCT
eurjchem-2553	286	7	f.	f.	PROPN
eurjchem-2553	286	8	;	;	PUNCT
eurjchem-2553	286	9	schaefer	schaefer	NOUN
eurjchem-2553	286	10	-	-	PUNCT
eurjchem-2553	286	11	babajew	babajew	NOUN
eurjchem-2553	286	12	,	,	PUNCT
eurjchem-2553	286	13	d.	d.	PROPN
eurjchem-2553	286	14	;	;	PUNCT
eurjchem-2553	286	15	finkin	finkin	PROPN
eurjchem-2553	286	16	,	,	PUNCT
eurjchem-2553	286	17	s.	s.	PROPN
eurjchem-2553	286	18	;	;	PUNCT
eurjchem-2553	286	19	viant	viant	PROPN
eurjchem-2553	286	20	,	,	PUNCT
eurjchem-2553	286	21	c.	c.	NOUN
eurjchem-2553	286	22	;	;	PUNCT
eurjchem-2553	286	23	gaebler	gaebler	NOUN
eurjchem-2553	286	24	,	,	PUNCT
eurjchem-2553	286	25	c.	c.	PROPN
eurjchem-2553	286	26	;	;	PUNCT
eurjchem-2553	286	27	hoffmann	hoffmann	PROPN
eurjchem-2553	286	28	,	,	PUNCT
eurjchem-2553	286	29	h.-h	h.-h	NOUN
eurjchem-2553	286	30	.	.	PUNCT
eurjchem-2553	286	31	;	;	PUNCT
eurjchem-2553	286	32	barnes	barnes	PROPN
eurjchem-2553	286	33	,	,	PUNCT
eurjchem-2553	286	34	c.	c.	PROPN
eurjchem-2553	286	35	o.	o.	PROPN
eurjchem-2553	286	36	;	;	PUNCT
eurjchem-2553	286	37	cipolla	cipolla	PROPN
eurjchem-2553	286	38	,	,	PUNCT
eurjchem-2553	286	39	m.	m.	NOUN
eurjchem-2553	286	40	;	;	PUNCT
eurjchem-2553	286	41	ramos	ramos	PROPN
eurjchem-2553	286	42	,	,	PUNCT
eurjchem-2553	286	43	v.	v.	PROPN
eurjchem-2553	286	44	;	;	PUNCT
eurjchem-2553	286	45	oliveira	oliveira	PROPN
eurjchem-2553	286	46	,	,	PUNCT
eurjchem-2553	286	47	t.	t.	PROPN
eurjchem-2553	286	48	y.	y.	PROPN
eurjchem-2553	286	49	;	;	PUNCT
eurjchem-2553	286	50	cho	cho	PROPN
eurjchem-2553	286	51	,	,	PUNCT
eurjchem-2553	286	52	a.	a.	NOUN
eurjchem-2553	286	53	;	;	PUNCT
eurjchem-2553	286	54	schmidt	schmidt	PROPN
eurjchem-2553	286	55	,	,	PUNCT
eurjchem-2553	286	56	f.	f.	PROPN
eurjchem-2553	286	57	;	;	PUNCT
eurjchem-2553	286	58	da	da	PROPN
eurjchem-2553	286	59	silva	silva	PROPN
eurjchem-2553	286	60	,	,	PUNCT
eurjchem-2553	286	61	j.	j.	PROPN
eurjchem-2553	286	62	;	;	PUNCT
eurjchem-2553	286	63	bednarski	bednarski	PROPN
eurjchem-2553	286	64	,	,	PUNCT
eurjchem-2553	286	65	e.	e.	PROPN
eurjchem-2553	286	66	;	;	PUNCT
eurjchem-2553	286	67	aguado	aguado	PROPN
eurjchem-2553	286	68	,	,	PUNCT
eurjchem-2553	286	69	l.	l.	PROPN
eurjchem-2553	286	70	;	;	PUNCT
eurjchem-2553	286	71	yee	yee	PROPN
eurjchem-2553	286	72	,	,	PUNCT
eurjchem-2553	286	73	j.	j.	PROPN
eurjchem-2553	286	74	;	;	PUNCT
eurjchem-2553	286	75	daga	daga	NOUN
eurjchem-2553	286	76	,	,	PUNCT
eurjchem-2553	286	77	m.	m.	NOUN
eurjchem-2553	286	78	;	;	PUNCT
eurjchem-2553	286	79	turroja	turroja	NOUN
eurjchem-2553	286	80	,	,	PUNCT
eurjchem-2553	286	81	m.	m.	NOUN
eurjchem-2553	286	82	;	;	PUNCT
eurjchem-2553	286	83	millard	millard	PROPN
eurjchem-2553	286	84	,	,	PUNCT
eurjchem-2553	286	85	k.	k.	PROPN
eurjchem-2553	286	86	g.	g.	PROPN
eurjchem-2553	286	87	;	;	PUNCT
eurjchem-2553	286	88	jankovic	jankovic	PROPN
eurjchem-2553	286	89	,	,	PUNCT
eurjchem-2553	286	90	m.	m.	NOUN
eurjchem-2553	286	91	;	;	PUNCT
eurjchem-2553	286	92	gazumyan	gazumyan	ADJ
eurjchem-2553	286	93	,	,	PUNCT
eurjchem-2553	286	94	a.	a.	NOUN
eurjchem-2553	286	95	;	;	PUNCT
eurjchem-2553	286	96	zhao	zhao	PROPN
eurjchem-2553	286	97	,	,	PUNCT
eurjchem-2553	286	98	z.	z.	PROPN
eurjchem-2553	286	99	;	;	PUNCT
eurjchem-2553	286	100	rice	rice	PROPN
eurjchem-2553	286	101	,	,	PUNCT
eurjchem-2553	286	102	c.	c.	PROPN
eurjchem-2553	286	103	m.	m.	NOUN
eurjchem-2553	286	104	;	;	PUNCT
eurjchem-2553	286	105	bieniasz	bieniasz	PROPN
eurjchem-2553	286	106	,	,	PUNCT
eurjchem-2553	286	107	p.	p.	PROPN
eurjchem-2553	286	108	d.	d.	PROPN
eurjchem-2553	286	109	;	;	PUNCT
eurjchem-2553	286	110	caskey	caskey	PROPN
eurjchem-2553	286	111	,	,	PUNCT
eurjchem-2553	286	112	m.	m.	NOUN
eurjchem-2553	286	113	;	;	PUNCT
eurjchem-2553	286	114	hatziioannou	hatziioannou	NOUN
eurjchem-2553	286	115	,	,	PUNCT
eurjchem-2553	286	116	t.	t.	PROPN
eurjchem-2553	286	117	;	;	PUNCT
eurjchem-2553	286	118	nussenzweig	nussenzweig	PROPN
eurjchem-2553	286	119	,	,	PUNCT
eurjchem-2553	286	120	m.	m.	NOUN
eurjchem-2553	286	121	c.	c.	PROPN
eurjchem-2553	286	122	naturally	naturally	ADV
eurjchem-2553	286	123	enhanced	enhance	VERB
eurjchem-2553	286	124	neutralizing	neutralize	VERB
eurjchem-2553	286	125	breadth	breadth	NOUN
eurjchem-2553	286	126	against	against	ADP
eurjchem-2553	286	127	sars	sar	NOUN
eurjchem-2553	286	128	-	-	PUNCT
eurjchem-2553	286	129	cov-2	cov-2	NUM
eurjchem-2553	286	130	one	one	NUM
eurjchem-2553	286	131	year	year	NOUN
eurjchem-2553	286	132	after	after	ADP
eurjchem-2553	286	133	infection	infection	NOUN
eurjchem-2553	286	134	.	.	PUNCT
eurjchem-2553	287	1	nature	nature	NOUN
eurjchem-2553	287	2	2021	2021	NUM
eurjchem-2553	287	3	,	,	PUNCT
eurjchem-2553	287	4	595	595	NUM
eurjchem-2553	287	5	,	,	PUNCT
eurjchem-2553	287	6	426–431	426–431	NUM
eurjchem-2553	287	7	.	.	PUNCT
eurjchem-2553	288	1	[	[	X
eurjchem-2553	288	2	25	25	NUM
eurjchem-2553	288	3	]	]	PUNCT
eurjchem-2553	288	4	.	.	PUNCT
eurjchem-2553	289	1	chiereghin	chiereghin	PROPN
eurjchem-2553	289	2	,	,	PUNCT
eurjchem-2553	289	3	a.	a.	NOUN
eurjchem-2553	289	4	;	;	PUNCT
eurjchem-2553	289	5	verucchi	verucchi	NOUN
eurjchem-2553	289	6	,	,	PUNCT
eurjchem-2553	289	7	g.	g.	PROPN
eurjchem-2553	289	8	;	;	PUNCT
eurjchem-2553	289	9	lazzarotto	lazzarotto	ADJ
eurjchem-2553	289	10	,	,	PUNCT
eurjchem-2553	289	11	t.	t.	PROPN
eurjchem-2553	289	12	cmv	cmv	NOUN
eurjchem-2553	289	13	-	-	PUNCT
eurjchem-2553	289	14	specific	specific	ADJ
eurjchem-2553	289	15	cell	cell	NOUN
eurjchem-2553	289	16	-	-	PUNCT
eurjchem-2553	289	17	mediated	mediate	VERB
eurjchem-2553	289	18	immunity	immunity	NOUN
eurjchem-2553	289	19	in	in	ADP
eurjchem-2553	289	20	immunocompetent	immunocompetent	ADJ
eurjchem-2553	289	21	adults	adult	NOUN
eurjchem-2553	289	22	with	with	ADP
eurjchem-2553	289	23	primary	primary	ADJ
eurjchem-2553	289	24	cmv	cmv	NOUN
eurjchem-2553	289	25	infection	infection	NOUN
eurjchem-2553	289	26	:	:	PUNCT
eurjchem-2553	289	27	a	a	DET
eurjchem-2553	289	28	case	case	NOUN
eurjchem-2553	289	29	series	series	NOUN
eurjchem-2553	289	30	and	and	CCONJ
eurjchem-2553	289	31	review	review	NOUN
eurjchem-2553	289	32	of	of	ADP
eurjchem-2553	289	33	the	the	DET
eurjchem-2553	289	34	literature	literature	NOUN
eurjchem-2553	289	35	.	.	PUNCT
eurjchem-2553	290	1	viruses	virus	NOUN
eurjchem-2553	290	2	2021	2021	NUM
eurjchem-2553	290	3	,	,	PUNCT
eurjchem-2553	290	4	13	13	NUM
eurjchem-2553	290	5	,	,	PUNCT
eurjchem-2553	290	6	816	816	NUM
eurjchem-2553	290	7	.	.	PUNCT
eurjchem-2553	291	1	[	[	X
eurjchem-2553	291	2	26	26	NUM
eurjchem-2553	291	3	]	]	PUNCT
eurjchem-2553	291	4	.	.	PUNCT
eurjchem-2553	292	1	mehdi	mehdi	PROPN
eurjchem-2553	292	2	,	,	PUNCT
eurjchem-2553	292	3	f.	f.	PROPN
eurjchem-2553	292	4	;	;	PUNCT
eurjchem-2553	292	5	chattopadhyay	chattopadhyay	PROPN
eurjchem-2553	292	6	,	,	PUNCT
eurjchem-2553	292	7	s.	s.	PROPN
eurjchem-2553	292	8	;	;	PUNCT
eurjchem-2553	292	9	thiruvengadam	thiruvengadam	NOUN
eurjchem-2553	292	10	,	,	PUNCT
eurjchem-2553	292	11	r.	r.	PROPN
eurjchem-2553	292	12	;	;	PUNCT
eurjchem-2553	292	13	yadav	yadav	PROPN
eurjchem-2553	292	14	,	,	PUNCT
eurjchem-2553	292	15	s.	s.	PROPN
eurjchem-2553	292	16	;	;	PUNCT
eurjchem-2553	292	17	kumar	kumar	PROPN
eurjchem-2553	292	18	,	,	PUNCT
eurjchem-2553	292	19	m.	m.	NOUN
eurjchem-2553	292	20	;	;	PUNCT
eurjchem-2553	292	21	sinha	sinha	PROPN
eurjchem-2553	292	22	,	,	PUNCT
eurjchem-2553	292	23	s.	s.	PROPN
eurjchem-2553	292	24	k.	k.	PROPN
eurjchem-2553	292	25	;	;	PUNCT
eurjchem-2553	292	26	goswami	goswami	PROPN
eurjchem-2553	292	27	,	,	PUNCT
eurjchem-2553	292	28	s.	s.	PROPN
eurjchem-2553	292	29	;	;	PUNCT
eurjchem-2553	292	30	kshetrapal	kshetrapal	PROPN
eurjchem-2553	292	31	,	,	PUNCT
eurjchem-2553	292	32	p.	p.	PROPN
eurjchem-2553	292	33	;	;	PUNCT
eurjchem-2553	292	34	wadhwa	wadhwa	PROPN
eurjchem-2553	292	35	,	,	PUNCT
eurjchem-2553	292	36	n.	n.	NOUN
eurjchem-2553	292	37	;	;	PUNCT
eurjchem-2553	292	38	chandramouli	chandramouli	PROPN
eurjchem-2553	292	39	natchu	natchu	PROPN
eurjchem-2553	292	40	,	,	PUNCT
eurjchem-2553	292	41	u.	u.	PROPN
eurjchem-2553	292	42	;	;	PUNCT
eurjchem-2553	292	43	sopory	sopory	ADJ
eurjchem-2553	292	44	,	,	PUNCT
eurjchem-2553	292	45	s.	s.	PROPN
eurjchem-2553	292	46	;	;	PUNCT
eurjchem-2553	292	47	koundinya	koundinya	PROPN
eurjchem-2553	292	48	desiraju	desiraju	PROPN
eurjchem-2553	292	49	,	,	PUNCT
eurjchem-2553	292	50	b.	b.	PROPN
eurjchem-2553	292	51	;	;	PUNCT
eurjchem-2553	292	52	pandey	pandey	PROPN
eurjchem-2553	292	53	,	,	PUNCT
eurjchem-2553	292	54	a.	a.	PROPN
eurjchem-2553	292	55	k.	k.	PROPN
eurjchem-2553	292	56	;	;	PUNCT
eurjchem-2553	292	57	das	das	PROPN
eurjchem-2553	292	58	,	,	PUNCT
eurjchem-2553	292	59	a.	a.	NOUN
eurjchem-2553	292	60	;	;	PUNCT
eurjchem-2553	292	61	verma	verma	PROPN
eurjchem-2553	292	62	,	,	PUNCT
eurjchem-2553	292	63	n.	n.	NOUN
eurjchem-2553	292	64	;	;	PUNCT
eurjchem-2553	292	65	sharma	sharma	PROPN
eurjchem-2553	292	66	,	,	PUNCT
eurjchem-2553	292	67	n.	n.	NOUN
eurjchem-2553	292	68	;	;	PUNCT
eurjchem-2553	292	69	sharma	sharma	PROPN
eurjchem-2553	292	70	,	,	PUNCT
eurjchem-2553	292	71	p.	p.	PROPN
eurjchem-2553	292	72	;	;	PUNCT
eurjchem-2553	292	73	bhartia	bhartia	PROPN
eurjchem-2553	292	74	,	,	PUNCT
eurjchem-2553	292	75	v.	v.	ADV
eurjchem-2553	292	76	;	;	PUNCT
eurjchem-2553	292	77	gosain	gosain	NOUN
eurjchem-2553	292	78	,	,	PUNCT
eurjchem-2553	292	79	m.	m.	NOUN
eurjchem-2553	292	80	;	;	PUNCT
eurjchem-2553	292	81	lodha	lodha	PROPN
eurjchem-2553	292	82	,	,	PUNCT
eurjchem-2553	292	83	r.	r.	PROPN
eurjchem-2553	292	84	;	;	PUNCT
eurjchem-2553	292	85	lamminmäki	lamminmäki	PROPN
eurjchem-2553	292	86	,	,	PUNCT
eurjchem-2553	292	87	u.	u.	PROPN
eurjchem-2553	292	88	;	;	PUNCT
eurjchem-2553	292	89	shrivastava	shrivastava	PROPN
eurjchem-2553	292	90	,	,	PUNCT
eurjchem-2553	292	91	t.	t.	PROPN
eurjchem-2553	292	92	;	;	PUNCT
eurjchem-2553	292	93	bhatnagar	bhatnagar	PROPN
eurjchem-2553	292	94	,	,	PUNCT
eurjchem-2553	292	95	s.	s.	PROPN
eurjchem-2553	292	96	;	;	PUNCT
eurjchem-2553	292	97	batra	batra	PROPN
eurjchem-2553	292	98	,	,	PUNCT
eurjchem-2553	292	99	g.	g.	PROPN
eurjchem-2553	292	100	development	development	NOUN
eurjchem-2553	292	101	of	of	ADP
eurjchem-2553	292	102	a	a	DET
eurjchem-2553	292	103	fast	fast	ADJ
eurjchem-2553	292	104	sars	sar	NOUN
eurjchem-2553	292	105	-	-	PUNCT
eurjchem-2553	292	106	cov-2	cov-2	NOUN
eurjchem-2553	292	107	igg	igg	PROPN
eurjchem-2553	292	108	elisa	elisa	PROPN
eurjchem-2553	292	109	,	,	PUNCT
eurjchem-2553	292	110	based	base	VERB
eurjchem-2553	292	111	on	on	ADP
eurjchem-2553	292	112	receptor	receptor	NOUN
eurjchem-2553	292	113	-	-	PUNCT
eurjchem-2553	292	114	binding	bind	VERB
eurjchem-2553	292	115	domain	domain	NOUN
eurjchem-2553	292	116	,	,	PUNCT
eurjchem-2553	292	117	and	and	CCONJ
eurjchem-2553	292	118	its	its	PRON
eurjchem-2553	292	119	comparative	comparative	ADJ
eurjchem-2553	292	120	evaluation	evaluation	NOUN
eurjchem-2553	292	121	using	use	VERB
eurjchem-2553	292	122	temporally	temporally	ADV
eurjchem-2553	292	123	segregated	segregate	VERB
eurjchem-2553	292	124	samples	sample	NOUN
eurjchem-2553	292	125	from	from	ADP
eurjchem-2553	292	126	rt	rt	ADJ
eurjchem-2553	292	127	-	-	PUNCT
eurjchem-2553	292	128	pcr	pcr	ADJ
eurjchem-2553	292	129	positive	positive	ADJ
eurjchem-2553	292	130	individuals	individual	NOUN
eurjchem-2553	292	131	.	.	PUNCT
eurjchem-2553	293	1	front	front	ADJ
eurjchem-2553	293	2	.	.	PUNCT
eurjchem-2553	294	1	microbiol	microbiol	PROPN
eurjchem-2553	294	2	.	.	PUNCT
eurjchem-2553	295	1	2021	2021	NUM
eurjchem-2553	295	2	,	,	PUNCT
eurjchem-2553	295	3	11	11	NUM
eurjchem-2553	295	4	.	.	PUNCT
eurjchem-2553	296	1	https://doi.org/10.3389/fmicb.2020.618097	https://doi.org/10.3389/fmicb.2020.618097	NOUN
eurjchem-2553	296	2	copyright	copyright	NOUN
eurjchem-2553	296	3	©	©	ADP
eurjchem-2553	296	4	2024	2024	NUM
eurjchem-2553	296	5	by	by	ADP
eurjchem-2553	296	6	authors	author	NOUN
eurjchem-2553	296	7	.	.	PUNCT
eurjchem-2553	297	1	this	this	DET
eurjchem-2553	297	2	work	work	NOUN
eurjchem-2553	297	3	is	be	AUX
eurjchem-2553	297	4	published	publish	VERB
eurjchem-2553	297	5	and	and	CCONJ
eurjchem-2553	297	6	licensed	license	VERB
eurjchem-2553	297	7	by	by	ADP
eurjchem-2553	297	8	atlanta	atlanta	PROPN
eurjchem-2553	297	9	publishing	publishing	PROPN
eurjchem-2553	297	10	house	house	PROPN
eurjchem-2553	297	11	llc	llc	PROPN
eurjchem-2553	297	12	,	,	PUNCT
eurjchem-2553	297	13	atlanta	atlanta	PROPN
eurjchem-2553	297	14	,	,	PUNCT
eurjchem-2553	297	15	ga	ga	PROPN
eurjchem-2553	297	16	,	,	PUNCT
eurjchem-2553	297	17	usa	usa	PROPN
eurjchem-2553	297	18	.	.	PUNCT
eurjchem-2553	298	1	the	the	DET
eurjchem-2553	298	2	full	full	ADJ
eurjchem-2553	298	3	terms	term	NOUN
eurjchem-2553	298	4	of	of	ADP
eurjchem-2553	298	5	this	this	DET
eurjchem-2553	298	6	license	license	NOUN
eurjchem-2553	298	7	are	be	AUX
eurjchem-2553	298	8	available	available	ADJ
eurjchem-2553	298	9	at	at	ADP
eurjchem-2553	298	10	https://www.eurjchem.com/index.php/eurjchem/terms	https://www.eurjchem.com/index.php/eurjchem/term	NOUN
eurjchem-2553	298	11	and	and	CCONJ
eurjchem-2553	298	12	incorporate	incorporate	VERB
eurjchem-2553	298	13	the	the	DET
eurjchem-2553	298	14	creative	creative	ADJ
eurjchem-2553	298	15	commons	common	NOUN
eurjchem-2553	298	16	attribution	attribution	NOUN
eurjchem-2553	298	17	-	-	PUNCT
eurjchem-2553	298	18	non	non	ADJ
eurjchem-2553	298	19	commercial	commercial	NOUN
eurjchem-2553	298	20	(	(	PUNCT
eurjchem-2553	298	21	cc	cc	NOUN
eurjchem-2553	298	22	by	by	ADP
eurjchem-2553	298	23	nc	nc	PROPN
eurjchem-2553	298	24	)	)	PUNCT
eurjchem-2553	298	25	(	(	PUNCT
eurjchem-2553	298	26	international	international	ADJ
eurjchem-2553	298	27	,	,	PUNCT
eurjchem-2553	298	28	v4.0	v4.0	NOUN
eurjchem-2553	298	29	)	)	PUNCT
eurjchem-2553	298	30	license	license	NOUN
eurjchem-2553	298	31	(	(	PUNCT
eurjchem-2553	298	32	http://creativecommons.org/licenses/by-nc/4.0	http://creativecommons.org/licenses/by-nc/4.0	NOUN
eurjchem-2553	298	33	)	)	PUNCT
eurjchem-2553	298	34	.	.	PUNCT
eurjchem-2553	299	1	by	by	ADP
eurjchem-2553	299	2	accessing	access	VERB
eurjchem-2553	299	3	the	the	DET
eurjchem-2553	299	4	work	work	NOUN
eurjchem-2553	299	5	,	,	PUNCT
eurjchem-2553	299	6	you	you	PRON
eurjchem-2553	299	7	hereby	hereby	ADV
eurjchem-2553	299	8	accept	accept	VERB
eurjchem-2553	299	9	the	the	DET
eurjchem-2553	299	10	terms	term	NOUN
eurjchem-2553	299	11	.	.	PUNCT
eurjchem-2553	300	1	this	this	PRON
eurjchem-2553	300	2	is	be	AUX
eurjchem-2553	300	3	an	an	DET
eurjchem-2553	300	4	open	open	ADJ
eurjchem-2553	300	5	access	access	NOUN
eurjchem-2553	300	6	article	article	NOUN
eurjchem-2553	300	7	distributed	distribute	VERB
eurjchem-2553	300	8	under	under	ADP
eurjchem-2553	300	9	the	the	DET
eurjchem-2553	300	10	terms	term	NOUN
eurjchem-2553	300	11	and	and	CCONJ
eurjchem-2553	300	12	conditions	condition	NOUN
eurjchem-2553	300	13	of	of	ADP
eurjchem-2553	300	14	the	the	DET
eurjchem-2553	300	15	cc	cc	PROPN
eurjchem-2553	300	16	by	by	ADP
eurjchem-2553	300	17	nc	nc	PROPN
eurjchem-2553	300	18	license	license	PROPN
eurjchem-2553	300	19	,	,	PUNCT
eurjchem-2553	300	20	which	which	PRON
eurjchem-2553	300	21	permits	permit	VERB
eurjchem-2553	300	22	unrestricted	unrestricted	ADJ
eurjchem-2553	300	23	non	non	ADJ
eurjchem-2553	300	24	-	-	ADJ
eurjchem-2553	300	25	commercial	commercial	ADJ
eurjchem-2553	300	26	use	use	NOUN
eurjchem-2553	300	27	,	,	PUNCT
eurjchem-2553	300	28	distribution	distribution	NOUN
eurjchem-2553	300	29	,	,	PUNCT
eurjchem-2553	300	30	and	and	CCONJ
eurjchem-2553	300	31	reproduction	reproduction	NOUN
eurjchem-2553	300	32	in	in	ADP
eurjchem-2553	300	33	any	any	DET
eurjchem-2553	300	34	medium	medium	NOUN
eurjchem-2553	300	35	,	,	PUNCT
eurjchem-2553	300	36	provided	provide	VERB
eurjchem-2553	300	37	the	the	DET
eurjchem-2553	300	38	original	original	ADJ
eurjchem-2553	300	39	work	work	NOUN
eurjchem-2553	300	40	is	be	AUX
eurjchem-2553	300	41	properly	properly	ADV
eurjchem-2553	300	42	cited	cite	VERB
eurjchem-2553	300	43	without	without	ADP
eurjchem-2553	300	44	any	any	DET
eurjchem-2553	300	45	further	further	ADJ
eurjchem-2553	300	46	permission	permission	NOUN
eurjchem-2553	300	47	from	from	ADP
eurjchem-2553	300	48	atlanta	atlanta	PROPN
eurjchem-2553	300	49	publishing	publishing	PROPN
eurjchem-2553	300	50	house	house	PROPN
eurjchem-2553	300	51	llc	llc	PROPN
eurjchem-2553	300	52	(	(	PUNCT
eurjchem-2553	300	53	european	european	PROPN
eurjchem-2553	300	54	journal	journal	PROPN
eurjchem-2553	300	55	of	of	ADP
eurjchem-2553	300	56	chemistry	chemistry	NOUN
eurjchem-2553	300	57	)	)	PUNCT
eurjchem-2553	300	58	.	.	PUNCT
eurjchem-2553	301	1	no	no	DET
eurjchem-2553	301	2	use	use	NOUN
eurjchem-2553	301	3	,	,	PUNCT
eurjchem-2553	301	4	distribution	distribution	NOUN
eurjchem-2553	301	5	,	,	PUNCT
eurjchem-2553	301	6	or	or	CCONJ
eurjchem-2553	301	7	reproduction	reproduction	NOUN
eurjchem-2553	301	8	is	be	AUX
eurjchem-2553	301	9	permitted	permit	VERB
eurjchem-2553	301	10	which	which	PRON
eurjchem-2553	301	11	does	do	AUX
eurjchem-2553	301	12	not	not	PART
eurjchem-2553	301	13	comply	comply	VERB
eurjchem-2553	301	14	with	with	ADP
eurjchem-2553	301	15	these	these	DET
eurjchem-2553	301	16	terms	term	NOUN
eurjchem-2553	301	17	.	.	PUNCT
eurjchem-2553	302	1	permissions	permission	NOUN
eurjchem-2553	302	2	for	for	ADP
eurjchem-2553	302	3	commercial	commercial	ADJ
eurjchem-2553	302	4	use	use	NOUN
eurjchem-2553	302	5	of	of	ADP
eurjchem-2553	302	6	this	this	DET
eurjchem-2553	302	7	work	work	NOUN
eurjchem-2553	302	8	beyond	beyond	ADP
eurjchem-2553	302	9	the	the	DET
eurjchem-2553	302	10	scope	scope	NOUN
eurjchem-2553	302	11	of	of	ADP
eurjchem-2553	302	12	the	the	DET
eurjchem-2553	302	13	license	license	NOUN
eurjchem-2553	302	14	(	(	PUNCT
eurjchem-2553	302	15	https://www.eurjchem.com/index.php/eurjchem/terms	https://www.eurjchem.com/index.php/eurjchem/term	NOUN
eurjchem-2553	302	16	)	)	PUNCT
eurjchem-2553	302	17	are	be	AUX
eurjchem-2553	302	18	administered	administer	VERB
eurjchem-2553	302	19	by	by	ADP
eurjchem-2553	302	20	atlanta	atlanta	PROPN
eurjchem-2553	302	21	publishing	publishing	PROPN
eurjchem-2553	302	22	house	house	PROPN
eurjchem-2553	302	23	llc	llc	PROPN
eurjchem-2553	302	24	(	(	PUNCT
eurjchem-2553	302	25	european	european	PROPN
eurjchem-2553	302	26	journal	journal	PROPN
eurjchem-2553	302	27	of	of	ADP
eurjchem-2553	302	28	chemistry	chemistry	NOUN
eurjchem-2553	302	29	)	)	PUNCT
eurjchem-2553	302	30	.	.	PUNCT
eurjchem-2553	303	1	https://doi.org/10.7860/jcdr/2022/56189.16758	https://doi.org/10.7860/jcdr/2022/56189.16758	PROPN
eurjchem-2553	304	1	https://doi.org/10.1101/2021.05.05.442760	https://doi.org/10.1101/2021.05.05.442760	PROPN
eurjchem-2553	304	2	https://www.statista.com/statistics/1248301/india-covid-19-vaccines-administered-by-vaccine-type	https://www.statista.com/statistics/1248301/india-covid-19-vaccines-administered-by-vaccine-type	PUNCT
eurjchem-2553	304	3	https://www.statista.com/statistics/1248301/india-covid-19-vaccines-administered-by-vaccine-type	https://www.statista.com/statistics/1248301/india-covid-19-vaccines-administered-by-vaccine-type	NOUN
eurjchem-2553	304	4	https://doi.org/10.7759/cureus.57149	https://doi.org/10.7759/cureus.57149	NOUN
eurjchem-2553	304	5	https://jmitra.co.in/product-details/covid19-ag-microlisa-elisa-test-kit/	https://jmitra.co.in/product-details/covid19-ag-microlisa-elisa-test-kit/	PROPN
eurjchem-2553	304	6	https://jmitra.co.in/product-details/covid19-ag-microlisa-elisa-test-kit/	https://jmitra.co.in/product-details/covid19-ag-microlisa-elisa-test-kit/	PROPN
eurjchem-2553	304	7	https://doi.org/10.3389/fmicb.2020.618097	https://doi.org/10.3389/fmicb.2020.618097	PROPN
eurjchem-2553	304	8	https://www.eurjchem.com/index.php/eurjchem/terms	https://www.eurjchem.com/index.php/eurjchem/term	VERB
eurjchem-2553	304	9	http://creativecommons.org/licenses/by-nc/4.0	http://creativecommons.org/licenses/by-nc/4.0	PROPN
eurjchem-2553	304	10	https://www.eurjchem.com/index.php/eurjchem/terms	https://www.eurjchem.com/index.php/eurjchem/term	NOUN
eurjchem-2553	304	11	1	1	NUM
eurjchem-2553	304	12	.	.	PUNCT
eurjchem-2553	304	13	introduction	introduction	NOUN
eurjchem-2553	304	14	2	2	NUM
eurjchem-2553	304	15	.	.	PUNCT
eurjchem-2553	304	16	methods	method	NOUN
eurjchem-2553	304	17	2.1	2.1	NUM
eurjchem-2553	304	18	.	.	PUNCT
eurjchem-2553	305	1	study	study	NOUN
eurjchem-2553	305	2	population	population	NOUN
eurjchem-2553	305	3	and	and	CCONJ
eurjchem-2553	305	4	characteristics	characteristic	NOUN
eurjchem-2553	305	5	2.2	2.2	NUM
eurjchem-2553	305	6	.	.	PUNCT
eurjchem-2553	306	1	sample	sample	NOUN
eurjchem-2553	306	2	collection	collection	NOUN
eurjchem-2553	306	3	and	and	CCONJ
eurjchem-2553	306	4	evaluation	evaluation	NOUN
eurjchem-2553	306	5	of	of	ADP
eurjchem-2553	306	6	sars	sar	NOUN
eurjchem-2553	306	7	-	-	PUNCT
eurjchem-2553	306	8	cov-2	cov-2	ADP
eurjchem-2553	306	9	specific	specific	ADJ
eurjchem-2553	306	10	neutralizing	neutralizing	ADJ
eurjchem-2553	306	11	antibodies	antibody	NOUN
eurjchem-2553	306	12	in	in	ADP
eurjchem-2553	306	13	serum	serum	NOUN
eurjchem-2553	306	14	and	and	CCONJ
eurjchem-2553	306	15	measurements	measurement	NOUN
eurjchem-2553	306	16	2.3	2.3	NUM
eurjchem-2553	306	17	.	.	PUNCT
eurjchem-2553	307	1	statistical	statistical	ADJ
eurjchem-2553	307	2	analysis	analysis	NOUN
eurjchem-2553	307	3	3	3	NUM
eurjchem-2553	307	4	.	.	NOUN
eurjchem-2553	307	5	results	result	NOUN
eurjchem-2553	307	6	3.1	3.1	NUM
eurjchem-2553	307	7	.	.	PUNCT
eurjchem-2553	308	1	characteristics	characteristic	NOUN
eurjchem-2553	308	2	of	of	ADP
eurjchem-2553	308	3	participants	participant	NOUN
eurjchem-2553	308	4	3.2	3.2	NUM
eurjchem-2553	308	5	.	.	PUNCT
eurjchem-2553	309	1	covid-19	covid-19	PROPN
eurjchem-2553	309	2	vaccine	vaccine	NOUN
eurjchem-2553	309	3	cohort	cohort	VERB
eurjchem-2553	309	4	3.3	3.3	NUM
eurjchem-2553	309	5	.	.	PUNCT
eurjchem-2553	310	1	analysis	analysis	NOUN
eurjchem-2553	310	2	of	of	ADP
eurjchem-2553	310	3	neutralization	neutralization	NOUN
eurjchem-2553	310	4	titers	titer	NOUN
eurjchem-2553	310	5	of	of	ADP
eurjchem-2553	310	6	the	the	DET
eurjchem-2553	310	7	same	same	ADJ
eurjchem-2553	310	8	individual	individual	NOUN
eurjchem-2553	310	9	’s	’s	PART
eurjchem-2553	310	10	sera	sera	NOUN
eurjchem-2553	310	11	variables	variable	NOUN
eurjchem-2553	310	12	associated	associate	VERB
eurjchem-2553	310	13	with	with	ADP
eurjchem-2553	310	14	anti	anti	ADJ
eurjchem-2553	310	15	-	-	ADJ
eurjchem-2553	310	16	spike	spike	ADJ
eurjchem-2553	310	17	anti	anti	ADJ
eurjchem-2553	310	18	-	-	ADJ
eurjchem-2553	310	19	body	body	ADJ
eurjchem-2553	310	20	titers	titer	NOUN
eurjchem-2553	310	21	after	after	ADP
eurjchem-2553	310	22	three	three	NUM
eurjchem-2553	310	23	doses	dose	NOUN
eurjchem-2553	310	24	of	of	ADP
eurjchem-2553	310	25	vaccine	vaccine	NOUN
eurjchem-2553	310	26	chadox1	chadox1	NOUN
eurjchem-2553	310	27	-	-	PUNCT
eurjchem-2553	310	28	ncov	ncov	NOUN
eurjchem-2553	310	29	(	(	PUNCT
eurjchem-2553	310	30	covishield	covishield	NOUN
eurjchem-2553	310	31	™	™	PROPN
eurjchem-2553	310	32	)	)	PUNCT
eurjchem-2553	310	33	3.4	3.4	NUM
eurjchem-2553	310	34	.	.	PUNCT
eurjchem-2553	311	1	present	present	ADJ
eurjchem-2553	311	2	study	study	NOUN
eurjchem-2553	311	3	findings	finding	NOUN
eurjchem-2553	311	4	and	and	CCONJ
eurjchem-2553	311	5	further	further	ADJ
eurjchem-2553	311	6	implications	implication	NOUN
eurjchem-2553	311	7	for	for	ADP
eurjchem-2553	311	8	practice	practice	NOUN
eurjchem-2553	311	9	and	and	CCONJ
eurjchem-2553	311	10	research	research	NOUN
eurjchem-2553	311	11	4	4	NUM
eurjchem-2553	311	12	.	.	PUNCT
eurjchem-2553	312	1	discussions	discussion	NOUN
eurjchem-2553	312	2	acknowledgements	acknowledgement	NOUN
eurjchem-2553	312	3	disclosure	disclosure	NOUN
eurjchem-2553	312	4	statement	statement	NOUN
eurjchem-2553	312	5	credit	credit	NOUN
eurjchem-2553	312	6	authorship	authorship	NOUN
eurjchem-2553	312	7	contribution	contribution	NOUN
eurjchem-2553	312	8	statement	statement	NOUN
eurjchem-2553	312	9	funding	fund	VERB
eurjchem-2553	312	10	orcid	orcid	NOUN
eurjchem-2553	312	11	and	and	CCONJ
eurjchem-2553	312	12	email	email	NOUN
eurjchem-2553	312	13	references	reference	NOUN
eurjchem-2553	312	14	printfield10	printfield10	PROPN
eurjchem-2553	312	15	:	:	PUNCT
eurjchem-2553	312	16	printfield11	printfield11	NOUN
eurjchem-2553	312	17	:	:	PUNCT
eurjchem-2553	312	18	printfield12	printfield12	PROPN
eurjchem-2553	312	19	:	:	PUNCT
eurjchem-2553	312	20	printfield13	printfield13	VERB
eurjchem-2553	312	21	:	:	PUNCT
eurjchem-2553	312	22	printfield14	printfield14	NOUN
eurjchem-2553	312	23	:	:	PUNCT
eurjchem-2553	312	24	printfield15	printfield15	NOUN
eurjchem-2553	312	25	:	:	PUNCT
eurjchem-2553	312	26	printfield16	printfield16	ADJ
eurjchem-2553	312	27	:	:	PUNCT
eurjchem-2553	312	28	printfield17	printfield17	NOUN
eurjchem-2553	312	29	:	:	PUNCT
eurjchem-2553	312	30	printfield20	printfield20	PROPN
eurjchem-2553	312	31	:	:	PUNCT
eurjchem-2553	312	32	printfield21	printfield21	ADJ
eurjchem-2553	312	33	:	:	PUNCT
eurjchem-2553	312	34	printfield22	printfield22	NOUN
eurjchem-2553	312	35	:	:	PUNCT
eurjchem-2553	312	36	printfield23	printfield23	NOUN
eurjchem-2553	312	37	:	:	PUNCT
eurjchem-2553	312	38	printfield24	printfield24	NOUN
eurjchem-2553	312	39	:	:	PUNCT
eurjchem-2553	312	40	printfield25	printfield25	NOUN
eurjchem-2553	312	41	:	:	PUNCT
eurjchem-2553	312	42	printfield26	printfield26	ADJ
eurjchem-2553	312	43	:	:	PUNCT
eurjchem-2553	312	44	printfield27	printfield27	NOUN
eurjchem-2553	312	45	:	:	PUNCT